eversana.com
Last updated: 6/16/2026valid
Independent Directory - Important Information
This llms.txt file was publicly accessible and retrieved from eversana.com. LLMS Central does not claim ownership of this content and hosts it for informational purposes only to help AI systems discover and respect website policies.
This listing is not an endorsement by eversana.com and they have not sponsored this page. We are an independent directory service with no affiliation to the listed domain.
Copyright & Terms: Users should respect the original terms of service of eversana.com. If you believe there is a copyright or terms of service violation, please contact us at support@llmscentral.com for prompt removal. Domain owners can also claim their listing.
Current llms.txt Content
Generated by All in One SEO v4.9.8, this is an llms.txt file, used by LLMs to index the site. # EVERSANA EVERSANA ## Sitemaps - [XML Sitemap](https://www.eversana.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [News](https://www.eversana.com/news/) - [Recognizing Asian American Pacific Islander (AAPI) Heritage Month with Angela Fukuda, Executive Legal Assistant](https://www.eversana.com/2023/05/18/recognizing-asian-american-pacific-islander-heritage-month-with-angela-fukuda-executive-legal-assistant/) - During the month of May EVERSANA recognizes Asian American Pacific Islander Heritage (AAPI) Month. Read on to learn what the month means to one employee. - [Maximising Success in Global Commercialisation: Insights and Strategies Across Life Sciences](https://www.eversana.com/2023/06/16/maximising-success-in-global-commercialisation-insights-and-strategies-across-life-sciences/) - Join us for this event to explore the lessons learned by senior industry experts who have successfully developed, launched and commercialised global assets. - [EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton](https://www.eversana.com/2026/06/09/eversana-appoints-jen-norton-market-access/) - EVERSANA expands its pharmaceutical market access solutions, appointing Jen Norton as President to lead global pricing, value, and commercialization strategies. - [Scaling Innovation Without Losing Executional Rigor: Q&A with Mark Thierer](https://www.eversana.com/2026/05/04/scaling-innovation-without-losing-executional-rigor-qa-with-mark-thierer/) - [A New Standard for Copay Excellence: Q&A with Brian Laird](https://www.eversana.com/2026/04/15/a-new-standard-for-copay-excellence-qa-with-brian-laird/) - [4 Takeaways from Google Cloud’s NEXT 2026 and what’s on the horizon for pharma](https://www.eversana.com/2026/04/28/4-takeaways-from-google-clouds-next-2026-and-whats-on-the-horizon-for-pharma/) - [Reimagining Annual Brand Planning with AI](https://www.eversana.com/2026/04/20/reimagining-annual-brand-planning-with-ai/) - [Driving Innovation in Specialty Pharmacy: Q&A Gregory Skalicky from EVERSANA Ahead of Asembia 2026](https://www.eversana.com/2026/04/23/driving-innovation-in-specialty-pharmacy-qa-gregory-skalicky-from-eversana-ahead-of-asembia-2026/) - [Nordic Life Science Days 2024](https://www.eversana.com/2024/07/23/nordic-life-science-days-2024/) - [CDA-AMC 2024 Symposium](https://www.eversana.com/2024/07/25/cda-amc-2024/) - [MDRP Summit 2024](https://www.eversana.com/2024/08/15/mdrp-summit-2024/) - [ASRM 2024](https://www.eversana.com/2024/08/19/asrm-2024/) - [EPP Life Sciences Pricing Forum 2024](https://www.eversana.com/2024/08/15/epp-life-sciences-pricing-forum-2024/) - [BIO-Europe 2024](https://www.eversana.com/2024/10/04/bio-europe-2024/) - EVERSANA is proud to be attending this year’s BIO-Europe. BIO-Europe 2024 will gather representatives of the biotech and pharma sectors for an in-person meeting in Stockholm, Sweden from 4 to 6 November 2024. - [ISPOR 2026](https://www.eversana.com/2026/04/06/ispor-2026-2/) - [2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://www.eversana.com/2026/05/04/asco-2026/) - [Pricing & Contracting 2026](https://www.eversana.com/2026/04/27/pricing-and-contracting-2026/) - EVERSANA is a proud sponsor of the Pricing & Contracting USA conference May 18-20, 2026 in Philadelphia, PA. Meet with our team of pricing and market access experts on-site. - [Revenue Management Thought Leadership](https://www.eversana.com/2026/05/06/revenue-management-thought-leadership/) - [EVERSANA Appoints Agency and Commercialization Veteran Mike Guarino to Lead Global Agency EVERSANA INTOUCH](https://www.eversana.com/2026/05/06/eversana-appoints-agency-and-commercialization-veteran-mike-guarino-to-lead-global-agency-eversana-intouch/) - EVERSANA appoints Mike Guarino as CEO of EVERSANA INTOUCH to drive AI-powered, data-driven marketing innovation for life sciences brands. - [Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer](https://www.eversana.com/2026/04/29/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potential-u-s-launch-of-aglatimagene-besadenovec-in-localized-prostate-cancer/) - EVERSANA partners with Candel Therapeutics to support potential U.S. launch of CAN‑2409 for localized prostate cancer ahead of a planned 2026 BLA submission. - [PPIC – Pharma Pricing & Access Innovation Conference 2026](https://www.eversana.com/2026/04/28/ppic-pharma-pricing-access-innovation-conference-2026/) - [Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.](https://www.eversana.com/2026/04/27/xcovery-partners-with-eversana-to-commercialize-lung-cancer-drug-ensacove-in-the-u-s/) - EVERSANA and Xcovery partner to expand the U.S. commercial launch of ENSACOVE™ (ensartinib), a new, once-daily oral therapy for ALK-positive NSCLC. - [What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them](https://www.eversana.com/2026/03/17/what-pharma-marketers-need-to-know-about-recent-gartner-predictions-about-ai-and-what-it-means-to-them/) - [BIO International Convention 2026](https://www.eversana.com/2026/03/07/bio-international-convention-2026/) - EVERSANA is a 7000+-person private-equity backed global commercialization platform for life science products. Our integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. We proudly serve over 650+ organizations, including innovative start-ups and established pharmaceutical companies, - [Donor Egg Meeting 2026](https://www.eversana.com/2026/04/16/donor-egg-meeting-2026/) - Join EVERSANA at The Donor Egg Meeting 2026 Join EVERSANA in Charleston from April 30 – May 3 for The Donor Egg Meeting! As a leading provider of global commercial services to the life sciences industry, we are committed to supporting the advancement of technologies in reproductive medicine. Our Donor Eligibility experts will be on-site to discuss how we help - [Meet at Google Cloud NEXT 2026](https://www.eversana.com/2026/03/16/meet-at-google-cloud-next-2026/) - Explore the industry’s fully integrated Medical Affairs ecosystem at MAPS Americas 2026; bringing together scientific expertise, evidence strategy, operational excellence and practical AI enablement. - [Why women’s health is at an inflection point and why commercialization models must advance](https://www.eversana.com/2026/03/16/why-womens-health-is-at-an-inflection-point-and-why-commercialization-models-must-advance/) - [Meet EVERSANA at Asembia 2026](https://www.eversana.com/2026/03/05/meet-eversana-at-asembia-2026/) - [Building a scalable GLP-1 care model](https://www.eversana.com/2026/02/26/building-a-scalable-glp-1-care-model/) - [Creative matters: Connecting with the rare disease community](https://www.eversana.com/2026/02/26/creative-matters-connecting-with-the-rare-disease-community/) - [ISPOR Europe 2025](https://www.eversana.com/2025/08/20/ispor-europe-2025/) - Join EVERSANA and global healthcare leaders as they convene at ISPOR Europe 2025. - [EVERSANA™ expands global channel management capabilities with new 260,000 square foot distribution center](https://www.eversana.com/2019/10/10/eversana-expands-global-channel-management-capabilities-with-new-260000-square-foot-distribution-center/) - [EVERSANA™ appoints experienced life science industry leaders to executive management team](https://www.eversana.com/2019/02/26/eversana-appoints-experienced-life-science-industry-leaders-to-executive-management-team/) - [A Day in the Life: Bill Mattler, Specialty Pharmacy Warehouse Guardian](https://www.eversana.com/2023/09/06/day-in-life-bill-mattler-specialty-pharmacy-warehouse-guardian/) - Ever wondered what it takes to orchestrate seamless specialty pharmacy warehouse operations? From ensuring prompt deliveries to maintaining stringent quality standards, Bill does it all with finesse. - [World EPA Congress 2026](https://www.eversana.com/2026/01/27/world-epa-congress-2026/) - [MAPS Americas 2026 Annual Meeting](https://www.eversana.com/2026/01/27/maps-americas-2026/) - Explore the industry’s fully integrated Medical Affairs ecosystem at MAPS Americas 2026; bringing together scientific expertise, evidence strategy, operational excellence and practical AI enablement. - [Lessons Learned From a Commercial Launch: Q&A with Greg Skalicky](https://www.eversana.com/2026/01/29/lessons-learned-from-a-commercial-launch-qa-with-greg-skalicky/) - [How uniting tech and human touch can make a difference for rare disease patients](https://www.eversana.com/2026/02/18/how-uniting-tech-and-human-touch-can-make-a-difference-for-rare-disease-patients/) - [EVERSANA leaders on digital-first models, affordability, and the future of pharma](https://www.eversana.com/2025/12/11/eversana-leaders-on-digital-first-models-affordability-and-the-future-of-pharma/) - [The Key to Connecting with Patients: Pharma's Market Access Transformation](https://www.eversana.com/2025/12/16/the-key-to-connecting-with-patients-pharmas-market-access-transformation/) - [PM360 2025 Innovative ARTIFICIAL INTELLIGENCE: EVERSANA’s AI Agency Platform](https://www.eversana.com/2026/01/22/pm360-2025-innovative-artificial-intelligence-eversanas-ai-agency-platform/) - [Bringing a Breakthrough Rare Disease Product to Patients: Q&A with Helen Sabzevari](https://www.eversana.com/2026/01/28/bringing-a-breakthrough-rare-disease-product-to-patients-qa-with-helen-sabzevari/) - [Inside the Shifting Role of Pharma 3PLs: Resilience, Regulation, and the Road Ahead](https://www.eversana.com/2026/02/10/inside-the-shifting-role-of-pharma-3pls-resilience-regulation-and-the-road-ahead/) - [CDA-AMC 2026 Symposium](https://www.eversana.com/2026/02/02/cda-amc-2026-symposium/) - [OWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral Suspension](https://www.eversana.com/2025/10/23/owp-pharmaceuticals-selects-eversana-to-support-u-s-launch-of-subvenitelamotrigine-oral-suspension/) - [EVERSANA Names Monica Avram Executive Vice President and Chief Legal Officer to Advance Governance, Compliance, and Enterprise Growth](https://www.eversana.com/2026/02/11/eversana-monica-avram-chief-legal-officer/) - [BIO Europe Spring 2026](https://www.eversana.com/2026/02/02/bio-europe-spring-2026/) - Our experts will be onsite at BIO Europe Spring. Join them to explore commercialization models and options for your assets. Learn how EVERSANA provides smart launch strategies and commercialization models that build value for your asset. EVERSANA offers alternatives to selling, out-licensing or launching internally. Join us for a conversation. The life sciences sector has Join our experts at BIO Europe Spring 2025 to explore commercialisation models and options for your assets. Learn how EVERSANA provides smart launch strategies and commercialisation models that build value for your asset. - [PCIC - Pharma Pricing & Contracting Innovation Conference 2026](https://www.eversana.com/2026/02/02/pcic-pharma-pricing-contracting-innovation-conference-2026/) - EVERSANA is proud to announce the second edition of the PCIC – Pharma Pricing & Contracting Innovation Conference. Taking place March 9–10, 2026, in Tampa, Florida, PCIC brings together pricing, market access, and contracting professionals to discuss the latest advancements shaping the industry. Join leading experts in pricing, contracting, and market access for a comprehensive EVERSANA is proud to announce the second edition of the PCIC – Pharma Pricing & Contracting Innovation Conference - [DIA Medical Affairs and Scientific Communications Forum 2026](https://www.eversana.com/2026/01/21/dia-masc-2026/) - [J.P. Morgan 44rd Annual Healthcare Conference](https://www.eversana.com/2025/11/25/jp-morgan-annual-healthcare-conference/) - [Octane Aesthetics Tech Forum](https://www.eversana.com/2025/12/17/octane-aesthetics-tech-forum/) - [EVERSANA Elevates Agency Leadership Team with Key Talent to Drive Innovation and Maximize Impact for Pharma Brands](https://www.eversana.com/2025/05/21/eversana-elevates-agency-leadership-team-with-key-talent-to-drive-innovation-and-maximize-impact-for-pharma-brands/) - [Innovation, transformation, and the power of data to transform patient lives comes to life at Frontiers Health 2025](https://www.eversana.com/2025/11/25/innovation-transformation-and-the-power-of-data-to-transform-patient-lives-comes-to-life-at-frontiers-health-2025/) - [Eli Lilly unveils new direct-to-employer model for weight loss drugs](https://www.eversana.com/2025/11/21/eli-lilly-unveils-new-direct-to-employer-model-for-weight-loss-drugs/) - [Waltz dances into direct-to-employer sales of obesity drugs](https://www.eversana.com/2025/11/21/waltz-dances-into-direct-to-employer-sales-of-obesity-drugs/) - [Direct-to-Employer Access Model for Obesity Management Medications](https://www.eversana.com/2025/11/21/direct-to-employer-access-model-for-obesity-management-medications/) - [Brave New Commercialisation World: Frontiers Health 2025](https://www.eversana.com/2025/11/21/brave-new-commercialisation-world-frontiers-health-2025/) - [Is that pharma influencer human or AI?](https://www.eversana.com/2025/11/14/is-that-pharma-influencer-human-or-ai/) - [Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025](https://www.eversana.com/2025/11/07/celebrating-a-decade-of-innovation-and-collaboration-in-berlin-november-11-12-2025/) - [AI doesn’t have to be 100% reliable to be useful](https://www.eversana.com/2025/11/12/ai-doesnt-have-to-be-100-reliable-to-be-useful/) - [Beyond clicks: Striking a new content chord in the age of AI](https://www.eversana.com/2025/11/11/beyond-clicks-striking-a-new-content-chord-in-the-age-of-ai/) - [EVERSANA Named AI Company of the Year by BioTech Breakthrough](https://www.eversana.com/2025/11/06/eversana-named-ai-company-of-the-year-by-biotech-breakthrough-3/) - [EVERSANA named AI Company of the Year by BioTech Breakthrough](https://www.eversana.com/2025/11/06/eversana-named-ai-company-of-the-year-by-biotech-breakthrough-2/) - [Changing Faces – Agency, investor, and legal hires – August and September 2025 Sales & Marketing](https://www.eversana.com/2025/10/30/changing-faces-agency-investor-and-legal-hires-august-and-september-2025-sales-marketing/) - [OWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral Suspension](https://www.eversana.com/2025/10/24/owp-pharmaceuticals-selects-eversana-to-support-u-s-launch-of-subvenite-lamotrigine-oral-suspension/) - [IndustryBRIEFS](https://www.eversana.com/2025/10/23/industrybriefs/) - [What personalized, measurable MSL engagement could mean to pharma](https://www.eversana.com/2025/10/21/what-personalized-measurable-msl-engagement-could-mean-to-pharma/) - [4 ads that prove pharma marketers can break through despite regulations](https://www.eversana.com/2025/10/17/4-ads-that-prove-pharma-marketers-can-break-through-despite-regulations/) - [Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA](https://www.eversana.com/2025/10/17/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana/) - [Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™](https://www.eversana.com/2025/10/16/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-q4-2025-launch-of-lymphir-3/) - [Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™](https://www.eversana.com/2025/10/16/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-q4-2025-launch-of-lymphir-2/) - [Waltz Health and Serve You Rx reach partnership to offer millions in specialty pharmacy savings to health plans, employers, and patients](https://www.eversana.com/2025/10/15/waltz-health-and-serve-you-rx-reach-partnership-to-offer-millions-in-specialty-pharmacy-savings-to-health-plans-employers-and-patients/) - [Market Access Agency of the Year 2025](https://www.eversana.com/2025/10/09/market-access-agency-of-the-year-2025/) - [Digital Initiative for Non-Consumers 2025](https://www.eversana.com/2025/10/09/digital-initiative-for-non-consumers-2025/) - [Frontiers Health 2025](https://www.eversana.com/2025/10/27/frontiers-health-2025/) - Explore the next frontier of global pharmaceutical commercialization with sessions on AI, data strategies, and access, and live demos at Frontiers Health. - [EVERSANA Named AI Company of the Year by BioTech Breakthrough](https://www.eversana.com/2025/11/06/eversana-named-ai-company-of-the-year-by-biotech-breakthrough/) - [ASH 2025](https://www.eversana.com/2025/10/03/ash-2025/) - [Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™](https://www.eversana.com/2025/10/16/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-q4-2025-launch-of-lymphir/) - [World Drug Safety Congress Europe and World Drug Safety Congress Americas](https://www.eversana.com/2024/09/16/world-drug-safety-congress-europe-and-world-drug-safety-congress-americas/) - [PM360’s 2025 Trailblazer Awards Winners](https://www.eversana.com/2025/10/02/pm360s-2025-trailblazer-awards-winners/) - [Rising Stars: Eversana InTouch’s Carolyn Yee thrives on the constant learning curve of pharma marketing](https://www.eversana.com/2025/10/01/rising-stars-eversana-intouchs-carolyn-yee-thrives-on-the-constant-learning-curve-of-pharma-marketing/) - [Side effects may include: A double standard](https://www.eversana.com/2025/09/30/side-effects-may-include-a-double-standard/) - [Beyond delivery: How AI is making direct-to-patient more personal](https://www.eversana.com/2025/09/25/beyond-delivery-how-ai-is-making-direct-to-patient-more-personal/) - [What can FDA really do about DTC pharma advertising?](https://www.eversana.com/2025/09/22/what-can-fda-really-do-about-dtc-pharma-advertising/) - [The Scene – EVERSANA and Google Redefine the Agency Model with AI](https://www.eversana.com/2025/09/19/the-scene-eversana-and-google-redefine-the-agency-model-with-ai/) - [EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS](https://www.eversana.com/2025/09/17/eversana-named-by-precigen-for-u-s-commercialization-of-papzimeos-2/) - [Agents of change: AI’s role in the future of pharma commercialisation](https://www.eversana.com/2025/09/11/agents-of-change-ais-role-in-the-future-of-pharma-commercialisation/) - [60+ Years of Impact: Honoring Three EVERSANA Veterans](https://www.eversana.com/2025/10/08/60-years-of-impact-honoring-three-eversana-veterans/) - [EPP Life Sciences Pricing Forum 2025](https://www.eversana.com/2025/09/15/epp2025/) - Schedule a meeting to meet with EVERSANA’s team of experts at EPP Life Sciences Pricing Forum 2025. - [World Orphan Drug Congress Europe 2025](https://www.eversana.com/2025/09/03/world-orphan-drug-congress-eu-2025/) - [DIA Medical Information & Communications Conference](https://www.eversana.com/2025/09/04/dia-medical-information/) - [EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS](https://www.eversana.com/2025/09/11/eversana-named-by-precigen-for-u-s-commercialization-of-papzimeos/) - [ESMO 2025](https://www.eversana.com/2025/09/08/esmo-2025/) - EVERSANA is proud to announce our participation in ESMO 2025, the premier European event for oncology professionals and thought leaders. - [BIO-Europe 2025](https://www.eversana.com/2025/08/25/bio-europe-2025/) - Schedule a meeting to meet with EVERSANA’s team of experts at BIO-Europe 2025. - [Forget mass media: Pharma’s future is influence](https://www.eversana.com/2025/09/08/forget-mass-media-pharmas-future-is-influence/) - [EVERSANA and Waltz Health Unite to Address Drug Pricing and Access Issues](https://www.eversana.com/2025/08/27/eversana-and-waltz-health-unite-to-address-drug-pricing-and-access-issues/) - [EVERSANA, Waltz Health Form Combined Platform to Tackle Drug Costs and Access Challenges](https://www.eversana.com/2025/08/27/eversana-waltz-health-form-combined-platform-to-tackle-drug-costs-and-access-challenges/) - [Eversana, Waltz Health to merge and form combined pharmaceutical pricing platform](https://www.eversana.com/2025/08/27/eversana-waltz-health-to-merge-and-form-combined-pharmaceutical-pricing-platform/) - [EVERSANA Merges with Waltz Health](https://www.eversana.com/2025/08/26/eversana-merges-with-waltz-health/) - [Early strategic evidence planning is a key success factor in the EU HTA landscape: Pamela Vo on navigating the JCA era](https://www.eversana.com/2025/08/26/early-strategic-evidence-planning-is-a-key-success-factor-in-the-eu-hta-landscape-pamela-vo-on-navigating-the-jca-era/) - [What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications](https://www.eversana.com/2025/08/20/what-the-most-favored-nation-executive-order-means-to-pharma-brands-and-future-implications/) - [Eversana Reveals Historic Transformation into a Next Gen AI Agency](https://www.eversana.com/2025/08/19/eversana-reveals-historic-transformation-into-a-next-gen-ai-agency/) - [Can AI agents reimagine pharma marketing from the ground up?](https://www.eversana.com/2025/08/19/can-ai-agents-reimagine-pharma-marketing-from-the-ground-up/) - [Goodbye agencies, hello AI agency? Inside Eversana’s latest innovation](https://www.eversana.com/2025/08/19/goodbye-agencies-hello-ai-agency-inside-eversanas-latest-innovation/) - [Marketing in rhythm: Redefining omnichannel for the modern pharma journey](https://www.eversana.com/2025/08/19/marketing-in-rhythm-redefining-omnichannel-for-the-modern-pharma-journey/) - [EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology](https://www.eversana.com/2025/08/04/eversana-announces-development-of-end-to-end-ai-powered-life-sciences-marketing-agency-built-on-google-cloud-technology/) - [EVERSANA Unveils EVERSANA ORCHESTRATE PV, An AI-Propelled Solution to Shape the Future of Pharmacovigilance](https://www.eversana.com/2025/07/17/eversana-unveils-eversana-orchestrate-pv-an-ai-propelled-solution-to-shape-the-future-of-pharmacovigilance/) - [EVERSANA Announces Enterprise Advancement to ‘Pharmatize AI” With the Launch of the EVERSANA AI Accelerator](https://www.eversana.com/2025/07/15/eversana-announces-enterprise-advancement-to-pharmatize-ai-with-the-launch-of-the-eversana-ai-accelerator/) - [Iterum Therapeutics Announces Partnership for Commercialization Services](https://www.eversana.com/2025/06/11/iterum-therapeutics-announces-partnership-for-commercialization-services/) - [OS Therapies Selects EVERSANA to Lead U.S. Commercialization of OST-HER2 for Pediatric Osteosarcoma](https://www.eversana.com/2025/06/10/os-therapies-selects-eversana-to-lead-u-s-commercialization-of-ost-her2-for-pediatric-osteosarcoma/) - [EVERSANA Strengthens Position as a Leading 3PL & Channel Provider with New 358,000 Square Foot Distribution Center, Expanded Cold Chain Capabilities, Enhanced Warehouse Management System and AI-Powered Robotics](https://www.eversana.com/2025/04/24/eversana-strengthens-position-as-a-leading-3pl-channel-provider-with-new-358000-square-foot-distribution-center-expanded-cold-chain-capabilities-enhanced-warehouse-management-system-and-ai-powere/) - [EVERSANA Unveils EVERSANA ORCHESTRATE™ MLR, an AI-Powered Solution to Transform the Medical, Legal & Regulatory Process](https://www.eversana.com/2025/04/10/eversana-unveils-eversana-orchestrate-mlr-an-ai-powered-solution-to-transform-the-medical-legal-regulatory-process/) - [EVERSANA Joins Veeva AI Partner Program](https://www.eversana.com/2025/04/01/eversana-joins-veeva-ai-partner-program/) - [Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams](https://www.eversana.com/2025/03/04/shorla-oncology-announces-expansion-of-u-s-commercial-footprint-with-launch-of-dedicated-sales-force-and-market-access-teams/) - [EVERSANA Named a Vault Top Consulting Firm for Fourth Consecutive Year in North America, Third Year in Asia Pacific Region](https://www.eversana.com/2025/02/12/eversana-named-a-vault-top-consulting-firm-for-fourth-consecutive-year-in-north-america-third-year-in-asia-pacific-region-2/) - [Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights](https://www.eversana.com/2025/01/28/lyfegen-and-eversana-collaborate-to-revolutionize-drug-pricing-and-access-with-ai-driven-insights/) - [EVERSANA Merges with Waltz Health to Create a New Force in Pharma Commercialization and Prescription Drug Access](https://www.eversana.com/2025/08/26/eversana-merges-with-waltz-health-to-create-a-new-force-in-pharma-commercialization-and-prescription-drug-access/) - [Wharton: Disrupting the Life Sciences Commercial Model](https://www.eversana.com/2025/08/18/wharton-disrupting-the-life-sciences-commercial-model/) - Join the Wharton and EVERSANA event on Disrupting the Life Sciences Commercial Model, September 26 in Philadelphia. - [Omnichannel, Evolved: Redefining the Model for Modern Pharma Marketing](https://www.eversana.com/2025/08/13/omnichannel-evolved-redefining-the-model-for-modern-pharma-marketing/) - [EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology](https://www.eversana.com/2025/08/06/eversana-announces-development-of-end-to-end-ai-powered-life-sciences-marketing-agency-built-on-google-cloud-technology-3/) - [EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology](https://www.eversana.com/2025/08/04/eversana-announces-development-of-end-to-end-ai-powered-life-sciences-marketing-agency-built-on-google-cloud-technology-2/) - [EVERSANA announces end-to-end AI-powered life sciences marketing agency built on Google Cloud technology](https://www.eversana.com/2025/08/04/eversana-announces-end-to-end-ai-powered-life-sciences-marketing-agency-built-on-google-cloud-technology/) - [EVERSANA unveils industry's 'first AI marketing agency'](https://www.eversana.com/2025/08/04/eversana-unveils-industrys-first-ai-marketing-agency/) - [Transforming Drug Safety Through Innovation - Q&A with Vikram Anand](https://www.eversana.com/2025/07/22/transforming-drug-safety-through-innovation-qa-with-vikram-anand/) - [ASRM 2025](https://www.eversana.com/2025/08/13/asrm-2025/) - [NACDS TSE](https://www.eversana.com/2023/07/12/nacds-tse/) - [MDRP Summit 2025](https://www.eversana.com/2025/07/29/mdrp-summit-2025/) - [Global unity in the face of uncertainty, with Paul Romness and Farah Ahmad](https://www.eversana.com/2025/07/21/global-unity-in-the-face-of-uncertainty-with-paul-romness-and-farah-ahmad/) - [Accelerating AI: Q&A with Faruk Capan and Scott Snyder](https://www.eversana.com/2025/07/21/accelerating-ai-qa-with-faruk-capan-and-scott-snyder/) - [EVERSANA Unveils EVERSANA ORCHESTRATE PV, An AI-Propelled Solution to Shape the Future of Pharmacovigilance](https://www.eversana.com/2025/07/17/eversana-unveils-eversana-orchestrate-pv-an-ai-propelled-solution-to-shape-the-future-of-pharmacovigilance-2/) - [EVERSANA unveils new AI-powered pharmacovigilance suite](https://www.eversana.com/2025/07/17/eversana-unveils-new-ai-powered-pharmacovigilance-suite/) - [EVERSANA launches AI solution to accelerate pharmacovigilance workflow](https://www.eversana.com/2025/07/17/eversana-launches-ai-solution-to-accelerate-pharmacovigilance-workflow/) - [EVERSANA Announces Enterprise Advancement to ‘Pharmatize AI” With the Launch of the EVERSANA AI Accelerator](https://www.eversana.com/2025/07/15/eversana-announces-enterprise-advancement-to-pharmatize-ai-with-the-launch-of-the-eversana-ai-accelerator-2/) - [EVERSANA launches enterprise advancement to ‘Pharmatize AI” with AI Accelerator](https://www.eversana.com/2025/07/15/eversana-launches-enterprise-advancement-to-pharmatize-ai-with-ai-accelerator/) - [Insights from Cannes – How CMOs define the future of work and what’s to come](https://www.eversana.com/2025/07/08/insights-from-cannes-how-cmos-define-the-future-of-work-and-whats-to-come/) - [Influencer in the loop: Branding, AI and the growth of the creator content – Lessons from Cannes 2025](https://www.eversana.com/2025/06/30/influencer-in-the-loop-branding-ai-and-the-growth-of-the-creator-content-lessons-from-cannes-2025/) - [Healthcare creatives break down why these 9 pieces of work won in Cannes](https://www.eversana.com/2025/06/26/healthcare-creatives-break-down-why-these-9-pieces-of-work-won-in-cannes/) - [Pharma’s creative inflection point: What Cannes 2025 taught us about brand power, platform strategy, and business-driving ideas](https://www.eversana.com/2025/06/23/pharmas-creative-inflection-point-what-cannes-2025-taught-us-about-brand-power-platform-strategy-and-business-driving-ideas/) - [Rx Rundown: BioNTech, Merck, RayzeBio and more](https://www.eversana.com/2025/06/12/rx-rundown-biontech-merck-rayzebio-and-more/) - [Annual LTEN Conference](https://www.eversana.com/2022/04/15/annual-lten-conference-meet-eversana/) - [Iterum Therapeutics announces partnership with EVERSANA](https://www.eversana.com/2025/06/11/iterum-therapeutics-announces-partnership-with-eversana/) - [Iterum Therapeutics Announces Partnership for Commercialization Services](https://www.eversana.com/2025/06/11/iterum-therapeutics-announces-partnership-for-commercialization-services-2/) - [OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma](https://www.eversana.com/2025/06/10/os-therapies-partners-with-eversana-for-the-u-s-commercialization-of-ost-her2-in-recurrent-fully-resected-pediatric-lung-metastatic-osteosarcoma/) - [AI in oncology: solving the sequencing puzzle in a biomarker-driven era](https://www.eversana.com/2025/06/10/ai-in-oncology-solving-the-sequencing-puzzle-in-a-biomarker-driven-era/) - [Agency 100](https://www.eversana.com/2025/06/10/agency-100/) - [American Diabetes Association 85th Scientific Sessions (ADA 2025)](https://www.eversana.com/2025/06/06/ada-85th-scientific-sessions/) - [Just call it ‘good marketing’: Dan Gandor on why omnichannel matters](https://www.eversana.com/2025/05/29/just-call-it-good-marketing-dan-gandor-on-why-omnichannel-matters/) - [ASCO 2025 insights: EVERSANA experts on AI, biomarkers, and the future of oncology](https://www.eversana.com/2025/06/05/asco-2025-insights-eversana-experts-on-ai-biomarkers-and-the-future-of-oncology/) - [Pharma Leadership Summit 2025](https://www.eversana.com/2025/06/05/pharma-leadership-summit-2025/) - Join EVERSANA’s Pharma Leadership Summit 2025: Unlocking Growth Through Functional Strategic Convergence on June 20 in Mumbai. - [2025 pharma generative search report: what it means for today’s pharma marketers](https://www.eversana.com/2025/05/28/2025-pharma-generative-search-report-what-it-means-for-todays-pharma-marketers/) - [ACCESS US 2025](https://www.eversana.com/2025/05/28/access-us-2025-austin/) - The NAVLIN by EVERSANA team will join the US ACCESS Forum, taking place June 8–10 at the AT&T Hotel & Conference Center at the University of Texas in Austin. - [EVERSANA Elevates Agency Leadership Team with Key Talent to Drive Innovation and Maximize Impact for Pharma Brands](https://www.eversana.com/2025/05/22/eversana-elevates-agency-leadership-team-with-key-talent-to-drive-innovation-and-maximize-impact-for-pharma-brands-3/) - [EVERSANA elevates agency leadership team with key talent to drive innovation and maximize impact for pharma brands](https://www.eversana.com/2025/05/21/eversana-elevates-agency-leadership-team-with-key-talent-to-drive-innovation-and-maximize-impact-for-pharma-brands-2/) - [Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch](https://www.eversana.com/2025/05/20/former-abbvie-takeda-omnichannel-lead-dan-gandor-joins-eversana-intouch/) - [BIO International Convention 2025](https://www.eversana.com/2025/05/14/bio-international-convention-2025/) - EVERSANA will be at BIO2024 and would love to meet with you to discuss a co-financing commercialization partnership. - [ELITE 2025 – CREATIVE DIRECTOR – Katie Beller of EVERSANA INTOUCH](https://www.eversana.com/2025/05/09/elite-2025-creative-director-katie-beller-of-eversana-intouch/) - [ELITE 2025 – DATA MINER – Daniel Pfeffer of EVERSANA](https://www.eversana.com/2025/05/09/elite-2025-data-miner-daniel-pfeffer-of-eversana/) - [Demystifying market access: Inside the complex journey from lab to patient](https://www.eversana.com/2025/05/01/demystifying-market-access-inside-the-complex-journey-from-lab-to-patient/) - [EVERSANA Launches ORCHESTRATE MLR Platform: Q&A with Faruk Capan](https://www.eversana.com/2025/05/01/eversana-launches-orchestrate-mlr-platform-qa-with-faruk-capan/) - [Pinnacle Awards 2025: Angela Tenuta](https://www.eversana.com/2025/04/29/pinnacle-awards-2025-angela-tenuta/) - [AWS Life Sciences Symposium 2025](https://www.eversana.com/2025/04/24/aws-life-sciences-symposium-2025/) - Connect with EVERSANA at AWS Life Sciences Symposium to transform your MLR process with EVERSANA ORCHESTRATE MLR. - [Artificial intelligence brings real results](https://www.eversana.com/2025/04/25/artificial-intelligence-brings-real-results/) - [EVERSANA strengthens position as a leading 3PL & channel provider, increasing cold chain capacity](https://www.eversana.com/2025/04/24/eversana-strengthens-position-as-a-leading-3pl-channel-provider-increasing-cold-chain-capacity/) - [Eversana’s Orchestrate MLR is an AI tool aiming to optimize the MLR process](https://www.eversana.com/2025/04/15/eversanas-orchestrate-mlr-is-an-ai-tool-aiming-to-optimize-the-mlr-process/) - [EVERSANA Unveils EVERSANA ORCHESTRATE™ MLR, an AI-Powered Solution to Transform the Medical, Legal & Regulatory Process](https://www.eversana.com/2025/04/15/eversana-unveils-eversana-orchestrate-mlr-an-ai-powered-solution-to-transform-the-medical-legal-regulatory-process-3/) - [American Society of Clinical Oncology (ASCO) Annual Meeting](https://www.eversana.com/2025/04/22/american-society-of-clinical-oncology-asco-annual-meeting/) - [Veeva Commercial Summit 2025](https://www.eversana.com/2025/04/16/veeva-commercial-summit/) - [EVERSANA Unveils EVERSANA ORCHESTRATE™ MLR, an AI-Powered Solution to Transform the Medical, Legal & Regulatory Process](https://www.eversana.com/2025/04/11/eversana-unveils-eversana-orchestrate-mlr-an-ai-powered-solution-to-transform-the-medical-legal-regulatory-process-2/) - [EVERSANA adds AI to medical, legal and regulatory reviews](https://www.eversana.com/2025/04/10/eversana-adds-ai-to-medical-legal-and-regulatory-reviews/) - [EVERSANA Unveils AI-powered EVERSANA ORCHESTRATE MLR](https://www.eversana.com/2025/04/10/eversana-unveils-ai-powered-eversana-orchestrate-mlr/) - [Pricing & Contracting USA 2025](https://www.eversana.com/2025/04/11/pricing-contracting-usa-2025/) - [Market Access & Medical Affairs Leadership Summit 2025](https://www.eversana.com/2025/04/11/market-access-medical-affairs-leadership-summit-2025/) - Join EVERSANA’s Market Access & Medical Affairs Leadership Summit 2025 to explore the evolving collaboration between Market Access and Medical Affairs. - [How pharma is tackling new direct-to-patient programmes](https://www.eversana.com/2025/04/04/how-pharma-is-tackling-new-direct-to-patient-programmes/) - [Think Tank: Getting More Meaningful Time with HCPs](https://www.eversana.com/2025/04/04/think-tank-getting-more-meaningful-time-with-hcps/) - [Google Gemini, AI Commercialization in Pharma and More: Q&A with Abid Rahman, SVP, Innovation, EVERSANA](https://www.eversana.com/2025/04/03/google-gemini-ai-commercialization-in-pharma-and-more-qa-with-abid-rahman-svp-innovation-eversana/) - [EVERSANA joins with Veeva in push to 'pharmatise AI'](https://www.eversana.com/2025/04/01/eversana-joins-with-veeva-in-push-to-pharmatise-ai/) - [World Orphan Drug Congress USA 2025](https://www.eversana.com/2025/03/08/world-orphan-drug-congress-2025/) - [ISPOR 2025](https://www.eversana.com/2025/03/20/ispor-2025/) - [Trends Shaping Direct to Patient in Pharma: Q&A with Scott Snyder](https://www.eversana.com/2025/03/12/trends-shaping-direct-to-patient-in-pharma-qa-with-scott-snyder/) - [Pharma Europe 2025](https://www.eversana.com/2025/02/19/pharma-europe-2025/) - [5 ways to address pricing and access challenges across the European landscape](https://www.eversana.com/2025/03/26/5-ways-to-address-pricing-and-access-challenges-across-the-european-landscape/) - [The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan](https://www.eversana.com/2025/03/20/successfully-navigating-the-complexity-of-market-access-across-europe/) - [Med Ad News announces 2025 Manny Awards finalists and Industry Person of the Year](https://www.eversana.com/2025/03/12/med-ad-news-announces-2025-manny-awards-finalists-and-industry-person-of-the-year/) - [How harnessing creativity, data, and innovation can help make a difference in a rare disease patient’s journey](https://www.eversana.com/2025/02/28/how-harnessing-creativity-data-and-innovation-can-help-make-a-difference-in-a-rare-disease-patients-journey/) - [Regulating the invisible hand: Inside the FDA's AI playbook](https://www.eversana.com/2025/02/27/regulating-the-invisible-hand-inside-the-fdas-ai-playbook/) - [The 2025 PM360 Pharma Choice Awards – Professional Campaign Gold Winner](https://www.eversana.com/2025/02/18/eversana-named-a-vault-top-consulting-firm-for-fourth-consecutive-year-in-north-america-third-year-in-asia-pacific-region-3/) - [PMSA 2025](https://www.eversana.com/2025/03/20/pmsa-2025/) - Join EVERSANA at the PMSA 2025. - [Pharma USA 2025](https://www.eversana.com/2025/02/14/pharma-usa-2025/) - [Meet EVERSANA at Asembia 2025](https://www.eversana.com/2025/03/05/meet-eversana-at-asembia-2025/) - We leverage technology and automation to reduce access, affordability barriers, simplify onboarding, get patients on therapy faster and drive therapy adoption. - [MAPS AMERICAS (Medical Affairs Professional Society)](https://www.eversana.com/2025/02/17/maps-americas-medical-affairs-professional-society/) - [PCMA Business Forum 2025](https://www.eversana.com/2025/02/18/pcma-business-forum-2025/) - Connect with EVERSANA at the PCMA Business Forum to learn how our end-to-end Market Access solutions can help your brand realize commercial success. - [State of DTP in Pharma Roundtable](https://www.eversana.com/2025/03/05/dtp-roundtable/) - Connect with EVERSANA and other life sciences experts for an intimate discussion about the state of direct-to-patient in pharma. Register to attend! - [DIA Medical Affairs and Scientific Communications Forum](https://www.eversana.com/2025/02/04/dia-medical-affairs-and-scientific-communications-forum/) - [EVERSANA Named a Vault Top Consulting Firm for Fourth Consecutive Year in North America, Third Year in Asia Pacific Region](https://www.eversana.com/2025/02/18/eversana-named-a-vault-top-consulting-firm-for-fourth-consecutive-year-in-north-america-third-year-in-asia-pacific-region/) - [3PLs: From Resilience to Sustainability](https://www.eversana.com/2025/02/11/3pls-from-resilience-to-sustainability/) - [5 takeaways from Super Bowl LIX: What health and pharma can learn from it](https://www.eversana.com/2025/02/11/5-takeaways-from-super-bowl-lix-what-health-and-pharma-can-learn-from-it/) - [Pharma learns to play the Super Bowl](https://www.eversana.com/2025/02/10/pharma-learns-to-play-the-super-bowl/) - [Why isn’t the Super Bowl a bigger moment for pharma marketing?](https://www.eversana.com/2025/02/04/why-isnt-the-super-bowl-a-bigger-moment-for-pharma-marketing/) - [The power of data and machine learning to optimize HCP prescription volume](https://www.eversana.com/2025/01/30/the-power-of-data-and-machine-learning-to-optimize-hcp-prescription-volume/) - [EVERSANA Partners with Lyfegen to Bring AI to Drug Pricing and Market Access](https://www.eversana.com/2025/01/30/eversana-partners-with-lyfegen-to-bring-ai-to-drug-pricing-and-market-access/) - [What Is Pharma Marketing in 2025?](https://www.eversana.com/2025/01/24/what-is-pharma-marketing-in-2025/) - [16 datapoints that define the state of pharma marketing](https://www.eversana.com/2025/01/02/49153/) - [Access USA](https://www.eversana.com/2025/02/12/access-usa-3/) - [EVERSANA streamlines data connectivity and strengthens predictive commercialization solutions with Datavant partnership](https://www.eversana.com/2020/11/12/eversana-streamlines-data-connectivity-and-strengthens-predictive-commercialization-solutions-with-datavant-partnership/) - [Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI](https://www.eversana.com/2024/06/17/evoke-pharma-reports-commercial-strategy-progress-positive-momentum-for-gimoti/) - [EVERSANA Earns Prestigious Designations from Leading Organizations for Specialty Pharmacy Operations Excellence, Superior Care for Rare Disease Patients](https://www.eversana.com/2024/12/12/eversana-earns-prestigious-designations-from-leading-organizations-for-specialty-pharmacy-operations-excellence-superior-care-for-rare-disease-patients/) - [ConTIPI Medical & EVERSANA Announce U.S. Commercial Launch of Non-Surgical Medical Device ProVate for Women With Pelvic Organ Prolapse](https://www.eversana.com/2024/12/10/contipi-medical-eversana-announce-u-s-commercial-launch-of-non-surgical-medical-device-provate-for-women-with-pelvic-organ-prolapse/) - [EVERSANA Named a Great Place to Work for Six Consecutive Years; Now Certified Across Nine Countries](https://www.eversana.com/2024/10/16/eversana-named-a-great-place-to-work-for-six-consecutive-years-now-certified-across-nine-countries/) - [EVERSANA Transforms Pharmacovigilance & Drug Safety Industry with Oracle Collaboration, New Global Patient Support Model](https://www.eversana.com/2024/10/10/eversana-transforms-pharmacovigilance-drug-safety-industry-with-oracle-collaboration-new-global-patient-support-model/) - [EVERSANA President Greg Skalicky Named to Prestigious 2024 PharmaVoice 100 List](https://www.eversana.com/2024/10/08/eversana-president-greg-skalicky-named-to-prestigious-2024-pharmavoice-100-list/) - [EVERSANA Expands Safety Case Management Capabilities with Oracle](https://www.eversana.com/2024/10/08/eversana-expands-safety-case-management-capabilities-with-oracle/) - [EVERSANA Expands Global Commercialisation Operations With Berlin, Germany Office](https://www.eversana.com/2024/10/07/eversana-expands-global-commercialisation-operations-with-berlin-germany-office/) - [ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse](https://www.eversana.com/2024/08/27/contipi-medical-selects-eversana-to-support-u-s-commercialization-of-non-surgical-medical-device-provate-for-women-with-pelvic-organ-prolapse/) - [EVERSANA Unveils TEDAVI, the Breakthrough Content Creation Hub to Transform Agency Marketing Models and Maximize Brand Impact](https://www.eversana.com/2024/08/01/eversana-unveils-tedavi-the-breakthrough-content-creation-hub-to-transform-agency-marketing-models-and-maximize-brand-impact/) - [EVERSANA Completes Integration of Healthware Group and Strengthens Its Global Agency Network EVERSANA INTOUCH With Addition of New Full-Service Affiliate](https://www.eversana.com/2024/04/15/eversana-completes-integration-of-healthware-group-and-strengthens-its-global-agency-network-eversana-intouch-with-addition-of-new-full-service-affiliate/) - [EVERSANA Named AI Excellence Award Winner for Third Consecutive Year, Recognized in Company Category for 2024](https://www.eversana.com/2024/03/21/eversana-named-ai-excellence-award-winner-for-third-consecutive-year-recognized-in-company-category-for-2024/) - [EVERSANA CONSULTING Named a Forbes 2024 Top Management Consulting Firm in the United States](https://www.eversana.com/2024/03/12/eversana-consulting-named-a-forbes-2024-top-management-consulting-firm-in-the-united-states/) - [Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia](https://www.eversana.com/2024/03/06/tonix-pharmaceuticals-selects-eversana-to-support-launch-strategy-and-commercialization-planning-of-tonmya-for-the-management-of-fibromyalgia/) - [EVERSANA CONSULTING Named a Top Consulting Firm in Asia Pacific Region for the Second Consecutive Year](https://www.eversana.com/2024/02/22/eversana-consulting-named-a-top-consulting-firm-in-asia-pacific-region-for-the-second-consecutive-year/) - [EVERSANA CONSULTING Named a Vault Top Ranked Consulting Firm in North America for the Third Consecutive Year](https://www.eversana.com/2024/02/08/eversana-consulting-named-a-vault-top-ranked-consulting-firm-in-north-america-for-the-third-consecutive-year/) - [EVERSANA Named 2024 BIG Innovation Award Winner for ACTICS eAccess ](https://www.eversana.com/2024/01/11/eversana-named-2024-big-innovation-award-winner-for-actics-eaccess/) - [Shorla Oncology & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO, the First and Only Oral Methotrexate Solution Approved in the U.S. for Adults](https://www.eversana.com/2023/12/19/shorla-oncology-eversana-announce-u-s-commercial-launch-of-fda-approved-jylamvo-the-first-and-only-oral-methotrexate-solution-approved-in-the-u-s-for-adults/) - [EVERSANA Recognized for Developing Multiple Top Innovations for 2023 by PM360 ](https://www.eversana.com/2023/12/15/eversana-recognized-for-developing-multiple-top-innovations-for-2023-by-pm360/) - [EVERSANA Builds on Commitment to “Pharmatize” AI with Amazon Web Services, Introduces Transformative Medical & Regulatory Review Solution](https://www.eversana.com/2023/11/27/eversana-builds-on-commitment-to-pharmatize-ai-with-amazon-web-services-introduces-transformative-medical-regulatory-review-solution/) - [EVERSANA to Use Adobe Firefly for Enterprise in Creative Development & Modular Content Production for Life Sciences Marketing](https://www.eversana.com/2023/11/20/eversana-to-use-adobe-firefly-for-enterprise-in-creative-development-modular-content-production-for-life-sciences-marketing/) - [EVERSANA INTOUCH Named Global Independent Pharma Agency of the Year by London International Awards](https://www.eversana.com/2023/11/06/eversana-intouch-named-global-independent-pharma-agency-of-the-year-by-london-international-awards/) - [EVERSANA Earns Great Place to Work Recognition for Fifth Consecutive Year, Now Certified Across Seven Countries](https://www.eversana.com/2023/10/26/eversana-earns-great-place-to-work-recognition-for-fifth-consecutive-year-now-certified-across-seven-countries/) - [EVERSANA Expands Global Commercialisation Capabilities and Strengthens Agency Network with Healthware Group Acquisition](https://www.eversana.com/2023/10/11/eversana-expands-global-commercialisation-capabilities-and-strengthens-agency-network-with-healthware-group-acquisition/) - [EVERSANA INTOUCH Wins Five Clio Awards](https://www.eversana.com/2023/06/05/eversana-intouch-wins-five-clio-awards/) - [EVERSANA Forms Strategic Alliance with China Resource Pharmaceutical Commercial Group to Bring New Novel Treatments to Patients Globally](https://www.eversana.com/2023/06/01/eversana-forms-strategic-alliance-with-china-resource-pharmaceutical-commercial-group-to-bring-new-novel-treatments-to-patients-globally/) - [Renalytix Selects EVERSANA to Expand Commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes](https://www.eversana.com/2023/05/25/renalytix-selects-eversana-to-expand-commercialization-of-kidneyintelx-for-early-stage-kidney-disease-prognosis-detection-in-patients-with-type-2-diabetes/) - [Two EVERSANA Leaders Named to Prestigious PM360 Elite 100 List](https://www.eversana.com/2023/05/16/two-eversana-leaders-named-to-prestigious-pm360-elite-100-list/) - [Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States](https://www.eversana.com/2023/05/16/shorla-oncology-eversana-announce-commercial-launch-of-recent-fda-approved-nelarabine-injection-for-the-treatment-of-t-cell-leukemia-across-the-united-states/) - [EVERSANA announces broad-scale strategic partnerships with industry leaders in claims, EMR, formulary and provider-institutional data to optimize real-time commercial services](https://www.eversana.com/2020/11/09/eversana-announces-broad-scale-strategic-partnerships-with-industry-leaders-in-claims-emr-formulary-and-provider-institutional-data-to-optimize-real-time-commercial-services/) - [Pharma Pricing & Contracting Innovation Conference 2025](https://www.eversana.com/2025/01/28/pharma-pricing-contracting-innovation-conference-2025/) - [World EPA Congress 2025](https://www.eversana.com/2025/01/21/world-epa-congress-2025/) - [BIO Europe Spring 2025](https://www.eversana.com/2025/01/24/bio-europe-spring-2025/) - Our experts will be onsite at BIO Europe Spring. Join them to explore commercialization models and options for your assets. Learn how EVERSANA provides smart launch strategies and commercialization models that build value for your asset. EVERSANA offers alternatives to selling, out-licensing or launching internally. Join us for a conversation. The life sciences sector has Join our experts at BIO Europe Spring 2025 to explore commercialisation models and options for your assets. Learn how EVERSANA provides smart launch strategies and commercialisation models that build value for your asset. - [What Role Can Pharma Play in Achieving Health Equity for All?](https://www.eversana.com/2024/12/16/what-role-can-pharma-play-in-achieving-health-equity-for-all/) - [Beyond Translation: The Art of Cross-Cultural Communication in Pharma](https://www.eversana.com/2024/12/17/beyond-translation-the-art-of-cross-cultural-communication-in-pharma/) - [PM360 2024 Innovative MARKETING TECHNOLOGY OR SERVICES: TEDAVI](https://www.eversana.com/2024/12/20/pm360-2024-innovative-marketing-technology-or-services-tedavi/) - [PM360 2024 Innovative ARTIFICIAL INTELLIGENCE: AI-Powered HCP Panels Redefining Training Excellence](https://www.eversana.com/2024/12/20/pm360-2024-innovative-artificial-intelligence-ai-powered-hcp-panels-redefining-training-excellence/) - [Rx Rundown: Merck, Ro, Eli Lilly and more](https://www.eversana.com/2024/12/13/rx-rundown-merck-ro-eli-lilly-and-more/) - [Trade & Channel Strategies 2024: Patient-Centric 3.0 — How Direct-to-Patient is the New Commercialization Model](https://www.eversana.com/2024/12/11/trade-channel-strategies-2024-patient-centric-3-0-how-direct-to-patient-is-the-new-commercialization-model/) - [JP Morgan 43rd Annual Healthcare Conference](https://www.eversana.com/2024/10/30/jp-morgan-43-annual-healthcare-conference/) - [How Can We Ensure Ethical Use of AI in Pharma Marketing?](https://www.eversana.com/2024/12/11/how-can-we-ensure-ethical-use-of-ai-in-pharma-marketing/) - [ConTIPI starts rollout of pelvic organ prolapse device in US](https://www.eversana.com/2024/12/10/https-pharmaphorum-com-news-contipi-starts-rollout-pelvic-organ-prolapse-device-us/) - [Healthcare Agency Roundtable 2024: Moving into 2025](https://www.eversana.com/2024/12/09/healthcare-agency-roundtable-2024-moving-into-2025/) - [Healthcare Agency Roundtable 2024: Building an environment of diversity, equity, inclusion, and belonging](https://www.eversana.com/2024/12/09/healthcare-agency-roundtable-2024-building-an-environment-of-diversity-equity-inclusion-and-belonging/) - [Healthcare Agency Roundtable 2024: From TikTok to digital opinion leaders, social media’s integral role in strategy and engagement](https://www.eversana.com/2024/12/09/healthcare-agency-roundtable-2024-from-tiktok-to-digital-opinion-leaders-social-medias-integral-role-in-strategy-and-engagement/) - [From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services](https://www.eversana.com/2024/12/06/from-challenges-to-solutions-breaking-barriers-to-revolutionize-patient-services/) - [Healthcare Agency Roundtable 2024: Technologies fuel better connectivity with HCPs, patients, and caregivers](https://www.eversana.com/2024/12/09/healthcare-agency-roundtable-2024-technologies-fuel-better-connectivity-with-hcps-patients-and-caregivers/) - [Pharma Pulse 12/6/24: Adoption Lag in AI, Financial Difficulty Through Early Breast Cancer Survivorship & more](https://www.eversana.com/2024/12/06/pharma-pulse-12-6-24-adoption-lag-in-ai-financial-difficulty-through-early-breast-cancer-survivorship-more/) - [Globalization and health equity are finally gaining focus, in 2025 and beyond](https://www.eversana.com/2024/12/02/globalization-and-health-equity-are-finally-gaining-focus-in-2025-and-beyond/) - [Focus On – Payer Strategies / Crowdsource](https://www.eversana.com/2024/11/21/focus-on-payer-strategies-crowdsource/) - [Voices of EVERSANA: What Makes Our Workplace Great?](https://www.eversana.com/2024/12/11/voices-of-eversana-what-makes-our-workplace-great/) - [‘Artful Ingenuity’ and what it means to pharma](https://www.eversana.com/2024/11/13/artful-ingenuity-and-what-it-means-to-pharma/) - [Global Expansion: Q&A with Mike Ryan](https://www.eversana.com/2024/11/13/global-expansion-qa-with-mike-ryan/) - [Inside EVERSANA INTOUCH’s AI-focused ad campaign](https://www.eversana.com/2024/11/07/inside-eversana-intouchs-ai-focused-ad-campaign/) - [Trade & Channel Strategies](https://www.eversana.com/2024/11/12/trade-channel-strategies-2/) - [ISPOR Europe 2024](https://www.eversana.com/2024/10/04/ispor-europe-2024/) - [ASH 2024](https://www.eversana.com/2024/10/30/ash-2024/) - [World Orphan Drug Congress USA 2024](https://www.eversana.com/2024/01/17/world-orphan-drug-congress-usa-2024/) - [The Global Stage: Q&A with EVERSANA’s Vikram Anand](https://www.eversana.com/2024/10/29/the-global-stage-qa-with-eversanas-vikram-anand/) - [Can a Celebrity Influencer Work for Your Brand?](https://www.eversana.com/2024/10/22/can-a-celebrity-influencer-work-for-your-brand/) - [Want to launch a blockbuster? An AstraZeneca exec breaks it down.](https://www.eversana.com/2024/10/16/want-to-launch-a-blockbuster-an-astrazeneca-exec-breaks-it-down/) - [EVERSANA sets up shop in Germany with newest pharma commercialization services outpost](https://www.eversana.com/2024/10/09/eversana-sets-up-shop-in-germany-with-newest-pharma-commercialization-services-outpost/) - [Celebrating National Disability Employment Awareness Month: Fostering Inclusivity and Well-being](https://www.eversana.com/2024/10/30/disability-employment-awareness-month/) - [EVERSANA partners Oracle on pharmacovigilance platform](https://www.eversana.com/2024/10/11/eversana-partners-oracle-on-pharmacovigilance-platform/) - [Stand Out Leaders - Greg Skalicky](https://www.eversana.com/2024/10/08/stand-out-leaders-greg-skalicky/) - [Eversana expands European footprint by opening Berlin office](https://www.eversana.com/2024/10/07/eversana-expands-european-footprint-by-opening-berlin-office/) - [OpenAI’s new o1 Series models’ focus on “reasoning” and what it could mean to lifesciences brands and marketers](https://www.eversana.com/2024/10/03/openais-new-o1-series-models-focus-on-reasoning-and-what-it-could-mean-to-lifesciences-brands-and-marketers/) - [Specialty Pharmacy: The Trends Shaping Best Practices](https://www.eversana.com/2024/10/02/specialty-pharmacy-the-trends-shaping-best-practices/) - [Think Tank – Building Trust Equity](https://www.eversana.com/2024/09/30/think-tank-building-trust-equity/) - [Frontiers Health 2024](https://www.eversana.com/2024/09/19/frontiers-health-2024/) - [Celebrating Hispanic Heritage Month at EVERSANA: Honoring Diversity and Unity](https://www.eversana.com/2024/10/15/celebrating-hispanic-heritage-month-at-eversana-honoring-diversity-and-unity/) - [AusBiotech 2024](https://www.eversana.com/2024/10/07/ausbiotech-2024/) - EVERSANA is a proud sponsor of AusBiotech 2023 taking place 1-3 November in Brisbane. - [EVERSANA and pharmaphorum in conversation: ESMO 2024](https://www.eversana.com/2024/09/24/eversana-and-pharmaphorum-in-conversation-esmo-2024/) - [As Threads introduces ads, it’s time for advertisers to consider an all-Meta strategy](https://www.eversana.com/2024/09/05/as-threads-introduces-ads-its-time-for-advertisers-to-consider-an-all-meta-strategy/) - [ConTIPI Medical selects EVERSANA to support U.S. commercialization of non-surgical medical device ProVate for women with pelvic organ prolapse](https://www.eversana.com/2024/08/27/contipi-medical-selects-eversana-to-support-u-s-commercialization-of-non-surgical-medical-device-provate-for-women-with-pelvic-organ-prolapse-2/) - [Ask NAVLIN: The AI chatbot innovation driving a better global customer experience](https://www.eversana.com/2024/08/21/ask-navlin-the-ai-chatbot-innovation-driving-a-better-global-customer-experience/) - [Beyond the Buzz: Gauging the True Benefits of AI Today](https://www.eversana.com/2024/08/14/beyond-the-buzz-gauging-the-true-benefits-of-ai-today/) - [Navigating the evolution of precision medicine](https://www.eversana.com/2024/08/09/navigating-the-evolution-of-precision-medicine/) - [Think Tank: Mastering Metrics](https://www.eversana.com/2024/08/08/think-tank-mastering-metrics/) - [Real World Evidence and Life Science Analytics Conference](https://www.eversana.com/2024/09/16/real-world-evidence-and-life-science-analytics-conference-2/) - [Digital Health Coalition Live Summit at GSK](https://www.eversana.com/2024/09/16/digital-health-coalition-live-summit-at-gsk/) - Register to attend the Digital Health Coalition's Live Summit at GSK to hear first-hand insights about the future of patient engagement. - [Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky](https://www.eversana.com/2024/08/02/understanding-idns-and-what-they-mean-to-the-pharmaceutical-industry-qa-with-greg-skalicky/) - [EVERSANA Unveils TEDAVI, the Breakthrough Content Creation Hub to Transform Agency Marketing Models and Maximize Brand Impact](https://www.eversana.com/2024/08/02/eversana-unveils-tedavi-the-breakthrough-content-creation-hub-to-transform-agency-marketing-models-and-maximize-brand-impact-2/) - [EVERSANA unveils TEDAVI, the breakthrough content creation hub to transform agency marketing models and maximise brand impact](https://www.eversana.com/2024/08/01/eversana-unveils-tedavi-the-breakthrough-content-creation-hub-to-transform-agency-marketing-models-and-maximise-brand-impact/) - [Google's Change of Plans on Phasing Out Third-Party Cookies in Chrome and What it Means to Pharma Marketers](https://www.eversana.com/2024/07/25/googles-change-of-plans-on-phasing-out-third-party-cookies-in-chrome-and-what-it-means-to-pharma-marketers/) - [What does Google’s third-party cookies decision mean for medical marketers?](https://www.eversana.com/2024/07/24/what-does-googles-third-party-cookies-decision-mean-for-medical-marketers/) - [THINK TANK: Creating Better Rare Disease Patient Support Programs](https://www.eversana.com/2024/06/24/think-tank-creating-better-rare-disease-patient-support-programs/) - [Commercialisation in oncology: Challenges and innovative solutions for pharma manufacturers](https://www.eversana.com/2024/07/10/commercialisation-in-oncology-challenges-and-innovative-solutions-for-pharma-manufacturers/) - [AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman](https://www.eversana.com/2024/07/16/ais-role-in-drug-launches-operations-and-drug-pricing-qa-with-abid-rahman/) - [2024 Digital Therapeutics Alliance Summit](https://www.eversana.com/2024/05/17/2024-dta-summit/) - [EVERSANA CONSULTING Named a Forbes 2024 Top Management Consulting Firm in the United States](https://www.eversana.com/2024/03/18/eversana-consulting-named-a-forbes-2024-top-management-consulting-firm-in-the-united-states-2/) - [Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023](https://www.eversana.com/2023/10/31/evoke-pharma-eversana-unveil-cost-savings-real-world-data-demonstrating-meaningfully-reduced-healthcare-costs-for-patients-using-gimoti-over-oral-metoclopramide-presented-at-the-american-college-of/) - [MSL Society Conference](https://www.eversana.com/2024/06/25/msl-society-conference-3/) - [MSL Society Conference](https://www.eversana.com/2023/07/28/msl-society-conference-2/) - [Meet EVERSANA at Asembia 2024](https://www.eversana.com/2024/02/13/meet-eversana-at-asembia-2024/) - We leverage technology and automation to reduce access, affordability barriers, simplify onboarding, get patients on therapy faster and drive therapy adoption. - [Strategic Launch: Accelerating Innovative Therapies in the Chinese Market](https://www.eversana.com/2024/06/07/strategic-launch-chinese-market/) - [How Pharma Can Navigate the Tik Tok Ban: Q&A with Justin Chase](https://www.eversana.com/2024/06/05/how-pharma-can-navigate-the-tik-tok-ban-qa-with-justin-chase/) - [In an era of big patent losses, drug launches need years of runway](https://www.eversana.com/2024/06/03/in-an-era-of-big-patent-losses-drug-launches-need-years-of-runway/) - [Elite 2024 Tech-Know Geek Abid Rahman of EVERSANA](https://www.eversana.com/2024/05/23/elite-2024-tech-know-geek-abid-rahman-of-eversana/) - [Elite 2024 Data Miner Ramaa Nathan of EVERSANA](https://www.eversana.com/2024/05/22/elite-2024-data-miner-ramaa-nathan-of-eversana/) - [FOCUS ON: Connected TV](https://www.eversana.com/2024/05/22/focus-on-connected-tv/) - [MEDICAL AFFAIRS INDUSTRY LEADER MARY MANNA ANDERSON JOINS EVERSANA INTOUCH](https://www.eversana.com/2024/05/16/medical-affairs-industry-leader-mary-manna-anderson-joins-eversana-intouch/) - [Pioneering the Path Pre- and Post-Launch Strategies](https://www.eversana.com/2024/04/22/pioneering-the-path-pre-and-post-launch-strategies/) - [Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA](https://www.eversana.com/2024/04/19/will-synthetic-ai-based-digital-humans-change-pharma-and-life-sciences-qa-with-abid-rahman-svp-innovation-eversana/) - [Healthware re-launches as Eversana Intouch full service affiliate](https://www.eversana.com/2024/04/15/healthware-re-launches-as-eversana-intouch-full-service-affiliate/) - [ARCS Annual Conference](https://www.eversana.com/2024/06/05/arcs-annual-conference/) - [Our People Are Patients Too!](https://www.eversana.com/2024/06/05/our-people-are-patients-too/) - [Celebrating AANHPI Heritage Month at EVERSANA: Advancing Stories and Culture](https://www.eversana.com/2024/05/29/aanhpi-wrap-up/) - [HIMSS24 European Health Conference & Exhibition](https://www.eversana.com/2024/05/24/himss-24-european-health-conference-exhibition/) - [Radical Health Festival Helsinki 2024](https://www.eversana.com/2024/05/13/radical-health-festival-helsinki-2024/) - EVERSANA is proud to announce our participation in the upcoming Radical Health Festival Helsinki 2024. - [BIO International Convention 2024](https://www.eversana.com/2023/04/11/bio-2024/) - EVERSANA will be at BIO2024 and would love to meet with you to discuss a co-financing commercialization partnership. - [2024 American Society of Clinical Oncology Annual Meeting](https://www.eversana.com/2024/04/09/2024-american-society-of-clinical-oncology-annual-meeting/) - [2024 Midwest Reproductive Symposium International](https://www.eversana.com/2024/05/02/2024-midwest-reproductive-symposium-international/) - [Donor Egg Meeting 2024](https://www.eversana.com/2024/03/05/donor-egg-meeting-2024/) - [HBA New England Region Event: AI Innovation in Healthcare](https://www.eversana.com/2024/04/12/hba-new-england-region-event-ai-innovation-in-healthcare/) - [ISPOR 2024](https://www.eversana.com/2024/04/16/ispor-2024/) - [Monsters, dinosaurs and superheroes: Why pharma is bringing characters back into the ad mix](https://www.eversana.com/2024/04/09/monsters-dinosaurs-and-superheroes-why-pharma-is-bringing-characters-back-into-the-ad-mix/) - [INNOVATION AS A STRATEGY AND HOW THIS MINDSET CAN DRIVE CHANGE FOR LIFESCIENCES COMPANIES](https://www.eversana.com/2024/04/03/innovation-as-a-strategy-and-how-this-mindset-can-drive-change-for-lifesciences-companies/) - [Pharma is betting big on connecting potential patients to its medications. It's just the beginning](https://www.eversana.com/2024/04/02/pharma-is-betting-big-on-connecting-potential-patients-to-its-medications-its-just-the-beginning/) - [The Power of Patient Adherence Tools to Improve the Patient Journey](https://www.eversana.com/2024/04/02/the-power-of-patient-adherence-tools-to-improve-the-patient-journey/) - [Teva puts a face on tardive dyskinesia in latest Austedo XR spots](https://www.eversana.com/2024/04/01/teva-puts-a-face-on-tardive-dyskinesia-in-latest-austedo-xr-spots/) - [Pricing & Contracting USA](https://www.eversana.com/2024/04/01/pricing-contracting-usa/) - [Eversana to work with patient social network to help pharma speed time to diagnosis and treatment](https://www.eversana.com/2024/03/26/eversana-to-work-with-patient-social-network-to-help-pharma-speed-time-to-diagnosis-and-treatment/) - [EVERSANA AND MYHEALTHTEAM LAUNCH GROUNDBREAKING DIRECT-TO-PATIENT SOLUTION TO ACCELERATE TIME TO DIAGNOSIS AND TREATMENT](https://www.eversana.com/2024/03/25/eversana-and-myhealthteam-launch-groundbreaking-direct-to-patient-solution-to-accelerate-time-to-diagnosis-and-treatment-2/) - [Pharmatizing AI](https://www.eversana.com/2024/03/20/pharmatizing-ai/) - [FROM SXSW ’24: THE POWER OF CO-CREATION IN CULTIVATING AUTHENTICITY](https://www.eversana.com/2024/03/14/from-sxsw-24-the-power-of-co-creation-in-cultivating-authenticity/) - [Empowering Women: Reflecting on a Month of Inspiration at EVERSANA](https://www.eversana.com/2024/03/27/empowering-women-reflecting-on-a-month-of-inspiration-at-eversana/) - [PM360 SPARK Innovation Summit](https://www.eversana.com/2024/03/20/pm360-spark-2024-3/) - [Branding in the Digital Age: Q&A with Justin Chase, Executive Vice President of EVERSANA INTOUCH](https://www.eversana.com/2024/03/07/branding-in-the-digital-age-qa-with-justin-chase-executive-vice-president-of-eversana-intouch/) - [EVERSANA CONSULTING Named a Top Consulting Firm in Asia Pacific Region for the Second Consecutive Year](https://www.eversana.com/2024/02/22/eversana-consulting-named-a-top-consulting-firm-in-asia-pacific-region-for-the-second-consecutive-year-2/) - [PRIVACY ON SOCIAL COMES WITH A PRICE: HOW SUBSCRIPTIONS ARE CHANGING THE WAY WE CONSUME AND ADVERTISE ON SOCIAL MEDIA](https://www.eversana.com/2024/03/04/privacy-on-social-comes-with-a-price-how-subscriptions-are-changing-the-way-we-consume-and-advertise-on-social-media/) - [What AR (Augmented Reality) & Apple Vision Pro Could Mean to Health & Life Sciences Sector Navigating the New Reality](https://www.eversana.com/2024/02/08/what-ar-augmented-reality-apple-vision-pro-could-mean-to-health-life-sciences-sector-navigating-the-new-reality/) - [EVERSANA CONSULTING Named a Vault Top Ranked Consulting Firm in North America for the Third Consecutive Year](https://www.eversana.com/2024/02/08/eversana-consulting-named-a-vault-top-ranked-consulting-firm-in-north-america-for-the-third-consecutive-year-2/) - [Peeking Behind the Curtain: The Current State of Pharma 3PLs and Future Outlook](https://www.eversana.com/2024/02/02/peeking-behind-the-curtain-the-current-state-of-pharma-3pls-and-future-outlook/) - [The Hospital of the Future and How Data, Digital, and AI Will Merge to Make Care Better: Q&A With Dr. Pierantonio Russo, Chief Medical Officer, EVERSANA](https://www.eversana.com/2024/01/29/the-hospital-of-the-future-and-how-data-digital-and-ai-will-merge-to-make-care-better-qa-with-dr-pierantonio-russo-chief-medical-officer-eversana/) - [FROM THE MANHATTAN PROJECT TO AI: TRACING THE ETHICAL PARALLELS IN BUSINESS INNOVATION](https://www.eversana.com/2024/01/18/from-the-manhattan-project-to-ai-tracing-the-ethical-parallels-in-business-innovation/) - [EVERSANA NAMED 2024 BIG INNOVATION AWARD WINNER FOR ACTICS EACCESS](https://www.eversana.com/2024/01/11/eversana-named-2024-big-innovation-award-winner-for-actics-eaccess-2/) - [More Gen AI, Direct to Patient Models & Digital Health Top What’s On the Horizon in 2024: Q&A With Scott Snyder, Chief Digital Officer at EVERSANA](https://www.eversana.com/2024/01/10/more-gen-ai-direct-to-patient-models-digital-health-top-whats-on-the-horizon-in-2024-qa-with-scott-snyder-chief-digital-officer-at-eversana/) - [PharmaVoice’s Crystal Ball: Perspectives on the financial future](https://www.eversana.com/2024/01/09/pharmavoices-crystal-ball-perspectives-on-the-financial-future/) - [Shorla and Eversana launch Jylamvo](https://www.eversana.com/2023/12/19/shorla-and-eversana-launch-jylamvo/) - [Navigating the Extraordinary: EVERSANA’s Employees Speak Out About Their “Why” this Rare Disease Day](https://www.eversana.com/2024/02/28/navigating-the-extraordinary-eversanas-employees-speak-out-about-their-why-this-rare-disease-day/) - [Pharma Pricing Innovation Conference](https://www.eversana.com/2024/02/27/pharma-pricing-innovation-conference/) - [World EPA Congress](https://www.eversana.com/2024/02/12/world-epa-congress-2/) - [Pharma Europe 2024](https://www.eversana.com/2024/02/19/pharma-europe-2024/) - [Access Miami 2024](https://www.eversana.com/2024/02/01/access-miami-2024/) - [ACCESS USA](https://www.eversana.com/2024/01/17/access-usa-2/) - [BIO-Europe Spring 2024](https://www.eversana.com/2024/02/09/bio-europe-spring-2024/) - [DIA MASC 2024](https://www.eversana.com/2024/02/02/dia-masc-2024-2/) - [Pharma USA 2024](https://www.eversana.com/2024/01/17/pharma-usa-2024/) - [NAVLIN Insights Special Report: Three Mergers and Acquisitions Changing the Health Insurance Landscape for 2024](https://www.eversana.com/2024/02/05/navlin-insights-special-report-three-mergers-and-acquisitions-changing-the-health-insurance-landscape-for-2024/) - Three Mergers and Acquisitions Changing the Health Insurance Landscape for 2024 Three recent deals—Elevance Health’s proposed merger with Blue Cross Blue Shield of Louisiana (BCBS-LA), Health Care Service Corporation (HCSC)’s proposed acquisition of Cigna’s Medicare Advantage and PDP businesses, and Rite Aid’s sale of its PBM to MedImpact—are shaking up the health insurance landscape. The - [MAPS](https://www.eversana.com/2024/02/02/maps/) - [JP Morgan 42nd Annual Healthcare Conference](https://www.eversana.com/2023/10/30/jp-morgan-42nd-annual-healthcare-conference-2024/) - [65th ASH Annual Meeting and Exposition](https://www.eversana.com/2023/11/07/65th-ash-annual-meeting-and-exposition/) - [EVERSANA Gives Back](https://www.eversana.com/2023/12/20/44126-community-eversanagivesback/) - EVERSANA shines a spotlight on the inspiring efforts of our global team members who are dedicated to making a positive impact in their local communities. - [Clearing Away the Clutter: Implementing Value-Based Contracting in Pharma](https://www.eversana.com/2023/12/12/clearing-away-the-clutter-implementing-value-based-contracting-in-pharma/) - [Healthcare Agency Roundtable 2023: Moving into 2024](https://www.eversana.com/2023/12/11/healthcare-agency-roundtable-2023-moving-into-2024/) - [Think pharma ads have too many celebrities and jingles? Not many actually use them, study finds](https://www.eversana.com/2023/12/08/think-pharma-ads-have-too-many-celebrities-and-jingles-not-many-actually-use-them-study-finds/) - [Unveiling the Evolution: A thought leader's insights into the pharmacovigilance industry](https://www.eversana.com/2023/12/06/unveiling-the-evolution-a-thought-leaders-insights-into-the-pharmacovigilance-industry/) - [Eversana’s AWS alliance aims to cut red tape in pharma regulatory paperwork](https://www.eversana.com/2023/12/01/eversanas-aws-alliance-aims-to-cut-red-tape-in-pharma-regulatory-paperwork/) - [What’s on the Horizon in Pharma Marketing & Innovation: Q&A With Faruk Capan, Chief Innovation Officer at EVERSANA](https://www.eversana.com/2023/11/29/whats-on-the-horizon-in-pharma-marketing-innovation-qa-with-faruk-capan-chief-innovation-officer-at-eversana/) - [MarketingRx roundup: Pfizer adds holiday twist to Covid booster effort; Novavax signs up for sports](https://www.eversana.com/2023/11/27/marketingrx-roundup-pfizer-adds-holiday-twist-to-covid-booster-effort-novavax-signs-up-for-sports/) - [EVERSANA and Amazon Web Services Introduce Transformative Medical & Regulatory Review AI Solution](https://www.eversana.com/2023/11/27/eversana-and-amazon-web-services-introduce-transformative-medical-regulatory-review-ai-solution/) - [EVERSANA taps Adobe Firefly in quest to ‘pharmatise’ GenAI](https://www.eversana.com/2023/11/20/eversana-taps-adobe-firefly-in-quest-to-pharmatise-genai/) - [EVERSANA to use Adobe Firefly for enterprise in creative development & modular content production for life sciences marketing](https://www.eversana.com/2023/11/20/eversana-to-use-adobe-firefly-for-enterprise-in-creative-development-modular-content-production-for-life-sciences-marketing-2/) - [Beyond Borders: Celebrating Our Great Place To Work® Status](https://www.eversana.com/2023/11/17/beyond-borders-celebrating-our-great-place-to-work-status/) - [The 2023 PharmaVoice 100](https://www.eversana.com/2023/09/19/the-2023-pharmavoice-100/) - [How Pharma Brands Grow: An Evidence-based Approach to Pharma Brand Marketing](https://www.eversana.com/2023/09/21/how-pharma-brands-grow-an-evidence-based-approach-to-pharma-brand-marketing/) - [Navigating Health Insurance Coverage for Innovative and Specialty Drugs: Q&A With Maria Kirsch, President of Patients Services at EVERSANA](https://www.eversana.com/2023/10/02/navigating-health-insurance-coverage-for-innovative-and-specialty-drugs-qa-with-maria-kirsch-president-of-patients-services-at-eversana/) - [“Oh, oh, oh! Ozempic” turns five](https://www.eversana.com/2023/10/04/oh-oh-oh-ozempic-turns-five/) - [EVERSANA Expands Global Commercialization Capabilities and Strengthens Agency Network with Healthware Group Acquisition](https://www.eversana.com/2023/10/11/eversana-expands-global-commercialization-capabilities-and-strengthens-agency-network-with-healthware-group-acquisition/) - [EVERSANA snaps up Italian innovation consultancy Healthware Group](https://www.eversana.com/2023/10/12/eversana-snaps-up-italian-innovation-consultancy-healthware-group/) - [Media Retrenchment Is Opening a Window for Pharma to Rethink Ad Spend](https://www.eversana.com/2023/10/13/media-retrenchment-is-opening-a-window-for-pharma-to-rethink-ad-spend/) - [The Business Case for RWE](https://www.eversana.com/2023/10/31/the-business-case-for-rwe/) - [Jingle all the way? Pharma marketers adapt their music strategies for channels like TikTok](https://www.eversana.com/2023/10/17/jingle-all-the-way-pharma-marketers-adapt-their-music-strategies-for-channels-like-tiktok/) - [PM360 2023 Trailblazer Awards Interactive/Immersive Marketing Program Gold Winner The Chrysalis Initiative and EVERSANA INTOUCH](https://www.eversana.com/2023/11/13/pm360-2023-trailblazer-awards-interactive-immersive-marketing-program-gold-winner-the-chrysalis-initiative-and-eversana-intouch/) - [Could AI-generated key opinion leader videos become the norm? Market research says, Yes.](https://www.eversana.com/2023/11/03/could-ai-generated-key-opinion-leader-videos-become-the-norm-market-research-says-yes/) - [EVERSANA Expands Commercialization Capabilities](https://www.eversana.com/2023/10/19/eversana-expands-commercialization-capabilities/) - [An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs](https://www.eversana.com/2023/10/13/an-evolving-opinion-landscape-new-paths-and-synergies-for-pharma-kols-dols/) - [Trade and Channel Strategies](https://www.eversana.com/2023/11/13/trade-and-channel-strategies/) - [Celebrating National Disability Employment Awareness Month 2023 at EVERSANA: Embracing Employee Experiences](https://www.eversana.com/2023/11/03/celebrating-national-disability-employment-awareness-month-2023-at-eversana-embracing-employee-experiences/) - [BIO-Europe 2023](https://www.eversana.com/2023/10/12/bio-europe-2023/) - [EVERSANA to Present at the 41st Annual J.P. Morgan Healthcare Conference](https://www.eversana.com/2023/01/06/eversana-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/) - [World Orphan Drug Congress Europe 2023](https://www.eversana.com/2023/10/10/world-orphan-drug-congress-europe-2023/) - [Frontiers Health 2023](https://www.eversana.com/2023/10/11/frontiers-health-2023/) - [NAVLIN Insights Sneak Peek: Brand Access Landscape, Multiple Sclerosis Now Available](https://www.eversana.com/2023/10/19/navlin-insights-sneak-peek-brand-access-landscape-multiple-sclerosis-now-available/) - Brand Access Landscape: Multiple Sclerosis Unmet needs continue to exist even though the newest generation of Multiple Sclerosis (MS) disease-modifying therapies are considered safe and effective. Improving access in this market requires strong value propositions that tie back to unmet needs and/or dispel perceptions of limited intra-class differentiation. Understand the evolving multiple sclerosis market landscape - [Tender War Games Training](https://www.eversana.com/2023/10/19/tender-war-games-training/) - [ISPOR Europe 2023](https://www.eversana.com/2023/10/02/ispor-europe-2023/) - [NAVLIN Insights Sneak Peek: 340B for Specialty Pharmacies 2.0 Now Available](https://www.eversana.com/2023/10/17/navlin-insights-sneak-peek-340b-for-specialty-pharmacies-2-0-now-available/) - 340B for Specialty Pharmacies 2.0 - Vital, Uncertain, Misused Uncertainty surrounding the future of the 340B program is causing specialty pharmacies (SPs) to re-think operational enhancements, specifically around patient adherence services. Biopharma companies relying on SPs for adherence support may be forced to fill operational gaps to ensure patient adherence. Discover the latest trends in - [NAVLIN Insights Sneak Peek: Medicare Part B Payer Strategies Now Available](https://www.eversana.com/2023/10/17/navlin-insights-sneak-peek-channel-access-medicare-part-b-payer-strategies-now-available/) - Understanding Medicare Part B Payer Strategies Medicare Advantage payers juggle a broad set of legislative and regulatory policy changes, several of which, including high-impact IRA components, are compounded by the uncertainty of their eventual implementation. Payers expect these policies to result in changes to an array of market impacts, including new pressures to biopharma contracts - [Nordic Life Science Days 2023](https://www.eversana.com/2023/10/16/nlsday2023/) - [Real-World Evidence and Life Science Analytics Conference](https://www.eversana.com/2023/09/07/real-world-evidence-and-life-science-analytics-conference/) - [Gen AI: Generative and Synthetic Content in Life Sciences | ライフサイエンス領域における、生成AIを含めた実用化が期待されるエマージングテクノロジーの展望と活用](https://www.eversana.com/2023/10/05/webinar-gen-ai-generative-and-synthetic-content/) - [Agency Team Earns Awards at 2023 PM360 Trailblazer, MM+M Awards](https://www.eversana.com/2023/10/10/agency-team-earns-awards-at-2023-pm360-trailblazer-mmm-awards/) - [EVERSANA UNVEILS ACTICS EACCESS, NEW TECHNOLOGY-ENABLED EBV AND EPA PATIENT SUPPORT PLATFORM TO IMPROVE PATIENT ACCESS AND ACCELERATE SPEED TO THERAPY](https://www.eversana.com/2023/09/18/eversana-unveils-actics-eaccess-new-technology-enabled-ebv-and-epa-patient-support-platform-to-improve-patient-access-and-accelerate-speed-to-therapy-2/) - [Q&A with Jim Lang & Faruk Capan of EVERSANA and EVERSANA INTOUCH](https://www.eversana.com/2023/09/08/qa-with-jim-lang-faruk-capan-of-eversana-and-eversana-intouch/) - [Eversana debuts ‘operating system’ for targeting HCPs, patients](https://www.eversana.com/2023/09/05/eversana-debuts-operating-system-for-targeting-hcps-patients/) - [Q&A With EVERSANA Leaders on Bringing a Medical Information Chatbot to Life](https://www.eversana.com/2023/09/01/qa-with-eversana-leaders-on-bringing-a-medical-information-chatbot-to-life/) - [Reuters Pharma and Patient USA](https://www.eversana.com/2023/09/15/reuters-pharma-and-patient-usa/) - [AusBiotech 2023](https://www.eversana.com/2023/10/03/ausbiotech-2023/) - EVERSANA is a proud sponsor of AusBiotech 2023 taking place 1-3 November in Brisbane. - [Informa Copay, Reimbursement and Access Congress](https://www.eversana.com/2023/09/15/informa-copay-reimbursement-and-access-congress/) - [BioJapan 2023](https://www.eversana.com/2023/09/12/biojapan-2023/) - [DTx East](https://www.eversana.com/2023/09/13/dtx-east-2/) - [World Drug Safety Congress Europe](https://www.eversana.com/2023/09/07/world-drug-safety-congress-europe/) - [EPP Life Sciences Pricing Forum 2023](https://www.eversana.com/2023/09/19/epp-life-sciences-pricing-forum-2023/) - [EVERSANA Unveils ACTICS eAccess, New Technology-Enabled eBV and ePA Patient Support Platform to Improve Patient Access and Accelerate Speed to Therapy](https://www.eversana.com/2023/09/18/eversana-unveils-actics-eaccess-new-technology-enabled-ebv-and-epa-patient-support-platform-to-improve-patient-access-and-accelerate-speed-to-therapy/) - [Rare Diseases and Orphan Products Breakthrough Summit](https://www.eversana.com/2023/09/15/rare-diseases-and-orphan-products-breakthrough-summit-2/) - [Medicaid Drug Rebate Program Summit (MDRP)](https://www.eversana.com/2023/08/17/medicaid-drug-rebate-program-summit-mdrp/) - [EVERSANA Unveils EVERSANA ORCHESTRATE](https://www.eversana.com/2023/08/30/eversana-unveils-eversana-orchestrate/) - [Navigating the Complex Road Towards a Successful Commercialization](https://www.eversana.com/2023/08/11/navigating-the-complex-road-towards-a-successful-commercialization/) - [The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing](https://www.eversana.com/2023/08/02/the-ai-revolution-has-arrived-shaping-the-next-generation-of-pharma-marketing-2/) - [Unraveling the Path to Market in Canada: Q&A Addressing Seven Common Questions from Manufacturers](https://www.eversana.com/2023/08/01/unraveling-the-path-to-market-in-canada-qa-addressing-seven-common-questions-from-manufacturers/) - [EVERSANA and AWS Partner on AI Project: Q&A With Scott Snyder, Chief Digital Officer at EVERSANA](https://www.eversana.com/2023/07/31/eversana-and-aws-partner-on-ai-project-qa-with-scott-snyder-chief-digital-officer-at-eversana/) - [American Society for Reproductive Medicine 2023](https://www.eversana.com/2023/09/07/american-society-for-reproductive-medicine-2023/) - [World Drug Safety Congress Americas](https://www.eversana.com/2023/09/07/world-drug-safety-congress-americas/) - [Hub and Specialty Pharmacy Models East](https://www.eversana.com/2022/05/26/hub-and-specialty-pharmacy-models-east/) - [Copay, Reimbursement and Access Congress](https://www.eversana.com/2022/09/07/copay-reimbursement-access-congress/) - [EVERSANA Unveils EVERSANA ORCHESTRATE, Life Science Industry’s First End-to-End Omnichannel Solution Driving Brand Connectivity and Activating Commercialization Services](https://www.eversana.com/2023/08/30/eversana-unveils-eversana-orchestrate-life-science-industrys-first-end-to-end-omnichannel-solution-driving-brand-connectivity-and-activating-commercialization-services/) - EVERSANA today announced the launch of EVERSANA ORCHESTRATE, the life science industry’s first end-to-end omnichannel solution to amplify brand impact. - [Webinar: Empowering HTA in Europe: Unleashing the Potential of ITC, ECA & PROM Methods to Improve Access](https://www.eversana.com/2023/08/31/webinar-empowering-hta-in-europe-unleashing-the-potential-of-itc-eca-prom-methods-to-improve-access/) - [NAVLIN Insights Special Report: Department of Health and Human Services Releases Intended Targets for Medicare Price Negotiations](https://www.eversana.com/2023/08/31/navlin-insights-special-report-department-of-health-and-human-services-releases-intended-targets-for-medicare-price-negotiations/) - Surprises and Unanswered Questions in the List of Drugs Selected for Direct Negotiations What happened? The Department of Health and Human Services (HHS) released its intended targets for Medicare price negotiations on August 29, 2023, putting affected biopharmaceutical companies on official notice for lower Medicare reimbursements in 2026 (and possible market repercussions more immediately). Need - [Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting](https://www.eversana.com/2023/07/25/evoke-pharma-and-eversana-announce-abstract-selection-for-plenary-oral-presentation-at-the-american-college-of-gastroenterology-acg-2023-annual-meeting/) - [A Boomerang's Return: Ramaa Nathan, PhD, VP, Data Science & RWE Insights](https://www.eversana.com/2023/08/28/a-boomerangs-return-ramaa-nathan-data-science-rwe-insights/) - Discover the journey of Ramaa Nathan, Data Science & RWE, as she shares her boomerang experience. Explore how D&A is in her AND our DNA. - [NAVLIN Insights Special Report: Blue Shield of California Moves Against the Big 3 PBMs](https://www.eversana.com/2023/08/24/navlin-insights-news-alert-blue-shield-of-california-moves-against-the-big-3-pbms/) - Blue Shield of California Moves Against the Big 3 PBMs – But Not Without Their Help What is driving BS of CA’s decision to adopt a new PBM approach? BS of CA (Blue Shield of California), a prominent regional Blues plan with 4.8M members and $3.3B in drug spend as of 2022, has made a - [Celebrating Pride Month Across EVERSANA](https://www.eversana.com/2023/06/29/celebrating-pride-month-across-eversana/) - [NAVLIN Insights Sneak Peek: Channel Access - Leading Payer Evolution Report Now Available](https://www.eversana.com/2023/08/16/navlin-insights-sneak-peek-channel-access-leading-payer-evolution-report-now-available/) - Developing Value Propositions that Optimize Brand Access for Leading Payers Leading payers pursue strategies that evolve their business models, and approaches to care and drug management, such as clinical innovation, Medicare growth and more. Biopharma must understand the implications of these strategies to develop differentiated value propositions that optimize brand access. A full report with - [NAVLIN Insights Sneak Peek: New Market Access - Payer Medical Benefit Strategies Research Now Available](https://www.eversana.com/2023/07/07/navlin-insights-sneak-peek-new-channel-access-payer-medical-benefit-strategies-research-now-available/) - In the latest research from NAVLIN Insights, discover how medical benefit management and utilization management tactics are evolving and how drug coverage is impacted under the medical benefit. Understand how payers perceive the value of step therapy, preferred distribution channels, and site-of-care routing as utilization management tools. A full report with additional insights is available - [ISPOR 2023](https://www.eversana.com/2023/04/11/ispor-2023/) - [EVERSANA, Amazon Web Service Partner to Accelerate Artificial Intelligence Across Life Sciences Industry](https://www.eversana.com/2023/07/25/eversana-amazon-web-service-partner-to-accelerate-artificial-intelligence-across-life-sciences-industry/) - [MarketingRx roundup: Sanofi teases #DefeatMeningitis on social; Moderna launches mRNAMonday series on Threads](https://www.eversana.com/2023/07/25/marketingrx-roundup-sanofi-teases-defeatmeningitis-on-social-moderna-launches-mrnamonday-series-on-threads/) - [EVERSANA & AMAZON WEB SERVICES TO “PHARMATIZE” ARTIFICIAL INTELLIGENCE ACROSS THE LIFE SCIENCES INDUSTRY](https://www.eversana.com/2023/07/24/eversana-amazon-web-services-to-pharmatize-artificial-intelligence-across-the-life-sciences-industry-2/) - [Threads, the Twitter Competitor's Impact on Pharma Marketing: Q&A with Justin Chase](https://www.eversana.com/2023/07/18/threads-the-twitter-competitors-impact-on-pharma-marketing-qa-with-justin-chase/) - [The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing](https://www.eversana.com/2023/07/10/the-ai-revolution-has-arrived-shaping-the-next-generation-of-pharma-marketing/) - [EVERSANA & Amazon Web Services to “Pharmatize” Artificial Intelligence across the Life Sciences Industry](https://www.eversana.com/2023/07/24/eversana-amazon-web-services-to-pharmatize-artificial-intelligence-across-the-life-sciences-industry/) - [A Day in the Life: Mary Harbin, the Empowerment Enthusiast](https://www.eversana.com/2023/07/24/career-mary-harbin-empowerment-enthusiast/) - Meet Mary Harbin, Empowerment Enthusiast and Supervisor, Program Management at EVERSANA, in this 'Day in the Life' career interview. - [ASCO 2023](https://www.eversana.com/2023/05/11/asco-2023/) - [Eversana, China Resource Pharmaceutical Commercial Group Announce Global Partnership](https://www.eversana.com/2023/06/01/eversana-china-resource-pharmaceutical-commercial-group-announce-global-partnership/) - [Reaction from ASCO 2023: Breakthrough Cancer Brands Need Breakthrough Creative](https://www.eversana.com/2023/06/26/reaction-from-asco-2023-breakthrough-cancer-brands-need-breakthrough-creative/) - [Unpacking Inequality You Can’t Ignore, which won a Gold Pharma Lion at Cannes](https://www.eversana.com/2023/06/20/unpacking-inequality-you-cant-ignore-which-won-a-gold-pharma-lion-at-cannes/) - [Data-Driven Connections: Linking Rare Disease Patients to Clinical Trials, Experts, and Resources](https://www.eversana.com/2023/06/16/data-driven-connections-linking-rare-disease-patients-to-clinical-trials-experts-and-resources/) - [Agency 100 2023: EVERSANA INTOUCH](https://www.eversana.com/2023/06/12/agency-100-2023-eversana-intouch/) - [WHY FIGHTING CANCER MEANS FIGHTING CREATIVE CLICHES](https://www.eversana.com/2023/06/09/why-fighting-cancer-means-fighting-creative-cliches/) - [Shifting to Commercialization](https://www.eversana.com/2023/06/08/shifting-to-commercialization/) - [Q&A With Marty Culjat, PhD, Global Head of Digital Medicine & Regulatory Innovation at Eversana](https://www.eversana.com/2023/06/05/qa-with-marty-culjat-phd-global-head-of-digital-medicine-regulatory-innovation-at-eversana/) - [Innovation in Heart Disease: A Deep Dive](https://www.eversana.com/2023/06/01/innovation-in-heart-disease-a-deep-dive/) - [EVERSANA FORMS STRATEGIC ALLIANCE WITH CHINA RESOURCE PHARMACEUTICAL COMMERCIAL GROUP TO BRING NEW NOVEL TREATMENTS TO PATIENTS GLOBALLY](https://www.eversana.com/2023/06/01/eversana-forms-strategic-alliance-with-china-resource-pharmaceutical-commercial-group-to-bring-new-novel-treatments-to-patients-globally-2/) - [NAVLIN Insights Sneak Peek: New Patient Access - Biosimilar Boom Research Now Available](https://www.eversana.com/2023/07/18/navlin-insights-sneak-peek-new-patient-access-biosimilar-boom-research-now-available/) - Specialty Pharmacies and the Biosimilar Boom Understanding the various revenue streams of Specialty Pharmacy (SP) network partners is the key to identifying how biopharma can best incentivize SPs. A critical success factor for biosimilars is the ability to deploy unique contracting strategies that will not affect Average Sale Price (ASP). In the latest research from - [NAVLIN Insights Sneak Peek: New Channel Access - PBM and GPO Influence Research Now Available](https://www.eversana.com/2023/07/07/navlin-insights-sneak-peek-new-channel-access-pbm-and-gpo-influence-research-now-available/) - In the latest report from NAVLIN Insights, examine the evolving role of PBM-led GPOs and independent PBMs, with in-depth profiles of Ascent, Zinc, and Emisar. Gain actionable insights into PBM relationships with healthcare payers to support negotiations and formulary optimization. A full report with additional insights is available as part of the NAVLIN Insights subscription. - [NAVLIN Insights News Alert - Optum to Acquire Amedisys for $101 Per Share or ~$3.3 billion](https://www.eversana.com/2023/07/03/navlin-insights-news-alert-optum-to-acquire-amedisys-for-101-per-share-or-3-3-billion/) - On June 26, 2023, UnitedHealth Group’s Optum division outbid Option Care Health to acquire Amedisys. Upon completion of the deal (following shareholder and regulatory approval), Amedysis would fall under the Optum Health business segment of Optum. Optum Health provides wellness and consumer engagement programs/tools and health financial services and virtual, in-home, and clinic-based primary, specialty, - [EVERSANA INTOUCH Wins Gold at Cannes Lions International Festival of Creativity](https://www.eversana.com/2023/06/26/eversana-intouch-wins-gold-at-cannes-lions-international-festival-of-creativity/) - [2023 Midwest Reproductive Symposium International](https://www.eversana.com/2023/06/07/2023-midwest-reproductive-symposium-international/) - [2023 DIA China Annual Meeting](https://www.eversana.com/2023/06/06/2023-dia-china-annual-meeting/) - [FDA prepares rules for drug-related apps](https://www.eversana.com/2023/05/26/fda-prepares-rules-for-drug-related-apps/) - [Q&A With Scott Snyder, Chief Digital Officer at Eversana](https://www.eversana.com/2023/05/02/qa-with-scott-snyder-chief-digital-officer-at-eversana/) - [Yaral Pharma partners with EVERSANA](https://www.eversana.com/2023/05/22/yaral-pharma-partners-with-eversana/) - [YARAL PHARMA PARTNERS WITH EVERSANA TO SUPPORT THE COMMERCIALIZATION OF ITS EXPANDING GENERICS PORTFOLIO](https://www.eversana.com/2023/05/22/yaral-pharma-partners-with-eversana-to-support-the-commercialization-of-its-expanding-generics-portfolio/) - [Use Your Social Media Canvas to Engage, Educate and Empower](https://www.eversana.com/2023/05/25/use-your-social-media-canvas-to-engage-educate-and-empower/) - [Yaral Pharma Partners with EVERSANA to Support the Commercialization of its Expanded Generics Portfolio](https://www.eversana.com/2023/05/22/yaral-pharma-partners-with-eversana-to-support-the-commercialization-of-its-expanded-generics-portfolio/) - [Shorla Oncology, Eversana Introduce FDA-Approved Leukemia Treatment](https://www.eversana.com/2023/05/16/shorla-oncology-eversana-introduce-fda-approved-leukemia-treatment/) - [ELITE 2023 Data Miner Omnya El Massad of EVERSANA](https://www.eversana.com/2023/05/16/elite-2023-data-miner-omnya-el-massad-of-eversana/) - [Woman of Distinction 2023: Susan Perlbachs](https://www.eversana.com/2023/04/18/woman-of-distinction-2023-susan-perlbachs/) - [Women to Watch 2023](https://www.eversana.com/2023/04/18/women-to-watch-2023/) - [EVERSANA INTOUCH: 2023](https://www.eversana.com/2023/04/27/eversana-intouch-2023/) - [Pain Points: All the responses, part 2](https://www.eversana.com/2023/04/25/pain-points-all-the-responses-part-2/) - [Pain Points: All the responses, part 1](https://www.eversana.com/2023/04/25/pain-points-all-the-responses-part-1/) - [2023 CADTH Symposium](https://www.eversana.com/2023/04/20/2023-cadth-symposium/) - [Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources](https://www.eversana.com/2023/05/09/real-world-data-presented-by-evoke-pharma-and-eversana-at-digestive-disease-week-2023-shows-gimoti-meaningfully-reduces-utilization-of-healthcare-resources/) - [Recognizing National Nurses Week with Carla Yorro, RN, Clinical Nurse Coordinator](https://www.eversana.com/2023/05/05/recognizing-national-nurses-week-with-carla-yorro-rn-clinical-nurse-coordinator-2/) - [NAVLIN Insights Special Report: Kaiser Permanente launches Risant Health with Geisinger Health](https://www.eversana.com/2023/05/04/navlin-insights-special-report-kaiser-permanente-launches-risant-health-with-geisinger-health/) - [Phishing Scams and Cybersecurity: The Good and Bad of AI](https://www.eversana.com/2023/04/08/phishing-scams-and-cybersecurity-the-good-and-bad-of-ai/) - [Project seeks to shape digital health reimbursement in APAC](https://www.eversana.com/2023/03/23/project-seeks-to-shape-digital-health-reimbursement-in-apac/) - [EVERSANA Announces Partnership with ChemoMouthpiece, LLC](https://www.eversana.com/2023/03/24/eversana-announces-partnership-with-chemomouthpiece-llc/) - [EVERSANA ANNOUNCES PARTNERSHIP WITH CHEMOMOUTHPIECE, LLC TO SUPPORT U.S. LAUNCH & COMMERCIALIZATION OF MEDICAL DEVICE TO HELP CANCER PATIENTS MANAGE AND TREAT ORAL MUCOSITIS](https://www.eversana.com/2023/03/23/eversana-announces-partnership-with-chemomouthpiece-llc-to-support-u-s-launch-commercialization-of-medical-device-to-help-cancer-patients-manage-and-treat-oral-mucositis-2/) - [EVERSANA Named 2023 Artificial Intelligence Excellence Award Winner for Synthetic Content Program](https://www.eversana.com/2023/04/03/eversana-named-2023-artificial-intelligence-excellence-award-winner-for-synthetic-content-program-2/) - [Meet EVERSANA at Asembia 2023](https://www.eversana.com/2023/03/10/meet-eversana-at-asembia-2023/) - [Medicaid & Government Pricing Congress](https://www.eversana.com/2023/04/20/medicaid-government-pricing-congress-2/) - [EVERSANA Named 2023 Artificial Intelligence Excellence Award Winner for Synthetic Content Program](https://www.eversana.com/2023/03/30/eversana-named-2023-artificial-intelligence-excellence-award-winner-for-synthetic-content-program/) - [EVERSANA<sup>®</sup> Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis ](https://www.eversana.com/2023/03/23/eversana-announces-partnership-with-chemomouthpiece-llc-to-support-u-s-launch-commercialization-of-medical-device-to-help-cancer-patients-manage-and-treat-oral-mucositis/) - [APACMed Names EVERSANA<sup>®</sup> Knowledge Partner to Shape Digital Health Reimbursement Framework Across Region](https://www.eversana.com/2023/03/21/apacmed-names-eversana-knowledge-partner-to-shape-digital-health-reimbursement-framework-across-region/) - [Xspray Pharma Partners with EVERSANA<sup>®</sup> for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)](https://www.eversana.com/2023/02/23/xspray-pharma-partners-with-eversana-for-the-u-s-launch-and-commercialization-of-its-lead-product-dasynoc-xs004-for-the-treatment-of-chronic-myeloid-leukemia-cml-and-acute-lymphatic-leukem/) - [EVERSANA<sup>®</sup> CONSULTING Named a Top Ranked Consulting Firm by Vault Across Asia Pacific](https://www.eversana.com/2023/02/22/eversana-consulting-named-a-top-ranked-consulting-firm-by-vault-across-asia-pacific/) - [Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Analysis for Diabetic Gastroparesis Patients Treated with GIMOTI® Versus Oral Metoclopramide at the Digestive Disease Week Plenary Session](https://www.eversana.com/2023/02/21/evoke-pharma-and-eversana-selected-to-present-results-of-real-world-healthcare-utilization-analysis-for-diabetic-gastroparesis-patients-treated-with-gimoti-versus-oral-metoclopramide-at-the-dige/) - [EVERSANA CONSULTING Named a Best Boutique Consulting Firm by Vault For the Second Consecutive Year](https://www.eversana.com/2023/02/08/eversana-consulting-named-a-best-boutique-consulting-firm-by-vault-for-the-second-consecutive-year/) - [EVERSANA INTOUCH Wins Multiple 2023 PM360 Pharma Choice Awards](https://www.eversana.com/2023/02/01/eversana-intouch-wins-multiple-2023-pm360-pharma-choice-awards/) - [EVERSANA’s Direct-to-Patient Care Model Named One of The Most Innovative Strategies of 2022 by PM360](https://www.eversana.com/2022/12/15/eversanas-direct-to-patient-care-model-named-one-of-the-most-innovative-strategies-of-2022-by-pm360/) - [EVERSANA<sup>®</sup> Names Experienced Life Sciences Leader Sy Pretorius Chief Operating Officer & President, Outsourced Solutions to Propel Next-Generation Commercialization Services Worldwide](https://www.eversana.com/2022/11/14/eversana-names-experienced-life-sciences-leader-sy-pretorius-chief-operating-officer-president-outsourced-solutions-to-propel-next-generation-commercialization-services-worldwide/) - [EVERSANA<sup>®</sup> Named Great Place to Work Across Five Countries on Three Continents](https://www.eversana.com/2022/11/08/eversana-named-great-place-to-work-across-five-countries-on-three-continents/) - [EVERSANA INTOUCH Wins Best in Show at 2022 MM+M Awards](https://www.eversana.com/2022/10/07/eversana-intouch-wins-best-in-show-at-2022-mmm-awards/) - [Nemaura and EVERSANA<sup>®</sup> Sign Preliminary Agreement for Large-Scale Launch of Nemaura’s Diabetes Management Program in the U.S.](https://www.eversana.com/2022/09/27/nemaura-and-eversana-sign-preliminary-agreement-for-large-scale-launch-of-nemauras-diabetes-management-program-in-the-u-s/) - [Prosoma Digital Therapeutics and EVERSANA<sup>®</sup> Announce Commercialisation Partnership for New Therapeutic Supporting Mental Health and Behavioural Needs of Cancer Patients](https://www.eversana.com/2022/09/26/prosoma-digital-therapeutics-and-eversana-announce-commercialisation-partnership-for-new-therapeutic-supporting-mental-health-and-behavioural-needs-of-cancer-patients/) - [EVERSANA™ and Vector Pharma FZCO Announce Strategic Partnership to Expand Commercialisation Services Throughout Middle East and North Africa](https://www.eversana.com/2022/04/28/eversana-and-vector-pharma-fzco-announce-strategic-partnership-to-expand-commercialisation-services-throughout-middle-east-and-north-africa/) - [EVERSANA Announces European Expansion with New Location in the United Kingdom](https://www.eversana.com/2022/04/27/eversana-announces-european-expansion-with-new-location-in-the-united-kingdom/) - [EVERSANA’s Data & Analytics Platform ACTICS by EVERSANA Named a 2022 Artificial Intelligence Award Winner](https://www.eversana.com/2022/03/22/eversanas-data-analytics-platform-actics-by-eversana-named-a-2022-artificial-intelligence-award-winner/) - [EVERSANA™ MANAGEMENT CONSULTING Named a Best Boutique Consulting Firm by Vault](https://www.eversana.com/2022/02/23/eversana-management-consulting-named-a-best-boutique-consulting-firm-by-vault/) - [EVERSANA and Integra Connect Form Strategic Partnership to Advance Next Generation Oncology Commercialization Services Propelled by Real-World Evidence & Technology Platforms](https://www.eversana.com/2022/02/03/eversana-and-integra-connect-form-strategic-partnership-to-advance-next-generation-oncology-commercialization-services-propelled-by-real-world-evidence-technology-platforms/) - [OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders](https://www.eversana.com/2022/01/05/owp-pharmaceuticals-and-eversana-announce-partnership-to-commercialize-oral-liquid-formulations-to-treat-neuroscience-disorders/) - [EVERSANA’s Omnichannel Activation Model Named One of The Most Innovative Strategies of 2021 by PM360](https://www.eversana.com/2021/12/13/eversanas-omnichannel-activation-model-named-one-of-the-most-innovative-strategies-of-2021-by-pm360/) - [Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership](https://www.eversana.com/2021/11/08/q-biomed-bolsters-commercialization-of-strontium89-with-eversana-partnership/) - [MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders](https://www.eversana.com/2021/10/12/mindpax-and-eversana-announce-u-s-commercialization-partnership-to-launch-revolutionary-digital-therapeutic-solution-for-bipolar-disorders/) - [EVERSANA™ named a Great Place to Work for third consecutive year in U.S.; earns valuable recognition in Canada, China and India](https://www.eversana.com/2021/10/11/eversana-named-a-great-place-to-work-for-third-consecutive-year-in-u-s-earns-valuable-recognition-in-canada-china-and-india/) - [Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment](https://www.eversana.com/2021/08/17/shorla-pharma-announces-partnership-with-eversana-to-support-the-launch-and-commercialization-of-t-cell-leukemia-treatment/) - [EVERSANA announces strategic partnership with Roivant Sciences to advance commercialization services and predictive analytics for healthcare](https://www.eversana.com/2020/11/12/eversana-announces-strategic-partnership-with-roivant-sciences-to-advance-commercialization-services-and-predictive-analytics-for-healthcare/) - [A Day in the Life: Crystal Merklin, Supply Chain Savant](https://www.eversana.com/2023/04/05/a-day-in-the-life-crystal-merklin-supply-chain-savant/) - [A Day in the Life: Sean O’Connor, the Seller of Sellers](https://www.eversana.com/2023/02/10/a-day-in-the-life-sean-oconnor-the-seller-of-sellers/) - [PM360’s Masterclass of Storytelling 2023 EVERSANA INTOUCH and KindnessOverMD.org](https://www.eversana.com/2023/03/09/pm360s-masterclass-of-storytelling-2023-eversana-intouch-and-kindnessovermd-org/) - [2023 Greatest Creators Cover Competition Runners-Up](https://www.eversana.com/2023/03/09/2023-greatest-creators-cover-competition-runners-up/) - [SHORLA ONCOLOGY ANNOUNCES U.S. FDA APPROVAL OF NELARABINE INJECTION FOR THE TREATMENT OF T-CELL LEUKEMIA](https://www.eversana.com/2023/03/07/shorla-oncology-announces-u-s-fda-approval-of-nelarabine-injection-for-the-treatment-of-t-cell-leukemia/) - [MM+M names 2023 classes of Women of Distinction, Women to Watch](https://www.eversana.com/2023/03/06/mmm-names-2023-classes-of-women-of-distinction-women-to-watch/) - [The Promise and Peril of ChatGPT in Healthcare and Pharma Marketing](https://www.eversana.com/2023/02/24/the-promise-and-peril-of-chatgpt-in-healthcare-and-pharma-marketing/) - [Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product Dasynoc](https://www.eversana.com/2023/02/27/xspray-pharma-partners-with-eversana-for-the-u-s-launch-and-commercialization-of-its-lead-product-dasynoc/) - [Q and A With Greg Skalicky, president and chief revenue officer of EVERSANA](https://www.eversana.com/2023/02/22/q-and-a-with-greg-skalicky-president-and-chief-revenue-officer-of-eversana/) - [PM360 Greatest Creators Showcase 2023 Selection EVERSANA INTOUCH](https://www.eversana.com/2023/03/09/pm360-greatest-creators-showcase-2023-selection-eversana-intouch/) - [Generative AI’s Breakthrough Potential in Pharma Marketing](https://www.eversana.com/2023/03/10/generative-ais-breakthrough-potential-in-pharma-marketing/) - [Balancing Pharma Hiring Practices in Good Times and Bad](https://www.eversana.com/2023/03/10/balancing-pharma-hiring-practices-in-good-times-and-bad/) - [Pharma Europe 2023](https://www.eversana.com/2023/03/24/pharma-europe-2023/) - [7th Bio Partnering APAC](https://www.eversana.com/2023/03/16/7th-bio-partnering-apac/) - [Reuters Events: Pharma USA 2023](https://www.eversana.com/2023/02/06/reuters-events-pharma-usa-2023/) - [A Day in the Life: Anna Smith, the Trend Detective for NAVLIN Daily](https://www.eversana.com/2023/02/28/a-day-in-the-life-anna-smith-the-trend-detective-at-navlin-daily/) - [NAVLIN Insights Special Report - CVS Health to Acquire Oak Street Health](https://www.eversana.com/2023/03/01/navlin-insights-special-report-cvs-health-to-acquire-oak-street-health/) - [Access USA](https://www.eversana.com/2023/02/16/access-usa/) - [EVERSANA INTOUCH Wins Agency of the Year, Faruk Capan Named Advertising Agency CEO of the Year in PM360 Trailblazer Awards](https://www.eversana.com/2022/09/23/eversana-intouch-wins-agency-of-the-year-faruk-capan-named-advertising-agency-ceo-of-the-year-in-pm360-trailblazer-awards/) - [BIO-Europe Spring](https://www.eversana.com/2023/02/21/bio-europe-spring/) - [2023 Pharma Choice Philanthropic Gold Winner EVERSANA INTOUCH and The Chrysalis Initiative](https://www.eversana.com/2023/02/01/2023-pharma-choice-philanthropic-gold-winner-eversana-intouch-and-the-chrysalis-initiative/) - [2023 Pharma Choice Self-promotion/Corporate Campaign Silver Winner EVERSANA INTOUCH](https://www.eversana.com/2023/02/01/2023-pharma-choice-self-promotion-corporate-campaign-silver-winner-eversana-intouch/) - [2023 Pharma Choice App Gold Winner EVERSANA INTOUCH and The Chrysalis Initiative](https://www.eversana.com/2023/02/01/2023-pharma-choice-app-gold-winner-eversana-intouch-and-the-chrysalis-initiative/) - [MM+M Podcast 2.8.23: Eisai’s pricing transparency, GAO’s report on ‘gain-of-function’ research and MrBeast’s polarizing video](https://www.eversana.com/2023/02/08/mmm-podcast-2-8-23-eisais-pricing-transparency-gaos-report-on-gain-of-function-research-and-mrbeasts-polarizing-video/) - [2023 PM360 Pharma Choice Award Winners](https://www.eversana.com/2023/02/01/2023-pm360-pharma-choice-award-winners/) - [Inside the Pharma Name Game: Drug Word Choice Key to Building a Lasting Identity](https://www.eversana.com/2023/02/09/inside-the-pharma-name-game-drug-word-choice-key-to-building-a-lasting-identity/) - [ChatGPT and generative AI land in pharma marketing with sense of awe — and plenty of caution](https://www.eversana.com/2023/02/07/chatgpt-and-generative-ai-land-in-pharma-marketing-with-sense-of-awe-and-plenty-of-caution/) - [Disruptive Factors Shape RA Landscape](https://www.eversana.com/2023/02/09/disruptive-factors-shape-ra-landscape/) - [The Explosive Arrival of Chat GPT and Generative AI](https://www.eversana.com/2023/02/16/the-explosive-arrival-of-chat-gpt-and-generative-ai/) - [Can ChatGPT revolutionize pharma marketing?](https://www.eversana.com/2023/02/17/can-chatgpt-revolutionize-pharma-marketing/) - [EVERSANA Celebrates Black History Month 2023](https://www.eversana.com/2023/02/20/eversana-celebrates-black-history-month-2023/) - [DTx West 2023](https://www.eversana.com/2023/01/23/dtx-west-2023/) - [World EPA Congress](https://www.eversana.com/2023/02/08/world-epa-congress/) - [Taking Oncology Therapies to Market Requires Change in Commercialization Models](https://www.eversana.com/2023/01/26/taking-oncology-therapies-to-market-requires-change-in-commercialization-models/) - [40 Under 40: Sean Rapson, EVERSANA CONSULTING](https://www.eversana.com/2023/01/18/40-under-40-sean-rapson-eversana-consulting/) - [Q&A with Kelly Baker, CFO of EVERSANA](https://www.eversana.com/2023/01/04/qa-with-kelly-baker-cfo-of-eversana/) - [The 50th Annual Infusion Nursing Society Meeting](https://www.eversana.com/2023/01/30/the-50th-annual-infusion-nursing-society-meeting/) - [An Interview with Eric Terry on Martin Luther King Jr. Day, 2023](https://www.eversana.com/2023/01/13/an-interview-with-eric-terry-on-martin-luther-king-jr-day-2023/) - [PACT Digital Health Series: Connected Health & Patient Controlled Data](https://www.eversana.com/2023/01/12/pact-digital-health-series-connected-health-patient-controlled-data/) - [Exploring the Digital Therapeutics Landscape](https://www.eversana.com/2022/12/28/exploring-the-digital-therapeutics-landscape/) - [Trends in 2023: What's coming next in pharma marketing and drug commercialization?](https://www.eversana.com/2022/12/20/trends-in-2023-whats-coming-next-in-pharma-marketing-and-drug-commercialization/) - [Pharma and RWE: Hitting Its Stride](https://www.eversana.com/2022/12/08/pharma-and-rwe-hitting-its-stride/) - [Q&A With Jim Lang, CEO at Eversana](https://www.eversana.com/2022/12/13/qa-with-jim-lang-ceo-at-eversana/) - [Dr. Sy Pretorius, EVERSANA's New COO, is Flipping the Script on His Career](https://www.eversana.com/2022/12/09/dr-sy-pretorius-eversanas-new-coo-is-flipping-the-script-on-his-career/) - [PM360 2022 Innovative Strategy Direct-to-Patient Care Model from EVERSANA](https://www.eversana.com/2022/12/15/pm360-2022-innovative-strategy-direct-to-patient-care-model-from-eversana/) - [The State of National Healthcare Policy and Pricing Webinar 2023](https://www.eversana.com/2022/12/14/the-state-of-national-healthcare-policy-and-pricing-webinar-2023/) - [BIO Hong Kong 2022](https://www.eversana.com/2022/12/05/bio-hongkong22/) - [Pharma Japan 2022](https://www.eversana.com/2022/07/27/pharma-japan-2022/) - [Trade & Channel Strategies](https://www.eversana.com/2022/11/09/trade-channel-strategies/) - [NAVLIN Insights Special Report - Health Equity is the New Unmet Need of Payer-Pharma Relationships](https://www.eversana.com/2022/12/06/navlin-insights-special-report-health-equity-is-the-new-unmet-need-of-payer-pharma-relationships/) - [Executive changes at Teva, Eversana could spell commercial growth in the new year](https://www.eversana.com/2022/11/23/executive-changes-at-teva-eversana-could-spell-commercial-growth-in-the-new-year/) - [Engagement Opportunities in Healthcare’s Digital Front Door](https://www.eversana.com/2022/11/22/engagement-opportunities-in-healthcares-digital-front-door/) - [Eversana taps Sy Pretorius as COO and president, Outsourced Solutions](https://www.eversana.com/2022/11/14/eversana-taps-sy-pretorius-as-coo-and-president-outsourced-solutions/) - [EVERSANA NAMED GREAT PLACE TO WORK ACROSS FIVE COUNTRIES ON THREE CONTINENTS](https://www.eversana.com/2022/11/08/eversana-named-great-place-to-work-across-five-countries-on-three-continents-2/) - [What Pharma Companies Need to Know About Entering the Great White North](https://www.eversana.com/2022/10/27/what-pharma-companies-need-to-know-about-entering-the-great-white-north/) - [The medical metaverse is already here, but what does that mean for pharma?](https://www.eversana.com/2022/10/25/the-medical-metaverse-is-already-here-but-what-does-that-mean-for-pharma/) - [Two Key Questions About Data Analytics in 2022](https://www.eversana.com/2022/10/24/two-key-questions-about-data-analytics-in-2022/) - [Life Sciences Ontario: EVERSANA](https://www.eversana.com/2022/11/21/life-sciences-ontario-eversana/) - [Global Pricing Insights News Alert - Walgreens Boots Alliance's VillageMD to Purchase Summit Health](https://www.eversana.com/2022/11/15/global-pricing-insights-news-alert-walgreens-boots-alliances-villagemd-to-purchase-summit-health/) - [Global Pricing Insights News Alert - Elevance Health to Acquire BioPlus Specialty Pharmacy](https://www.eversana.com/2022/11/15/global-pricing-insights-news-alert-walgreens-boots-alliances-villagemd-to-purchase-summit-health-2/) - [ISPOR 2022](https://www.eversana.com/2022/04/27/ispor-2022/) - [ASH Annual Meeting & Exposition](https://www.eversana.com/2022/11/04/ash-annual-meeting-exposition/) - [World Orphan Drug Congress (WODC) Europe 2022](https://www.eversana.com/2022/10/20/world-orphan-drug-congress-wodc-europe-2022/) - [COMMERCIALIZATION OF DIGITAL THERAPEUTICS](https://www.eversana.com/2021/01/17/commercialization-of-digital-therapeutics/) - [AHA Scientific Sessions 2022](https://www.eversana.com/2022/10/20/aha-scientific-sessions-2022/) - [AusBiotech 2022](https://www.eversana.com/2022/10/19/ausbiotech-2022/) - [Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.](https://www.eversana.com/2022/09/28/nemaura-and-eversana-sign-preliminary-agreement-for-large-scale-launch-of-nemauras-diabetes-management-program-in-the-u-s-3/) - [Lab coats and microscopes in marketing: Does science still sell in pharma advertising?](https://www.eversana.com/2022/09/20/lab-coats-and-microscopes-in-marketing-does-science-still-sell-in-pharma-advertising/) - [Telehealth: Connecting the Dots](https://www.eversana.com/2022/10/07/telehealth-connecting-the-dots/) - [Betting The House on Orphans](https://www.eversana.com/2022/10/07/betting-the-house-on-orphans/) - [Prosoma taps EVERSANA to support commercialization of mental health digital therapy](https://www.eversana.com/2022/10/11/prosoma-taps-eversana-to-support-commercialization-of-mental-health-digital-therapy/) - [ISPOR Europe](https://www.eversana.com/2022/10/18/ispor-europe/) - [ASRM 2022](https://www.eversana.com/2022/10/17/asrm-2022/) - [Pharma/Biotech GTN Summit](https://www.eversana.com/2022/10/12/pharma-biotech-gtn-summit/) - [Pharma Europe 2022](https://www.eversana.com/2022/09/12/pharma-europe-2022/) - [Commercialising in the U.S. and Navigating Complexities Globally](https://www.eversana.com/2022/09/29/a-stong-partner-in-europe/) - [Special Report: Inflation Reduction Act Sets Part D Stakeholders Scrambling](https://www.eversana.com/2022/09/28/special-report-inflation-reduction-act-sets-part-d-stakeholders-scrambling/) - [NEMAURA AND EVERSANA SIGN PRELIMINARY AGREEMENT FOR LARGE-SCALE LAUNCH OF NEMAURA’S DIABETES MANAGEMENT PROGRAM IN THE U.S.](https://www.eversana.com/2022/09/27/nemaura-and-eversana-sign-preliminary-agreement-for-large-scale-launch-of-nemauras-diabetes-management-program-in-the-u-s-2/) - [PROSOMA DIGITAL THERAPEUTICS AND EVERSANA ANNOUNCE COMMERCIALIZATION PARTNERSHIP FOR NEW THERAPEUTIC SUPPORTING MENTAL HEALTH AND BEHAVIORAL NEEDS OF CANCER PATIENTS](https://www.eversana.com/2022/09/26/prosoma-digital-therapeutics-and-eversana-announce-commercialization-partnership-for-new-therapeutic-supporting-mental-health-and-behavioral-needs-of-cancer-patients/) - [Red Jacket: Jim Lang](https://www.eversana.com/2022/09/15/red-jacket-jim-lang/) - [Taking the Necessary Steps to Enhance the Patient Experience](https://www.eversana.com/2022/09/15/taking-the-necessary-steps-to-enhance-the-patient-experience/) - [Tricks for Navigating The ‘Talent War’ In Life Sciences](https://www.eversana.com/2022/09/09/tricks-for-navigating-the-talent-war-in-life-sciences/) - [Nothing to laugh about: What happened to humor in pharma advertising?](https://www.eversana.com/2022/09/06/nothing-to-laugh-about-what-happened-to-humor-in-pharma-advertising/) - [Flipping the script to disrupt, redefine and accelerate the patient care journey](https://www.eversana.com/2022/08/22/flipping-the-script-to-disrupt-redefine-and-accelerate-the-patient-care-journey/) - [EPP Life Sciences Pricing Forum](https://www.eversana.com/2022/09/23/epp-life-sciences-pricing-forum/) - [BIO-Europe 2022](https://www.eversana.com/2022/09/22/bio-europe-2022/) - [EVERSANA CEO Jim Lang Receives Prestigious PharmaVoice 100 Red Jacket Award](https://www.eversana.com/2022/09/15/eversana-ceo-jim-lang-receives-prestigious-pharmavoice-100-red-jacket-award/) - [Advancing the Adoption and Commercialization of Digital Medicines](https://www.eversana.com/2022/09/12/fall-2022-digital-medicines-therapeutics-conferences/) - [Global Pricing Insights - Last Week In Review - September 5 - 9, 2022](https://www.eversana.com/2022/09/13/global-pricing-insights-last-week-in-review-september-5-9-2022/) - [Rare Diseases and Orphan Products Breakthrough Summit](https://www.eversana.com/2022/09/12/rare-diseases-and-orphan-products-breakthrough-summit/) - [7th Annual CAR-TCR Summit](https://www.eversana.com/2022/07/27/7th-annual-car-tcr-summit/) - [Medicaid Drug Rebate Program](https://www.eversana.com/2022/09/07/medicaid-drug-rebate-program/) - [Global Pricing Insights - Last Week In Review - August 29 - September 2, 2022](https://www.eversana.com/2022/09/06/global-pricing-insights-last-week-in-review-august-29-september-2-2022/) - [Global Pricing Insights - Last Week In Review - August 22 - 26, 2022](https://www.eversana.com/2022/08/30/global-pricing-insights-last-week-in-review-august-22-26-2022/) - [Granfluencers and boomfluencers: Is the hipster oldster social media trend moving to pharma?](https://www.eversana.com/2022/08/02/granfluencers-and-boomfluencers-is-the-hipster-oldster-social-media-trend-moving-to-pharma/) - [Global Pricing Insights - Last Week In Review - August 15 - 19, 2022](https://www.eversana.com/2022/08/22/global-pricing-insights-last-week-in-review-august-15-19-2022/) - [Evoke, EVERSANA Expand Patient Access to Gimoti with New Telehealth Solution](https://www.eversana.com/2022/08/16/evoke-eversana-expand-patient-access-to-gimoti-with-new-telehealth-solution/) - [Real-World Data & Real-World Evidence - Not Just For Payers](https://www.eversana.com/2022/08/15/real-world-data-real-world-evidence-not-just-for-payers/) - [Securing Sales Solutions in Pharma](https://www.eversana.com/2022/08/11/securing-sales-solutions-in-pharma/) - [10 New Solutions, Strategies, and Devices to Boost Adherence](https://www.eversana.com/2022/08/10/10-new-solutions-strategies-and-devices-to-boost-adherence/) - [A medical marketing blind spot: LGBTQIA+ communities being left behind](https://www.eversana.com/2022/08/02/a-medical-marketing-blind-spot-lgbtqia-communities-being-left-behind/) - [MSL Society Conference](https://www.eversana.com/2022/08/18/msl-society-conference/) - [Global Pricing Insights - Last Week In Review - August 8 - 12, 2022](https://www.eversana.com/2022/08/15/global-pricing-insights-last-week-in-review-august-8-12-2022/) - [Global Pricing News Alert: German Cabinet Passes “Financial Stabilisation of the Statutory Health Insurance System” Bill](https://www.eversana.com/2022/08/04/global-pricing-news-alert-german-cabinet-passes-financial-stabilisation-of-the-statutory-health-insurance-system-bill/) - [Global Pricing Insights - Last Week In Review - July 25 - 29, 2022](https://www.eversana.com/2022/08/04/global-pricing-insights-last-week-in-review-july-25-29-2022/) - [EVERSANA Announces Partnership to Expand Commercialization Services across Asia Pacific](https://www.eversana.com/2022/07/14/eversana-announces-partnership-to-expand-commercialization-services-across-asia-pacific/) - [EVERSANA ANNOUNCES STRATEGIC PARTNERSHIP WITH COMPAI PHARMA TO EXPAND COMMERCIALIZATION SERVICES ACROSS THE ASIA PACIFIC REGION](https://www.eversana.com/2022/07/13/eversana-announces-strategic-partnership-with-compai-pharma-to-expand-commercialization-services-across-the-asia-pacific-region/) - [Nordic Life Science Days](https://www.eversana.com/2022/07/27/nordic-life-science-days/) - [DTx East 2022](https://www.eversana.com/2022/07/27/dtx-east-2022/) - [NACDS Total Store Expo](https://www.eversana.com/2022/07/27/nacds-total-store-expo/) - [EVERSANA, Accord BioPharma: launch of Camcevi prostate cancer treatment](https://www.eversana.com/2022/07/11/eversana-accord-biopharma-launch-of-camcevi-prostate-cancer-treatment/) - [Developing a Successful Data & Analytics Strategy: Four Common Questions](https://www.eversana.com/2022/07/11/developing-a-successful-data-analytics-strategy-four-common-questions/) - [Global Pricing Insights - Last Week In Review - July 18 - 22, 2022](https://www.eversana.com/2022/07/26/global-pricing-insights-last-week-in-review-july-18-22-2022/) - [EVERSANA™ Announces Strategic Partnership with Compai Pharma to Expand Commercialisation Services Across the Asia Pacific Region](https://www.eversana.com/2022/07/12/eversana-announces-strategic-partnership-with-compai-pharma-to-expand-commercialisation-services-across-the-asia-pacific-region/) - [Global Pricing Insights - Last Week In Review - July 4 - 8, 2022](https://www.eversana.com/2022/07/11/global-pricing-insights-last-week-in-review-july-4-8-2022/) - [Accord taps EVERSANA for Camcevi support](https://www.eversana.com/2022/07/01/accord-taps-eversana-for-camcevi-support/) - [ACCORD BIOPHARMA AND EVERSANA ANNOUNCE PARTNERSHIP TO SUPPORT THE LAUNCH OF CAMCEVI FOR THE TREATMENT OF ADVANCED PROSTATE CANCER IN ADULTS IN THE U.S.](https://www.eversana.com/2022/06/29/accord-biopharma-and-eversana-announce-partnership-to-support-the-launch-of-camcevi-for-the-treatment-of-advanced-prostate-cancer-in-adults-in-the-u-s-2/) - [Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI](https://www.eversana.com/2022/02/02/evoke-pharma-and-eversana-extend-commercialization-partnership-to-further-support-gimoti/) - [Accord BioPharma and EVERSANA Announce Partnership to Support the Launch of CAMCEVI® for the Treatment of Advanced Prostate Cancer in Adults in the U.S.](https://www.eversana.com/2022/06/29/accord-biopharma-and-eversana-announce-partnership-to-support-the-launch-of-camcevi-for-the-treatment-of-advanced-prostate-cancer-in-adults-in-the-u-s/) - [Alleviating the Complexities of Patient Care with Digital Innovation and One-on-One Connections](https://www.eversana.com/2022/06/22/alleviating-the-complexities-of-patient-care-with-digital-innovation-and-one-on-one-connections/) - [World Orphan Drug Congress USA](https://www.eversana.com/2022/06/21/world-orphan-drug-congress-usa/) - [Global Pricing Insights - Last Week In Review - June 20 - 24, 2022](https://www.eversana.com/2022/06/24/global-pricing-insights-last-week-in-review-june-20-24-2022/) - [Global Pricing Insights - Last Week In Review - June 13 - 17, 2022](https://www.eversana.com/2022/06/21/global-pricing-insights-last-week-in-review-june-13-17-2022/) - [EVERSANA: partnership with Limitless Minds](https://www.eversana.com/2022/06/16/eversana-partnership-with-limitless-minds/) - [MAKING MEDICAL INFORMATION CONTENT MATTER MORE THAN EVER](https://www.eversana.com/2022/06/15/making-medical-information-content-matter-more-than-ever/) - [Countdown to 2023 DSCSA Compliance](https://www.eversana.com/2022/06/10/countdown-to-2023-dscsa-compliance/) - [The Best New Platforms, Trends, and Advertising Strategies to Leverage in Social Media feat. Bonnie Southcott, EVERSANA INTOUCH Engage](https://www.eversana.com/2022/06/11/the-best-new-platforms-trends-and-advertising-strategies-to-leverage-in-social-media-feat-bonnie-southcott-eversana-intouch-engage/) - [EVERSANA UNVEILS EVERSANA INTOUCH, A NEXT-GENERATION AGENCY NETWORK DELIVERING AWARD-WINNING CREATIVE, DIGITAL, AND GLOBAL MARKET ACCESS SOLUTIONS FOR LIFE SCIENCES](https://www.eversana.com/2022/06/07/eversana-unveils-eversana-intouch-a-next-generation-agency-network-delivering-award-winning-creative-digital-and-global-market-access-solutions-for-life-sciences-3/) - [EVERSANA™ Unveils EVERSANA INTOUCH, a Next-Generation Agency Network Delivering Award-Winning Creative, Digital, and Global Market Access Solutions for Life Sciences](https://www.eversana.com/2022/06/07/eversana-unveils-eversana-intouch-a-next-generation-agency-network-delivering-award-winning-creative-digital-and-global-market-access-solutions-for-life-sciences-2/) - [Agency 100 2022: EVERSANA INTOUCH](https://www.eversana.com/2022/06/07/agency-100-2022-eversana-intouc/) - [EVERSANA and Limitless Minds Advance Pharmaceutical Sales Performance with New Cognitive & Behavioral Training Solution](https://www.eversana.com/2022/06/06/eversana-and-limitless-minds-advance-pharmaceutical-sales-performance-with-new-cognitive-behavioral-training-solution-3/) - [EVERSANA aims athletes’ mental coaching at pharma sales reps](https://www.eversana.com/2022/06/06/eversana-aims-athletes-mental-coaching-at-pharma-sales-reps/) - [EVERSANA AND LIMITLESS MINDS ADVANCE PHARMACEUTICAL SALES PERFORMANCE WITH NEW COGNITIVE & BEHAVIORAL TRAINING SOLUTION](https://www.eversana.com/2022/06/02/eversana-and-limitless-minds-advance-pharmaceutical-sales-performance-with-new-cognitive-behavioral-training-solution-2/) - [Global Pricing Insights - Last Week In Review - June 6 - 10 , 2022](https://www.eversana.com/2022/06/10/global-pricing-insights-last-week-in-review-june-6-10-2022/) - [Global Pricing News Alert: Quebec Unveils First Rare Disease Policy](https://www.eversana.com/2022/06/10/global-pricing-news-alert-quebec-unveils-first-rare-disease-policy/) - [MRSi 2022](https://www.eversana.com/2022/06/08/mrsi-2022/) - [EVERSANA™ Unveils EVERSANA INTOUCH, a Next-Generation Agency Network Delivering Award-Winning Creative, Digital, and Global Market Access Solutions for Life Sciences](https://www.eversana.com/2022/06/07/eversana-unveils-eversana-intouch-a-next-generation-agency-network-delivering-award-winning-creative-digital-and-global-market-access-solutions-for-life-sciences/) - [Global Pricing Insights - Last Week In Review - May 30 - June 3 , 2022](https://www.eversana.com/2022/06/06/global-pricing-insights-last-week-in-review-may-30-june-3-2022/) - [EVERSANA and Limitless Minds Advance Pharmaceutical Sales Performance with New Cognitive & Behavioral Training Solution](https://www.eversana.com/2022/06/02/eversana-and-limitless-minds-advance-pharmaceutical-sales-performance-with-new-cognitive-behavioral-training-solution/) - [EVERSANA ENGAGE: 2022](https://www.eversana.com/2022/05/02/eversana-engage-2022/) - [EVERSANA™ and Vector Pharma FZCO Announce Strategic Partnership to Expand Commercialisation Services Throughout Middle East and North Africa](https://www.eversana.com/2022/04/28/eversana-and-vector-pharma-fzco-announce-strategic-partnership-to-expand-commercialisation-services-throughout-middle-east-and-north-africa-2/) - [EVERSANA ANNOUNCES EUROPEAN EXPANSION WITH NEW LOCATION IN THE UNITED KINGDOM](https://www.eversana.com/2022/04/26/eversana-announces-european-expansion-with-new-location-in-the-united-kingdom-3/) - [EVERSANA AND VECTOR PHARMA FZCO ANNOUNCE STRATEGIC PARTNERSHIP TO EXPAND COMMERCIALIZATION SERVICES THROUGHOUT MIDDLE EAST AND NORTH AFRICA](https://www.eversana.com/2022/04/28/eversana-and-vector-pharma-fzco-announce-strategic-partnership-to-expand-commercialization-services-throughout-middle-east-and-north-africa/) - [Global Pricing Insights - Last Week In Review - May 23 - 27, 2022](https://www.eversana.com/2022/05/31/global-pricing-insights-last-week-in-review-may-23-27-2022/) - [HEART TO HEART INTERNATIONAL AND INTOUCH GROUP PARTNER TO PLACE MUCH-NEEDED LABS IN SAFETY-NET CLINICS](https://www.eversana.com/2022/05/05/heart-to-heart-international-and-intouch-group-partner-to-place-much-needed-labs-in-safety-net-clinics/) - [PM360 Elite: Amy Peek](https://www.eversana.com/2022/05/17/pm360-elite-amy-peek/) - [PM 360 Elite 100: Jim Lang & Faruk Capan](https://www.eversana.com/2022/05/17/pm-360-elite-100-jim-lang-faruk-capan/) - [Why ‘soft’ skills matter in the new era of leadership](https://www.eversana.com/2022/05/15/why-soft-skills-matter-in-the-new-era-of-leadership/) - [We're Just Getting Started - Catching up with Jim Lang, CEO, EVERSANA](https://www.eversana.com/2022/05/25/were-just-getting-started-catching-up-with-jim-lang-ceo-eversana/) - [BIO 2022](https://www.eversana.com/2022/05/06/bio-2022/) - [DTx Europe](https://www.eversana.com/2022/05/25/dtx-europe/) - [Global Pricing Insights - Last Week In Review - May 16 - 20, 2022](https://www.eversana.com/2022/05/20/global-pricing-insights-last-week-in-review-may-16-20-2022/) - [Four EVERSANA Leaders Named to 2022 PM360 ELITE 100](https://www.eversana.com/2022/05/17/four-eversana-leaders-named-to-2022-pm360-elite-100/) - [Data Scientists: Don’t Let Career Growth Keep You From Coding](https://www.eversana.com/2022/04/05/data-scientists-dont-let-career-growth-keep-you-from-coding/) - [EVERSANA Announces European Expansion with New Location in the United Kingdom](https://www.eversana.com/2022/04/27/eversana-announces-european-expansion-with-new-location-in-the-united-kingdom-2/) - [EVERSANA and UpScriptHealth Announce Integrated, Direct-to-Patient Platform, Transforming the Patient Journey to Accelerate Therapy Access, Affordability and Adherence](https://www.eversana.com/2022/04/14/eversana-and-upscripthealth-announce-integrated-direct-to-patient-platform-transforming-the-patient-journey-to-accelerate-therapy-access-affordability-and-adherence-2/) - [ASCO 2022](https://www.eversana.com/2022/05/05/asco-2022/) - [EVERSANA and UpScriptHealth Announce Direct-to-Patient Platform](https://www.eversana.com/2022/04/15/eversana-and-upscripthealth-announce-direct-to-patient-platform/) - [Medicaid & Government Pricing Congress](https://www.eversana.com/2022/04/29/medicaid-government-pricing-congress/) - [EVERSANA Pharma Pricing Innovation Conference 2022](https://www.eversana.com/2022/05/04/eversana-pharma-pricing-innovation-conference-2022/) - [Global Pricing Insights - Last Week In Review - April 25 - 29, 2022](https://www.eversana.com/2022/05/03/global-pricing-insights-last-week-in-review-april-25-29-2022/) - [The Pulse of Rare Disease Support](https://www.eversana.com/2022/04/08/the-pulse-of-rare-disease-support/) - [EVERSANA AND UPSCRIPTHEALTH ANNOUNCE INTEGRATED, DIRECT-TO-PATIENT PLATFORM, TRANSFORMING THE PATIENT JOURNEY TO ACCELERATE THERAPY ACCESS, AFFORDABILITY AND ADHERENCE](https://www.eversana.com/2022/04/14/eversana-and-upscripthealth-announce-integrated-direct-to-patient-platform-transforming-the-patient-journey-to-accelerate-therapy-access-affordability-and-adherence-3/) - [EVERSANA Announces European Expansion](https://www.eversana.com/2022/04/27/eversana-announces-european-expansion/) - [EVERSANA, UpScriptHealth ally on digital patient platform](https://www.eversana.com/2022/04/18/eversana-upscripthealth-ally-on-digital-patient-platform/) - [Improving Your Patient Support Programs for Expanded Affordability](https://www.eversana.com/2022/04/27/improving-your-patient-support-programs-for-expanded-affordability/) - [EVERSANA, UpScriptHealth partner to improve patient experience, access](https://www.eversana.com/2022/04/15/eversana-upscripthealth-partner-to-improve-patient-experience-access/) - [EVERSANA: ACTICS named Artificial Intelligence Award winner](https://www.eversana.com/2022/04/21/eversana-actics-named-artificial-intelligence-award-winner/) - [A New Approach to the Commercialization Challenges Facing the Oncology Industry](https://www.eversana.com/2022/04/08/a-new-approach-to-the-commercialization-challenges-facing-the-oncology-industry/) - [With pharma still struggling in Alzheimer’s, health tech companies want a swing](https://www.eversana.com/2022/03/31/25797/) - [Global Pricing Insights - Last Week In Review - April 18 - 22, 2022](https://www.eversana.com/2022/04/26/global-pricing-insights-last-week-in-review-april-18-22-2022/) - [Global Pricing News Alert - Saudi Arabia’s New Clinical Guidelines Could Influence Drug Pricing Decisions](https://www.eversana.com/2022/04/22/global-pricing-news-alert-saudi-arabias-new-clinical-guidelines-could-influence-drug-pricing-decisions/) - [Pharma Partnering Summit 2022](https://www.eversana.com/2022/04/20/pharma-partnering-summit-2022/) - [Global Pricing Insights - Last Week In Review - April 11 - 15, 2022](https://www.eversana.com/2022/04/20/global-pricing-insights-last-week-in-review-april-11-15-2022/) - [EVERSANA and UpScriptHealth Announce Integrated, Direct-to-Patient Platform, Transforming the Patient Journey to Accelerate Therapy Access, Affordability and Adherence](https://www.eversana.com/2022/04/14/eversana-and-upscripthealth-announce-integrated-direct-to-patient-platform-transforming-the-patient-journey-to-accelerate-therapy-access-affordability-and-adherence/) - [Global Pricing News Alert - EMA, EUnetHTA Publish Priorities for Upcoming Joint HTA](https://www.eversana.com/2022/04/14/global-pricing-news-alert-ema-eunethta-publish-priorities-for-upcoming-joint-hta/) - [Global Pricing Insights - Last Week In Review - April 4 - 8, 2022](https://www.eversana.com/2022/04/08/global-pricing-insights-last-week-in-review-april-4-8-2022/) - [Join EVERSANA at BIO-Europe Spring 2022](https://www.eversana.com/2022/03/14/bio-europe-spring-2022/) - [Global Pricing Insights - Last Week In Review - March 28 - Apr 1, 2022](https://www.eversana.com/2022/04/02/global-pricing-insights-last-week-in-review-march-28-apr-1-2022/) - [Global Pricing Insights - Last Week In Review - March 21 - 25, 2022](https://www.eversana.com/2022/03/28/global-pricing-insights-last-week-in-review-march-21-25-2022/) - [EVERSANA’S DATA & ANALYTICS PLATFORM ACTICS BY EVERSANA NAMED A 2022 ARTIFICIAL INTELLIGENCE AWARD WINNER](https://www.eversana.com/2022/03/22/eversanas-data-analytics-platform-actics-by-eversana-named-a-2022-artificial-intelligence-award-winner-2/) - [Think global, act local: rethinking commercialisation models](https://www.eversana.com/2022/03/17/think-global-act-local-rethinking-commercialisation-models/) - [30 Years of 3PL](https://www.eversana.com/2022/03/21/30-years-of-3pl/) - [Global Pricing Insights - Last Week In Review - March 14 - 18, 2022](https://www.eversana.com/2022/03/21/global-pricing-insights-last-week-in-review-march-14-18-2022/) - [EVERSANA patient enrollment platform targets hard to reach populations](https://www.eversana.com/2022/03/16/eversana-patient-enrollment-platform-targets-hard-to-reach-populations/) - [Eversana debuts pricing/access platform](https://www.eversana.com/2022/03/17/eversana-debuts-pricing-access-platform/) - [EVERSANA Launches Global Price and Market Access Solution](https://www.eversana.com/2022/03/17/eversana-launches-global-price-and-market-access-solution/) - [EVERSANA unveils global price and market access solution NAVLIN by EVERSANA](https://www.eversana.com/2022/03/17/eversana-unveils-global-price-and-market-access-solution-navlin-by-eversana/) - [Reuters Events: Pharma USA 2022](https://www.eversana.com/2022/02/24/reuters-events-pharma-usa-2022/) - [Global Pricing Insights - Last Week In Review - March 7 - 11, 2022](https://www.eversana.com/2022/03/15/global-pricing-insights-last-week-in-review-march-7-11-2022/) - [Visit EVERSANA at World EPA Congress](https://www.eversana.com/2022/03/10/visit-eversana-at-world-epa-congress/) - [Succeed when others fail: Avoiding 20% in investment waste during launch](https://www.eversana.com/2022/03/07/succeed-when-others-fail-avoiding-20-in-investment-waste-during-launch/) - [EVERSANA, THREAD connect RWD and decentralized trial platforms](https://www.eversana.com/2022/03/07/eversana-thread-connect-rwd-and-decentralized-trial-platforms/) - [Global Pricing Insights - Last Week In Review - Feb 28 - March 1, 2022](https://www.eversana.com/2022/03/07/global-pricing-insights-last-week-in-review-feb-28-march-1-2022/) - [‘Alexa, I want to talk to a doctor’: Amazon, Teladoc partner on virtual care](https://www.eversana.com/2022/03/03/alexa-i-want-to-talk-to-a-doctor-amazon-teladoc-partner-on-virtual-care/) - [Global Pricing Insights - Last Week In Review - Feb 21 - 25, 2022](https://www.eversana.com/2022/02/25/global-pricing-insights-last-week-in-review-feb-21-25-2022/) - [News Alert: G-BA’s 2022 Work Program Anticipates Changes Under GSAV](https://www.eversana.com/2022/02/25/news-alert-g-bas-2022-work-program-anticipates-changes-under-gsav/) - [News Alert: Orchard Therapeutics Agrees to Have Libmeldy Assessed via BeNeLuXa](https://www.eversana.com/2022/02/25/news-alert-orchard-therapeutics-agrees-to-have-libmeldy-assessed-via-beneluxa/) - [News Alert: Quebec Court of Appeal Rules Against PMPRB Amendments](https://www.eversana.com/2022/02/23/news-alert-quebec-court-of-appeal-rules-against-pmprb-amendments/) - [Thread, Eversana join forces on real-world data platform](https://www.eversana.com/2022/02/16/thread-eversana-join-forces-on-real-world-data-platform/) - [Thread, Eversana partner to offer real-world data-driven solution](https://www.eversana.com/2022/02/18/thread-eversana-partner-to-offer-real-world-data-driven-solution/) - [Eversana, Thread Collaborate on Decentralized Registry Deal](https://www.eversana.com/2022/02/16/eversana-thread-collaborate-on-decentralized-registry-deal/) - [News Alert: China VBP Round 7 Includes 58 Varieties Covering 208 Product Specifications](https://www.eversana.com/2022/02/17/news-alert-china-vbp-round-7-includes-58-varieties-covering-208-product-specifications/) - [THREAD and EVERSANA Announce Industry’s First Integrated, Decentralized Registry and Real-World Data (RWD)-Driven Evidence and Commercialization Solution](https://www.eversana.com/2022/02/16/thread-and-eversana-announce-industrys-first-integrated-decentralized-registry-and-real-world-data-rwd-driven-evidence-and-commercialization-solution/) - [DTx West](https://www.eversana.com/2022/02/14/dtx-west/) - [Global Pricing Insights - Last Week In Review - Feb 7 - 11, 2022](https://www.eversana.com/2022/02/14/global-pricing-insights-last-week-in-review-feb-7-11-2022/) - [EVERSANA and Integra Connect Form Strategic Partnership](https://www.eversana.com/2022/02/03/eversana-and-integra-connect-form-strategic-partnership/) - [Evoke Pharma and EVERSANA Extend Commercialization Partnership](https://www.eversana.com/2022/02/02/evoke-pharma-and-eversana-extend-commercialization-partnership/) - [Global Pricing Insights - Last Week In Review - Jan 31 - Feb 4, 2022](https://www.eversana.com/2022/02/05/global-pricing-insights-last-week-in-review-jan-31-feb-4-2022/) - [Global Pricing Insights - Last Week In Review - Jan 24 - 28, 2022](https://www.eversana.com/2022/01/31/global-pricing-insights-last-week-in-review-jan-24-28-2022/) - [EVERSANA Announces Real-World Data Agreement with Janssen to Augment Development of Chronic Disease Care Therapies](https://www.eversana.com/2021/12/16/eversana-announces-real-world-data-agreement-with-janssen-to-augment-development-of-chronic-disease-care-therapies/) - [Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council](https://www.eversana.com/2021/06/29/evoke-pharma-eversana-and-the-international-foundation-for-gastrointestinal-disorders-announce-membership-into-iffgds-industry-council/) - [EVERSANA Named PM360 Trailblazer Award Winner In 2021 For Both Data & Analytics Innovation and Engaging Sales Collateral](https://www.eversana.com/2021/09/27/eversana-named-pm360-trailblazer-award-winner-in-2021-for-both-data-analytics-innovation-and-engaging-sales-collateral/) - [EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization](https://www.eversana.com/2021/10/20/eversana-and-intouch-group-join-forces-adding-the-premiere-digital-first-agency-network-to-the-market-leader-in-next-generation-commercialization/) - [EVERSANA completes acquisition of Intouch Group, adds the premiere digital-first agency network to the market leader in next generation commercialization](https://www.eversana.com/2021/12/21/eversana-completes-acquisition-of-intouch-group-adds-the-premiere-digital-first-agency-network-to-the-market-leader-in-next-generation-commercialization/) - [News Alert: NICE to Make Therapy Assessments More “Flexible” With Amendments](https://www.eversana.com/2022/01/20/news-alert-nice-to-make-therapy-assessments-more-flexible-with-amendments/) - [Global Pricing Insights - Last Week In Review - Jan 10 - 14, 2022](https://www.eversana.com/2022/01/17/global-pricing-insights-last-week-in-review-jan-10-14-2022/) - [Virtual Webinar: The State of National Healthcare Policy & Pricing](https://www.eversana.com/2022/01/13/webinar-the-state-of-national-healthcare-policy-pricing/) - [News Alert: CMS Proposes Coverage for Biogen's Aduhelm for Patients Enrolled in Qualifying Clinical Trials](https://www.eversana.com/2022/01/12/news-alert-cms-proposes-coverage-for-biogens-aduhelm/) - [America's Most Loved Workplaces 2021](https://www.eversana.com/2022/01/04/americas-most-loved-workplaces-2021/) - [Meet the ‘most loved’ healthcare companies](https://www.eversana.com/2022/01/04/meet-the-most-loved-healthcare-companies/) - [Overcoming Life Sciences Marketers’ Common Data Pain Points](https://www.eversana.com/2022/01/04/overcoming-life-sciences-marketers-common-data-pain-points/) - [Adheris Health and Improved Patient Outcomes Inc. Partner Up](https://www.eversana.com/2022/01/04/adheris-health-and-improved-patient-outcomes-inc-partner-up/) - [Reimagining the SpecialtyRx Patient Journey Through the Lens of a Digital Consumer](https://www.eversana.com/2022/01/04/reimagining-the-specialtyrx-patient-journey-through-the-lens-of-a-digital-consumer/) - [SHOWCASE: Patient Engagement: Digital Control: Putting Solutions Into the Hands of Patients](https://www.eversana.com/2022/01/04/showcase-patient-engagement-digital-control-putting-solutions-into-the-hands-of-patients/) - [Bridging the Patient Support Gap With Integrated Technology Solutions and Strategies](https://www.eversana.com/2022/01/04/bridging-the-patient-support-gap-with-integrated-technology-solutions-and-strategies/) - [EVERSANA Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)](https://www.eversana.com/2022/01/04/eversana-announces-membership-in-european-confederation-of-pharmaceutical-entrepreneurs-eucope/) - [Artrya Announces UK Commercialisation Partnership with EVERSANA](https://www.eversana.com/2022/01/04/artrya-announces-uk-commercialisation-partnership-with-eversana/) - [Measuring the Impact of Coordinated Field and Digital Engagement](https://www.eversana.com/2022/01/03/measuring-the-impact-of-coordinated-field-and-digital-engagement/) - [Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership](https://www.eversana.com/2022/01/03/q-biomed-bolsters-commercialization-of-strontium89-with-eversana-partnership-2/) - [Special Report: Pharma Under Fire in House Oversight Drug Pricing Report](https://www.eversana.com/2021/12/15/special-report-pharma-under-fire-in-house-oversight-drug-pricing-report/) - [Join EVERSANA at the Trade & Channel Conference](https://www.eversana.com/2021/10/27/trade-and-channel-conference-2021/) - [News Alert: China’s 2021 NRDL Welcomes 67 New Additions at an Average 62% Price Reduction](https://www.eversana.com/2021/12/06/news-alert-chinas-2021-nrdl-welcomes-67-new-additions-at-an-average-62-price-reduction/) - [News Alert: VFA Says Germany’s Innovation Environment “Unnecessarily Jeopardized” by Coalition Government’s Plans](https://www.eversana.com/2021/11/30/news-alert-vfa-says-germanys-innovation-environment-unnecessarily-jeopardized-by-coalition-governments-plans/) - [Australian AI Company Artrya Announces Major UK Commercialisation Partnership With EVERSANA](https://www.eversana.com/2021/11/23/australian-ai-company-artrya-announces-major-uk-commercialisation-partnership-with-eversana/) - [Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States](https://www.eversana.com/2020/10/15/mirum-pharmaceuticals-announces-partnership-with-eversana-to-support-launch-and-commercialization-of-maralixibat-for-alagille-syndrome-in-the-united-states/) - [Evoke and EVERSANA Announce Commercial Launch of Gimoti™](https://www.eversana.com/2020/10/26/evoke-and-eversana-announce-commercial-launch-of-gimoti/) - [Global Pricing Insights - Last Week In Review - Nov 15 - 19, 2021](https://www.eversana.com/2021/11/22/global-pricing-insights-last-week-in-review-nov-15-19-2021/) - [EVERSANA Acquires Protean; strengthens operational strategy and excellence in market access, channel and patient services](https://www.eversana.com/2021/10/15/eversana-acquires-protean-strengthens-operational-strategy-and-excellence-in-market-access-channel-and-patient-services/) - [News Alert: Pfizer & Medicines Patent Pool Ink Agreement for Pfizer’s COVID-19 Oral Antiviral](https://www.eversana.com/2021/11/18/news-alert-pfizer-medicines-patent-pool-ink-agreement-for-pfizers-covid-19-oral-antiviral/) - [Global Pricing Insights - Last Week In Review - Nov 8 - 12, 2021](https://www.eversana.com/2021/11/15/global-pricing-insights-last-week-in-review-nov-8-12-2021/) - [News Alert: G-BA Restricts Use of Novartis’s Leqvio in Germany](https://www.eversana.com/2021/11/12/news-alert-g-ba-restricts-use-of-novartis-leqvio-in-germany/) - [EVERSANA at Virtual ISPOR Europe 2021](https://www.eversana.com/2021/11/09/eversana-at-virtual-ispor-europe-2021/) - [Global Pricing Insights - Last Week In Review - Nov 1 - 5, 2021](https://www.eversana.com/2021/11/05/global-pricing-insights-last-week-in-review-nov-1-5-2021-2/) - [Join EVERSANA at the Gross-to-Net Summit](https://www.eversana.com/2021/10/27/gross-to-net-summit-2021/) - [Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)](https://www.eversana.com/2021/11/04/membership-in-european-confederation-of-pharmaceutical-entrepreneurs-eucope/) - [News Alert: Democrats’ Prescription Drug Pricing Deal Allows Medicare to Negotiate Prices for 30 Drugs by 2028](https://www.eversana.com/2021/11/03/democrats-prescription-drug-pricing-deal/) - [World Orphan Drug Congress Europe 2021](https://www.eversana.com/2021/11/02/world-orphan-drug-congress-europe-2021/) - [Global Pricing Insights - Last Week In Review - Oct 25 - 29, 2021](https://www.eversana.com/2021/11/01/global-pricing-insights-last-week-in-review-oct-25-29-2021/) - [News Alert: Germany’s largest statutory health insurance fund negotiates rebates of more than 99% for some generics](https://www.eversana.com/2021/10/28/news-alert-largest-german-statutory-health-insurance-fund-negotiates-rebates/) - [Global Pricing Insights - Last Week In Review - Oct 18 - 22, 2021](https://www.eversana.com/2021/10/22/global-pricing-insights-last-week-in-review-oct-18-22-2021-2/) - [News Alert: 4th Draft of Northern Ireland Protocol Focuses on “Uninterrupted Security of Supply of Medicines”](https://www.eversana.com/2021/10/21/news-alert-northern-ireland-protocol-focuses-on-supply-of-medicines/) - [Evoke Pharma Reports Second Quarter 2021 Financial Results](https://www.eversana.com/2021/08/12/evoke-pharma-reports-second-quarter-2021-financial-results/) - [Three Tips for Navigating Post-Approval Pharmacovigilance](https://www.eversana.com/2021/08/09/three-tips-for-navigating-post-approval-pharmacovigilance/) - [Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment](https://www.eversana.com/2021/08/17/shorla-pharma-announces-partnership-with-eversana-to-support-the-launch-and-commercialization-of-t-cell-leukemia-treatment-2/) - [ArisGlobal Announces Leading Speakers for Breakthrough 2021 Conference](https://www.eversana.com/2021/09/15/arisglobal-announces-leading-speakers-for-breakthrough-2021-conference/) - [Digital Therapeutics Alliance Announces New Resource Partner Program to Accelerate Access and Impact of Digital Therapeutics for Patients Worldwide](https://www.eversana.com/2021/09/23/digital-therapeutics-alliance-announces-new-resource-partner-program-to-accelerate-access-and-impact-of-digital-therapeutics-for-patients-worldwide-2/) - [The PM360 Magazine Trailblazer Awards 2021 Winners](https://www.eversana.com/2021/09/23/the-pm360-magazine-trailblazer-awards-2021-winners/) - [Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI](https://www.eversana.com/2021/09/29/evoke-pharmas-commercial-partner-eversana-receives-pm360s-trailblazer-initiative-award-for-innovation-in-healthcare-marketing-for-gimoti/) - [Filling Gaps in the Patient Experience Exposed by COVID](https://www.eversana.com/2021/09/11/filling-gaps-in-the-patient-experience-exposed-by-covid/) - [When Choosing a Pharmacovigilance Partner, Pick a Safety-Minded CRO](https://www.eversana.com/2021/10/04/when-choosing-a-pharmacovigilance-partner-pick-a-safety-minded-cro/) - [PM360 Magazine Announces Winners of 2021 Trailblazer Awards](https://www.eversana.com/2021/09/24/pm360-magazine-announces-winners-of-2021-trailblazer-awards/) - [Global Pricing Insights - Last Week In Review - Oct 11 - 15, 2021](https://www.eversana.com/2021/10/15/global-pricing-insights-last-week-in-review-oct-11-15-2021/) - [Meet EVERSANA at the Annual LTEN Conference](https://www.eversana.com/2021/09/30/meet-eversana-at-the-annual-lten-conference/) - [EVERSANA Sponsors 2021 ASRM Scientific Congress & Expo](https://www.eversana.com/2021/08/19/eversana-sponsors-2021-asrm-scientific-congress-expo/) - [News Alert: ICER Reviews MyoKardia & Bristol-Myers Squibb’s Mavacamten in HCM](https://www.eversana.com/2021/10/12/news-alert-icer-reviews-myokardia-bristol-myers-squibbs-mavacamten-in-hcm/) - [News Alert: France PLFSS 2022 Widens Scope for Drug Reimbursement, Increases Temporary Access Options](https://www.eversana.com/2021/10/11/france-plfss-2022-widens-widens-scope-for-drug-reimbursement-increases-temporary-access-optons/) - [EVERSANA Sponsors Medicaid Drug Rebate Program Summit](https://www.eversana.com/2021/09/07/eversana-sponsors-medicaid-drug-rebate-program-summit-2/) - [EVERSANA at AMCP Nexus 2021](https://www.eversana.com/2021/10/06/amcp-nexus-2021/) - [EVERSANA joins phactMI Corporate Partner Program, helping to shape the future of medical information services](https://www.eversana.com/2021/10/05/eversana-joins-phactmi-corporate-partner-program-helping-to-shape-the-future-of-medical-information-services/) - [EVERSANA Sponsors Informa’s 2021 Coupon & Copay Hybrid Event](https://www.eversana.com/2021/09/30/eversana-sponsors-informas-2021-coupon-copay-hybrid-event/) - [Navigate Pricing & Access Complexities Globally](https://www.eversana.com/2021/09/30/navigate-pricing-access-complexities-globally/) - [Advancing Commercialisation Across Europe & Globally](https://www.eversana.com/2021/08/20/advancing-commercialisation-across-europe-globally/) - [Join EVERSANA at Bio Europe 2021](https://www.eversana.com/2021/09/30/bio-europe-2021/) - [News Alert: Eli Lilly to lower the list price of Insulin Lispro injection by 40%](https://www.eversana.com/2021/09/29/news-alert-eli-lilly-to-lower-the-list-price-of-insulin-lispro-injection-by-40/) - [Global Pricing Insights - A Week In Review - Sept 20-Sept 24, 2021](https://www.eversana.com/2021/09/27/global-pricing-insights-a-week-in-review-sept-20-sept-24-2021/) - [Digital Therapeutics Alliance Announces New Resource Partner Program to Accelerate Access and Impact of Digital Therapeutics for Patients Worldwide](https://www.eversana.com/2021/09/23/digital-therapeutics-alliance-announces-new-resource-partner-program-to-accelerate-access-and-impact-of-digital-therapeutics-for-patients-worldwide/) - [DTx East](https://www.eversana.com/2021/09/13/dtx-east/) - [Pharma JAPAN 2021](https://www.eversana.com/2021/08/20/pharma-japan-2021/) - EVERSANA is proud to be a Global Sponsor at this year’s Pharma Japan 2020 (formerly eyeforpharma Japan), taking place on September 1-4. - [EVERSANA Sponsors 2021 HUB, SPP & eServices Optimization Event](https://www.eversana.com/2021/08/16/eversana-sponsors-2021-hub-spp-eservices-optimization-hybrid-event/) - [CEO Jim Lang Honored With PharmaVOICE Top 100 Commanders & Chiefs Award](https://www.eversana.com/2021/09/09/ceo-jim-lang-honored-with-pharmavoice-top-100-commanders-chiefs-award/) - [EVERSANA™ expands global commercialization solutions with acquisition of Accelera Canada and its partner companies](https://www.eversana.com/2021/07/26/eversana-expands-global-commercialization-solutions-with-acquisition-of-accelera-canada-and-its-partner-companies/) - [EVERSANA™ expands medical information and integrated compliance services across Europe](https://www.eversana.com/2021/06/21/eversana-expands-medical-information-and-integrated-compliance-services-across-europe/) - [GENinCode announces major US commercialisation partnership with EVERSANA](https://www.eversana.com/2021/06/14/genincode-announces-major-us-commercialisation-partnership-with-eversana/) - [Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada](https://www.eversana.com/2021/06/03/resverlogix-and-eversana-announce-pending-launch-of-the-initial-commercialization-of-apabetalone-for-covid-19-in-the-united-states-and-canada/) - [EVERSANA™ and S3 Connected Health Announce Strategic Partnership to Advance the Adoption and Commercialization of Digital Health Solutions Across Life Sciences](https://www.eversana.com/2021/05/26/eversana-and-s3-connected-health-announce-strategic-partnership-to-advance-the-adoption-and-commercialization-of-digital-health-solutions-across-life-sciences/) - [MedRhythms and EVERSANA announce partnership to launch and commercialize chronic stroke software-based medical device](https://www.eversana.com/2021/05/19/medrhythms-and-eversana-announce-partnership-to-launch-and-commercialize-chronic-stroke-software-based-medical-device/) - [EVERSANA™ expands global agency and marketing capabilities through partnership with thenetworkone](https://www.eversana.com/2021/05/18/eversana-expands-global-agency-and-marketing-capabilities-through-partnership-with-thenetworkone/) - [EVERSANA™ strengthens global market access and pricing leadership in European expansion](https://www.eversana.com/2021/05/06/eversana-strengthens-global-market-access-and-pricing-leadership-in-european-expansion/) - [EVERSANA advances commercialization readiness as Humanigen announces publication of phase 3 randomized double-blind placebo-controlled study demonstrating the efficacy and safety of lenzilumab™ in newly hospitalized COVID-19 patients](https://www.eversana.com/2021/05/06/eversana-advances-commercialization-readiness-as-humanigen-announces-publication-of-phase-3-randomized-double-blind-placebo-controlled-study-demonstrating-the-efficacy-and-safety-of-lenzilumab/) - [EVERSANA Launches Chronic Disease Real-World Data Solution Covering More Than 80 Million Deidentified Patients to Drive Regulatory-Grade Clinical Research and Improve Patient Outcomes](https://www.eversana.com/2021/02/25/eversana-launches-chronic-disease-real-world-data-solution-covering-more-than-80-million-deidentified-patients-to-drive-regulatory-grade-clinical-research-and-improve-patient-outcomes/) - [Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch](https://www.eversana.com/2021/02/01/iterum-therapeutics-announces-partnership-with-eversana-to-support-oral-sulopenem-launch/) - [Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19](https://www.eversana.com/2021/01/10/humanigen-and-eversana-announce-partnership-to-support-the-launch-and-commercialization-of-lenzilumab-for-the-treatment-of-covid-19/) - [EVERSANA and Experic announce strategic partnership to optimize end-to-end contract manufacturing and commercialization services for life sciences industry](https://www.eversana.com/2020/12/17/eversana-and-experic-announce-strategic-partnership-to-optimize-end-to-end-contract-manufacturing-and-commercialization-services-for-life-sciences-industry/) - [EVERSANA and ArisGlobal announce strategic partnership to transform drug safety automation and advance integrated compliance models](https://www.eversana.com/2020/12/03/eversana-and-arisglobal-announce-strategic-partnership-to-transform-drug-safety-automation-and-advance-integrated-compliance-models/) - [MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab](https://www.eversana.com/2020/11/30/macrogenics-and-eversana-announce-agreement-to-support-the-potential-launch-and-commercialization-of-margetuximab/) - [EVERSANA and WorldQuant Predictive significantly improve patient adherence and outcomes through real-time Artificial Intelligence & Machine Learning technology partnership](https://www.eversana.com/2020/11/17/eversana-and-worldquant-predictive-significantly-improve-patient-adherence-and-outcomes-through-real-time-artificial-intelligence-machine-learning-technology-partnership/) - [EVERSANA™ named a Great Place to Work by global workplace authority for second consecutive year](https://www.eversana.com/2020/11/05/eversana-named-a-great-place-to-work-by-global-workplace-authority-for-second-consecutive-year/) - [PPMA 2020 Insights: Trends in HTA Decisions](https://www.eversana.com/2020/09/25/ppma-2020-trends-in-hta-decisions/) - At PPMA 2020, EVERSANA’s Dr. Magdi Stino and Alan Crowther came together to detail some recent trends and share approaches for using Health Technology Assessment (HTA) data when decision making, leveraging information from the Pricentric HTA database - [EVERSANA launches ACTICS by EVERSANA™, the technology-enabled solution combining predictive analytics integrated with real-time commercial services to drive next best action in the life science sector](https://www.eversana.com/2020/09/16/eversana-launches-actics-by-eversana-the-technology-enabled-solution-combining-predictive-analytics-integrated-with-real-time-commercial-services-to-drive-next-best-action-in-the-life-scienc/) - [EVERSANA™ expands pharmaceutical training and digital engagement capabilities with acquisition of Alkemy Partners](https://www.eversana.com/2020/09/09/eversana-expands-pharmaceutical-training-and-digital-engagement-capabilities-with-acquisition-of-alkemy-partners/) - [Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™](https://www.eversana.com/2020/08/06/zosano-pharma-announces-partnership-agreement-with-eversana-to-support-the-launch-and-commercialization-of-qtrypta/) - [Vineti and EVERSANA™ form strategic alliance to advance patient-centered services and supply chain automation for regenerative medicine](https://www.eversana.com/2020/07/29/vineti-and-eversana-form-strategic-alliance-to-advance-patient-centered-services-and-supply-chain-automation-for-regenerative-medicine/) - [EVERSANA™ launches data & analytics business to drive next-generation integrated commercial services](https://www.eversana.com/2020/04/23/eversana-launches-data-analytics-business-to-drive-next-generation-integrated-commercial-services/) - [Evoke Pharma Enters Commercialization Agreement with EVERSANA for Gimoti™](https://www.eversana.com/2020/01/23/evoke-pharma-enters-commercialization-agreement-with-eversana-life-sciences-for-gimoti/) - [EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies](https://www.eversana.com/2020/01/09/eversana-and-noom-announce-strategic-partnership-to-improve-therapy-adherence-and-patient-engagement-for-complex-therapies/) - [EVERSANA™ named a Great Place to Work by global workplace authority](https://www.eversana.com/2019/10/28/eversana-named-a-great-place-to-work-by-global-workplace-authority/) - [Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines](https://www.eversana.com/2019/09/10/cognoa-and-eversana-announce-partnership-to-advance-the-commercialization-standard-for-prescription-digital-medicines/) - [Novartis Strikes “World First” Deal With UK NHS Following Leqvio NICE Recommendation](https://www.eversana.com/2021/09/02/novartis-strikes-world-first-deal-with-uk-nhs-following-leqvio-nice-recommendation/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA Sponsors 2021 Global Genes RARE Patient Advocacy Summit](https://www.eversana.com/2021/08/15/eversana-sponsors-2021-global-genes-rare-patient-advocacy-summit/) - [EVERSANA Sponsors 2021 NORD Rare Summit Virtual Event](https://www.eversana.com/2021/08/19/eversana-sponsors-2021-nord-rare-summit-virtual-event/) - [6th Annual CAR-TCR Summit](https://www.eversana.com/2021/08/10/6th-annual-car-tcr-summit/) - [Our commitment to a healthier world: EVERSANA’s vaccine requirements for employees](https://www.eversana.com/2021/08/05/our-commitment-to-a-healthier-world-eversanas-vaccine-requirements-for-employees/) - [EVERSANA Sponsors Informa's 2021 Formulary, Reimbursement & Access Summit](https://www.eversana.com/2021/07/27/eversana-sponsors-informas-2021-formulary-reimbursement-access-summit/) - [U.S. Lawmakers Request Transparency on Defense Department’s Use of March-in Power to Reduce Drug Prices](https://www.eversana.com/2021/07/30/u-s-lawmakers-request-transparency-on-defense-departments-use-of-march-in-power-to-reduce-drug-prices/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Israel Embarks on Partnership with FDA’s Project Orbis, Generic Drug Cluster](https://www.eversana.com/2021/07/29/israel-embarks-on-partnership-with-fdas-project-orbis-generic-drug-cluster/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Zorginstituut Advises 5% Price Reduction for Yescarta Following Reassessment of Survival Data](https://www.eversana.com/2021/07/28/zorginstituut-advises-5-price-reduction-for-yescarta-following-reassessment-of-survival-data/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA Sponsors NACDS Total Store Expo](https://www.eversana.com/2021/07/27/eversana-sponsors-nacds-total-store-expo/) - [EVERSANA Expands Global Commercialization Solutions With Acquisition Of Accelera Canada And Its Partner Companies](https://www.eversana.com/2021/07/27/eversana-expands-global-commercialization-solutions-with-acquisition-of-accelera-canada-and-its-partner-companies-2/) - [EVERSANA expands North American reach, pens deal for Accelera Canada](https://www.eversana.com/2021/07/26/eversana-expands-north-american-reach-pens-deal-for-accelera-canada/) - [UK Details Next Steps in Northern Ireland Protocol](https://www.eversana.com/2021/07/23/uk-details-next-steps-in-northern-ireland-protocol/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [World Orphan Drug Congress USA 2021](https://www.eversana.com/2021/07/21/world-orphan-drug-congress-usa-2021/) - [Join EVERSANA at HIMSS 2021 Global Health Conference & Exhibition](https://www.eversana.com/2021/07/08/join-eversana-at-himss-2021-global-health-conference-exhibition/) - [GARDP, CHAI, Shionogi Team Up to Bring Fetcroja to Low-, Middle-Income Countries](https://www.eversana.com/2021/07/15/gardp-chai-shionogi-team-up-to-bring-fetcroja-to-low-middle-income-countries/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Romania to Set Drug Prices Against Average of Lowest 3 EU Countries](https://www.eversana.com/2021/07/14/romania-to-set-drug-prices-against-average-of-lowest-3-eu-countries/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Biden Signs Executive Order Targeting Competition in Pharma, Healthcare Industries](https://www.eversana.com/2021/07/13/biden-signs-executive-order-targeting-competition-in-pharma-healthcare-industries/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [UK Life Sciences Vision 10-Year Strategy Outlines 7 Missions to Solve Major Health Problems](https://www.eversana.com/2021/07/09/uk-life-sciences-vision-10-year-strategy-outlines-7-missions-to-solve-major-health-problems/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [NICE Backs Zolgensma for Type 1 SMA Infants, Managed Entry Agreement Set Up for Use in Types 2, 3](https://www.eversana.com/2021/07/08/nice-backs-zolgensma-for-type-1-sma-infants-managed-entry-agreement-set-up-for-use-in-types-2-3/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Last Week in Review: 6/28/2021 – 7/2/2021](https://www.eversana.com/2021/07/06/last-week-in-review-6-28-2021-7-2-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [ICER Stands by 85% Lower Price for Aduhelm in Revised Evidence Report](https://www.eversana.com/2021/07/01/icer-stands-by-85-lower-price-for-aduhelm-in-revised-evidence-report/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [DTx Europe Conference](https://www.eversana.com/2021/06/27/dtx-europe-conference-2021/) - [China’s First Cross-Provincial Drug Procurement Alliance Scores Average Price Reductions of 55.03%](https://www.eversana.com/2021/06/29/chinas-first-cross-provincial-drug-procurement-alliance-scores-average-price-reductions-of-55-03/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [PMPRB Amendments Delayed Again, Due to Take Effect January 1, 2022](https://www.eversana.com/2021/06/30/pmprb-amendments-delayed-again-due-to-take-effect-january-1-2022/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [France’s ATU Scheme Reform to Come into Force from July](https://www.eversana.com/2021/06/28/frances-atu-scheme-reform-to-come-into-force-from-july/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [China’s Record-Breaking 5th VBP Round Achieves Average Price Reductions of 56%](https://www.eversana.com/2021/06/25/chinas-record-breaking-5th-vbp-round-achieves-average-price-reductions-of-56/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [China’s 5th Round VBP Largest Yet](https://www.eversana.com/2021/06/23/chinas-5th-round-vbp-largest-yet/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA ™ Expands Medical Information and Integrated Compliance Services Across Europe](https://www.eversana.com/2021/06/21/eversana-expands-medical-information-and-integrated-compliance-services-across-europe-3/) - [EVERSANA Expands Medical Information and Integrated Compliance Services Across Europe](https://www.eversana.com/2021/06/22/eversana-expands-medical-information-and-integrated-compliance-services-across-europe-2/) - [Netherlands’ Parallel Procedures Pilot Expedites Registration, Reimbursement of New Medicines](https://www.eversana.com/2021/06/22/netherlands-parallel-procedures-pilot-expedites-registration-reimbursement-of-new-medicines/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [PASTEUR Act Proposes Subscription Payment Model to Encourage Novel Antibiotic Development](https://www.eversana.com/2021/06/18/pasteur-act-proposes-subscription-payment-model-to-encourage-novel-antibiotic-development/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [MHRA Nixes Confirmatory Clinical Trial Requirement for Biosimilars](https://www.eversana.com/2021/06/16/mhra-nixes-confirmatory-clinical-trial-requirement-for-biosimilars/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EU Parliament Backs Temporary COVID-19 Patent Waiver in U-Turn Decision](https://www.eversana.com/2021/06/15/eu-parliament-backs-temporary-covid-19-patent-waiver-in-u-turn-decision/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Resverlogix And EVERSANA Announce Partnership To Support The Pending Launch Of The Initial Commercialization Of Apabetalone For COVID-19 In The United States And Canada](https://www.eversana.com/2021/06/03/resverlogix-and-eversana-announce-partnership-to-support-the-pending-launch-of-the-initial-commercialization-of-apabetalone-for-covid-19-in-the-united-states-and-canada/) - [GENinCode, EVERSANA Enter Major U.S. Commercialization Pact](https://www.eversana.com/2021/06/14/genincode-eversana-enter-major-u-s-commercialization-pact/) - [The Knock-on Effect of Biogen’s Aducanumab Approval](https://www.eversana.com/2021/06/08/the-knock-on-effect-of-biogens-aducanumab-approval/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [RESVERLOGIX AND EVERSANA ANNOUNCE PARTNERSHIP TO SUPPORT PENDING LAUNCH OF APABETALONE FOR COVID-19](https://www.eversana.com/2021/06/02/resverlogix-and-eversana-announce-partnership-to-support-pending-launch-of-apabetalone-for-covid-19/) - [Commanders & Chiefs: Chief Medical Officers](https://www.eversana.com/2021/06/01/commanders-chiefs-chief-medical-officers/) - [Marketing to Zoomers](https://www.eversana.com/2021/06/01/marketing-to-zoomers/) - [Krista Pinto, EVERSANA - Hall of Femme](https://www.eversana.com/2021/06/02/krista-pinto-eversana-hall-of-femme/) - [EVERSANA Sponsors The Medicaid and Government Pricing Congress](https://www.eversana.com/2021/05/20/eversana-sponsors-the-medicaid-and-government-pricing-congress/) - [First Patient Treated with Zolgensma in UK](https://www.eversana.com/2021/06/01/first-patient-treated-with-zolgensma-in-uk/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [MedRhythms and EVERSANA to launch software-based device for stroke](https://www.eversana.com/2021/05/20/medrhythms-and-eversana-to-launch-software-based-device-for-stroke/) - [King Saud University Establishes HTA Unit for Saudi Arabia](https://www.eversana.com/2021/05/26/king-saud-university-establishes-hta-unit-for-saudi-arabia/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA to Present at Pharma USA 2021](https://www.eversana.com/2021/05/06/eversana-to-present-at-pharma-usa-2021/) - [EVERSANA expands global agency and marketing capabilities through partnership with thenetworkone](https://www.eversana.com/2021/05/18/eversana-expands-global-agency-and-marketing-capabilities-through-partnership-with-thenetworkone-2/) - [Nevada’s Drug Price Transparency Bill Up for Permanent Funding](https://www.eversana.com/2021/05/19/nevadas-drug-price-transparency-bill-up-for-permanent-funding/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [TLV Suggests Access to National Health Data Registers Could Help Enable Follow-up Care](https://www.eversana.com/2021/05/18/tlv-suggests-access-to-national-health-data-registers-could-help-enable-follow-up-care/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Last Week in Review: 5/10/2021 – 5/14/2021](https://www.eversana.com/2021/05/17/last-week-in-review-5-10-2021-5-14-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA advances commercialization readiness as Humanigen announces publication of phase 3 randomized double-blind placebo-controlled study demonstrating the efficacy and safety of lenzilumab™ in newly hospitalized COVID-19 patients](https://www.eversana.com/2021/05/06/eversana-advances-commercialization-readiness-as-humanigen-announces-publication-of-phase-3-randomized-double-blind-placebo-controlled-study-demonstrating-the-efficacy-and-safety-of-lenzilumab-2/) - [ELITE 2021 Data Miner Brigham Hyde of EVERSANA](https://www.eversana.com/2021/05/14/elite-2021-data-miner-brigham-hyde-of-eversana/) - [ELITE 2021 Transformational Leader Jim Lang of EVERSANA](https://www.eversana.com/2021/05/14/elite-2021-transformational-leader-jim-lang-of-eversana/) - [Rare Disease Company Coalition Forms to Educate Policymakers on Rare Disease Business Model, Experience Bringing Treatments to Market](https://www.eversana.com/2021/05/14/rare-disease-company-coalition-forms-to-educate-policymakers-on-rare-disease-business-model-experience-bringing-treatments-to-market/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA at Virtual ISPOR 2021](https://www.eversana.com/2021/04/21/eversana-at-virtual-ispor-2021/) - [Real-world data to the rescue](https://www.eversana.com/2021/05/01/real-world-data-to-the-rescue/) - [Expect More From Your Omnichannel Strategy and Investments](https://www.eversana.com/2021/05/01/expect-more-from-your-omnichannel-strategy-and-investments/) - [EVERSANA Strengthens Global Access and Pricing Leadership in European Expansion](https://www.eversana.com/2021/05/06/eversana-strengthens-global-access-and-pricing-leadership-in-european-expansion/) - [MM+M Hall of Femme 2021 honorees announced](https://www.eversana.com/2021/04/06/mmm-hall-of-femme-2021-honorees-announced/) - [China’s 5th Round of VBP Officially Covers 60 Drugs, 202 Specifications, Says Joint Procurement Office Notice](https://www.eversana.com/2021/05/11/chinas-5th-round-of-vbp-officially-covers-60-drugs-202-specifications-says-joint-procurement-office-notice/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [ZIN Rejects Kaftrio Plus Kalydeco, Urges 75% Price Reduction and Renegotiation of All Vertex Drugs](https://www.eversana.com/2021/05/06/zin-rejects-kaftrio-plus-kalydeco-urges-75-price-reduction-and-renegotiation-of-all-vertex-drugs/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [NICE Extends Clinical Eligibility Criteria for Spinraza](https://www.eversana.com/2021/05/05/nice-extends-clinical-eligibility-criteria-for-spinraza/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EFPIA Report Highlights 6 Core Principles to Govern Transparency in Evidence Under Novel Pricing Agreements](https://www.eversana.com/2021/05/04/efpia-report-highlights-6-core-principles-to-govern-transparency-in-evidence-under-novel-pricing-agreements/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [US Onshoring Essential Antibiotics Act Seeks to Re-Localize Production of Essential Antibiotics](https://www.eversana.com/2021/04/28/us-onshoring-essential-antibiotics-act-seeks-to-re-localize-production-of-essential-antibiotics/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Elijah J. Cummings Lower Drug Costs Now Act (HR 3) Reintroduced in United States](https://www.eversana.com/2021/04/26/elijah-j-cummings-lower-drug-costs-now-act-hr-3-reintroduced-in-united-states/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [World EPA Congress DAY 2: Global Trends in Net Price](https://www.eversana.com/2021/04/26/world-epa-congress-day-2-global-trends-in-net-price/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA ENGAGE: 2021](https://www.eversana.com/2021/04/23/eversana-engage-2021/) - [Kymriah, Yescarta Subject to Cost-Effectiveness Assessment-Based Price Adjustments in Japan](https://www.eversana.com/2021/04/21/kymriah-yescarta-subject-to-cost-effectiveness-assessment-based-price-adjustments-in-japan/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Bluebird to Withdraw Zynteglo from Germany After Price Negotiations Failed to Recognize Drug’s Value](https://www.eversana.com/2021/04/21/bluebird-to-withdraw-zynteglo-from-germany-after-price-negotiations-failed-to-recognize-drugs-value/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Amgen’s Bemarituzumab Granted Breakthrough Designation in U.S.](https://www.eversana.com/2021/04/20/amgens-bemarituzumab-granted-breakthrough-designation-in-u-s/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [NICE Launches 5-year Strategy](https://www.eversana.com/2021/04/20/nice-launches-5-year-strategy/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Two Bills Aiming to Lower Prescription Drug Costs Await Signatures from Biden](https://www.eversana.com/2021/04/19/two-bills-aiming-to-lower-prescription-drug-costs-await-signatures-from-biden/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Precision Medicine: Expanding the Frontiers of Precision Medicine](https://www.eversana.com/2021/04/02/precision-medicine-expanding-the-frontiers-of-precision-medicine/) - [EVERSANA: ACTICS RWD for chronic disease research](https://www.eversana.com/2021/04/15/eversana-actics-rwd-for-chronic-disease-research/) - [ICER Utilizes Real World Evidence to Update Assessment of HAE Attack Prophylactics Takhzyro, Haegarda, Cinryze](https://www.eversana.com/2021/04/15/icer-utilizes-real-world-evidence-to-update-assessment-of-hae-attack-prophylactics-takhzyro-haegarda-cinryze/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA to Sponsor the World Orphan Drug Congress USA 2021](https://www.eversana.com/2021/04/14/eversana-to-sponsor-the-world-orphan-drug-congress-usa-2021/) - [Meeting on the Meds | Ultra-Orphan Drugs Should Be First Area of Focus for Regulatory Alignment, Say Drug Regulators](https://www.eversana.com/2021/04/13/meeting-on-the-meds-ultra-orphan-drugs-should-be-first-area-of-focus-for-regulatory-alignment-say-drug-regulators/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Malta MEP Saliba Urges EU Intervention to Ensure Affordable Medicines for Smallest Member States](https://www.eversana.com/2021/04/09/malta-mep-saliba-urges-eu-intervention-to-ensure-affordable-medicines-for-smallest-member-states/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Spanish SEFC Eyes Up Drug Evaluation Overhaul Through “Multidisciplinary Collaboration”](https://www.eversana.com/2021/04/08/spanish-sefc-eyes-up-drug-evaluation-overhaul-through-multidisciplinary-collaboration/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi for Mydriasis](https://www.eversana.com/2021/03/23/eyenovia-and-eversana-announce-partnership-to-support-the-potential-launch-and-commercialization-of-mydcombi-for-mydriasis/) - [EVERSANA Commercialization Executive Krista Pinto Named 2021 MM+M Hall of Femme Honoree](https://www.eversana.com/2021/04/06/eversana-commercialization-executive-krista-pinto-named-2021-mmm-hall-of-femme-honoree/) - [Last Week in Review: 3/29/2021 – 4/2/2021](https://www.eversana.com/2021/04/05/last-week-in-review-3-29-2021-4-2-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [IQWiG Tasked by G-BA to Collect Application-Related Data on CAR-T Therapies](https://www.eversana.com/2021/04/02/iqwig-tasked-by-g-ba-to-collect-application-related-data-on-car-t-therapies/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Precision Medicine and Predictive Action Drive Measurable Impact for Patients](https://www.eversana.com/2021/04/01/precision-medicine-and-predictive-action-drive-measurable-impact-for-patients/) - [AIFA Introduces Simplified Pricing, Reimbursement Negotiation Procedure for Parallel Imported Drugs](https://www.eversana.com/2021/03/31/aifa-introduces-simplified-pricing-reimbursement-negotiation-procedure-for-parallel-imported-drugs/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [U.S. Senators Reintroduce FAIR Drug Pricing Act Requiring Transparency Surrounding Drug Price Increases](https://www.eversana.com/2021/03/29/u-s-senators-reintroduce-fair-drug-pricing-act-requiring-transparency-surrounding-drug-price-increases/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Last Week in Review: 3/22/2021 – 3/26/2021](https://www.eversana.com/2021/03/29/last-week-in-review-3-22-2021-3-26-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Italy’s AGCM Proposes Increased Public-Private Integration, Scrapping Laws that Prohibit Competition Among Biosimilars, Generics](https://www.eversana.com/2021/03/26/italys-agcm-proposes-increased-public-private-integration-scrapping-laws-that-prohibit-competition-among-biosimilars-generics/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Sanders’ 3 Acts Latest Entry in United States’ Prescription Drug Price Saga](https://www.eversana.com/2021/03/25/sanders-3-acts-latest-entry-in-united-states-prescription-drug-price-saga/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Chengdu Launches Rare Disease Drug Program with Capped Reimbursement](https://www.eversana.com/2021/03/24/chengdu-launches-rare-disease-drug-program-with-capped-reimbursement/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EU Set to Tighten Vaccine Export Restrictions, Cutting Supplies to UK for 6 Weeks](https://www.eversana.com/2021/03/24/eu-set-to-tighten-vaccine-export-restrictions-cutting-supplies-to-uk-for-6-weeks/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Dubai Introduces New Unified Formerly SHIFA](https://www.eversana.com/2021/03/24/dubai-introduces-new-unified-formerly-shifa/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [On AMNOG’s 10th Anniversary, G-BA’s Hecken Questions Whether 1-Year Free Pricing Is Too Long](https://www.eversana.com/2021/03/22/on-amnogs-10th-anniversary-g-bas-hecken-questions-whether-1-year-free-pricing-is-too-long/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [The legal landscape for patient support services](https://www.eversana.com/2021/03/18/the-legal-landscape-for-patient-support-services/) - [Today's hub blueprint: Lock in on the journey](https://www.eversana.com/2021/03/18/todays-hub-blueprint-lock-in-on-the-journey/) - [EUCOPE Calls for Additional Considerations in Joint EU HTA Discussions](https://www.eversana.com/2021/03/19/eucope-calls-for-additional-considerations-in-joint-eu-hta-discussions/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Italy Reimburses Zolgensma Through “Payment at Result” Model, Priced at EUR 2.155 M](https://www.eversana.com/2021/03/18/italy-reimburses-zolgensma-through-payment-at-result-model-priced-at-eur-2-155-m/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EMA ‘Firmly Convinced’ of AZ Vaccine Safety Ahead of Official Review Results](https://www.eversana.com/2021/03/17/ema-firmly-convinced-of-az-vaccine-safety-ahead-of-official-review-results/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Amazon Registers ‘Amazon Pharmacy’ Trademark in UK as It Eyes Launch](https://www.eversana.com/2021/03/16/amazon-registers-amazon-pharmacy-trademark-in-uk-as-it-eyes-launch/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA launches chronic RWD solution](https://www.eversana.com/2021/02/26/eversana-launches-chronic-rwd-solution/) - [WHO Emergency Approves J&J One-shot COVID-19 Vaccine](https://www.eversana.com/2021/03/15/who-emergency-approves-jj-one-shot-covid-19-vaccine/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [FDA to Hold ODAC Meeting for Recently Withdrawn PD-1, PD-L1 Inhibitors](https://www.eversana.com/2021/03/12/fda-to-hold-odac-meeting-for-recently-withdrawn-pd-1-pd-l1-inhibitors/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [J&J Vaccine Granted Conditional Approval in Europe as Company Announces Plans to Produce Up to 3BN Shots Next Year](https://www.eversana.com/2021/03/12/jj-vaccine-granted-conditional-approval-in-europe-as-company-announces-plans-to-produce-up-to-3bn-shots-next-year/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Biden Orders Additional 100 M Doses of J&J’s COVID-19 Vaccine](https://www.eversana.com/2021/03/11/biden-orders-additional-100-m-doses-of-jjs-covid-19-vaccine/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [China Lays Out Path Forward for Volume-Based Procurement, Tendering](https://www.eversana.com/2021/03/10/china-lays-out-path-forward-for-volume-based-procurement-tendering/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [European Commission, EMA Pilot Launched to Challenge Centralized Authorization Procedure](https://www.eversana.com/2021/03/09/european-commission-ema-pilot-launched-to-challenge-centralized-authorization-procedure/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Minnesota’s SF 990 Bill Would Promote Increased Access to Biosimilars](https://www.eversana.com/2021/03/09/minnesotas-sf-990-bill-would-promote-increased-access-to-biosimilars/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [NHS England, Novartis Strike ‘Landmark’ Deal for Zolgensma Access](https://www.eversana.com/2021/03/08/nhs-england-novartis-strike-landmark-deal-for-zolgensma-access/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [China Publishes Final PD-1 Agreed Prices as NRDL Takes Effect](https://www.eversana.com/2021/03/03/china-publishes-final-pd-1-agreed-prices-as-nrdl-takes-effect/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [LEEM, CEPS Framework Agreement Focuses on Innovative Drugs (ASMR 1-3), Stabilizing Prices](https://www.eversana.com/2021/03/08/leem-ceps-framework-agreement-focuses-on-innovative-drugs-asmr-1-3-stabilizing-prices/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Oklahoma Senate Bill 734 Would Base Drug Prices on Those in Canada](https://www.eversana.com/2021/03/05/oklahoma-senate-bill-734-would-base-drug-prices-on-those-in-canada/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EMA, Health Canada Publish Full Moderna COVID-19 Vaccine Filing Support Data](https://www.eversana.com/2021/03/04/ema-health-canada-publish-full-moderna-covid-19-vaccine-filing-support-data/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Belzutifan Becomes First Medicine Approved Via UK’S New ILAP Pathway](https://www.eversana.com/2021/03/02/belzutifan-becomes-first-medicine-approved-via-uks-new-ilap-pathway/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Iterum Therapeutics, EVERSANA Announces Collaboration to Support Oral Sulopenem Launch](https://www.eversana.com/2021/02/01/iterum-therapeutics-eversana-announces-collaboration-to-support-oral-sulopenem-launch/) - [EVERSANA Launches Chronic Disease Real-World Data Solution](https://www.eversana.com/2021/02/25/18570/) - [Leveraging RWE to Enhance Experiences Across the Patient Journey](https://www.eversana.com/2021/03/01/leveraging-rwe-to-enhance-experiences-across-the-patient-journey/) - [Last Week in Review: 2/22/2021 - 2/26/2021](https://www.eversana.com/2021/03/01/last-week-in-review-2-22-2021-2-26-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Brazil Approves Pfizer & BioNTech’s Comirnaty](https://www.eversana.com/2021/02/25/brazil-approves-pfizer-biontechs-comirnaty/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [China Rewards Breakthrough Therapy Designation to Innovent & IASO’s CAR-T Cell Therapy](https://www.eversana.com/2021/02/24/china-rewards-breakthrough-therapy-designation-to-innovent-iasos-car-t-cell-therapy/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [AMR Action Fund Gets First CEO, Funding Boost](https://www.eversana.com/2021/02/23/amr-action-fund-gets-first-ceo-funding-boost/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Last Week in Review: 2/15/2021 - 2/19/2021](https://www.eversana.com/2021/02/22/last-week-in-review-2-15-2021-2-19-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Vertex’s Kaftrio Plus Kalydeco Offers Considerable Added Benefit, Finds G-BA](https://www.eversana.com/2021/02/19/vertexs-kaftrio-plus-kalydeco-offers-considerable-added-benefit-finds-g-ba/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Last Week in Review: 2/8/2021 - 2/12/2021](https://www.eversana.com/2021/02/15/last-week-in-review-2-8-2021-2-12-2021/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [NICE Draft Guidance Rejects Zynteglo for Transfusion-dependent Beta-thalassaemia](https://www.eversana.com/2021/02/12/nice-draft-guidance-rejects-zynteglo-for-transfusion-dependent-beta-thalassaemia/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EC Commits Aspen to Reducing Off-patent Cancer Meds by 73% Following Investigation](https://www.eversana.com/2021/02/12/ec-commits-aspen-to-reducing-off-patent-cancer-meds-by-73-following-investigation/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [WHO Backs AZ Vaccine Amid Concerns, Supports Longer Dosing Schedule](https://www.eversana.com/2021/02/11/who-backs-az-vaccine-amid-concerns-supports-longer-dosing-schedule/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EU Finalizes Agreement for Extra 300M Pfizer COVID-19 Vaccines](https://www.eversana.com/2021/02/10/eu-finalizes-agreement-for-extra-300m-pfizer-covid-19-vaccines/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [PhRMA Report Sheds Light on How Hospital Practices Increase Costs for Employers, Patients](https://www.eversana.com/2021/02/09/phrma-report-sheds-light-on-how-hospital-practices-increase-costs-for-employers-patients/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [G-BA Proposes RWE Scheme for Zolgensma Use in Germany](https://www.eversana.com/2021/02/08/g-ba-proposes-rwe-scheme-for-zolgensma-use-in-germany/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Lombardy’s Next Tender: A Big Opportunity for Name-Brand and Generic Drugmakers Alike](https://www.eversana.com/2021/02/05/lombardys-next-tender-a-big-opportunity-for-name-brand-and-generic-drugmakers-alike/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EC Publishes ‘Europe's Beating Cancer Plan’ Detailing 4 Key Areas for Action](https://www.eversana.com/2021/02/04/ec-publishes-europes-beating-cancer-plan-detailing-4-key-areas-for-action/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [KPBMA Wants South Korea to be Self-Sufficient, Pharmaceutical Powerhouse](https://www.eversana.com/2021/02/03/kpbma-wants-south-korea-to-be-self-sufficient-pharmaceutical-powerhouse/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Pricentric Insights: China Issues New Volume-Based Procurement Policy Document](https://www.eversana.com/2021/02/02/pricentric-insights-china-issues-new-volume-based-procurement-policy-document/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EMA Recommends AZ Vaccine as European Commission Publishes Contract Amid Export Block Row](https://www.eversana.com/2021/02/01/ema-recommends-az-vaccine-as-european-commission-publishes-contract-amid-export-block-row/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EVERSANA Sponsors CBI's PAP Conference](https://www.eversana.com/2021/01/29/eversana-sponsors-cbis-pap-conference/) - [EVERSANA Sponsors CBI's HUB, SPP and e-Services Conference](https://www.eversana.com/2021/01/29/eversana-sponsors-cbis-hub-spp-and-e-services-conference-2/) - [NCBN, JPMA Team Up for Disease-Specific Drug Databank for Drug Discovery and Personalized Medicine](https://www.eversana.com/2021/01/29/ncbn-jpma-team-up-for-disease-specific-drug-databank-for-drug-discovery-and-personalized-medicine/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Senate Finance Committee Report on Rising Insulin Costs Criticizes Industry, PBM Practices](https://www.eversana.com/2021/01/27/senate-finance-committee-report-on-rising-insulin-costs-criticizes-industry-pbm-practices/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [EMA Recommended 97 New Meds in 2020, According to Highlights Report](https://www.eversana.com/2021/01/25/ema-recommended-97-new-meds-in-2020-according-to-highlights-report/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Italy Reimburses Novartis’ Luxturna for Hereditary Retinal Disease](https://www.eversana.com/2021/01/22/italy-reimburses-novartis-luxturna-for-hereditary-retinal-disease/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [CMS Aims to Combat Health Disparities, Improve Home Health Care, Lower Drug Prices, & Ease Into VBP Contracts](https://www.eversana.com/2021/01/20/cms-aims-to-combat-health-disparities-improve-home-health-care-lower-drug-prices-ease-into-vbp-contracts/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Saudi Arabia Rolls Out New Pricing Guidelines](https://www.eversana.com/2021/01/19/saudi-arabia-rolls-out-new-pricing-guidelines/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Humanigen and EVERSANA announce partnership to support launch, commercialization of lenzilumab for treatment of COVID-19](https://www.eversana.com/2021/01/10/humanigen-and-eversana-announce-partnership-to-support-launch-commercialization-of-lenzilumab-for-treatment-of-covid-19/) - [BMS, Roche, AZ Lose Out as China Favors Domestic Companies in 2020 NRDL PD-1 Bid](https://www.eversana.com/2021/01/14/bms-roche-az-lose-out-as-china-favors-domestic-companies-in-2020-nrdl-pd-1-bid/) - In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL). - [Humanigen and EVERSANA collaborate for Covid-19 drug commercialisation](https://www.eversana.com/2021/01/11/humanigen-and-eversana-collaborate-for-covid-19-drug-commercialisation/) - [NHC Regulations on Medical Care Management Urge Accountability, Rational Drug Use, and Treatment Guide Adherence](https://www.eversana.com/2021/01/11/nhc-regulations-on-medical-care-management-urge-accountability-rational-drug-use-and-treatment-guide-adherence/) - The National Health Commission (NHC) of China has issued wide-weeping guidance on medical care behavior and management, with a focus on accountability and reasonable and rational drug use that promotes increased adherence to national regulations. - [UK’s MHRA Approves Moderna’s COVID-19 Vaccine, Eyes 10M Additional Doses to Roll-out From Spring](https://www.eversana.com/2021/01/08/uks-mhra-approves-modernas-covid-19-vaccine-eyes-10m-additional-doses-to-roll-out-from-spring/) - The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its third COVID-19 vaccine for use, Moderna’s messenger RNA (mRNA) shot. - [Trump’s MFN Rule Roll-Out Stalled by California, Maryland Courts](https://www.eversana.com/2021/01/06/trump-mfn-rule-roll-out-stalled/) - The year 2021 seems off to a good start for pharmaceutical companies in the United States, as district court judges in Maryland and Northern California have ruled to stall the implementation of President Donald Trump's “Most Favored Nations (MFN)” rule that was supposed to take effect on January 1, 2021. - [Data Is Transforming The Landscape](https://www.eversana.com/2021/01/04/data-is-transforming-the-landscape/) - [High-Efficiency Commercialization for High-Science Brands](https://www.eversana.com/2021/01/04/high-efficiency-commercialization-for-high-science-brands/) - [How to Enhance Provider and Patient Engagement in Tech-Savvy Healthcare](https://www.eversana.com/2021/01/04/how-to-enhance-provider-and-patient-engagement-in-tech-savvy-healthcare/) - [Executive Viewpoints: The Patient at the Heart](https://www.eversana.com/2021/01/04/executive-viewpoints-the-patient-at-the-heart/) - [Executive Viewpoints: The Skills and Talent Needed in a Virtual World](https://www.eversana.com/2021/01/04/17702/) - [China Issues 2020 National Reimbursement Drug List](https://www.eversana.com/2021/01/04/china-2020-national-reimbursement-drug-list/) - China’s National Healthcare Security Administration and Ministry of Human Resources and Social Security have issued the 2020 Edition of the National Reimbursement Drug List. - [The 2020 Pharma Playbook Addendum: Augment Your Frontline To Boost Sales Momentum](https://www.eversana.com/2020/08/10/the-2020-pharma-playbook-addendum-augment-your-frontline-to-boost-sales-momentum/) - [Pushing Your Frontline into a New Frontier](https://www.eversana.com/2019/09/23/pushing-your-frontline-into-a-new-frontier/) - [The New Gold Standard of Drug Commercialization](https://www.eversana.com/2020/09/14/the-new-gold-standard-of-drug-commercialization/) - [Global Life Science Services Platform Unites Under New Name, EVERSANA](https://www.eversana.com/2018/10/15/global-life-science-services-platform-unites-under-new-name-eversana-2/) - [Four Ways Predictive Analytics Can Strengthen Your Commercialization Efforts](https://www.eversana.com/2020/12/13/four-ways-predictive-analytics-can-strengthen-your-commercialization-efforts/) - [EVERSANA ACQUIRES ALAMO PHARMA SERVICES AND BEXR LOGISTIX TELESALES](https://www.eversana.com/2019/05/28/eversana-acquires-alamo-pharma-services-and-bexr-logistix-telesales/) - [EVERSANA and OptimizeRx Partnership](https://www.eversana.com/2019/04/30/eversana-and-optimizerx-partnership/) - [EVERSANA Reveals new Market Access Portfolio](https://www.eversana.com/2019/01/30/eversana-reveals-new-market-access-portfolio/) - [Are your ready for Patient Services 2.0?](https://www.eversana.com/2019/10/01/are-your-ready-for-patient-services-2-0/) - [Navigating the Cycle of Supply Chain Complexity](https://www.eversana.com/2019/11/19/navigating-the-cycle-of-supply-chain-complexity/) - [The Year Ahead](https://www.eversana.com/2019/11/01/the-year-ahead/) - [EVERSANA named a Great Place to Work](https://www.eversana.com/2019/10/28/eversana-named-a-great-place-to-work/) - [EVERSANA to acquire Cornerstone Research Group](https://www.eversana.com/2019/10/30/eversana-to-acquire-cornerstone-research-group/) - [How COVID-19 has changed payer engagement strategies](https://www.eversana.com/2020/04/01/how-covid-19-has-changed-payer-engagement-strategies/) - [Agency Profile: EVERSANA ENGAGE](https://www.eversana.com/2020/07/01/agency-profile-eversana-engage/) - [Ask the Experts: How Does Real World Evidence Ensure Market Access?](https://www.eversana.com/2020/03/01/ask-the-experts-how-does-real-world-evidence-ensure-market-access/) - [PharmaVOICE 100 - Peter Marchesini, Pumping Up the Value](https://www.eversana.com/2020/07/29/pharmavoice-100-peter-marchesini-pumping-up-the-value/) - [PharmaVOICE 100 - Commanders & Chiefs: Jim Lang](https://www.eversana.com/2020/07/29/pharmavoice-100-commanders-chiefs-jim-lang/) - [EVERSANA and Noom announce partnership to improve therapy adherence, patient adherence](https://www.eversana.com/2020/01/09/eversana-and-noom-announce-partnership-to-improve-therapy-adherence-patient-adherence/) - [SHOWCASE: Rare Disease: Rare But Not Scarce: The Struggle Faced By Millions](https://www.eversana.com/2020/02/28/showcase-rare-disease-rare-but-not-scarce-the-struggle-faced-by-millions/) - [SHOWCASE: Outsourcing in a New Decade: Changing the Relationship](https://www.eversana.com/2020/02/01/showcase-outsourcing-in-a-new-decade-changing-the-relationship/) - [If I Could Only Ask Two Questions, The First One Would Be: What is Your Data Integration and Analytics Platform Strategy?](https://www.eversana.com/2020/05/03/if-i-could-only-ask-two-questions-the-first-one-would-be-what-is-your-data-integration-and-analytics-platform-strategy/) - [Improving Patient Adherence with Behavioral Health Technology](https://www.eversana.com/2020/04/01/improving-patient-adherence-with-behavioral-health-technology/) - [EVERSANA Appoints Kelly Baker to Chief Financial Officer](https://www.eversana.com/2020/05/04/eversana-appoints-kelly-baker-to-chief-financial-officer-2/) - [Why are we settling for mediocre patient services programs?](https://www.eversana.com/2020/09/01/why-are-we-settling-for-mediocre-patient-services-programs/) - [Zosano Pharma announces partnership agreement with EVERSANA](https://www.eversana.com/2020/08/06/zosano-pharma-announces-partnership-agreement-with-eversana/) - [EVERSANA partners on migraine treatment launch](https://www.eversana.com/2020/08/25/eversana-partners-on-migraine-treatment-launch/) - [EVERSANA named Great Place to Work by global workplace authority for second consecutive year](https://www.eversana.com/2020/11/05/eversana-named-great-place-to-work-by-global-workplace-authority-for-second-consecutive-year/) - [Understanding the Commercial Lifecycle](https://www.eversana.com/2020/10/01/understanding-the-commercial-lifecycle/) - [EVERSANA and Experic form life sciences collaboration](https://www.eversana.com/2020/12/18/eversana-and-experic-form-life-sciences-collaboration/) - [EVERSANA establishes data and analytics offering, appoints Brigham Hyde president](https://www.eversana.com/2020/04/24/eversana-establishes-data-and-analytics-offering-appoints-brigham-hyde-president/) - [Agency 100 2020: EVERSANA ENGAGE](https://www.eversana.com/2020/06/08/agency-100-2020-eversana-engage/) - [EVERSANA ups data and AI power with acquisition of HVH Precision Analytics](https://www.eversana.com/2020/07/16/eversana-ups-data-and-ai-power-with-acquisition-of-hvh-precision-analytics/) ## Pages - [Home](https://www.eversana.com/) - The life sciences sector is changing by the minute. That’s why we’ve built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. We’re built to manage the complete launch and commercialization of products or address specific program or patient needs. We are EVERSANA. - [Awards](https://www.eversana.com/about/awards/) - EVERSANA proudly earns industry accreditations and recognitions for our products and services. - [In-Line Assets](https://www.eversana.com/our-expertise/commercialization-models/mature-brand-growth/) - Run your existing brands better—so you can invest in the future. - [Optimize Launch Performance](https://www.eversana.com/solutions/solve-commercial-challenges/optimize-launch-performance/) - [Distribute in Effective & Efficient Ways](https://www.eversana.com/solutions/solve-commercial-challenges/distribute-in-effective-efficient-ways/) - [Penetrate & Expand Markets](https://www.eversana.com/solutions/solve-commercial-challenges/penetrate-expand-markets/) - [Outsourcing & Operations](https://www.eversana.com/solutions/outsourcing-operations/) - [Maintain Safe & Effective Usage](https://www.eversana.com/solutions/solve-commercial-challenges/maintain-safe-and-effective-usage/) - [Mobilize High Performing Sales Force](https://www.eversana.com/solutions/solve-commercial-challenges/mobilize-high-performance-sales-force/) - [Oncology Commercialization](https://www.eversana.com/our-expertise/commercialization-models/oncology-commercialization/) - EVERSANA’s oncology therapy commercialization model deploys strategies to achieve maximum market impact, drive product adoption and optimize your investments. - [Direct-to-Patient](https://www.eversana.com/our-expertise/commercialization-models/direct-to-patient/) - [Digital Medicines](https://www.eversana.com/our-expertise/therapeutic-depth/digital-medicines/) - [Custom Market Research & Insights](https://www.eversana.com/custom-research-solutions/) - [Cell & Gene](https://www.eversana.com/our-expertise/therapeutic-depth/cell-and-gene/) - [Commercial Readiness in Asia Pacific: China](https://www.eversana.com/our-expertise-global-commercialization-china/) - [Access Commercial Readiness in Asia Pacific](https://www.eversana.com/our-expertise/global-commercialization/apac/) - [Our Leaders](https://www.eversana.com/ourleaders/) - [Pharmacovigilance](https://www.eversana.com/our-services/medical-affairs/pharmacovigilance/) - We elevate pharmacovigilance from a regulatory obligation to a strategic advantage. - [Careers](https://www.eversana.com/careers/) - [Commercial Compliance Solutions](https://www.eversana.com/our-services/medical-affairs/commercial-compliance/) - [Commercialize a Product](https://www.eversana.com/i-want-to/commercialize-a-product/) - EVERSANA’s award-winning life sciences commercialization model delivers an accelerated path to market, reducing the financial risk and streamlining patient care. - [Locations](https://www.eversana.com/about/locations/) - [Clinical Trial Programs](https://www.eversana.com/our-services/patient-services/clinical-trial-programs/) - Streamline your clinical trials with EVERSANA's Direct-to-Participant model to achieve higher participant enrollment, engagement and retention. - [Specialty Pharmacy](https://www.eversana.com/our-services/patient-services/specialty-pharmacy/) - EVERSANA's Specialty Pharmacy combines expert medication management with personalized support to improve outcomes for patients. URAC, ACHC and NABP accredited. - [Events](https://www.eversana.com/events/) - [In-Home Nursing & Clinical Support](https://www.eversana.com/our-services/patient-services/in-home-nursing-and-clinical-support/) - EVERSANA's comprehensive in-home nursing and clinical care solutions improve access, adherence and outcomes for patients with complex conditions. - [Patient Assistance Programs](https://www.eversana.com/our-services/patient-services/affordability-co-pay-and-pap/patient-assistance-programs/) - Streamline patient support with EVERSANA's Patient Assistance Programs, leveraging advanced technology to enhance efficiency and reduce patient barriers. - [AI Accelerator](https://www.eversana.com/our-expertise/ai-accelerator/) - Discover EVERSANA's center of excellence dedicated to transforming every stage of life sciences commercialization with AI. - [Health Communications](https://www.eversana.com/solutions/lifecycle/launch-readiness/health-communications/) - [Market Access Strategies](https://www.eversana.com/our-services/market-access-and-value/market-access-strategies/) - [AI Agency Platform](https://www.eversana.com/products/ai-enabled-marketing/ai-agency/) - Revolutionize life sciences marketing with the industry's first AI Agency platform, built by Google and EVERSANA. - [Navigate Global & Regional Markets](https://www.eversana.com/i-want-to/navigate-global-regional-markets/) - [About Us](https://www.eversana.com/about/) - [Resources Library](https://www.eversana.com/our-services/market-access-and-value/market-access-reimbursement/resources-library/) - [Patient Affordability Programs](https://www.eversana.com/our-services/patient-services/affordability-co-pay-and-pap/co-pay-programs/) - The Intelligent Copay Solution equips manufacturers to navigate evolving industry challenges, including accumulator and maximizer programs, while ensuring consistent patient access to savings and improving gross-to-net performance. - [Market Access & Value](https://www.eversana.com/our-services/market-access-and-value/) - [A European Commercial Readiness Opportunity Assessment](https://www.eversana.com/our-expertise/global-commercialization/european-commercialization/a-european-commercial-readiness-opportunity-assessment/) - EVERSANA has created a fixed-rate “European Commercial Readiness Opportunity Assessment” to help companies develop optimal launch plans, powered by deep market expertise and propriety data & software. - [Assess Commercial Readiness in Europe](https://www.eversana.com/our-expertise/global-commercialization/european-commercialization/) - [Data & Analytics](https://www.eversana.com/products/data-and-analytics/) - [Affordability, Co-Pay & PAP](https://www.eversana.com/our-services/patient-services/affordability-co-pay-and-pap/) - Elevate patient care with EVERSANA's affordability programs, balancing high-tech, high-touch support for better medication access, affordability and adherence. - [Commercial Intelligence 360](https://www.eversana.com/products/data-and-analytics/commercial-intelligence-360/) - [Winning Together! EVERSANA Team Members in India Have Some Friendly Competition](https://www.eversana.com/careers/winning-together-eversana-team-members-in-india-have-some-friendly-competition/) - EVERSANA India APAC Team Members Culture blog - [Regulatory Consulting](https://www.eversana.com/our-services/strategy-and-consulting/regulatory-consulting/) - [Medical Affairs Strategy](https://www.eversana.com/our-services/medical-affairs/medical-affairs-strategy/) - [Digital Transformation & Innovation](https://www.eversana.com/our-services/marketing/digital-transformation-and-innovation/) - [Market Access & Reimbursement](https://www.eversana.com/our-services/market-access-and-value/market-access-reimbursement/) - [Market Shaping Activation Model](https://www.eversana.com/our-services/market-access-and-value/activate-market-shaping/) - [Launch a Product](https://www.eversana.com/our-expertise/commercialization-models/launch-a-product/) - EVERSANA’s award-winning life sciences commercialization model delivers an accelerated path to market, reducing the financial risk and streamlining patient care. - [Adherence Solutions](https://www.eversana.com/our-services/patient-services/adherence-solutions/) - Improve patient adherence with personalized support combining real-time tech, in-home nursing, pharmacists and case managers for better outcomes. - [Access & Hub](https://www.eversana.com/our-services/patient-services/access-and-hub/) - EVERSANA eliminates patient access barriers through real-time data integration and automation, delivering therapies faster and improving patient outcomes. - [Learning & Performance Services](https://www.eversana.com/our-services/field-deployment/learning-and-performance-services/) - [Medical Deployment](https://www.eversana.com/our-services/field-deployment/medical-deployment/) - In light of industry challenges, EVERSANA redefines how to approach medical deployment by embracing innovative strategies that prioritize meeting and exceeding forecast expectations. - [Field Deployment Solutions](https://www.eversana.com/our-services/field-deployment/field-deployment-solutions/) - Drive sales growth, maximize market reach, secure product access and elevate promotional activity with EVERSANA’s contracted sales team for pharma. - [Vacant Territory Management](https://www.eversana.com/our-services/field-deployment/field-deployment-solutions/vacant-territory-management/) - Rapid Response Activation - Vacant Territory Coverage in 5 Days or Less. EVERSANA deploys cross-trained reps to keep territories engaged and forecasts on track. - [e-Commerce](https://www.eversana.com/our-services/distribution-channel-management/e-commerce/) - [Rare](https://www.eversana.com/our-expertise/therapeutic-depth/rare/) - [Oncology](https://www.eversana.com/our-expertise/therapeutic-depth/oncology/) - Discover EVERSANA's center of excellence dedicated to accelerating oncology therapies with scientific rigor, commercial innovation, and patient-first strategies. - [Orchestrate Operating System](https://www.eversana.com/our-expertise/ai-accelerator/orchestrate-operating-system/) - [Leverage Data, AI & Technology](https://www.eversana.com/i-want-to/leverage-date-ai-technology/) - [Optimize Patient Engagement & Access](https://www.eversana.com/i-want-to/optimize-patient-engagement-access/) - [Maximize In-Market Performance](https://www.eversana.com/i-want-to/maximize-in-market-performance/) - [RWE & HEOR](https://www.eversana.com/products/data-and-analytics/rwe-heor/) - [Pricing & Revenue Management](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/) - [HEOR, Value & Evidence](https://www.eversana.com/our-services/market-access-and-value/heor-value-evidence/) - [Commercial Analytics](https://www.eversana.com/products/data-and-analytics/commercial-analytics/) - [Donor Eligibility System](https://www.eversana.com/products/compliance-operations/donor-eligibility-system/) - [Value Assessment & Validations (HEOR & RWE)](https://www.eversana.com/value-assessment-validations-heor-rwe/) - [Integrated Patient Analytics](https://www.eversana.com/products/data-and-analytics/integrated-patient-analytics/) - [Literature Monitoring & Aggregate Authoring](https://www.eversana.com/our-expertise/ai-accelerator/orchestrate-operating-system/literature-monitoring-and-aggregate-authoring/) - Explore the AI-powered platform built by EVERSANA and Quantiphi that is transforming the PV process. - [Privacy Notice](https://www.eversana.com/legal/privacy/) - [ACTICS eAccess](https://www.eversana.com/products/data-and-analytics/actics-eaccess/) - Using electronic connectivity with 1,500+ payers, benefits verification for pharmacy and medical coverage is confirmed in minutes with just five data points. - [Omnichannel](https://www.eversana.com/our-expertise/ai-accelerator/orchestrate-operating-system/omnichannel/) - [Management Consulting](https://www.eversana.com/our-services/strategy-and-consulting/management-consulting/) - At EVERSANA® MANAGEMENT CONSULTING, we are dedicated to transforming the healthcare industry through innovative solutions and strategic insights. - [Regulatory Medical Affairs](https://www.eversana.com/our-services/medical-affairs/regulatory-medical-affairs/) - [Quality Assurance / Quality Management Systems](https://www.eversana.com/our-services/medical-affairs/quality-assurance-quality-management-systems/) - [Medical Information](https://www.eversana.com/our-services/medical-affairs/medical-information/) - [Global Channel Management & 3PL](https://www.eversana.com/our-services/distribution-channel-management/global-channel-management-3pl/) - [Neurology & CNS](https://www.eversana.com/our-expertise/therapeutic-depth/neurology-and-cns/) - [Medical, Legal, Reviews](https://www.eversana.com/our-expertise/ai-accelerator/orchestrate-operating-system/medical-legal-reviews/) - Explore the AI-powered platform built by AWS, EVERSANA and Modus Create, and integrated with Veeva PromoMats, that is transforming the MLR review process. - [Our Products](https://www.eversana.com/products/) - [Corporate Social Responsibility](https://www.eversana.com/about/our-corporate-social-responsibility/) - [Our Beliefs](https://www.eversana.com/about/our-beliefs-2/) - [Our Beliefs](https://www.eversana.com/about/our-beliefs/) - [Compliance Operations](https://www.eversana.com/products/compliance-operations/) - [AI Enabled Marketing](https://www.eversana.com/products/ai-enabled-marketing/) - [Cookie Policy](https://www.eversana.com/legal/privacy/eversana-cookie-policy/) - [Patient Relationship Access](https://www.eversana.com/products/data-and-analytics/patient-relationship-access/) - [Global Pricing & Access](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/global-pricing-access/) - [Pricing & Market Access Products](https://www.eversana.com/products/pricing-and-market-access-products/) - [Patient, Payer & Provider Marketing](https://www.eversana.com/our-services/marketing/patient-payer-and-provider-marketing/) - [Agency Solutions](https://www.eversana.com/our-services/marketing/agency-solutions/) - [Strategy & Consulting](https://www.eversana.com/our-services/strategy-and-consulting/) - [Revenue Management](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/) - [Technology & Data](https://www.eversana.com/our-services/technology-data/) - [Medical Affairs](https://www.eversana.com/our-services/medical-affairs/) - [Marketing](https://www.eversana.com/our-services/marketing/) - [Patient Services](https://www.eversana.com/our-services/patient-services/) - [Field Deployment](https://www.eversana.com/our-services/field-deployment/) - [Distribution & Channel Management](https://www.eversana.com/our-services/distribution-channel-management/) - [Terms of Use](https://www.eversana.com/legal/terms-of-use/) - [HIPAA Practices](https://www.eversana.com/legal/hipaa-practices/) - [Our Services](https://www.eversana.com/our-services/) - [Commercialization Models](https://www.eversana.com/our-expertise/commercialization-models/) - [Global Commercialization](https://www.eversana.com/our-expertise/global-commercialization/) - [Therapeutic Depth](https://www.eversana.com/our-expertise/therapeutic-depth/) - [Our Expertise](https://www.eversana.com/our-expertise/) - [I Want To](https://www.eversana.com/i-want-to/) - [Consulting Careers](https://www.eversana.com/careers/consulting-careers/) - [Corporate Careers](https://www.eversana.com/careers/corporate-careers/) - [Agency Careers](https://www.eversana.com/careers/marketing-branding-careers/) - [Pharma 3PL Careers](https://www.eversana.com/careers/memphis/) - [Commercialization Leadership](https://www.eversana.com/careers/commercialization-leadership/) - [Deployment Solutions Careers](https://www.eversana.com/careers/field-solution-careers/) - [Clinical & Patient Services Careers](https://www.eversana.com/careers/clinical-patient-services-careers/) - [News Resource Center](https://www.eversana.com/news/resource-center/) - [MEDICAL AFFAIRS DIGTIAL ENGAGEMENT AND INNOVATION](https://www.eversana.com/our-services/medical-affairs/medical-information/medical-information-solutions-services/) - [MEDICAL CONTENT DEVELOPMENT](https://www.eversana.com/our-services/medical-affairs/medical-information/medical-information-content-development/) - [MEDICAL LEGAL REGULATORY (MLR) SUPPORT](https://www.eversana.com/our-services/medical-affairs/medical-information/medical-legal-regulatory-mlr-support/) - [Medical Affairs Resources Library](https://www.eversana.com/our-services/medical-affairs/medical-information/medical-information-resources-library/) - [Contact Us](https://www.eversana.com/contact-us/) - [Therapeutic Expertise](https://www.eversana.com/therapeutic-expertise/) - [Life Cycle](https://www.eversana.com/solutions/lifecycle/) - [Solutions](https://www.eversana.com/solutions/) - [Solve Commercial Challenges](https://www.eversana.com/solutions/solve-commercial-challenges/) - [Integrated Commercial Services](https://www.eversana.com/solutions/integrated-commercial-services/) - [Join Our Growing Virtual Call Center Team](https://www.eversana.com/careers/join_virtual_call_center_job/) - [Transparency in Coverage Information](https://www.eversana.com/careers/transparency-in-coverage-information/) - [Generate Real-Time Data and Actionable Insights Across the Product Life Cycle](https://www.eversana.com/our-expertise/commercialization-models/direct-to-patient/generate-real-time-data-and-actionable-insights-across-the-product-life-cycle/) - [Drive Brand Promotion, HCP Adoption and Patient Fulfillment](https://www.eversana.com/our-expertise/commercialization-models/direct-to-patient/drive-brand-promotion-hcp-adoption-and-patient-fulfillment/) - [Streamline Patient Access, Engagement, Treatment Initiation and Adherence](https://www.eversana.com/our-expertise/commercialization-models/direct-to-patient/streamline-patient-access-engagement-treatment-initiation-and-adherence/) - [Patient Resources](https://www.eversana.com/patients/) - [Technology & Innovation](https://www.eversana.com/solutions/technology-innovation/) - [Oncology Market Insights and Strategy](https://www.eversana.com/solutions/solve-commercial-challenges/oncology-and-hematology/oncology-market-insights-and-strategy/) - [Pricing & Market Access](https://www.eversana.com/solutions/integrated-commercial-services/management-consulting/pricing-market-access/) - In a dynamic and fast-changing market environment, a nuanced understanding of pricing and market access is increasingly important for pharmaceutical and biotech companies to succeed commercially. Reimbursement, coding, and the influence of public policy on pricing and access are becoming more complex, requiring careful evaluation and evidence-based solutions. - [Finance Solutions](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/finance-solutions/) - [Brand Strategy & Marketing](https://www.eversana.com/solutions/integrated-commercial-services/management-consulting/brand-strategy-marketing/) - Our Management Consulting brand strategy and marketing practice area is dedicated to supporting marketing and market access leaders. We help you devise effective brand and portfolio strategies that drive execution through impactful campaigns and customer engagements across various functions. - [Data & Analytics Solutions](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/) - [Field Force Optimization Strategies](https://www.eversana.com/solutions/integrated-commercial-services/field-force-optimization-strategies/) - [Advanced Analytics](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/advanced-analytics/) - [Analytics as a Service](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/analytics-as-a-service/) - [Resources Library](https://www.eversana.com/solutions/solve-commercial-challenges/oncology-and-hematology/resources-library/) - [Event and Webinar Privacy Policy](https://www.eversana.com/legal/event-and-webinar-privacy-policy/) - [Video: EVERSANA COMPLETE Commercialization](https://www.eversana.com/videos/eversana-complete-commercialization/) - [Syndicated Market Research & Insights](https://www.eversana.com/our-services/market-access-and-value/market-access-strategies/market-research-and-insights/syndicated-market-research-and-insights/) - [Canadian Accessibility Statement](https://www.eversana.com/legal/canadian-accessibility-statement/) - [Reach Patients & Sustain Adherence](https://www.eversana.com/solutions/solve-commercial-challenges/reach-patients-sustain-adherence/) - [Rx Benchmarks®](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/rx-benchmarks/) - [Commercial Analytics Platform Solutions](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/commercial-analytics-platform-solutions/) - [Pricing and Market Access Analytics](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/pricing-and-market-access-analytics/) - [Integrated Patient-Level Data](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/integrated-patient-level-data/) - [Patient Analytics Services](https://www.eversana.com/solutions/integrated-commercial-services/data-analytics/patient-analytics-services/) - [Processor Terms](https://www.eversana.com/legal/processor-terms/) - [SCCs (Processor) for Client DPA](https://www.eversana.com/legal/scc/) - [Processor Terms](https://www.eversana.com/legal/subprocessor-terms/) - [DTA Inaugural Summit](https://www.eversana.com/dta-inaugural-summit/) - Join EVERSANA's Marty Culjat on June 8, 2023 at 11:05 AM as he joins industry experts on the panel Embracing Innovation in Regulation. - [Ensure Market Access](https://www.eversana.com/solutions/solve-commercial-challenges/ensure-market-access/) - For EVERSANA, Market Access is broader than just payer engagement; it’s getting the right treatment to the right patient at the right time in a consistent and sustained manner, and at an affordable price. - [Optimize Pricing & Reimbursement](https://www.eversana.com/solutions/solve-commercial-challenges/optimize-pricing-reimbursement/) - [Marketing Agency Services](https://www.eversana.com/solutions/integrated-commercial-services/patient-payer-provider-engagement-promotion/) - [CASE STUDY | MEDICAL INFORMATION CARDIOLOGY](https://www.eversana.com/case-studies/case-study-medical-information-cardiology/) - [CASE STUDY | ONCOLOGY MEDICAL INFORMATION](https://www.eversana.com/case-studies/case-study-oncology-medical-information/) - [CASE STUDY | ONCOLOGY TARGETED THERAPIES MEDICAL INFORMATION](https://www.eversana.com/case-studies/case-study-oncology-targeted-therapies-medical-information/) - [CASE STUDY | MEDICAL INFORMATION CART-T CLINICAL TRIAL SUPPORT ](https://www.eversana.com/case-studies/case-study-medical-information-cart-t-clinical-trial-support/) - [CASE STUDY | MEDICAL INFORMATION CLINICAL TRIAL SUPPORT ](https://www.eversana.com/case-studies/case-study-medical-information-clinical-trial-support/) - [CASE STUDY | RARE DISEASE MEDICAL INFORMATION](https://www.eversana.com/case-studies/case-study-rare-disease-medical-information/) - [CASE STUDY | PSYCHIATRY MEDICAL INFORMATION](https://www.eversana.com/case-studies/case-study-psychiatry-medical-information/) - [Achieve Stakeholder Intimacy](https://www.eversana.com/solutions/solve-commercial-challenges/achieve-stakeholder-intimacy/) - [CASE STUDY | EVERY PATIENT MATTERS](https://www.eversana.com/case-studies/every-patient-matters/) - [CASE STUDY | EVERY RELATIONSHIP MATTERS](https://www.eversana.com/case-studies/every-relationship-matters/) - [CASE STUDY | EVERY LIFE MATTERS](https://www.eversana.com/case-studies/every-life-matters/) - [CASE STUDY | ACCESS MATTERS](https://www.eversana.com/case-studies/access-matters/) - [Case Study: STANDARDIZATION AND SCALE MATTERS](https://www.eversana.com/case-studies/standardization-and-scale-matters/) - [CASE STUDY | SAFETY AND EFFECTIVENESS MATTER](https://www.eversana.com/case-studies/safety-and-effectiveness-matter/) - [CASE STUDY | PREFERRED STATUS MATTERS](https://www.eversana.com/case-studies/preferred-status-matters/) - [CASE STUDY | SHARE OF VOICE MATTERS](https://www.eversana.com/case-studies/share-of-voice-matters/) - [CASE STUDY | EVERY HOUR MATTERS](https://www.eversana.com/case-studies/every-hour-matters/) - [CASE STUDY | ANALYSIS MATTERS](https://www.eversana.com/case-studies/analysis-matters/) - [CASE STUDY | PRICING MATTERS](https://www.eversana.com/case-studies/pricing-matters/) - [CASE STUDY | EDUCATION MATTERS](https://www.eversana.com/case-studies/education-matters/) - [CASE STUDY | Brand Re-Entry into Crowded & Generic Market](https://www.eversana.com/case-studies/brand-re-entry/) - [CASE STUDY | FDA INSPECTION EXPERIENCE MATTERS](https://www.eversana.com/case-studies/case-study-fda-inspection-experience-matters/) - [CASE STUDY | DECISIVE ACTION MATTERS](https://www.eversana.com/case-studies/case-study-decisive-action-matters/) - [CASE STUDY | CLINICAL TRIAL EXPERIENCE MATTERS](https://www.eversana.com/case-studies/case-study-clinical-trial-experience-matters/) - [Propel Commercialization with D&A](https://www.eversana.com/solutions/solve-commercial-challenges/propel-commercialization-with-da/) - [VIDEO | ACTICS by EVERSANA: Creating unmatched value for your patients](https://www.eversana.com/videos/actics-by-eversana-creating-unmatched-value-for-your-patients/) - [Mapping the Patient Journey](https://www.eversana.com/solutions/solve-commercial-challenges/mapping-the-patient-journey/) - [CASE STUDY | MEDICAL WRITING WINS IN ADHD](https://www.eversana.com/case-studies/case-study-medical-writing-wins-in-adhd/) - [CASE STUDY | MEDICAL WRITING WINS IN PRIMARY IGA NEPHROPATHY](https://www.eversana.com/case-studies/case-study-medical-writing-wins-in-primary-iga-nephropathy/) - [Form Test - Production](https://www.eversana.com/form-test-production/) - [Form Test - Sandbox](https://www.eversana.com/form-test-sandbox/) - [Specialty Consulting](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/) - [Cookie Test](https://www.eversana.com/cookie-test/) - [this is a test page for pardot](https://www.eversana.com/this-is-a-test-page-for-pardot/) - [Reignite Mature Brand Revenue](https://www.eversana.com/solutions/solve-commercial-challenges/reignite-mature-brand-revenue-2/) - [Contract Operations & BPO](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/contract-operations-bpo/) - [Research & Insights](https://www.eversana.com/solutions/integrated-commercial-services/research-insights/) - [Insights, Data & Software](https://www.eversana.com/insights-data-software/) - [Pricing Governance & Management](https://www.eversana.com/solutions/lifecycle/product-launch/pricing-governance-management/) - [Payer Strategies](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/payer-strategies/) - [TRENDS IN HTA DECISIONS](https://www.eversana.com/videos/trends-in-hta-decisions/) - [IDENTIFY Value Opportunities and Evidence Gaps](https://www.eversana.com/our-services/market-access-and-value/heor-value-evidence/identify/) - [Gross-To-Net](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/revenue-lifecycle-management/gross-to-net/) - [Commercialize Oncology Innovation](https://www.eversana.com/solutions/solve-commercial-challenges/commercialize-oncology-innovation/) - [VIDEO | WODC Online 2021: Commercializing Advanced Therapies for Rare Diseases](https://www.eversana.com/videos/video-wodc-panel-video-2021/) - [Holiday 2021](https://www.eversana.com/internal/holiday-2021/) - [Internal](https://www.eversana.com/internal/) - [Channel & Trade Strategies](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/channel-trade-strategies/) - [Additional Specialty Consulting Practice Areas](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/additional-practice-areas/) - [Patient Services Strategies](https://www.eversana.com/solutions/integrated-commercial-services/specialty-consulting/patient-services-strategies/) - [Canadian Advisory Services](https://www.eversana.com/solutions/integrated-commercial-services/canadian-advisory-services/) - [Canadian Services](https://www.eversana.com/solutions/integrated-commercial-services/canadian-advisory-services/services/) - [Educate and Advocate](https://www.eversana.com/solutions/integrated-commercial-services/patient-payer-provider-engagement-promotion/educate-and-advocate/) - [Management Consulting](https://www.eversana.com/solutions/integrated-commercial-services/management-consulting/) - [Revenue Lifecycle Management](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/revenue-lifecycle-management/) - [Medical Communication and Pharmacovigilance](https://www.eversana.com/solutions/integrated-commercial-services/medical-information-and-pharmacovigilance/) - [VIDEO | 5 Brand Planning Must-Haves](https://www.eversana.com/videos/5-brand-planning-must-haves/) - [VIDEO | Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal](https://www.eversana.com/videos/leadership-briefing-the-u-s-pharmaceutical-market-outlook-the-path-to-recovery-and-the-new-normal/) - [Reignite Mature Brand Revenue](https://www.eversana.com/solutions/solve-commercial-challenges/reignite-mature-brand-revenue/) - [Article 1](https://www.eversana.com/article-1/) - [Subprocessors](https://www.eversana.com/legal/subprocessors/) - [Webinar | Achieve Price and Access Launch Excellence in a Disrupted World](https://www.eversana.com/videos/webinar-achieve-price-and-access-launch-excellence-in-a-disrupted-world/) - [Webinar | Insights From Trade & Channel Strategies Conference 2020](https://www.eversana.com/webinar-insights-from-trade-channel-strategies-conference-2020/) - [Webinar | DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration](https://www.eversana.com/videos/webinar-dscsa-guidelines-best-practices-for-compliance-and-supply-chain-integration/) - [VIDEO | DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration](https://www.eversana.com/videos/best-practices-for-compliance-and-supply-chain-integration/) - [Training Facilitation](https://www.eversana.com/our-services/field-deployment/learning-and-performance-services/training-facilitation/) - [Technology Platform](https://www.eversana.com/our-services/field-deployment/learning-and-performance-services/technology-platform/) - [Curriculum Design & Content Development](https://www.eversana.com/our-services/field-deployment/learning-and-performance-services/curriculum-design-content-development/) - [VIDEO | Solving Hard Go-To-Market Challenges](https://www.eversana.com/videos/video-solving-hard-go-to-market-challenges/) - [Snowflake Webinar Recording: Five Biggest Data Challenges for Life Sciences](https://www.eversana.com/snowflake-webinar-recording-five-biggest-data-challenges-for-life-sciences/) - [NEXT GENERATION COMMERCIALIZATION - A Conversation With The Innovators](https://www.eversana.com/videos/next-generation-commercialization-a-conversation-with-the-innovators/) - [Behavioral Health Technology to Improve Patient Outcomes & Adherence](https://www.eversana.com/videos/behavioral-health-technology-to-improve-patient-outcomes-adherence/) - [VIDEO | NEXT GENERATION COMMERCIALIZATION: A Conversation with the Innovators Part II](https://www.eversana.com/videos/video-next-gen-commercialization-partii/) - [VIDEO | NEXT GENERATION COMMERCIALIZATION: A Conversation with the Innovators](https://www.eversana.com/videos/conversation-with-the-innovators/) - [Videos](https://www.eversana.com/videos/) - [CASE STUDY | OPERATIONAL EXCELLENCE MATTERS](https://www.eversana.com/case-studies/case-study-operational-excellence-matters/) - [SPOPTIMIZER by EVERSANA™ | User Guide](https://www.eversana.com/solutions/integrated-commercial-services/research-insights/spoptimizer-by-eversana-user-guide/) - [Case Studies](https://www.eversana.com/case-studies/) - [Field Solutions Employee Referral Program](https://www.eversana.com/field-solutions-employee-referral-program/) - [Product Launch](https://www.eversana.com/solutions/lifecycle/product-launch/) - [Launch Readiness](https://www.eversana.com/solutions/lifecycle/launch-readiness/) - [Seeker Health® by EVERSANA](https://www.eversana.com/solutions/solve-commercial-challenges/reach-patients-sustain-adherence/seeker-video/) - The patient-finding technology for Rare and Complex Diseases. - [ACCESSEXPRESS® by EVERSANA: Be curious. Discover the unexpected.](https://www.eversana.com/solutions/integrated-commercial-services/research-insights/accessexpress-video/) - Simple, self-service market research tool that streamlines the complexities of the survey process - [COMMUNICATE Overall Value to Stakeholders](https://www.eversana.com/our-services/market-access-and-value/heor-value-evidence/communicate/) - [DEMONSTRATE Clinical and Economic Benefits](https://www.eversana.com/our-services/market-access-and-value/heor-value-evidence/demonstrate/) - [Seeker Portal™: Training Video](https://www.eversana.com/client-login/seeker-portal-training/) - Simple, self-service market research tool that streamlines the complexities of the survey process - [Membership Management by MemberCentric](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/revenue-lifecycle-management/membership-management-by-membercentric/) - [Optimize Product Launch](https://www.eversana.com/solutions/solve-commercial-challenges/optimize-product-launch/) - [Patient Journey](https://www.eversana.com/solutions/integrated-commercial-services/patient-journey/) - [Pricing Data](https://www.eversana.com/solutions/integrated-commercial-services/pricing-data/) - [Terms and Conditions - Samsca](https://www.eversana.com/legal/terms-and-conditions-samsca/) - [Terms and Conditions - CopayConnect](https://www.eversana.com/legal/terms-and-conditions-copayconnect/) - [Legal](https://www.eversana.com/legal/) - [Syndicated Research & Insights](https://www.eversana.com/solutions/integrated-commercial-services/research-insights/syndicated-research-insights/) - [Custom Market Research](https://www.eversana.com/solutions/integrated-commercial-services/research-insights/custom-market-research/) - [Government Pricing & Compliance](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/government-pricing-compliance/) - [Contract Analytics](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/revenue-lifecycle-management/contract-analytics/) - [Revenue Systems Implementations](https://www.eversana.com/our-services/market-access-and-value/pricing-revenue-management/revenue-management/revenue-lifecycle-management/revenue-systems-implementations/) - [Thank You](https://www.eversana.com/contact-us/thank-you/) - [Client Login](https://www.eversana.com/client-login/) - [Resources and Insights](https://www.eversana.com/resources-and-insights/) ## Content Library - [When A Curveball Threatens Your Product’s Launch](https://www.eversana.com/content-library/when-a-curveball-threatens-your-products-launch/) - [EVERSANA COMPLETE Commercialization in Action](https://www.eversana.com/content-library/complete-speed/) - [EVERSANA COMPLETE Commercialization in Action](https://www.eversana.com/content-library/complete-agility-model-redesign/) - [COMPLETE Commercialization: Risk Management & Aligned Incentives](https://www.eversana.com/content-library/complete-commercialization-risk-management/) - [Cost‑Effectiveness of Biosimilar Denosumab Versus Bisphosphonatesin Postmenopausal Osteoporosis](https://www.eversana.com/content-library/cost-effectiveness-of-biosimilar-denosumab-versus-bisphosphonatesin-postmenopausal-osteoporosis/) - [Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017–2024](https://www.eversana.com/content-library/outpatient-rsv-testing-rates-among-us-adults-with-lower-respiratory-tract-disease-2017-2024/) - [The environmental impact of tibial fracture-related infections](https://www.eversana.com/content-library/the-environmental-impact-of-tibial-fracture-related-infections/) - [Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants](https://www.eversana.com/content-library/efficacy-of-inebilizumab-in-n-momentum-trial-participants-with-or-without-prior-immunosuppressants/) - [Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis](https://www.eversana.com/content-library/indirect-comparison-of-nipocalimab-versus-efgartigimod-and-rozanolixizumab-in-the-treatment-of-generalized-myasthenia-gravis/) - [An economic analysis of Chemo Mouthpiece® versus supportive care for the reduction of oral mucositis incidence in patients receiving chemotherapy](https://www.eversana.com/content-library/an-economic-analysis-of-chemo-mouthpiece-versus-supportive-care-for-the-reduction-of-oral-mucositis-incidence-in-patients-receiving-chemotherapy/) - [Clinical and economic impact of vascular access teams utilizing an IC-ECG-based tip confirmation system for peripherally inserted central catheters](https://www.eversana.com/content-library/clinical-and-economic-impact-of-vascular-access-teams-utilizing-an-ic-ecg-based-tip-confirmation-system-for-peripherally-inserted-central-catheters/) - [Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and persistent anemia despite C5-inhibitor treatment](https://www.eversana.com/content-library/indirect-treatment-comparison-of-iptacopan-versus-pegcetacoplan-for-patients-with-paroxysmal-nocturnal-hemoglobinuria-and-persistent-anemia-despite-c5-inhibitor-treatment/) - [Clinical and cost impact of Cabazitaxel versus Lutetium-177 vipivotide tetraxetan (Lu-PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC)](https://www.eversana.com/content-library/clinical-and-cost-impact-of-cabazitaxel-versus-lutetium-177-vipivotide-tetraxetan-lu-psma-for-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc/) - [The Burden of Delayed Diabetic Retinopathy Management and Use of Artificial Intelligence-Driven Screening Tools: A Systematic Literature Review](https://www.eversana.com/content-library/the-burden-of-delayed-diabetic-retinopathy-management-and-use-of-artificial-intelligence-driven-screening-tools-a-systematic-literature-review/) - [Delphi working group. Delphi panel on neuromodulation as a treatment strategy for dry eye disease: Unlocking the potential of natural tear production](https://www.eversana.com/content-library/delphi-working-group-delphi-panel-on-neuromodulation-as-a-treatment-strategy-for-dry-eye-disease-unlocking-the-potential-of-natural-tear-production/) - [Economic Evaluation of Ready-to-Dilute Thiotepa (Tepylute®): Institutional Cost Offsets and Time Savings Compared to Lyophilized Thiotepa in a United States Hospital Pharmacy](https://www.eversana.com/content-library/economic-evaluation-of-ready-to-dilute-thiotepa-tepylute-institutional-cost-offsets-and-time-savings-compared-to-lyophilized-thiotepa-in-a-united-states-hospital-pharmacy/) - [Radiographic Progression-Free Survival as a Surrogate Endpoint for Overall Survival in First-Line ARPi Naïve Metastatic Castration-Resistant Prostate Cancer](https://www.eversana.com/content-library/radiographic-progression-free-survival-as-a-surrogate-endpoint-for-overall-survival-in-first-line-arpi-naive-metastatic-castration-resistant-prostate-cancer/) - [Systematic Review of Prognostic Factors and Treatment Effect Modifiers for Transthyretin Amyloid Cardiomyopathy](https://www.eversana.com/content-library/systematic-review-of-prognostic-factors-and-treatment-effect-modifiers-for-transthyretin-amyloid-cardiomyopathy/) - [Interim results from the HER-TEMPO Study: Real-world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan.](https://www.eversana.com/content-library/interim-results-from-the-her-tempo-study-real-world-study-of-treatment-discontinuations-and-modifications-for-patients-with-her2-low-metastatic-breast-cancer-on-trastuzumab-deruxtecan/) - [Interim results from the HER-TEMPO Study: Real-world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan.](https://www.eversana.com/content-library/interim-results-from-the-her-tempo-study-real-world-study-of-treatment-discontinuations-and-modifications-for-patients-with-her2-positive-metastatic-breast-cancer-on-trastuzumab-deruxtecan/) - [Clinical and Economic Impacts of a Multidisciplinary Approach for Reducing the Risk of Catheter-Related Thrombosis in a U.S. Health System: A Retrospective Study](https://www.eversana.com/content-library/clinical-and-economic-impacts-of-a-multidisciplinary-approach-for-reducing-the-risk-of-catheter-related-thrombosis-in-a-u-s-health-system-a-retrospective-study-2/) - [Operationalizing an Outcomes-Based MarketAccess Agreement Using Real-World Data From the Canadian Neuromuscular Disease Registry](https://www.eversana.com/content-library/operationalizing-an-outcomes-based-marketaccess-agreement-using-real-world-data-from-the-canadian-neuromuscular-disease-registry/) - [Bayesian non-parametric lumping and splitting of nodes in Network Meta-Analysis under heterogeneity](https://www.eversana.com/content-library/bayesian-non-parametric-lumping-and-splitting-of-nodes-in-network-meta-analysis-under-heterogeneity/) - [Prevention of Catheter-Related Infections and Complications: A Narrative Literature Review of Vascular Care and Maintenance](https://www.eversana.com/content-library/prevention-of-catheter-related-infections-and-complications-a-narrative-literature-review-of-vascular-care-and-maintenance/) - [Cost-effectiveness analysis of efgartigimod vs chronic immunoglobulin for the treatment of myasthenia gravis in Canada](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-efgartigimod-vs-chronic-immunoglobulin-for-the-treatment-of-myasthenia-gravis-in-canada/) - [Impact of the Next Generation of Phacoemulsification System on Cataract Surgery Efficiency: A Time and Motion Study](https://www.eversana.com/content-library/impact-of-the-next-generation-of-phacoemulsification-system-on-cataract-surgery-efficiency-a-time-and-motion-study/) - [A Multicenter Time and Motion Study Assessing The Efficiency Impact Of The Next Generation Of Phacoemulsification System On Cataract Surgery](https://www.eversana.com/content-library/a-multicenter-time-and-motion-study-assessing-the-efficiency-impact-of-the-next-generation-of-phacoemulsification-system-on-cataract-surgery/) - [A Time and Motion Study Assessing The Efficiency Impact Of The Next Generation Of Phacoemulsification System On Cataract Surgery Turnover](https://www.eversana.com/content-library/a-time-and-motion-study-assessing-the-efficiency-impact-of-the-next-generation-of-phacoemulsification-system-on-cataract-surgery-turnover/) - [Post-Operative Chair Time Requirement for Advanced Technology Intraocular Lenses: A Real-World Prospective Comparative Observational Study](https://www.eversana.com/content-library/post-operative-chair-time-requirement-for-advanced-technology-intraocular-lenses-a-real-world-prospective-comparative-observational-study/) - [A Real-World, Prospective, Comparative Study of Postoperative Chair Time for Advanced Technology IOLs](https://www.eversana.com/content-library/a-real-world-prospective-comparative-study-of-postoperative-chair-time-for-advanced-technology-iols/) - [Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review](https://www.eversana.com/content-library/ranking-the-importance-of-prognostic-factors-for-relapsed-refractory-multiple-myeloma-international-physician-panel-consensus-following-a-systematic-literature-review/) - [Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol](https://www.eversana.com/content-library/canadian-real-world-hybrid-longitudinal-cohort-study-of-treatment-discontinuations-and-modifications-for-patients-with-her2-and-her2-low-metastatic-breast-cancer-on-trastuzumab-deruxtecan-enrolled-in/) - [Cost-effectiveness of insulin icodec for the treatment of type 2diabetes in Canada](https://www.eversana.com/content-library/cost-effectiveness-of-insulin-icodec-for-the-treatment-of-type-2diabetes-in-canada/) - [Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review](https://www.eversana.com/content-library/global-societal-burden-of-alzheimers-disease-by-severity-a-targeted-literature-review/) - [Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis](https://www.eversana.com/content-library/network-meta-analysis-of-1-5-ruxolitinib-cream-versus-systemic-agents-in-the-treatment-of-moderate-atopic-dermatitis/) - [Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-biosimilar-denosumab-for-the-treatment-of-women-with-post-menopausal-osteoporosis-in-the-united-states-a-risk-based-analysis/) - [Cost-effectiveness analysis of somapacitan-beco versus somatropin in the treatment of patients with pediatric growth hormone deficiency (GHD) in the United States](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-somapacitan-beco-versus-somatropin-in-the-treatment-of-patients-with-pediatric-growth-hormone-deficiency-ghd-in-the-united-states/) - [Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis](https://www.eversana.com/content-library/mission-impossible-caveats-in-interpreting-and-comparing-long-term-efficacy-in-biologic-studies-for-moderate-to-severe-plaque-psoriasis-2/) - [A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks.](https://www.eversana.com/content-library/a-matching-adjusted-indirect-comparison-of-guselkumab-and-secukinumab-in-patients-with-psoriatic-arthritis-over-52-weeks/) - [Supporting a New Product Launch With Flexibility](https://www.eversana.com/content-library/supporting-a-new-product-launch-with-flexibility/) - [Supporting a Product Launch With Excellence](https://www.eversana.com/content-library/supporting-a-product-launch-with-excellence/) - [Supporting a Product Launch With Readiness](https://www.eversana.com/content-library/supporting-a-product-launch-with-readiness/) - [Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis](https://www.eversana.com/content-library/identifying-challenges-and-solutions-for-indirect-comparisons-in-myasthenia-gravis/) - [Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review](https://www.eversana.com/content-library/real-world-eck6461-breast-cancer-systematic-review/) - [Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes](https://www.eversana.com/content-library/where-process-meets-profit-how-strategic-order-to-cash-drives-real-revenue-outcomes/) - [Navigating the Not-So-Direct Path to Access – A Pharmacist’s Perspective](https://www.eversana.com/content-library/navigating-the-not-so-direct-path-to-access-a-pharmacists-perspective/) - [End-to-End MLR Coordinator Services](https://www.eversana.com/content-library/end-to-end-mlr-coordinator-services/) - [Comprehensive Commercialization and MLR Support](https://www.eversana.com/content-library/comprehensive-commercialization-and-mlr-support/) - [Expanding Services for Global MLR Coordinator Support](https://www.eversana.com/content-library/expanding-services-for-global-mlr-coordinator-support/) - [Global Fact-Checking Support for Medical Review Efficiency](https://www.eversana.com/content-library/global-fact-checking-support-for-medical-review-efficiency/) - [Comprehensive Commercialization and Medical Review Support for US Product Launch](https://www.eversana.com/content-library/comprehensive-commercialization-and-medical-review-support-for-us-product-launch/) - [US Medical Review Support](https://www.eversana.com/content-library/us-medical-review-support/) - [Large Pharmaceutical Company Transition to Navigable SRDs](https://www.eversana.com/content-library/large-pharmaceutical-company-transition-to-navigable-srds/) - [Handling Support for Maintenance of Med Info Materials](https://www.eversana.com/content-library/handling-support-for-maintenance-of-med-info-materials/) - [Product Launch Readiness for Advanced Cell Therapy](https://www.eversana.com/content-library/product-launch-readiness-for-advanced-cell-therapy/) - [Supporting a New Product Launch](https://www.eversana.com/content-library/supporting-a-new-product-launch/) - [Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema](https://www.eversana.com/content-library/network-meta-analysis-of-pharmacological-therapies-for-long-term-prophylactic-treatment-of-patients-with-hereditary-angioedema/) - [Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid](https://www.eversana.com/content-library/continuous-glucose-monitoring-for-self-management-of-diabetes-in-people-living-with-type-2-diabetes-mellitus-on-basal-insulin-therapy-a-microsimulation-model-and-cost-effectiveness-analysis-from-a-u-2/) - [Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective](https://www.eversana.com/content-library/cost-utility-analysis-of-a-flash-continuous-glucose-monitoring-system-in-the-management-of-people-with-type-2-diabetes-mellitus-on-basal-insulin-therapy-an-italian-healthcare-system-perspective-2/) - [One-year budget impact of InTandem, a Novel Neurorehabilitation System for Patients with Chronic Stroke Walking Impairment](https://www.eversana.com/content-library/one-year-budget-impact-of-intandem-a-novel-neurorehabilitation-system-for-patients-with-chronic-stroke-walking-impairment-2/) - [Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system](https://www.eversana.com/content-library/evaluating-unmet-needs-in-large-volume-subcutaneous-drug-delivery-u-s-payer-perspectives-on-a-novel-large-volume-on-body-delivery-system/) - [Multidisciplinary Delphi Panel on Rehabilitation Approaches and Unmet Needs for Chronic Stroke Walking Impairment and the Role of Rhythmic Auditory Stimulation](https://www.eversana.com/content-library/multidisciplinary-delphi-panel-on-rehabilitation-approaches-and-unmet-needs-for-chronic-stroke-walking-impairment-and-the-role-of-rhythmic-auditory-stimulation/) - [One-year budget impact of InTandem™: a novel neurorehabilitation system for individuals with chronic stroke walking impairment](https://www.eversana.com/content-library/one-year-budget-impact-of-intandem-a-novel-neurorehabilitation-system-for-individuals-with-chronic-stroke-walking-impairment/) - [Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies](https://www.eversana.com/content-library/brain-volume-loss-in-relapsing-multiple-sclerosis-indirect-treatment-comparisons-of-available-disease-modifying-therapies/) - [Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i](https://www.eversana.com/content-library/systematic-literature-review-of-real-world-evidence-for-treatments-in-hr-her2-second-line-labc-mbc-after-first-line-treatment-with-cdk4-6i/) - [Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence](https://www.eversana.com/content-library/efficacy-and-safety-of-crizotinib-in-the-treatment-of-advanced-non-small-cell-lung-cancer-with-ros1-gene-fusion-a-systematic-literature-review-and-meta-analysis-of-real-world-evidence-2/) - [The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective](https://www.eversana.com/content-library/the-economic-impact-associated-with-stent-retriever-selection-for-the-treatment-of-acute-ischemic-stroke-a-cost-effectiveness-analysis-of-mastro-i-data-from-a-chinese-healthcare-system-perspe-2/) - [A U.S. payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease](https://www.eversana.com/content-library/a-u-s-payer-budget-impact-analysis-of-flurpiridaz-pet-mpi-compared-to-spect-mpi-in-the-diagnosis-of-coronary-artery-disease-2/) - [Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer](https://www.eversana.com/content-library/systematic-literature-review-and-meta-analysis-of-health-state-utility-values-in-metastatic-castration-resistant-prostate-cancer-2/) - [Pitch Perfect: Strategic Guidance for Biotech Phase II Asset Acquisition](https://www.eversana.com/content-library/pitch-perfect-strategic-guidance-for-biotech-phase-ii-asset-acquisition/) - Pitch Deck: Partnership and/or Acquisition for an Oncology Asset - [The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective](https://www.eversana.com/content-library/the-economic-impact-associated-with-stent-retriever-selection-for-the-treatment-of-acute-ischemic-stroke-a-cost-effectiveness-analysis-of-mastro-i-data-from-a-chinese-healthcare-system-perspe/) - [Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada](https://www.eversana.com/content-library/cost-consequence-analysis-of-ofatumumab-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-canada/) - [Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence](https://www.eversana.com/content-library/efficacy-and-safety-of-crizotinib-in-the-treatment-of-advanced-non-small-cell-lung-cancer-with-ros1-gene-fusion-a-systematic-literature-review-and-meta-analysis-of-real-world-evidence/) - [A U.S. payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease](https://www.eversana.com/content-library/a-u-s-payer-budget-impact-analysis-of-flurpiridaz-pet-mpi-compared-to-spect-mpi-in-the-diagnosis-of-coronary-artery-disease/) - [Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer](https://www.eversana.com/content-library/systematic-literature-review-and-meta-analysis-of-health-state-utility-values-in-metastatic-castration-resistant-prostate-cancer/) - [Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons](https://www.eversana.com/content-library/comparative-efficacy-of-ofatumumab-versus-oral-therapies-for-relapsing-multiple-sclerosis-patients-using-propensity-score-analyses-and-simulated-treatment-comparisons/) - [Clinical and Economic Impacts of a Multidisciplinary Approach for Reducing the Risk of Catheter-Related Thrombosis in a U.S. Health System: A Retrospective Study](https://www.eversana.com/content-library/clinical-and-economic-impacts-of-a-multidisciplinary-approach-for-reducing-the-risk-of-catheter-related-thrombosis-in-a-u-s-health-system-a-retrospective-study/) - [Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early Onset Severe Toxicity](https://www.eversana.com/content-library/economic-model-of-uridine-triacetate-versus-supportive-care-for-the-treatment-of-patients-with-life-threatening-early-onset-severe-toxicity/) - [Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-efgartigimod-versus-chronic-intravenous-immunoglobulin-ivig-for-treatment-of-acetylcholine-receptor-antibody-positive-achr-ab-generalized-myasthenia-gravis-gmg-in/) - [Identifying Critical Evidence Gaps in Wound CLosure and Incision Management After Total Knee Arthroplasty: Delphi Panel Insights](https://www.eversana.com/content-library/identifying-critical-evidence-gaps-in-wound-closure-and-incision-management-after-total-knee-arthroplasty-delphi-panel-insights/) - [Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective](https://www.eversana.com/content-library/modelling-the-opportunity-for-cost-savings-or-patient-access-with-biosimilar-adalimumab-and-tocilizumab-a-european-perspective/) - [Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid](https://www.eversana.com/content-library/continuous-glucose-monitoring-for-self-management-of-diabetes-in-people-living-with-type-2-diabetes-mellitus-on-basal-insulin-therapy-a-microsimulation-model-and-cost-effectiveness-analysis-from-a-us/) - [Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective](https://www.eversana.com/content-library/cost-utility-analysis-of-a-flash-continuous-glucose-monitoring-system-in-the-management-of-people-with-type-2-diabetes-mellitus-on-basal-insulin-therapy-an-italian-healthcare-system-perspective/) - [Urine output is an early and strong predictor of acute kidney injury and associated mortality: a systematic literature review of 50 clinical studies](https://www.eversana.com/content-library/urine-output-is-an-early-and-strong-predictor-of-acute-kidney-injury-and-associated-mortality-a-systematic-literature-review-of-50-clinical-studies/) - [One-year Budget Impact of InTandem, a Novel Neurorehabilitation System for Patients with Chronic Stroke Walking Impairment](https://www.eversana.com/content-library/one-year-budget-impact-of-intandem-a-novel-neurorehabilitation-system-for-patients-with-chronic-stroke-walking-impairment/) - [Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis](https://www.eversana.com/content-library/mission-impossible-caveats-in-interpreting-and-comparing-long-term-efficacy-in-biologic-studies-for-moderate-to-severe-plaque-psoriasis/) - [Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective](https://www.eversana.com/content-library/cost-effectiveness-of-freestyle-libre-for-glucose-self-management-among-people-with-diabetes-mellitus-a-canadian-private-payer-perspective/) - [Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus – An economic evaluation](https://www.eversana.com/content-library/addition-of-continuous-glucose-monitoring-to-glucagon-like-peptide-1-receptor-agonist-treatment-for-type-2-diabetes-mellitus-an-economic-evaluation/) - [Costs of treating cataract surgery complications from a US provider perspective: a micro-costing approach for health economic analyses](https://www.eversana.com/content-library/costs-of-treating-cataract-surgery-complications-from-a-us-provider-perspective-a-micro-costing-approach-for-health-economic-analyses/) - [Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis & Matching-adjusted Indirect Comparison](https://www.eversana.com/content-library/teprotumumab-improves-quality-of-life-in-thyroid-eye-disease-meta-analysis-matching-adjusted-indirect-comparison/) - [Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis](https://www.eversana.com/content-library/daratumumab-lenalidomide-and-dexamethasone-versus-bortezomib-lenalidomide-and-dexamethasone-in-transplant-ineligible-newly-diagnosed-multiple-myeloma-a-systematic-literature-review-and-meta-analy/) - [Maximize Access](https://www.eversana.com/content-library/maximize-access/) - [Maximize Price](https://www.eversana.com/content-library/maximize-price/) - [Maximize Coverage](https://www.eversana.com/content-library/maximize-coverage/) - [Representative Engagements: Patient Access Platform for Digital Medicine Device](https://www.eversana.com/content-library/representative-engagements-patient-access-platform-for-digital-medicine-device/) - EVERSANA's patient access platform was customized to process prescriptions for a digital medicine product from a prescribing HCP, followed by reimbursement support, payment collection and dispensing using its specialty pharmacy. - [Artificial Intelligence in Real-World Evidence Generation: Systematic Review of Applications and Challenges](https://www.eversana.com/content-library/artificial-intelligence-in-real-world-evidence-generation-systematic-review-of-applications-and-challenges/) - [The Effectiveness of Telemedicine in Improving Access to Healthcare Services: A Systematic Review](https://www.eversana.com/content-library/the-effectiveness-of-telemedicine-in-improving-access-to-healthcare-services-a-systematic-review/) - [Cost-Effectiveness Analysis of 1.5% Ruxolitinib Cream for the Treatment of Patients With Atopic Dermatitis in Canada](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-1-5-ruxolitinib-cream-for-the-treatment-of-patients-with-atopic-dermatitis-in-canada/) - [Role of Health-Economics Application in Enhancing Personalized Medicine: A Comprehensive Systematic Review](https://www.eversana.com/content-library/role-of-health-economics-application-in-enhancing-personalized-medicine-a-comprehensive-systematic-review/) - [A Literature Review to Identify Prognostic Factors and Treatment Effect Modifiers in Population-Adjusted Indirect Comparisons for Multiple Myeloma](https://www.eversana.com/content-library/a-literature-review-to-identify-prognostic-factors-and-treatment-effect-modifiers-in-population-adjusted-indirect-comparisons-for-multiple-myeloma/) - [Health Economics Studies Assessment of the 2ND China Rare Disease Catalogue: A Scoping Review](https://www.eversana.com/content-library/health-economics-studies-assessment-of-the-2nd-china-rare-disease-catalogue-a-scoping-review/) - [CAR-T Cell Therapy Accessibility: A Targeted Review of Access Challenges and Opportunities in APAC Region](https://www.eversana.com/content-library/car-t-cell-therapy-accessibility-a-targeted-review-of-access-challenges-and-opportunities-in-apac-region/) - [Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada](https://www.eversana.com/content-library/model-projected-clinical-outcomes-of-exagamglogene-autotemcel-exa-cel-in-patients-with-sickle-cell-disease-with-recurrent-vaso-occlusive-crises-in-canada/) - [Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada](https://www.eversana.com/content-library/budget-impact-analyses-of-hemoglobin-a1c-and-lipid-panel-point-of-care-testing-with-afinion-2-in-italy-and-canada/) - [Treatment Patterns and Economic Burden of Guillain-Barré Syndrome: A Systematic Review](https://www.eversana.com/content-library/treatment-patterns-and-economic-burden-of-guillain-barre-syndrome-a-systematic-review/) - [Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis](https://www.eversana.com/content-library/evaluating-the-clinical-and-socioeconomic-impact-of-improved-ckd-diagnosis-and-adherence-to-guideline-directed-medical-therapy-in-australia-brazil-and-china-an-impact-ckd-analysis/) - [Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Transfusion-Dependent Beta-Thalassemia in Canada](https://www.eversana.com/content-library/model-projected-clinical-outcomes-of-exagamglogene-autotemcel-exa-cel-in-patients-with-transfusion-dependent-beta-thalassemia-in-canada/) - [Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems](https://www.eversana.com/content-library/systematic-literature-review-of-cost-effectiveness-evaluations-of-freestyle-libre-continuous-glucose-monitoring-systems/) - [Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients](https://www.eversana.com/content-library/systematic-literature-review-slr-of-randomized-controlled-trials-rcts-of-treatments-for-first-line-1l-gastric-cancer-gastroesophageal-junction-adenocarcinoma-gc-gej-in-adult-patients/) - [Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors](https://www.eversana.com/content-library/indirect-treatment-comparison-of-iptacopan-versus-eculizumab-and-ravulizumab-for-patients-with-paroxysmal-nocturnal-hemoglobinuria-naive-to-c5-inhibitors/) - [NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs](https://www.eversana.com/content-library/nice-vs-smc-reimbursement-differences-for-non-oncology-orphan-drugs/) - [Patient-Centric Approaches in Rare Disorder Research: An In-Depth Systematic Review](https://www.eversana.com/content-library/patient-centric-approaches-in-rare-disorder-research-an-in-depth-systematic-review/) - [Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L](https://www.eversana.com/content-library/health-state-utility-values-for-patients-with-paroxysmal-nocturnal-hemoglobinuria-using-eq-5d-5l/) - [The Economic and Environmental Burden of Hydrophilic and Hydrophobic IOLs in the UK](https://www.eversana.com/content-library/the-economic-and-environmental-burden-of-hydrophilic-and-hydrophobic-iols-in-the-uk/) - [Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)](https://www.eversana.com/content-library/systematic-literature-review-slr-of-disease-burden-related-to-first-line-1l-unresectable-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-escc/) - [Coding and Reimbursement Assessment for Potential Acquisition](https://www.eversana.com/content-library/coding-and-reimbursement-assessment-for-potential-acquisition/) - [Radiopharmaceutical Indication Prioritization](https://www.eversana.com/content-library/radiopharmaceutical-indication-prioritization/) - Case Study: Radiopharmaceutical Indication Prioritization - [Pricing Strategy for Inpatient Therapy](https://www.eversana.com/content-library/pricing-strategy-for-inpatient-therapy/) - Case Study: Pricing Strategy for Inpatient Therapy - [Cardiovascular Disease State Assessment with EVERSANA Management Consulting](https://www.eversana.com/content-library/cardiovascular-disease-state-assessment-with-eversana-management-consulting/) - Case Study:" Cardiovascular Disease State Assessment with EVERSANA Management Consulting - [Integrated Brand Planning with EVERSANA MANAGEMENT CONSULTING](https://www.eversana.com/content-library/integrated-brand-planning-with-eversana-management-consulting/) - Case Study: Integrated Brand Planning with EVERSANA Management Consulting - [Optimizing Patient Journey with EVERSANA MANAGEMENT CONSULTING](https://www.eversana.com/content-library/optimizing-patient-journey-with-eversana-management-consulting/) - Case Study: Patient Journey with EVERSANA MANAGEMENT CONSULTING - [Assess MPS II Diagnosis and Treatment Referral Pathways and Identify Potential Patients via Predictive Modeling](https://www.eversana.com/content-library/assess-mps-ii-diagnosis-and-treatment-referral-pathways-and-identify-potential-patients-via-predictive-modeling/) - [Finding APDS Patients Using Predictive Models](https://www.eversana.com/content-library/finding-apds-patients-using-predictive-models/) - [Machine Learning Model Using Insurance Claims Data to Help Predict ALS Diagnosis](https://www.eversana.com/content-library/machine-learning-model-using-insurance-claims-data-to-help-predict-als-diagnosis/) - [Predictive Modeling for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)](https://www.eversana.com/content-library/predictive-modeling-for-treatment-of-relapsing-remitting-multiple-sclerosis-rrms/) - Predictive Modeling for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS): Understanding First-Line Treatment and Factors Leading to Treatment Switching via Machine Learning - [Assessing the Telehealth Treatment Landscape and Building Predictive Models (AI/ML) to Identify Patients/Providers Most Likely to Use Telehealth](https://www.eversana.com/content-library/assessing-the-telehealth-treatment-landscape-and-building-predictive-models-ai-ml-to-identify-patients-providers-most-likely-to-use-telehealth/) - Assessing the Telehealth Treatment Landscape and Building Predictive Models (AI/ML) to Identify Patients/Providers Most Likely to Use Telehealth - [Identifying Potential High-Risk Factor Arrhythmia Patients Using Predictive Modeling](https://www.eversana.com/content-library/identifying-potential-high-risk-factor-arrhythmia-patients-using-predictive-modeling/) - Identifying Potential High-Risk Factor Arrhythmia Patients Using Predictive Modeling - [Scoring and Segmenting Key Opinion Leader Physicians With Innovative and Customizable Machine Learning Techniques](https://www.eversana.com/content-library/scoring-and-segmenting-key-opinion-leader-physicians-with-innovative-and-customizable-machine-learning-techniques/) - Scoring and Segmenting Key Opinion Leader with Machine Learning - [Improving an AATD Predictive Model Using EMR Data](https://www.eversana.com/content-library/improving-an-aatd-predictive-model-using-emr-data/) - [Predictive Modeling for Treatment Switching in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients](https://www.eversana.com/content-library/predictive-modeling-for-treatment-switching-in-paroxysmal-nocturnal-hemoglobinuria-pnh-patients/) - Plots comparing feature importance between the patient-based model, the physician-based model and the hybrid patient-physician-based model. Predictive Modeling for Treatment Switching - [Use of Machine Learning to Identify Gastroparesis Patients Suitable for Nasal Spray Metoclopramide](https://www.eversana.com/content-library/use-of-machine-learning-to-identify-gastroparesis-patients-suitable-for-nasal-spray-metoclopramide/) - [Transforming the Future of Pharma Commercialization Through Medical Affairs](https://www.eversana.com/content-library/transforming-the-future-of-pharma-commercialization-through-medical-affairs/) - [Decisive Action Matters](https://www.eversana.com/content-library/decisive-action-matters/) - [How a Start-Up Developing an Innovative AI-Enabled Imaging Device Achieved FDA Clearance in 24 Months](https://www.eversana.com/content-library/how-a-start-up-developing-an-innovative-ai-enabled-imaging-device-achieved-fda-clearance-in-24-months/) - [EVERSANA's Regulatory Consulting Saves Big for Virtual Manufacturer: Uncovers Non-Compliance, Excessive Costs, and Risks](https://www.eversana.com/content-library/eversana-regultory-consulting-saves-big-for-virtual-manufacturer-uncovers-non-compliance-excessive-costs-and-risks/) - [From Strategy to Launch, EVERSANA's Regulatory Consulting Helps European Pharma Achieve U.S. Approval](https://www.eversana.com/content-library/from-strategy-to-launch-eversanas-regulatory-consulting-helps-european-pharma-achieve-us-approval/) - [Early-Stage Pharmaceutical Company Overcomes Development Hurdles with Expert Clinical and CMC Regulatory Support](https://www.eversana.com/content-library/early-stage-pharmaceutical-company-overcomes-development-hurdles-with-expert-clinical-and-cmc-regulatory-support/) - [A European Pharmaceutical Company Acquiring US Drugs, Asked EVERSANA's Regulatory Consulting to Drive Ownership Transfers and Fill Regulatory and Quality Leadership Roles](https://www.eversana.com/content-library/a-european-pharmaceutical-company-acquiring-us-drugs-asked-eversanas-regulatory-consulting-to-drive-ownership-transfers-and-fill-regulatory-and-quality-leadership-roles/) - [Developing a Channel Strategy Through Benchmarking For a First-in-Class Product Portfolio](https://www.eversana.com/content-library/developing-a-channel-strategy-through-benchmarking-for-a-first-in-class-product-portfolio/) - [Responding to FDA Orders to Cease Manufacturing](https://www.eversana.com/content-library/fda-compliance/) - [Leveraging QMS and Regulatory Expertise to Support Tissue Compliance](https://www.eversana.com/content-library/leveraging-qms-and-regulatory-expertise-to-support-tissue-compliance/) - [Robust Signal Management to Achieve Patient Safety-Signal Case Study](https://www.eversana.com/content-library/robust-signal-management-to-achieve-patient-safety-signal-case-study/) - [FDA Inspection Win For a Mid-Sized Pharma Company with More Than 40+ Products in the USA and Outside the USA](https://www.eversana.com/content-library/43197/) - [FDA Inspection Win for Mid-Sized Pharma (50+ Products) with Extensive Generic Product Portfolio](https://www.eversana.com/content-library/fda-inspection-win-for-mid-sized-pharma-50-products-with-extensive-generic-product-portfolio/) - [Successful Implementation of End-To-End Pharmacovigilance Services For Drug-Device Combination Product Portfolio](https://www.eversana.com/content-library/successful-implementation-of-end-to-end-pharmacovigilance-services-for-drug-device-combination-product-portfolio/) - [The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis](https://www.eversana.com/content-library/the-importance-of-considering-differences-in-study-and-patient-characteristics-before-undertaking-indirect-treatment-comparisons-a-case-study-of-siponimod-for-secondary-progressive-multiple-sclerosi-2/) - [Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple scelrosis](https://www.eversana.com/content-library/matching-adjusted-indirect-treatment-comparison-of-siponimod-and-other-disease-modifying-treatments-in-secondary-progressive-multiple-scelrosis/) - [Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis](https://www.eversana.com/content-library/comparison-of-ofatumumab-and-other-disease-modifying-therapies-for-relapsing-multiple-sclerosis-a-network-meta-analysis/) - [Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients](https://www.eversana.com/content-library/budget-impact-analysis-of-treatment‐free-remission-in-nilotinib‐treated-japanese-chronic-myeloid-leukemia-patients/) - [Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany](https://www.eversana.com/content-library/cost-per-responder-analysis-of-guselkumab-versus-targeted-therapies-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-germany/) - [Network Meta-Analysis of Ulcerative Colitis Pharmacoptherapies: Carryover Effects from Induction and Bias of the Results](https://www.eversana.com/content-library/network-meta-analysis-of-ulcerative-colitis-pharmacoptherapies-carryover-effects-from-induction-and-bias-of-the-results/) - [Methodological challenges with conducting network meta-analyses assessing long-term comparative efficacy in psoriasis: A critique of assumptions underpinning recent indirect treatment comparisons](https://www.eversana.com/content-library/methodological-challenges-with-conducting-network-meta-analyses-assessing-long-term-comparative-efficacy-in-psoriasis-a-critique-of-assumptions-underpinning-recent-indirect-treatment-comparisons/) - [Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis](https://www.eversana.com/content-library/comparative-efficacy-of-guselkumab-in-patients-with-psoriatic-arthritis-results-from-systematic-literature-review-and-network-meta-analysis/) - ["Long-Term Economic Impact of First Pass Effect (FPE) in Endovascular Stroke Treatment with the EMBOTRAP™ Device from the ARISE-II Study: An Asia-Pacific Economic Analysis"](https://www.eversana.com/content-library/long-term-economic-impact-of-first-pass-effect-fpe-in-endovascular-stroke-treatment-with-the-embotrap-device-from-the-arise-ii-study-an-asia-pacific-economic-analysis/) - [ECONOMIC IMPACT OF FIRST PASS EFFECT (FPE) IN ENDOVASCULAR STROKE TREATMENT WITH THE EMBOTRAP II DEVICE FROM THE ARISE II STUDY – ANNUAL HEALTHCARE RESOURCE USE ECONOMIC ANALYSIS FROM A EUROPEAN PERSPECTIVE](https://www.eversana.com/content-library/economic-impact-of-first-pass-effect-fpe-in-endovascular-stroke-treatment-with-the-embotrap-ii-device-from-the-arise-ii-study-annual-healthcare-resource-use-economic-analysis-from-a-europe/) - [Health economic impact of first-pass success among patients with acute ischemic stroke treated with mechanical thrombectomy: a United States and European perspective.](https://www.eversana.com/content-library/health-economic-impact-of-first-pass-success-among-patients-with-acute-ischemic-stroke-treated-with-mechanical-thrombectomy-a-united-states-and-european-perspective/) - [Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)](https://www.eversana.com/content-library/comparative-efficacy-of-cc-486-versus-injectable-azacitidine-aza-in-patients-pts-with-acute-myeloid-leukemia-aml-in-first-remission-after-intensive-induction-chemotherapy-findings-from-an-indir/) - [Reduced Hospital Costs for Ultrasound-guided Vacuum-assisted Excision Compared with Open Surgery in Patients with Benign Breast Masses and High-risk Lesions.](https://www.eversana.com/content-library/reduced-hospital-costs-for-ultrasound-guided-vacuum-assisted-excision-compared-with-open-surgery-in-patients-with-benign-breast-masses-and-high-risk-lesions/) - [Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis](https://www.eversana.com/content-library/systematic-literature-review-of-the-epidemiology-and-clinical-burden-of-chronic-rhinosinusitis-with-nasal-polyposis/) - [Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis](https://www.eversana.com/content-library/systematic-literature-review-of-humanistic-and-economic-burdens-of-chronic-rhinosinusitis-with-nasal-polyposis/) - [The burden of osteoporosis in Saudi Arabia: a scorecard and economic model](https://www.eversana.com/content-library/the-burden-of-osteoporosis-in-saudi-arabia-a-scorecard-and-economic-model/) - [PND2 Indirect Treatment Comparisons of Apomorphine Sublingual Film Versus Apomorphine Subcutaneous Injection for the on-Demand Treatment of "Off" Episodes in Patients with Parkinson's Disease](https://www.eversana.com/content-library/pnd2-indirect-treatment-comparisons-of-apomorphine-sublingual-film-versus-apomorphine-subcutaneous-injection-for-the-on-demand-treatment-of-off-episodes-in-patients-with-parkinsons-disease/) - [Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina](https://www.eversana.com/content-library/benefits-of-fracture-liaison-services-fls-in-four-latin-american-countries-brazil-mexico-colombia-and-argentina/) - [European Guidelines and Real-World Evidence of Maintenance Treatments for Adults with Acute Myeloid Leukemia in First Complete Remission.](https://www.eversana.com/content-library/european-guidelines-and-real-world-evidence-of-maintenance-treatments-for-adults-with-acute-myeloid-leukemia-in-first-complete-remission-2/) - [Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy.](https://www.eversana.com/content-library/matching-adjusted-indirect-comparison-maic-of-oral-azacitidine-oral-aza-versus-injectable-aza-in-patients-pts-with-acute-myeloid-leukemia-aml-in-first-remission-after-intensive-induction-chemo-2/) - [A scorecard for osteoporosis in Canada and seven Canadian provinces](https://www.eversana.com/content-library/a-scorecard-for-osteoporosis-in-canada-and-seven-canadian-provinces-2/) - [Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses](https://www.eversana.com/content-library/indirect-comparisons-of-siponimod-with-fingolimod-and-ofatumumab-in-multiple-sclerosis-assessing-the-feasibility-of-propensity-score-matching-analyses-2/) - ["Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective"](https://www.eversana.com/content-library/economic-analysis-of-n-butyl-cyanoacrylate-compared-with-ethylene-vinyl-alcohol-copolymer-liquid-embolic-embolization-of-brain-arteriovenous-malformations-bavms-from-a-us-hospital-perspective-2/) - [Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy](https://www.eversana.com/content-library/annual-cardiovascular-related-hospitalization-days-avoided-with-tafamidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-2/) - [Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective](https://www.eversana.com/content-library/clinical-and-economic-benefits-of-lenzilumab-plus-standard-of-care-compared-with-standard-of-care-alone-for-the-treatment-of-hospitalized-patients-with-covid-19-in-the-united-states-from-the-hospita-2/) - [Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England](https://www.eversana.com/content-library/clinical-and-economic-benefits-of-lenzilumab-plus-standard-of-care-compared-with-standard-of-care-alone-for-the-treatment-of-hospitalized-patients-with-coronavirus-disease-19-covid-19-from-the-persp-2/) - [An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective](https://www.eversana.com/content-library/an-economic-evaluation-of-cabazitaxel-versus-a-second-androgen-receptor-targeted-agent-arta-for-patients-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel-and-an-2/) - [Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review](https://www.eversana.com/content-library/impact-of-disease-progression-line-of-therapy-and-response-on-health-related-quality-of-life-in-multiple-myeloma-a-systematic-literature-review-2/) - [ACTICS eAccess Brochure](https://www.eversana.com/content-library/actics-eaccess-brochure/) - [Health Care Resource Utilization With Asciminib And Bosutinib Among Adults With Chronic Myeloid Leukemia In Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Results From ASCEMBL Trial](https://www.eversana.com/content-library/health-care-resource-utilization-with-asciminib-and-bosutinib-among-adults-with-chronic-myeloid-leukemia-in-chronic-phase-previously-treated-with-≥2-tyrosine-kinase-inhibitors-results-from-as/) - [Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma](https://www.eversana.com/content-library/use-of-cost-per-responder-models-for-car-t-therapies-in-relapsed-or-refractory-multiple-myeloma/) - [Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease; A Meta-analysis and matching-adjusted indirect comparison](https://www.eversana.com/content-library/proptosis-and-diplopia-response-with-teprotumumab-and-placebo-vs-the-recommended-treatment-regimen-with-intravenous-methylprednisolone-in-moderate-to-severe-thyroid-eye-disease-a-meta-analysis-and-ma/) - [Comparing the Change from Base Case to Re-Analyzed ICER Values for CADTH Oncology Evaluations](https://www.eversana.com/content-library/comparing-the-change-from-base-case-to-re-analyzed-icer-values-for-cadth-oncology-evaluations/) - [Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder](https://www.eversana.com/content-library/letter-to-the-editor-regarding-network-meta-analysis-of-food-and-drug-administration-approved-treatment-options-for-adults-with-aquaporin-4-immunoglobulin-g-positive-neuromyelitis-optica/) - [A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry](https://www.eversana.com/content-library/a-natural-history-of-lower-risk-myelodysplastic-syndromes-with-ring-sideroblasts-an-analysis-of-the-mds-can-registry/) - [The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry](https://www.eversana.com/content-library/the-burden-of-red-blood-cell-transfusions-in-patients-with-lower-risk-myelodysplastic-syndromes-and-ring-sideroblasts-an-analysis-of-the-prospective-mds-can-registry/) - [P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes](https://www.eversana.com/content-library/p45-internal-external-and-cross-validation-of-the-deduce-model-a-cost-utility-tool-using-patient-level-microsimulation-to-evaluate-sensor-based-glucose-monitoring-systems-in-type-1-and-type-2-diabe-2/) - [P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes](https://www.eversana.com/content-library/p45-internal-external-and-cross-validation-of-the-deduce-model-a-cost-utility-tool-using-patient-level-microsimulation-to-evaluate-sensor-based-glucose-monitoring-systems-in-type-1-and-type-2-diabe/) - [Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States](https://www.eversana.com/content-library/unmet-need-in-people-with-psoriasis-and-skin-of-color-in-canada-and-the-united-states/) - [Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.](https://www.eversana.com/content-library/cost-effectiveness-analysis-of-ofatumumab-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-canada/) - [Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?](https://www.eversana.com/content-library/building-infrastructure-for-outcomes-based-agreements-in-canada-can-administrative-health-data-be-used-to-support-an-outcomes-based-agreement-in-oncology/) - [Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States](https://www.eversana.com/content-library/low-levels-of-rsv-testing-among-adults-hospitalized-for-lower-respiratory-tract-infection-in-the-united-states/) - [Adopting a portfolio of ultrasonic and advanced bipolar electrosurgery devices from a single manufacturer compared to currently used ultrasonic and advanced bipolar devices: a probabilistic budget impact analysis from a Spanish hospital perspective](https://www.eversana.com/content-library/adopting-a-portfolio-of-ultrasonic-and-advanced-bipolar-electrosurgery-devices-from-a-single-manufacturer-compared-to-currently-used-ultrasonic-and-advanced-bipolar-devices-a-probabilistic-budget-imp/) - [PO206 Indirect Treatment Comparisons Of The Gene Therapy Etranacogene Dezaparvovec (CSL222) Vs. Extended Half-life Factor Ix Therapies For Severe Or Moderately Severe Haemophilia B](https://www.eversana.com/content-library/po206-indirect-treatment-comparisons-of-the-gene-therapy-etranacogene-dezaparvovec-csl222-vs-extended-half-life-factor-ix-therapies-for-severe-or-moderately-severe-haemophilia-b/) - [Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis](https://www.eversana.com/content-library/glucarpidase-for-treating-adults-with-delayed-methotrexate-elimination-due-to-impaired-renal-function-an-economic-simulation-analysis/) - [Real-World Healthcare Resource Utilization of Patients Treated with Metoclopramide Nasal Spray for Diabetic Gastroparesis (DGP)](https://www.eversana.com/content-library/real-world-healthcare-resource-utilization-of-patients-treated-with-metoclopramide-nasal-spray-for-diabetic-gastroparesis-dgp/) - [Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review](https://www.eversana.com/content-library/impact-of-disease-progression-line-of-therapy-and-response-on-health-related-quality-of-life-in-multiple-myeloma-a-systematic-literature-review/) - [Strengths and Limitations of Different Costing Approaches used for Hospital Budget Impact Models: Application to Imaging Guidance in LAAO Procedures.](https://www.eversana.com/content-library/strengths-and-limitations-of-different-costing-approaches-used-for-hospital-budget-impact-models-application-to-imaging-guidance-in-laao-procedures/) - [Use of Real-World Data for Hard-to-Identify Patient Population: Methodology and a Case Study ](https://www.eversana.com/content-library/use-of-real-world-data-for-hard-to-identify-patient-population-methodology-and-a-case-study/) - [Challenges and Burdens in the Coronary Artery Disease Care Pathway for Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Narrative Review.](https://www.eversana.com/content-library/challenges-and-burdens-in-the-coronary-artery-disease-care-pathway-for-patients-undergoing-percutaneous-coronary-intervention-a-contemporary-narrative-review/) - [A Systematic Literature Review and Network Meta-Analysis of Therapies for Psoriatic Arthritis on Patient-reported Outcomes](https://www.eversana.com/content-library/a-systematic-literature-review-and-network-meta-analysis-of-therapies-for-psoriatic-arthritis-on-patient-reported-outcomes/) - [Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis](https://www.eversana.com/content-library/comparative-efficacy-of-therapies-for-relapsing-multiple-sclerosis-a-systematic-review-and-network-meta-analysis/) - [An improved definition and SAFE Rule for Predicting Difficult Intravascular Access (DIVA) in Hospitalized Adults](https://www.eversana.com/content-library/an-improved-definition-and-safe-rule-for-predicting-difficult-intravascular-access-diva-in-hospitalized-adults/) - [An umbrella review of the surgical performance of Harmonic ultrasonic devices and impact on patient outcomes](https://www.eversana.com/content-library/an-umbrella-review-of-the-surgical-performance-of-harmonic-ultrasonic-devices-and-impact-on-patient-outcomes/) - [Healthcare Resource Utilization and Costs Among Overweight and Obese Users of a Digital Weight Loss Intervention Compared to Non-Users:A Retrospective Analysis.](https://www.eversana.com/content-library/healthcare-resource-utilization-and-costs-among-overweight-and-obese-users-of-a-digital-weight-loss-intervention-compared-to-non-usersa-retrospective-analysis/) - [Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant](https://www.eversana.com/content-library/letter-in-reply-indirect-comparison-of-quality-of-life-scores-between-patients-with-advanced-breast-cancer-receiving-palbociclib-and-abemaciclib-in-combination-with-fulvestrant/) - [Improving Adherence & Compliance Via Patient Targeting](https://www.eversana.com/content-library/improving-adherence-compliance-via-patient-targeting/) - [Oncology Launch Scenario Planning](https://www.eversana.com/content-library/oncology-launch-scenario-planning/) - [Identifying Rare Disease HCPs with Omnichannel Targeting](https://www.eversana.com/content-library/identifying-rare-disease-hcps-with-omnichannel-targeting/) - [Defining the Rare Disease Patient Journey to Support Commercialization of Therapy](https://www.eversana.com/content-library/defining-the-rare-disease-patient-journey-to-support-commercialization-of-therapy/) - [Optimizing Launch & Maximizing Revenue Potential in Europe](https://www.eversana.com/content-library/optimizing-launch-maximizing-revenue-potential-in-europe/) - [Efficacy classification of modern therapies in multiple sclerosis](https://www.eversana.com/content-library/efficacy-classification-of-modern-therapies-in-multiple-sclerosis-2/) - [Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer](https://www.eversana.com/content-library/matching-adjusted-indirect-comparison-of-palbociclib-versus-ribociclib-and-abemaciclib-in-hormone-receptor-positive-her2-negative-advanced-breast-cancer-2/) - [CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies](https://www.eversana.com/content-library/cdk4-6-inhibitors-in-hr-her2-advanced-metastatic-breast-cancer-a-systematic-literature-review-of-real-world-evidence-studies-2/) - [Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis](https://www.eversana.com/content-library/risk-of-recurrence-among-patients-with-hr-positive-her2-negative-early-breast-cancer-receiving-adjuvant-endocrine-therapy-a-systematic-review-and-meta-analysis-2/) - [Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis](https://www.eversana.com/content-library/matching-adjusted-indirect-treatment-comparison-of-siponimod-and-other-disease-modifying-treatments-in-secondary-progressive-multiple-sclerosis/) - [The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis](https://www.eversana.com/content-library/the-importance-of-considering-differences-in-study-and-patient-characteristics-before-undertaking-indirect-treatment-comparisons-a-case-study-of-siponimod-for-secondary-progressive-multiple-sclerosis/) - [The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy](https://www.eversana.com/content-library/the-impact-of-clinical-heterogeneity-on-conducting-network-meta-analyses-in-transthyretin-amyloidosis-with-polyneuropathy/) - [Comparative efficacy of oral versus injectable azacytidine in patients with AML in first remission after intensive chemotherapy: an indirect treatment comparison (sub-analysis update)](https://www.eversana.com/content-library/comparative-efficacy-of-oral-versus-injectable-azacytidine-in-patients-with-aml-in-first-remission-after-intensive-chemotherapy-an-indirect-treatment-comparison-sub-analysis-update/) - [Procedure cost-comparison analysis of liquid embolic system techniques using EVOH and n-BCA in the embolization of brain arteriovenous malformations](https://www.eversana.com/content-library/procedure-cost-comparison-analysis-of-liquid-embolic-system-techniques-using-evoh-and-n-bca-in-the-embolization-of-brain-arteriovenous-malformations-3/) - [An umbrella review comparing the safety and effectiveness of femtosecond laser-assisted cataract surgery with manual cataract surgery](https://www.eversana.com/content-library/an-umbrella-review-comparing-the-safety-and-effectiveness-of-femtosecond-laser-assisted-cataract-surgery-with-manual-cataract-surgery-2/) - [Meta-analysis of proptosis response in thyroid eye disease: Efficacy of EUGOGO recommended treatment regimen with IV methylprednisolone](https://www.eversana.com/content-library/meta-analysis-of-proptosis-response-in-thyroid-eye-disease-efficacy-of-eugogo-recommended-treatment-regimen-with-iv-methylprednisolone-2/) - [Ozanimod for induction treatment of moderate-to-severe ulcerative colitis: results from a systematic literature review and network meta-analyses](https://www.eversana.com/content-library/ozanimod-for-induction-treatment-of-moderate-to-severe-ulcerative-colitis-results-from-a-systematic-literature-review-and-network-meta-analyses/) - [Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis](https://www.eversana.com/content-library/comparative-effectiveness-of-guselkumab-in-psoriatic-arthritis-results-from-systematic-literature-review-and-network-meta-analysis-2/) - [Indirect treatment comparison of Liso-Cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1](https://www.eversana.com/content-library/indirect-treatment-comparison-of-liso-cel-vs-salvage-chemotherapy-in-diffuse-large-b-cell-lymphoma-transcend-vs-scholar-1/) - [Health impact of tafmidis in transthyretin amyloid cardiomyopathy patients: an analysis from the tafamidis in transthyretic cardiomyopathy clinical trial (ATTR-ACT) and the open-label long-term extension studies](https://www.eversana.com/content-library/health-impact-of-tafmidis-in-transthyretin-amyloid-cardiomyopathy-patients-an-analysis-from-the-tafamidis-in-transthyretic-cardiomyopathy-clinical-trial-attr-act-and-the-open-label-long-term-extens/) - [Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors](https://www.eversana.com/content-library/umbrella-review-of-42-systematic-reviews-with-meta-analyses-the-safety-of-proton-pump-inhibitors-2/) - [CDK4/6 Inhibitors in HR+/HER2- Advanced/Metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies.](https://www.eversana.com/content-library/cdk4-6-inhibitors-in-hr-her2-advanced-metastatic-breast-cancer-a-systematic-literature-review-of-real-world-evidence-studies/) - [Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis](https://www.eversana.com/content-library/risk-of-recurrence-among-patients-with-hr-positive-her2-negative-early-breast-cancer-receiving-adjuvant-endocrine-therapy-a-systematic-review-and-meta-analysis/) - [Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer](https://www.eversana.com/content-library/matching-adjusted-indirect-comparison-of-palbociclib-versus-ribociclib-and-abemaciclib-in-hormone-receptor-positive-her2-negative-advanced-breast-cancer/) - [Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone](https://www.eversana.com/content-library/meta-analysis-of-proptosis-response-in-thyroid-eye-disease-efficacy-of-eugogo-recommended-treatment-regimen-with-iv-methylprednisolone/) - [Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain](https://www.eversana.com/content-library/estimating-the-annual-economic-burden-for-the-management-of-patients-with-transthyretin-amyloid-polyneuropathy-in-spain/) - [Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies](https://www.eversana.com/content-library/health-impact-of-tafamidis-in-transthyretin-amyloid-cardiomyopathy-patients-an-analysis-from-the-tafamidis-in-transthyretin-cardiomyopathy-clinical-trial-attr-act-and-the-open-label-long-term-exten/) - [Annual Cardiovascular-related Hospitalization Days Avoided With Tafamidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy](https://www.eversana.com/content-library/annual-cardiovascular-related-hospitalization-days-avoided-with-tafamidis-treatment-in-patients-with-transthyretin-amyloid-cardiomyopathy/) - [Modelling Lifetime Survival Gain in Patients With Transthyretin Amyloid Cardiomyopathy and Baseline NYHA Class III: An Analysis of ATTR-ACT and Long-Term Extension Study](https://www.eversana.com/content-library/modelling-lifetime-survival-gain-in-patients-with-transthyretin-amyloid-cardiomyopathy-and-baseline-nyha-class-iii-an-analysis-of-attr-act-and-long-term-extension-study/) - [Efficacy classification of modern therapies in multiple sclerosis](https://www.eversana.com/content-library/efficacy-classification-of-modern-therapies-in-multiple-sclerosis/) - [Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial Differences in Endpoint Definition](https://www.eversana.com/content-library/network-meta-analysis-of-disease-modifying-therapies-for-relapsing-multiple-sclerosis-based-on-confirmed-disability-progression-investigating-the-influence-of-cross-trial-differences-in-endpoint-defi/) - [Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis](https://www.eversana.com/content-library/relapse-reduction-by-disease-modifying-therapies-for-relapsing-multiple-sclerosis-a-network-meta-analysis/) - [Cost effectiveness of Ofatumumab in Comparison With Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada](https://www.eversana.com/content-library/cost-effectiveness-of-ofatumumab-in-comparison-with-other-disease-modifying-therapies-and-best-supportive-care-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-canada/) - [Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy](https://www.eversana.com/content-library/economic-model-to-evaluate-the-cost-effectiveness-of-second-line-nilotinib-versus-dasatinib-for-the-treatment-of-philadelphia-chromosome-positive-chronic-myeloid-leukemia-cml-cp-in-italy/) - [Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review](https://www.eversana.com/content-library/prevalence-and-burden-of-multiple-sclerosis-related-fatigue-a-systematic-literature-review/) - [Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis](https://www.eversana.com/content-library/comparative-effectiveness-of-guselkumab-in-psoriatic-arthritis-results-from-systematic-literature-review-and-network-meta-analysis/) - [Matching-Adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40](https://www.eversana.com/content-library/matching-adjusted-indirect-comparison-of-guselkumab-versus-risankizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-change-in-baseline-pasi-from-week-4-40/) - [Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma](https://www.eversana.com/content-library/meta-analysis-of-ciltacabtagene-autoleucel-versus-physicians-choice-in-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/) - [Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors](https://www.eversana.com/content-library/umbrella-review-of-42-systematic-reviews-with-meta-analyses-the-safety-of-proton-pump-inhibitors/) - [Procedure Cost-Comparison Analysis of Liquid Embolic System Techniques Using EVOH and n-BCA in the Embolization of Brain Arteriovenous Malformations](https://www.eversana.com/content-library/procedure-cost-comparison-analysis-of-liquid-embolic-system-techniques-using-evoh-and-n-bca-in-the-embolization-of-brain-arteriovenous-malformations-2/) - [Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs](https://www.eversana.com/content-library/influence-of-neurovascular-embolic-coil-primary-wind-diameter-on-aneurysm-packing-density-and-case-costs/) - [Burden of tough to retrieve clots in acute ischemic stroke: clinical and economic impact of increasing retrieval attempts in mechanical thrombectomy](https://www.eversana.com/content-library/burden-of-tough-to-retrieve-clots-in-acute-ischemic-stroke-clinical-and-economic-impact-of-increasing-retrieval-attempts-in-mechanical-thrombectomy/) - [DOP69 Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses](https://www.eversana.com/content-library/dop69-ozanimod-for-induction-treatment-of-moderate-to-severe-ulcerative-colitis-results-from-a-systematic-literature-review-and-network-meta-analyses/) - [Ozanimod for treatment of biologic-experienced patients with moderate-to-severe ulcerative colitis: Results from a systematic literature review and network meta-analyses](https://www.eversana.com/content-library/ozanimod-for-treatment-of-biologic-experienced-patients-with-moderate-to-severe-ulcerative-colitis-results-from-a-systematic-literature-review-and-network-meta-analyses/) - [Systematic Literature Reviews (SLRS) of Economic Evaluations and Health Utility Studies of AML Treatments for Adults Receiving High Intensity Induction Therapy, with or without Maintenance Therapy](https://www.eversana.com/content-library/systematic-literature-reviews-slrs-of-economic-evaluations-and-health-utility-studies-of-aml-treatments-for-adults-receiving-high-intensity-induction-therapy-with-or-without-maintenance-therapy/) - [Systematic Literature Review of the Efficacy and Safety of Maintenance Therapies for Adults with Acute Myeloid Leukemia in Complete Remission who are Ineligible for Hematopoetic Stem Cell Transplant](https://www.eversana.com/content-library/systematic-literature-review-of-the-efficacy-and-safety-of-maintenance-therapies-for-adults-with-acute-myeloid-leukemia-in-complete-remission-who-are-ineligible-for-hematopoetic-stem-cell-transplant/) - [European Guidelines and Real-World Evidence of Maintenance Treatments for Adults with Acute Myeloid Leukemia in First Complete Remission.](https://www.eversana.com/content-library/european-guidelines-and-real-world-evidence-of-maintenance-treatments-for-adults-with-acute-myeloid-leukemia-in-first-complete-remission/) - [Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy.](https://www.eversana.com/content-library/matching-adjusted-indirect-comparison-maic-of-oral-azacitidine-oral-aza-versus-injectable-aza-in-patients-pts-with-acute-myeloid-leukemia-aml-in-first-remission-after-intensive-induction-chemo/) - [A comparison of the costs of atrial fibrillation ablation using radiofrequency and cryoballoon technologies in the United Kingdom and Italy](https://www.eversana.com/content-library/a-comparison-of-the-costs-of-atrial-fibrillation-ablation-using-radiofrequency-and-cryoballoon-technologies-in-the-united-kingdom-and-italy/) - [A Scorecard for Osteoporosis in Canada and Seven Canadian Provinces.](https://www.eversana.com/content-library/a-scorecard-for-osteoporosis-in-canada-and-seven-canadian-provinces/) - [Oncology drugs without Phase III data: Comparison of reimbursement recommendations issued by the Canadian Agency for Drugs and Technologies in Health (CADTH), and the National Institute for Health and Care Excellence (NICE)](https://www.eversana.com/content-library/oncology-drugs-without-phase-iii-data-comparison-of-reimbursement-recommendations-issued-by-the-canadian-agency-for-drugs-and-technologies-in-health-cadth-and-the-national-institute-for-health-and/) - [Hospital Costs Associated with Cataract, Glaucoma, Vitreoretinal, and Laser Refractive Surgeries in Europe: A Comprehensive Literature Review](https://www.eversana.com/content-library/hospital-costs-associated-with-cataract-glaucoma-vitreoretinal-and-laser-refractive-surgeries-in-europe-a-comprehensive-literature-review/) - [Comparative assessment of ergonomic experience with heads-up display and conventional surgical microscope in the operating room](https://www.eversana.com/content-library/comparative-assessment-of-ergonomic-experience-with-heads-up-display-and-conventional-surgical-microscope-in-the-operating-room/) - [An Umbrella Review Comparing the Safety and Effectiveness of Femtosecond Laser-Assisted Cataract Surgery with Manual Cataract Surgery](https://www.eversana.com/content-library/an-umbrella-review-comparing-the-safety-and-effectiveness-of-femtosecond-laser-assisted-cataract-surgery-with-manual-cataract-surgery/) - [Impact of Hybrid Tip on Incidence and Cost of Posterior Capsule Ruprtures in Cataract Surgery.](https://www.eversana.com/content-library/impact-of-hybrid-tip-on-incidence-and-cost-of-posterior-capsule-ruprtures-in-cataract-surgery/) - [Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses](https://www.eversana.com/content-library/indirect-comparisons-of-siponimod-with-fingolimod-and-ofatumumab-in-multiple-sclerosis-assessing-the-feasibility-of-propensity-score-matching-analyses/) - [The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico](https://www.eversana.com/content-library/the-burden-of-skeletal-related-events-in-four-latin-american-countries-argentina-brazil-colombia-and-mexico/) - [Systematic literature review of evidence in amyloid light-chain amyloidosis](https://www.eversana.com/content-library/systematic-literature-review-of-evidence-in-amyloid-light-chain-amyloidosis/) - [Overall Survival Associated with Image-guided Thermal Ablation (IGTA) and Stereotactic Body Radiation Therapy (SBRT) for patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Regression Analysis](https://www.eversana.com/content-library/overall-survival-associated-with-image-guided-thermal-ablation-igta-and-stereotactic-body-radiation-therapy-sbrt-for-patients-with-non-small-cell-lung-cancer-a-systematic-review-and-meta-regressi/) - [Outcomes of Image-guided Thermal Ablation (IGTA) and Stereotactic Body Radiation Therapy (SBRT) for Patients with Pulmonary Metastases: A Systematic Review and Meta-Analysis](https://www.eversana.com/content-library/outcomes-of-image-guided-thermal-ablation-igta-and-stereotactic-body-radiation-therapy-sbrt-for-patients-with-pulmonary-metastases-a-systematic-review-and-meta-analysis/) - [Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective](https://www.eversana.com/content-library/economic-analysis-of-n-butyl-cyanoacrylate-compared-with-ethylene-vinyl-alcohol-copolymer-liquid-embolic-embolization-of-brain-arteriovenous-malformations-bavms-from-a-us-hospital-perspective/) - [Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy](https://www.eversana.com/content-library/annual-cardiovascular-related-hospitalization-days-avoided-with-tafamidis-in-patients-with-transthyretin-amyloid-cardiomyopathy/) - [Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective](https://www.eversana.com/content-library/clinical-and-economic-benefits-of-lenzilumab-plus-standard-of-care-compared-with-standard-of-care-alone-for-the-treatment-of-hospitalized-patients-with-covid-19-in-the-united-states-from-the-hospital/) - [Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England](https://www.eversana.com/content-library/clinical-and-economic-benefits-of-lenzilumab-plus-standard-of-care-compared-with-standard-of-care-alone-for-the-treatment-of-hospitalized-patients-with-coronavirus-disease-19-covid-19-from-the-persp/) - [Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis](https://www.eversana.com/content-library/simulated-treatment-comparison-of-efficacy-outcomes-for-ofatumumab-in-asclepios-i-ii-versus-ocrelizumab-in-opera-i-ii-for-the-treatment-of-patients-with-relapsing-multiple-sclerosis/) - [A systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis](https://www.eversana.com/content-library/a-systematic-review-and-network-meta‐analysis-comparing-ofatumumab-with-other-disease‐modifying-therapies-available-in-japan-for-the-treatment-of-patients-with-relapsing-multiple-scler/) - [An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective](https://www.eversana.com/content-library/an-economic-evaluation-of-cabazitaxel-versus-a-second-androgen-receptor-targeted-agent-arta-for-patients-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel-and-an/) - [Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review](https://www.eversana.com/content-library/healthcare-and-economic-burden-of-anticholinergic-use-in-adults-with-overactive-bladder-a-systematic-literature-review/) - [Comparative assessment of heads-up display and conventional surgical microscope for ergonomic and other benefits in posterior-segment surgeons](https://www.eversana.com/content-library/comparative-assessment-of-heads-up-display-and-conventional-surgical-microscope-for-ergonomic-and-other-benefits-in-posterior-segment-surgeons/) - [What challenges do pharma companies face that risk limiting their ability to capitalize on this unique opportunity?](https://www.eversana.com/content-library/what-challenges-do-pharma-companies-face-that-risk-limiting-their-ability-to-capitalize-on-this-unique-opportunity/) - [Overcome In-Licensing Challenges with EVERSANA](https://www.eversana.com/content-library/overcome-in-licensing-challenges-with-eversana/) - [In-Licensing - A Once-in-a-Lifetime Moment of Market Conditions](https://www.eversana.com/content-library/in-licensing-a-once-in-a-lifetime-moment-of-market-conditions/) - [High-Tech Medical Information Services](https://www.eversana.com/content-library/high-touch-medical-information-services/) - [Why is in-licensing such an important growth lever for companies?](https://www.eversana.com/content-library/why-is-in-licensing-such-an-important-growth-lever-for-companies/) - [Client + Vendor Partnerships Achieve Strategic Objectives](https://www.eversana.com/content-library/successful-client-vendor-partnerships/) - [Oncology Portfolio Portal Pilot](https://www.eversana.com/content-library/oncology-portfolio-portal-pilot/) - [Retail Product Launch](https://www.eversana.com/content-library/retail-product-launch/) - [Supporting Patients with Neurogenic Orthostatic Hypotention](https://www.eversana.com/content-library/supporting-patients-with-neurogenic-orthostatic-hypotention/) - [Assuring Adequate Care for Rare Neurological Condition](https://www.eversana.com/content-library/assuring-adequate-care-for-rare-neurological-condition/) - [Commercial Field Support for Neurology Brands](https://www.eversana.com/content-library/commercial-field-support-for-neurology-brands/) - [Leading CNS Product Lifecycle Management Support](https://www.eversana.com/content-library/lifecycle-management-analytics-and-insights-support/) - [CNS Brand Plan Refresh](https://www.eversana.com/content-library/cns-brand-plan-refresh/) - [Multiple Sclerosis Employer Strategy Development](https://www.eversana.com/content-library/multiple-sclerosis-employer-strategy-development/) - [Established Brands: How Macro-Economic Factors Impacting Cash Flow for Large Pharma](https://www.eversana.com/content-library/established-brands-how-macro-economic-factors-impacting-cash-flow-for-large-pharma/) - [COMPLETE Commercialization: Consistency](https://www.eversana.com/content-library/complete-commercialization-consistency/) - [Driving Commercial Excellence for CAR-T](https://www.eversana.com/content-library/driving-commercial-excellence-for-car-t/) - [PharmaVOICE: Next Gen Commercialization Model for Oncology](https://www.eversana.com/content-library/pharmavoice-webinar-next-gen-commercialization-model-for-oncology/) - [Insights from Clients: Shorla Pharma emphasizes how specialty pharmacy is streamlining commercialization in an unpredictable market and maximizing brand value in the oncology space through valuable partnership.](https://www.eversana.com/content-library/insights-from-clients-shorla-pharma-emphasizes-how-specialty-pharmacy-is-streamlining-commercialization-in-an-unpredictable-market-and-maximizing-brand-value-in-the-oncology-space-through-valuable-pa/) - [Insights from a CCO: Evolving oncology market dynamics and expediting therapy to metastatic HER2-positive breast cancer patients](https://www.eversana.com/content-library/insights-from-a-cco-evolving-oncology-market-dynamics-and-expediting-therapy-to-metastatic-her2-positive-breast-cancer-patients/) - [How Pre-Launch Financial Exposure Modeling and Planning Can Help a Biopharmaceutical Reach More Patients](https://www.eversana.com/content-library/how-pre-launch-financial-exposure-modeling-and-planning-can-help-a-biopharmaceutical-reach-more-patients/) - [Using Survey Research to Develop Payer Strategies for an Existing Biologic’s Unique Indication in a Highly Competitive Market](https://www.eversana.com/content-library/23756/) - [Canadian Health Submissions- Creativity Meets Science](https://www.eversana.com/content-library/canadian-health-submissions-creativity-meets-science/) - [Small U.S. Biotech Expands in Canada](https://www.eversana.com/content-library/small-u-s-biotech-expands-in-canada/) - [Navigating Approvals in Canada](https://www.eversana.com/content-library/navigating-approvals-in-canada/) - [Clinical Trial Recruitment for Breast Cancer with Genetic Modifier](https://www.eversana.com/content-library/clinical-trial-recruitment-for-breast-cancer-with-genetic-modifier/) - [Mike Deluca Shares Insights on the Value of Medical Information](https://www.eversana.com/content-library/ask-the-expert-mike-deluca-on-med-info-value/) - [Pharma's Mindset Regarding Medical Information with Carolyn Quon, PharmD](https://www.eversana.com/content-library/ask-the-expert-carolyn-quon-pharmd-on-pharmas-mindset-regarding-medical-information/) - [Ask The Expert: Carolyn Quon, PharmD, on Medial Information Communication Channels](https://www.eversana.com/content-library/ask-the-expert-carolyn-quon-pharmd-on-medial-information-communication-channels/) - [Ask The Expert: Mike Deluca on Med Info Platform](https://www.eversana.com/content-library/ask-the-expert-mike-deluca-on-med-info-platform/) - [Ask The Expert: Krista Pinto on Omnichannel Alignment](https://www.eversana.com/content-library/ask-the-expert-krista-pinto-on-omnichannel-alignment/) - [Ask The Expert: Krista Pinto on Omnichannel Insights](https://www.eversana.com/content-library/ask-the-expert-krista-pinto-on-omnichannel-insights/) - [Ask The Expert: Amy Hutnik on EVERSANA's Omnichannel Activation Model](https://www.eversana.com/content-library/ask-the-expert-amy-hutnik-on-eversanas-omnichannel-activation-model/) - [Ask The Expert: Amy Hutnik on the Omnichannel Commercialization Model](https://www.eversana.com/content-library/ask-the-expert-amy-hutnik-on-the-omnichannel-commercialization-model/) - [Omnichannel: A Conversation with the Innovators](https://www.eversana.com/content-library/omnichannel-a-conversation-with-the-innovators/) - [The Secret’s Out: The Impact of Net Price Transparency](https://www.eversana.com/content-library/the-secrets-out-the-impact-of-net-price-transparency/) - [Under Pressure: Global Trends in Net Price](https://www.eversana.com/content-library/under-pressure-global-trends-in-net-price/) - [Procedure Cost-Comparison Analysis of Liquid Embolic System Techniques Using EvOH and n-BCA in the Embolization of Brain Arteriovenous Malformations](https://www.eversana.com/content-library/procedure-cost-comparison-analysis-of-liquid-embolic-system-techniques-using-evoh-and-n-bca-in-the-embolization-of-brain-arteriovenous-malformations/) - [Dodgeball Dilution](https://www.eversana.com/content-library/dodgeball-dilution/) - [Access Matters](https://www.eversana.com/content-library/access-matters/) - [ANALYSIS MATTERS](https://www.eversana.com/content-library/analysis-matters/) - [Brand Re-Entry into Crowded & Generic Market](https://www.eversana.com/content-library/brand-re-entry-into-crowded-generic-market/) - [CLINICAL TRIAL EXPERIENCE MATTERS](https://www.eversana.com/content-library/clinical-trial-experience-matters/) - [EDUCATION MATTERS](https://www.eversana.com/content-library/education-matters/) - [EVERY HOUR MATTERS](https://www.eversana.com/content-library/every-hour-matters/) - [EVERY LIFE MATTERS](https://www.eversana.com/content-library/every-life-matters/) - [EVERY PATIENT MATTERS](https://www.eversana.com/content-library/every-patient-matters/) - [EVERY RELATIONSHIP MATTERS](https://www.eversana.com/content-library/every-relationship-matters/) - [FDA INSPECTION EXPERIENCE MATTERS](https://www.eversana.com/content-library/fda-inspection-experience-matters/) - [OPERATIONAL EXCELLENCE MATTERS](https://www.eversana.com/content-library/operational-excellence-matters/) - [PREFERRED STATUS MATTERS](https://www.eversana.com/content-library/preferred-status-matters/) - [PRICING MATTERS](https://www.eversana.com/content-library/pricing-matters/) - [SAFETY AND EFFECTIVENESS MATTER](https://www.eversana.com/content-library/safety-and-effectiveness-matter/) - [SHARE OF VOICE MATTERS](https://www.eversana.com/content-library/share-of-voice-matters/) - [STANDARDIZATION AND SCALE MATTERS](https://www.eversana.com/content-library/standardization-and-scale-matters/) - [ACTICS by EVERSANA: Creating unmatched value for your patients](https://www.eversana.com/content-library/actics-by-eversana-creating-unmatched-value-for-your-patients/) - [Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal](https://www.eversana.com/content-library/leadership-briefing-the-u-s-pharmaceutical-market-outlook-the-path-to-recovery-and-the-new-normal/) - [DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration](https://www.eversana.com/content-library/dscsa-guidelines-best-practices-for-compliance-and-supply-chain-integration/) - [NEXT GENERATION COMMERCIALIZATION: A Conversation with the Innovators](https://www.eversana.com/content-library/next-generation-commercialization-a-conversation-with-the-innovators/) - [NEXT GENERATION COMMERCIALIZATION: A Conversation with the Innovators Part II](https://www.eversana.com/content-library/next-generation-commercialization-a-conversation-with-the-innovators-part-ii/) - [Solving Hard Go-To-Market Challenges](https://www.eversana.com/content-library/solving-hard-go-to-market-challenges/) - [5 Brand Planning Must-Haves](https://www.eversana.com/content-library/5-brand-planning-must-haves/) ## Insights - [Informing Optimal Pricing Strategies with a Comprehensive Modeling Approach](https://www.eversana.com/insights/informing-optimal-pricing-strategies-with-a-comprehensive-modeling-approach/) - [Understanding the Inflation Reduction Act: Drug Price Negotiation](https://www.eversana.com/insights/understanding-the-inflation-reduction-act-drug-price-negotiation/) - We explore the details known so far about Medicare drug price negotiation resulting from the implementation of the Inflation Reduction Act. The Centers for Medicare and Medicaid Services (CMS) has gradually been releasing guidance for manufacturers on the negotiation process. - [Digital Guide to Commercializing Complex Therapeutics](https://www.eversana.com/insights/digital-guide-to-commercializing-advanced-therapies/) - [Past and Present U.S. Public Health Laws and Regulations, and Their Impact on the Corresponding FDA Regulated Products and Industries](https://www.eversana.com/insights/past-and-present-u-s-public-health-laws-and-regulations-and-their-impact-on-the-corresponding-fda-regulated-products-and-industries/) - [From Limitations to Expansions: How Prioritizing Patients' Speed to Therapy Drives Therapy Adoption](https://www.eversana.com/insights/from-limitations-to-expansions-how-prioritizing-patients-speed-to-therapy-drives-therapy-adoption/) - [Seven Challenges Traditional Omnichannel Tactics Cannot Overcome](https://www.eversana.com/insights/seven-challenges-traditional-omnichannel-tactics-cannot-overcome/) - [The Real Cost of Delayed Pharmacovigilance (PV) Launch Readiness](https://www.eversana.com/insights/the-real-cost-of-delayed-pharmacovigilance-pv-launch-readiness/) - Is your Pharmacovigilance launch ready? Avoid these mistakes and gain actionable strategies to help you build a compliant, scalable PV system from day one. - [The Evolving Role of Pharma 3PLs To Drive Value & Impact](https://www.eversana.com/insights/the-evolving-role-of-pharma-3pls-to-drive-value-impact/) - Discover how pharma 3PLs are evolving from traditional logistics into strategic partners, offering the flexibility modern commercialization demands. - [You Cannot Commercialize What is Not Compliant](https://www.eversana.com/insights/you-cannot-commercialize-what-is-not-compliant/) - Complete Response Letters (CRLs) are largely preventable with an early, integrated commercial compliance framework. - [Avoiding the Top 3 Pharmacovigilance Mistakes](https://www.eversana.com/insights/avoiding-the-top-3-pharmacovigilance-mistakes/) - Is your Pharmacovigilance launch ready? Avoid these mistakes and gain actionable strategies to help you build a compliant, scalable PV system from day one. - [Winning in the EU JCA Era: Why Proactive Intelligence Will Define Market Access Success](https://www.eversana.com/insights/eu-jca-market-access-success/) - Understand the EU Joint Clinical Assessment (JCA) and how proactive evidence planning and strategic insights can improve submission readiness and market access success. - [What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson](https://www.eversana.com/insights/whats-trending-in-oncology-a-discussion-following-asco-2026-with-anne-marie-robertson/) - Explore how targeted therapies, AI integration, and agile commercialization are driving the future of oncology. - [Webinar Recording | From MFPs to MFN: Navigating the New Rules of Drug Pricing in 2026](https://www.eversana.com/insights/webinar-recording-from-mfps-to-mfn-navigating-the-new-rules-of-drug-pricing-in-2026/) - [Why Humans Must Be Part of the Bigger AI Picture](https://www.eversana.com/insights/why-humans-must-be-part-of-the-bigger-ai-picture/) - Discover why a human-in-the-loop AI model is essential for life sciences. Learn how to balance AI speed with compliance, scientific accuracy, and MLR review. - [EVERSANA Back as Global Host and Presenting Sponsor for Frontiers Health 2026](https://www.eversana.com/insights/eversana-back-as-global-host-and-presenting-sponsor-for-frontiers-health-2026/) - EVERSANA returns as Global Host and Presenting Sponsor of Frontiers Health 2026, joining global leaders to advance innovation, AI, and the future of healthcare. - [The Stability Advantage: Why Revenue Protection is the New Standard in Commercial Deployment](https://www.eversana.com/insights/the-stability-advantage-why-revenue-protection-is-the-new-standard-in-commercial-deployment/) - Is your field team truly operating at full capacity? Here's how to protect your organization from forfeiting revenue from continuous cycles of vacant territory. - [Bridging Evidence Gaps in mCRPC: Highlighting the Potential of Talazoparib plus Enzalutamide](https://www.eversana.com/insights/bridging-evidence-gaps-mcrpc/) - Our team conducted a matching-adjusted indirect comparison (MAIC) to address the absence of head-to-head trials. - [Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency](https://www.eversana.com/insights/capital-time-efficient-commercialization/) - [U.S. Drug Pricing Is Entering a More Complex Phase](https://www.eversana.com/insights/u-s-drug-pricing-is-entering-a-more-complex-phase/) - U.S. drug pricing is entering a more complex phase. Discover how to navigate MFN dynamics and the emergence of TrumpRx with NAVLIN data. - [Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints](https://www.eversana.com/insights/filling-in-the-gaps-predicting-treatment-effects-from-surrogate-endpoints/) - The Value & Evidence team at EVERSANA applied the Daniels and Hughes Surrogate Model to estimate previously unavailable clinical outcome data for integration into NMAs. - [Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA](https://www.eversana.com/insights/comparing-first-line-treatments-for-mcrpc-insights-from-a-comprehensive-nma/) - The Value & Evidence team at EVERSANA conducted a comprehensive systematic literature review and network meta-analysis to estimate the relative treatment effects between talazoparib plus enzalutamide and other therapies for patients with asymptomatic or mildly symptomatic mCRPC in the 1L setting. - [Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis](https://www.eversana.com/insights/comparing-long-term-hae-treatments-insights-from-a-robust-network-meta-analysis/) - The EVERSANA Value and Evidence team along with the team at CSL Behring conducted a systematic literature review and network meta-analysis (NMA) comparing the efficacy, safety, and patient-reported outcomes of long-term prophylactic treatments for HAE. - [Bridging the Evidence Gap in Hereditary Angioedema (HAE): Indirect Comparison Highlights Garadacimab’s Potential](https://www.eversana.com/insights/bridging-the-evidence-gap-in-hereditary-angioedema-hae-indirect-comparison-highlights-garadacimabs-potential/) - A new matching-adjusted indirect comparison (MAIC) highlights garadacimab’s potential advantages over lanadelumab in reducing HAE attack severity and improving quality of life, offering valuable insights for treatment decisions in the absence of head-to-head trials. - [The Indispensable Edge: Why the EVERSANA AI Agency Platform is a Must-Have for Expert Oncology Marketers](https://www.eversana.com/insights/the-indispensable-edge-why-the-eversana-ai-agency-platform-is-a-must-have-for-expert-oncology-marketers/) - [Decoding the Dialogue: Transforming MSL Interactions into Congress Intelligence](https://www.eversana.com/insights/decoding-the-dialogue-transforming-msl-interactions-into-congress-intelligence/) - [The Shattered Glass: Why the Future of Oncology Patient Support is an Agentic Ecosystem, Not a Portal](https://www.eversana.com/insights/the-shattered-glass-why-the-future-of-oncology-patient-support-is-an-agentic-ecosystem-not-a-portal/) - [Canadian Market Access Success Starts With the Right Partner](https://www.eversana.com/insights/canadian-market-access-success-starts-with-the-right-partner/) - [Demystifying the New Prescription Drug Use-Related Software Framework](https://www.eversana.com/insights/demystifying-pdurs-framework/) - Our latest paper, "Demystifying the New Prescription Drug Use-Related Software Framework," breaks down the draft guidance on Prescription Drug Use-Related Software (PDURS) released in September 2023. We've analyzed public comments, engaged with the FDA, and collaborated extensively with pharmaceutical manufacturers to provide insights. - [Harnessing the Commercial Promise of Prescription Drug Use-Related Software (PDURS)](https://www.eversana.com/insights/harnessing-pdurs/) - This article explores the regulatory and clinical requirements of PDURS and the possible commercial impact manufacturers might expect from taking this approach. - [Your Market Access Model is Bleeding Value](https://www.eversana.com/insights/your-market-access-model-is-bleeding-value/) - Fragmented market access strategies are driving commercial risk. Biopharma leaders can achieve better outcomes with an integrated, accountable model. - [Build the Launch, Then Cut the Deal: A Smarter Playbook for Emerging Biotech Value](https://www.eversana.com/insights/build-the-launch-then-cut-the-deal-a-smarter-playbook-for-emerging-biotech-value/) - [Can Direct‑to‑Employer Models Redefine Access to Obesity Care?](https://www.eversana.com/insights/can-direct-to-employer-models-redefine-access-to-obesity-care/) - Explore how Direct-to-Employer models are reshaping access to GLP-1 therapies, improving affordability, transparency, and patient outcomes. - [Views from Asembia: What Pharma Leaders Are Prioritizing Now](https://www.eversana.com/insights/views-from-asembia-what-pharma-leaders-are-prioritizing-now/) - Explore key takeaways from Asembia 2026, including patient access, AI adoption, and the shift toward integrated commercialization models. - [How MFN is Reshaping Global Drug Pricing – and How NAVLIN Insights Tracks It](https://www.eversana.com/insights/how-mfn-is-reshaping-global-drug-pricing-and-how-navlin-insights-tracks-it/) - Nearly a year after the executive order to implement Most Favored Nation (MFN) drug pricing policy, NAVLIN Insights tracks clearly emerging strategic patterns. - [How Pharma Can Scale Innovation Without Losing Executional Rigor](https://www.eversana.com/insights/how-pharma-can-scale-innovation-without-losing-executional-rigor/) - Learn how pharma leaders are scaling innovation without losing execution. Mark Thierer shares insights on integrated commercialization, data, and AI. - [Predicting PICOs Under EU Joint Clinical Assessment: Is One Method Enough?](https://www.eversana.com/insights/predicting-picos-under-eu-joint-clinical-assessment-is-one-method-enough/) - [The Most-Favored-Nation Model: Global Benchmark or Global Risk?](https://www.eversana.com/insights/the-most-favored-nation-model-global-benchmark-or-global-risk/) - [The Future of Pharmaceutical Deployment](https://www.eversana.com/insights/the-future-of-pharmaceutical-deployment/) - The ground is shifting beneath the feet of the pharmaceutical industry. Are the partners of yesterday equipped for the challenges of today? Discover how EVERSANA is changing the game. - [Winners Circle Podcast: How EVERSANA Built an 80/20 AI Model That Works](https://www.eversana.com/insights/eversana-ai-agency-platform-80-20-model/) - Faruk Capan explains how EVERSANA rebuilt pharma marketing using an 80/20 AI‑to‑human model after winning an AI Excellence Award. - [The Strategic Advantage: Why a Vendor-Neutral Approach is Key to PV Success](https://www.eversana.com/insights/the-strategic-advantage-why-a-vendor-neutral-approach-is-key-to-pv-success/) - The biggest challenge with implementing new pharmacovigilance systems is the inherent bias that comes with a vendor-led solution. Here is how EVERSANA is changing the game. - [Medical Affairs Under Pressure: A Modern Operating Model for the Next Era](https://www.eversana.com/insights/medical-affairs-under-pressure-a-modern-operating-model-for-the-next-era/) - [You Can Build AI In House.<br>But Should You?](https://www.eversana.com/insights/build-or-own-ai/) - [Stay Ahead of Change with NAVLIN Daily’s Global Policy Watch](https://www.eversana.com/insights/stay-ahead-of-change-with-navlin-dailys-global-policy-watch/) - [Navigating the Complexities of Patient Care with Digital and Human Touchpoints](https://www.eversana.com/insights/navigating-the-complexities-of-patient-care-with-digital-and-human-touchpoints/) - [The New Role of Medical Field Teams and Their Impact on Launch Success](https://www.eversana.com/insights/the-new-role-of-medical-field-teams-their-impact-on-launch-success/) - [Pivot Pros: How EVERSANA Course Corrected When the Market Changed](https://www.eversana.com/insights/pivot-pros-how-eversana-course-corrected-when-the-market-changed/) - [From Experimentation to Ownership: Why the Future Belongs to Companies That Own AI](https://www.eversana.com/insights/from-experimentation-to-ownership-why-the-future-belongs-to-companies-that-own-ai/) - [Successfully Navigating Self-Commercialisation in Europe](https://www.eversana.com/insights/successfully-navigating-self-commercialisation-in-europe/) - [Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™](https://www.eversana.com/insights/asset-optimization-breathe-new-life-into-mature-brands-with-eversana-reignite/) - Learn how EVERSANA REIGNITE can create more impactful spend and net additional value for your established brands. - [Navigating the Intersection of AI, Global Commercialization and Patient Value](https://www.eversana.com/insights/ai-globalcommercialization-patient-value/) - [Building a scalable GLP-1 care model](https://www.eversana.com/insights/scalable-glp1-care-model/) - [Advancing Medical Affairs Through Data and Scientific Communications: Key Takeaways from DIA MASC 2026](https://www.eversana.com/insights/key-takeaways-dia-masc-2026/) - [Gartner Is Right — About the Wrong Kind of Agency AI Platform](https://www.eversana.com/insights/gartner-ai-agency-platform-risk/) - [Why Women’s Health Is at an Inflection Point and Why Commercialization Must Catch Up](https://www.eversana.com/insights/womens-health-commercialization-inflection-point/) - [EVERSANA’s AI Agency Platform Wins 2026 AI Excellence Award](https://www.eversana.com/insights/2026-ai-excellence-award-agentic-ai-platform/) - [Launching in the EU/U.K.: The 7-Step Countdown to Success](https://www.eversana.com/insights/launching-in-the-eu-u-k-the-7-step-countdown-to-success/) - Launching in the EU/U.K. market requires a strategic approach that encompasses these seven steps. - [Beyond the Pilot: Scaling the Steep Climb of AI in Drug Safety](https://www.eversana.com/insights/beyond-the-pilot-scaling-the-steep-climb-of-ai-in-drug-safety/) - [A New Standard for Copay Excellence: How Pharma Can Rethink Affordability](https://www.eversana.com/insights/a-new-standard-for-copay-excellence-how-pharma-can-rethink-affordability/) - As out‑of‑pocket costs rise and insurance designs grow more complex, traditional copay models are being pushed to their limits. High‑deductible plans, accumulator and maximizer programs, and growing payer and PBM variability are fundamentally reshaping how manufacturer affordability programs operate. In a recent Q&A with Pharmaceutical Executive, Brian Laird, President, Patient Services, shares his perspective on how the copay marketplace has - [Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products](https://www.eversana.com/insights/balancing-the-portfolio/) - Learn how EVERSANA REIGNITE helps balance manufacturers' portfolios and revitalize mature brands' revenue to replenish costs invested in launching new products. - [Redefining the QA Role in the Age of AI](https://www.eversana.com/insights/redefining-the-qa-role-in-the-age-of-ai/) - [SIUU vs. Unsolicited Off‑Label Requests: A Practical Comparison](https://www.eversana.com/insights/siuu-vs-unsolicited-off-label-requests-a-practical-comparison/) - [The Integrated Advantage: What Medical Affairs Needs Right Now](https://www.eversana.com/insights/the-integrated-advantage-what-medical-affairs-needs-right-now/) - [Solving The Rare Disease Launch Paradox — Using Pre‑Launch Planning and Partnership to Create Value](https://www.eversana.com/insights/solving-the-rare-disease-launch-paradox-using-pre-launch-planning-and-partnership-to-create-value/) - [It’s Time for Commercialization to Catch Up to Innovation in Women’s Health ](https://www.eversana.com/insights/its-time-for-commercialization-to-catch-up-to-innovation-in-womens-health/) - [4th Annual Brand Planning Report: Fueling Brand Plan Success Through AI‑Powered Integration](https://www.eversana.com/insights/4th-annual-brand-planning-report-fueling-brand-plan-success-through-ai-powered-integration/) - [Scaling Practical AI Across Commercial Teams](https://www.eversana.com/insights/scaling-practical-ai-across-commercial-teams/) - [Key Implications of Recent U.S. PBM Reforms](https://www.eversana.com/insights/key-implications-of-recent-u-s-pbm-reforms/) - [The AI Revolution: 7 Trends Shaping the AI Revolution in 2025](https://www.eversana.com/insights/the-ai-revolution-7-trends-shaping-the-ai-revolution-in-2025/) - [Rewiring Commercialization for Biotech’s New Reality](https://www.eversana.com/insights/rewiring-commercialization-for-biotechs-new-reality/) - [Recognizing Rare Disease Day: Advancing Hope, Access and Innovation](https://www.eversana.com/insights/rare-disease-day-2026/) - On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is central to who we are and the work we do every day. How is EVERSANA advancing rare disease commercialization? EVERSANA recognizes Rare Disease Day 2026 and shares how we support rare and ultra-rare therapy commercialization, AI-driven detection and patient access. - [Why Our AI Agency Is So Much More Than ChatGPT for Life Sciences Marketing](https://www.eversana.com/insights/why-our-ai-agency-is-so-much-more-than-chatgpt-for-life-sciences-marketing/) - Our AI Agency Platform offers a new approach — combining technology, data, creativity and compliance. AI is everywhere. We can generate emails, social posts, videos and research in seconds. But as Faruk Capan explains in his PM360 article, life sciences marketing requires more than a simple AI tool. It requires speed, compliance, security and human expertise working together. AI alone isn’t enough for pharma Campaigns in life sciences take time, and every delay affects patients. Tools like ChatGPT are - [Demonstrating the Clinical and Economic Value of Efgartigimod for AChR‑Positive gMG in Canada](https://www.eversana.com/insights/generalized-myasthenia-gravis-cost-effectiveness/) - A Markov model analysis shows efgartigimod improves QALYs and reduces costs versus chronic immunoglobulin therapy for AChR‑positive gMG in Canada. - [Inside the Shifting Role of Pharma 3PLs: Resilient, Regulated & Ready](https://www.eversana.com/insights/pharma-3pl-evolution-2026/) - Third-party logistics in the pharmaceutical industry must always be considered a strategic partnership, not a transactional handoff. Today’s 3PL is no longer about outsourcing a non-core function. It is about orchestrating a regulated, data-rich, end-to-end value chain. Danny Williams, President of Channel Management & 3PL with EVERSANA, recently was one of several experts interviewed by Pharmaceutical Commerce in their annual focus on 3PLs. As he discussed, Pharma 3PLs are evolving into strategic partners that integrate quality, data, order‑to‑cash, and cold chain operations to ensure therapies reach patients reliably. - [EVERSANA Recognized by Vault for the Fifth Consecutive Year](https://www.eversana.com/insights/eversana-vault-2026-consulting-rankings/) - EVERSANA has been recognized by Vault for the fifth consecutive year in its 2026 Consulting Rankings, earning placement in both the: Vault Consulting 50 – North America Health Sciences Consulting category Vault’s annual rankings are informed by verified consultant feedback across the industry, reflecting perspectives on firm prestige, culture and overall experience. Consistent Recognition, Driven by Our People This continued recognition reflects the EVERSANA has been recognized in the Consulting 50 and Health Sciences categories. - [How Pharma Marketers Can Prepare for the Next Wave of Healthcare AI ](https://www.eversana.com/insights/how-pharma-marketers-can-prepare-for-the-next-wave-of-healthcare-ai/) - This article outlines how platforms could reshape commercial models, clinical information delivery, and the broader digital ecosystem. - [Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia](https://www.eversana.com/insights/association-between-targeted-therapy-and-survival-in-patients-with-acute-myeloid-leukemia/) - [Association Between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes](https://www.eversana.com/insights/association-between-targeted-therapy-and-survival-in-patients-with-myelodysplastic-syndromes/) - [Bringing a Breakthrough Rare Disease Therapy to Market with Rapid Speed for Patients ](https://www.eversana.com/insights/bringing-a-breakthrough-rare-disease-therapy-to-market-with-rapid-speed-for-patients/) - [Insights from Frontiers Health 2025: How European Biotechs Can Navigate the U.S. Market](https://www.eversana.com/insights/insights-from-frontiers-health-2025-how-european-biotechs-can-navigate-the-u-s-market/) - For European life sciences companies, breaking into the U.S. market means navigating one of the most competitive and complex healthcare ecosystems in the world. This topic was explored last November at Frontiers Health 2025 in a session moderated by Mike Ryan, General Manager, Europe. Featuring seasoned industry voices, the discussion highlighted both the challenges and Breaking into the U.S. market is complex, but it’s possible with the right strategy. - [Insights from Frontiers Health 2025: The Future of Commercialization Models](https://www.eversana.com/insights/insights-from-frontiers-health-2025-the-future-of-commercialization-models/) - As the global healthcare landscape rapidly evolves, traditional launch playbooks are no longer enough. Emerging technologies, shifting pricing dynamics, and rising commercial expectations are reshaping how therapies and medical devices reach patients. At Frontiers Health 2025, experts from MENARINI Group, SpringWorks Therapeutics, and EVERSANA highlighted the growing role of artificial intelligence, digital platforms, and Direct‑to‑Disease As the global healthcare landscape rapidly evolves, traditional launch playbooks are no longer enough. - [Putting Data Science in the Spotlight](https://www.eversana.com/insights/putting-data-science-in-the-spotlight/) - [“Nothing changes if nothing changes.”](https://www.eversana.com/insights/nothing-changes-if-nothing-changes/) - Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must. - [Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process](https://www.eversana.com/insights/navigating-a-new-era-lessons-and-opportunities-from-canadas-enhanced-cda-amc-reimbursement-review/) - [NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access](https://www.eversana.com/insights/navlin-daily-2025-round-up/) - [Predicting PICO and Preparing for JCA: Insights from EVERSANA at ISPOR EU](https://www.eversana.com/insights/predicting-pico-and-preparing-for-jca-insights-from-eversana-at-ispor-eu/) - [The Combination Crossfire: Is Your Brand Strategy Strong Enough to Align Payers, Prescribers, and Patients?](https://www.eversana.com/insights/the-combination-crossfire-is-your-brand-strategy-strong-enough-to-align-payers-prescribers-and-patients/) - [The Strategic Value of Medical & Scientific Fact-Checking in Medical, Legal and Regulatory Review](https://www.eversana.com/insights/the-strategic-value-of-medical-scientific-fact-checking-in-medical-legal-and-regulatory-review/) - In today’s highly regulated pharmaceutical industry, promotional and non-promotional materials must meet the highest standards of scientific accuracy, compliance, and trust. With growing scrutiny from regulators, healthcare professionals, and the public, fact-checking has become a strategic imperative, not just a compliance checkbox. Our latest white paper, “The Strategic Value of Medical & Scientific Fact-Checking in The white paper, “The Strategic Value of Medical & Scientific Fact-Checking in Medical, Legal and Regulatory Review,” explores why fact-checking is a strategic imperative. - [New Evidence Confirms Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in Metastatic Castration-Resistant Prostate Cancer](https://www.eversana.com/insights/new-evidence-confirms-radiographic-progression-free-survival-rpfs-as-a-surrogate-endpoint-for-overall-survival-os-in-metastatic-castration-resistant-prostate-cancer/) - Confirms rPFS as a surrogate for OS in advanced prostate cancer through a systematic literature review and trial-level analysis, supporting faster access to therapies. - [No More Waiting: What the C-Suite Should Demand from an "AI Agency"](https://www.eversana.com/insights/no-more-waiting/) - Faruk Capan’s POV reveals how AI is transforming pharma commercialization now. Download to see how leaders achieve speed, compliance and impact. - [A New Marketing Mandate in Community Oncology](https://www.eversana.com/insights/a-new-marketing-mandate-in-community-oncology/) - [Clinical Data Portability for Regulatory Submissions Across Global Markets](https://www.eversana.com/insights/clinical-data-portability-for-regulatory-submissions-across-global-markets/) - Discover the complexities and nuances of navigating the regulatory landscape for medical devices using overseas clinical data in the U.S., EU, and U.K. - [An Impactful Year for Global Regulation of Digital Health](https://www.eversana.com/insights/an-impactful-year-for-global-regulation-of-digital-health/) - Exciting strides in digital health regulation in 2023 set the stage for a dynamic 2024! - [A Framework for Branded Pharma Companion Apps Is Coming Soon](https://www.eversana.com/insights/a-framework-for-branded-pharma-companion-apps-is-coming-soon/) - [Breaking Down Q1 2023 Digital Health Policy Updates](https://www.eversana.com/insights/q1-2023-digital-health-policy-recap/) - [How Pharma and PBMs Can Coexist and Lower Drug Costs Faster](https://www.eversana.com/insights/how-pharma-and-pbms-can-coexist-and-lower-drug-costs-faster/) - [The Evolution of Digital Health Policy: A 2024 Retrospective and 2025 Outlook](https://www.eversana.com/insights/the-evolution-of-digital-health-policy-a-2024-retrospective-and-2025-outlook/) - [Smarter, Faster, Compliant: Our Award-Winning Our AI-Powered Solutions Recognized in PM360’s Innovation Issue](https://www.eversana.com/insights/smarter-faster-compliant-our-award-winning-our-ai-powered-solutions-recognized-in-pm360s-innovation-issue/) - [Balancing Privacy, Compliance and Personalization in Direct-to-Patient Models](https://www.eversana.com/insights/balancing-privacy-compliance-and-personalization-in-direct-to-patient-models/) - [Transitioning an Enterprise Literature Monitoring Program with EVERSANA ORCHESTRATE™ PV](https://www.eversana.com/insights/case-study-enterprise-literature-monitoring-with-orchestrate-pv/) - Download the full case study to see how ORCHESTRATE™ PV delivers clarity, reliability, and compliance in enterprise literature monitoring. - [The Enablement Helix: An Evolving Framework for Market Success in Oncology](https://www.eversana.com/insights/the-enablement-helix-an-evolving-framework-for-market-success-in-oncology/) - [Going Beyond Compliance: Transforming Aggregate Reports into Strategic Safety Intelligence](https://www.eversana.com/insights/going-beyond-compliance-transforming-aggregate-reports-into-strategic-safety-intelligence/) - #post_contentAggregate reports aren’t just regulatory checkboxes—they’re powerful tools for smarter decision-making. - [Digital-First Care and Affordability: Our Leaders Share Insights with pharmaphorum](https://www.eversana.com/insights/digital-first-care-and-affordability-our-leaders-share-insights-with-pharmaphorum/) - [Consolidating Data Strategy For Global Success](https://www.eversana.com/insights/consolidating-data-strategy-for-global-success/) - [Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis](https://www.eversana.com/insights/predicting-picos-for-eu-hta-the-validated-pico-planner-approach-based-on-retrospective-analysis/) - [New Direct-to-Employer Access Model Provides Options for Employers to Improve Access to Weight Loss Medications](https://www.eversana.com/insights/new-direct-to-employer-access-model-provides-options-for-employers-to-improve-access-to-weight-loss-medications/) - [Pharmatizing AI: How Artificial Intelligence Is Transforming Pharma](https://www.eversana.com/insights/pharmatizing-ai-how-artificial-intelligence-is-transforming-pharma/) - [The Oncologist’s Next Ally: Why Cancer Is Forging the Future of Clinical AI](https://www.eversana.com/insights/the-oncologists-next-ally-why-cancer-is-forging-the-future-of-clinical-ai/) - Discover how oncology’s urgent demands are pushing AI beyond pattern recognition into the heart of strategic clinical partnership. - [Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency](https://www.eversana.com/insights/webinar-transformative-commercialization-for-new-biopharma-entrants-ensuring-success-with-capital-and-time-efficiency/) - This webinar focused on four major obstacles commonly encountered by first-time launchers included real-world case studies, such as: exceeding forecasts for an oncology company, reducing launch costs by 25% for an emerging biotech, enabling a rare disease company to be launch-ready in just eight months, and saving millions through contractual flexibility. - [Driving Measurable Impact for Pharma Brands: How Our AI Agency Platform Improves Operational Models](https://www.eversana.com/insights/driving-measurable-impact-for-pharma-brands-how-our-ai-agency-platform-improves-operational-models/) - [Brave New Commercialisation World](https://www.eversana.com/insights/brave-new-commercialization-world-insights-from-frontiers-health-2025/) - [Google Cloud Spotlights EVERSANA: A Milestone for Pharma Innovation](https://www.eversana.com/insights/google-cloud-spotlights-eversana-a-milestone-for-pharma-innovation/) - Google Cloud featured EVERSANA’s approach to pharmaceutical commercialization. Learn how AI-powered marketing and cloud innovation are transforming life sciences strategies. - [Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access](https://www.eversana.com/insights/evaluation-of-hta-frameworks-for-in-vivo-diagnostics-assessing-methodological-gaps-and-implications-for-market-access/) - Health technology assessments (HTAs) are crucial for market access and reimbursement of diagnostic innovations, yet current frameworks often fail to reflect the true value of in vivo diagnostics—such as molecular imaging (MI) tracers and contrast media (CM). These technologies are frequently assessed using methodologies designed for pharmaceuticals, resulting in inconsistent evaluations and delayed patient access A comprehensive review conducted by EVERSANA’s NAVLIN P&MA Consulting team (Shivani Shah and Chad Gibson) in collaboration with GE HealthCare (Dr. Ricardo De la Fuente and Hermilo Cabra Gomez) analyzed HTA frameworks across 28 countries - [Strategic PICO Planning: Enhancing Early-Phase Development for Market Access](https://www.eversana.com/insights/strategic-pico-planning-enhancing-early-phase-development-for-market-access/) - [Preparing for Joint Clinical Assessments: How Early PICO Planning Ensures Smoother Submissions](https://www.eversana.com/insights/preparing-for-joint-clinical-assessments-jcas-what-you-need-to-know/) - This analysis, conducted by DePuy Synthes and supported by EVERSANA’s Value & Evidence group, investigated the budget impact of MI-TLIF versus O-TLIF for single-level fusion from a European hospital perspective. - [Transformative Commercialization for New Biopharma Entrants: Ensuring Success With Capital and Time Efficiency](https://www.eversana.com/insights/transformative-commercialization-for-new-biopharma-entrants-ensuring-success-with-capital-and-time-efficiency/) - [EVDAS 2026: From Regulatory Requirement to Signal Advantage](https://www.eversana.com/insights/evdas-2026-from-regulatory-requirement-to-signal-advantage/) - [Human-in-the-Loop + AI: A Pragmatic Path Forward for Pharma Commercialization](https://www.eversana.com/insights/human-in-the-loop-ai-a-pragmatic-path-forward-for-pharma-commercialization/) - Learn how EVERSANA’s AI Agency Platform, built with Google, enables strategic, compliant pharma commercialization with human-in-the-loop intelligence. - [Interpretation of the Europe Regulatory Framework and Best Practices for MI Across the Pharma Industry](https://www.eversana.com/insights/interpretation-of-the-europe-regulatory-framework-and-best-practices-for-mi-across-the-pharma-industry/) - [Content Evolution: Shifting to Component-Based Authoring and Modular Strategies](https://www.eversana.com/insights/content-evolution-shifting-to-component-based-authoring-and-modular-strategies/) - [Content Acceleration Like Never Before: Meet Our AI Agency Platform](https://www.eversana.com/insights/content-acceleration-like-never-before-meet-eversanas-ai-agency-platform/) - [AI in Oncology: Acceleration, Accessibility, and Accuracy](https://www.eversana.com/insights/ai-in-oncology-acceleration-accessibility-and-accuracy/) - [AI at ESMO 2025: Navigating the New Frontier of Opportunity and Obstacles in Oncology](https://www.eversana.com/insights/ai-at-esmo-2025-navigating-the-new-frontier-of-opportunity-and-obstacles-in-oncology/) - [Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth](https://www.eversana.com/insights/escaping-the-chronic-microcap-trap-how-launching-alone-is-the-only-option-for-growth/) - In this article, our commercialization experts discuss two challenges small and mid-size companies face when deciding how to launch and why the risk of launching alone can be worth the reward. - [How a Strategic Global HEOR Package Drives Market Access and Pricing Success](https://www.eversana.com/insights/how-a-strategic-global-heor-package-drives-market-access-and-pricing-success/) - As ISPOR Europe 2025 approaches and momentum builds around how Health Economics and Outcomes Research (HEOR) continues to evolve—shaped by innovation, policy shifts and global collaboration, I’ve been reflecting on recent global product launches. What stands out is the enduring power of the core tenets of a global HEOR program in achieving optimal pricing and Discover how a strategic global HEOR package enhances market access, pricing, and evidence alignment across regions. - [The Future of Personalized, Measurable MSL Engagement: Key Takeaways from Susan Giacalone](https://www.eversana.com/insights/the-future-of-personalized-measurable-msl-engagement-key-takeaways-from-susan-giacalone/) - [Disrupting the Life Sciences Commercial Model: EVERSANA Joins Insightful Conference Sessions on AI & Patient-Centric Models](https://www.eversana.com/insights/disrupting-the-life-sciences-commercial-model-eversana-joins-insightful-conference-sessions-on-ai-patient-centric-models/) - Thought leaders gathered at The Wharton School to participate in “Disrupting the Life Sciences Commercial Model: Exploring the Future Impact of AI and Patient-Centric Healthcare.” - [Let's Be DIRECT: We Have An Access and Affordability Problem to Solve](https://www.eversana.com/insights/lets-be-direct-we-have-an-access-and-affordability-problem-to-solve/) - [Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis](https://www.eversana.com/insights/itc-gmc/) - Explore the first feasibility assessment of indirect treatment comparisons (ITCs) in generalized myasthenia gravis (gMG), highlighting challenges in trial comparability and the importance of using multiple methods to evaluate emerging therapies. - [Brave New Commercialization World: Reimagining Global Launch Strategies in Life Sciences](https://www.eversana.com/insights/brave-new-commercialization-world-reimagining-global-launch-strategies-in-life-sciences/) - [Seeing the Whole Picture: How Value & Evidence Generalists Drive Strategic Impact and Client Success](https://www.eversana.com/insights/seeing-the-whole-picture-how-value-evidence-generalists-drive-strategic-impact-and-client-success/) - [Uncovering the Drivers of Satisfaction for Patient Services](https://www.eversana.com/insights/uncovering-the-drivers-of-satisfaction-for-patient-services/) - Dive into our latest article, featuring insights from David Frey, Kevin O’Meara, and Lee Ann Steadman, to discover strategies for improving patient and provider experiences with patient service programs. - [Sound Off on Interoperability – Leveraging Next-Gen Tech for Enhanced Electronic Benefit Verification and Prior Authorizations to Streamline Workflow](https://www.eversana.com/insights/sound-off-on-interoperability-leveraging-next-gen-tech-for-enhanced-electronic-benefit-verification-and-prior-authorizations-to-streamline-workflow/) - Learn about technologies that enhance Electronic Benefit Verification and Prior Authorizations and streamline workflow. - [Patient Assistance for Gene Therapies](https://www.eversana.com/insights/patient-assistance-for-gene-therapies/) - [Tumor Types Drive Oncology Product Launch Strategies](https://www.eversana.com/insights/tumor-types-drive-oncology-launch-strategies/) - Our case study explores how oncology commercialization strategies must be tailored to both the therapy and tumor type. - [Navigating the New HTA Landscape: Pamela Vo on Strategic Evidence Planning](https://www.eversana.com/insights/navigating-the-new-hta-landscape-pamela-vo-on-strategic-evidence-planning/) - [Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA](https://www.eversana.com/insights/strategic-pico-planning-navigating-oncology-markets-with-navlin-by-eversana/) - [How AI & Automation Plays a Role in Powering the Future of Compliant Pharma Marketing](https://www.eversana.com/insights/how-ai-automation-plays-a-role-in-powering-the-future-of-compliant-pharma-marketing/) - [AI in DTP: Turning Data into Meaningful Care Moments](https://www.eversana.com/insights/ai-in-dtp-turning-data-into-meaningful-care-moments/) - [Reimagining Pharma Commercialization with AI Agents](https://www.eversana.com/insights/reimagining-pharma-commercialization-with-ai-agents-2/) - [A Deeper Dive into Pharmatizing AI & What It Will Mean to the Future of Commercialization](https://www.eversana.com/insights/a-deeper-dive-into-pharmatizing-ai-what-it-will-mean-to-the-future-of-commercialization/) - [Reimagining Pharma Commercialization with AI Agents](https://www.eversana.com/insights/reimagining-pharma-commercialization-with-ai-agents/) - [Unveiling the Real DTP: Beyond Common Misconceptions](https://www.eversana.com/insights/unveiling-the-real-dtp-beyond-common-misconceptions/) - [The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts](https://www.eversana.com/insights/the-evolution-of-the-340b-rebate-model-maintaining-patient-access-while-minimizing-duplicate-discounts/) - [Ready, Set, Simplify: PV Without the Hassle](https://www.eversana.com/insights/ready-set-simplify-pv-without-the-hassle/) - [2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers](https://www.eversana.com/insights/2026-cms-proposed-rule-bfsf-changes-and-potential-risks-for-pharma-manufacturers/) - [Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance](https://www.eversana.com/insights/navigating-obbba-why-a-strong-gp-team-is-essential-for-pharma-compliance/) - [“Nothing changes if nothing changes.”](https://www.eversana.com/insights/nothing-changes-if-nothing-changes-integrated-commercialization-platform-with-amplified-power-of-a-direct-to-patient-dtp-channel/) - Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must. - [The Future of Personalized, Measurable MSL Engagement](https://www.eversana.com/insights/the-future-of-personalized-measurable-msl-engagement/) - [One Team, One Voice: The Impact of Centralized Medical Content Development](https://www.eversana.com/insights/one-team-one-voice-the-impact-of-centralized-medical-content-development/) - [Rewriting the Rules of Pharma Commercialization: Why the AI Agency Is the Catalyst Life Sciences Has Been Waiting For](https://www.eversana.com/insights/rewriting-the-rules-of-pharma-commercialization-why-the-ai-agency-is-the-catalyst-life-sciences-has-been-waiting-for/) - [Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer](https://www.eversana.com/insights/cdk4-6i-literature-review-breast-cancer/) - Our Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. - [Navigating the New EU HTA Landscape: Pamela Vo on Strategic Evidence Planning](https://www.eversana.com/insights/navigating-the-new-eu-hta-landscape-pamela-vo-on-strategic-evidence-planning/) - [Redefining Field Deployment - Bridging "Share of Voice" with "Share of Influence" for Lasting Impact](https://www.eversana.com/insights/redefining-field-deployment-bridging-share-of-voice-with-share-of-influence-for-lasting-impact/) - [EVERSANA & Google Cloud Bring AI Agency Concept to Life](https://www.eversana.com/insights/eversana-google-cloud-bring-ai-agency-concept-to-life/) - [Optimizing Product Commercialization in Today’s IDN Environment](https://www.eversana.com/insights/optimizing-product-commercialization-in-todays-idn-environment-2/) - [Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now](https://www.eversana.com/insights/navigating-mfn-alan-crowther-on-what-pharma-brands-must-know-now/) - [Expanding the Evidence: Real-World Insights into CDK4/6i Use in Elderly and BIPOC Patients with Metastatic Breast Cancer](https://www.eversana.com/insights/cdk4-6i-elderly-bipoc-metastatic-breast-cancer/) - Explore real-world insights into the use of CDK4/6 inhibitors in elderly and BIPOC patients with metastatic breast cancer, highlighting the need for more inclusive research. - [Treatment Effect Modifiers and Prognostic Factors in Multiple Myeloma: Enabling Smarter Trials and Comparative Research](https://www.eversana.com/insights/literature-review-multiple-myeloma/) - The Value & Evidence team at EVERSANA, in collaboration with Johnson & Johnson Innovative Medicine, reviewed RCTs and PAICs in newly diagnosed and relapsed/refractory MM populations. - [Unlocking the Future of Medical Information Analytics: A Q&A with Michael DeLuca of EVERSANA](https://www.eversana.com/insights/unlocking-the-future-of-medical-information-analytics-a-qa-with-michael-deluca-of-eversana/) - [Redefining CAR-T Access: Strategic Implications of the FDA's REMS Decision](https://www.eversana.com/insights/redefining-car-t-access-strategic-implications-of-the-fdas-rems-decision/) - [From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services](https://www.eversana.com/insights/from-challenges-to-solutions-breaking-barriers-to-revolutionize-patient-services-3/) - [Repairing the Patient Journey: How Pharma Can Fix the Obvious – and Not So Obvious – Breaking Points of Nonadherence](https://www.eversana.com/insights/repairing-the-patient-journey-how-pharma-can-fix-the-obvious-and-not-so-obvious-breaking-points-of-nonadherence-2/) - [Reimagining Drug Safety: A New Era of Innovation](https://www.eversana.com/insights/reimagining-drug-safety-a-new-era-of-innovation/) - [The Promise of Direct-to-Patient - What's Really Needed for Patient Access](https://www.eversana.com/insights/the-promise-of-direct-to-patient/) - As the industry’s first and only fully integrated direct-to-patient model, EVERSANA is accelerating patients’ access to providers and treatment. - [From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services](https://www.eversana.com/insights/from-challenges-to-solutions-breaking-barriers-to-revolutionize-patient-services-2/) - [AI + RWE: Powering Smarter Patient Solutions](https://www.eversana.com/insights/ai-rwe-powering-smarter-patient-solutions/) - [Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses](https://www.eversana.com/insights/navigating-the-final-fda-siuu-guidance-strategic-considerations-for-scientific-exchange-at-asco-and-other-congresses/) - The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA ONCOLOGY’s experts explore how to align strategy with compliance while maximizing the impact of data across a variety of scientifically sound Explore how the FDA’s final SIUU guidance is reshaping scientific exchange at congresses like ASCO. Learn how pharma brands can stay compliant while maximizing data impact through strategic rep engagement, booth design, and digital tools. - [Specialty Pharmacies are Ready for the Biosimilar Boom. Are you?](https://www.eversana.com/insights/specialty-pharmacies-are-ready-for-the-biosimilar-boom-are-you/) - The pharmacy benefit biologic market is primed for disruption, with Specialty Pharmacies (SPs) eagerly awaiting the pending market shift. While biosimilars have been available for nearly a decade in the United States, this year will be the first time many SPs begin dispensing these brands. Currently, 22 biosimilars are available in the U.S. and, up - [Delivering Value to Leading Payers](https://www.eversana.com/insights/delivering-value-to-leading-payers/) - Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente Humana Centene As these organizations evolve their business models and ultimately their approaches to care and drug management, biopharma - [VOICE OF THE CUSTOMER: Payer Pharmacy Directors Report ‘Back-to-Basics’ Contracting, Product Updates, and Pipeline Forecasts Drive Pharma Company Perceptions](https://www.eversana.com/insights/voice-of-the-customer-payer-pharmacy-directors-report-back-to-basics-contracting-product-updates-and-pipeline-forecasts-drive-pharma-company-perceptions/) - Noticeable improvements in several relationship competencies separate the top companies from the rest of the industry. Post-pandemic industry dynamics have forced a shift in the way pharmaceutical companies call on their managed care customers. This past month, NAVLIN Insights concluded our annual research with payer pharmacy directors assessing their relationships and interactions with the pharmaceutical - [Pharmatizing AI & EVERSANA’s Bold Vision for Its AI Accelerator](https://www.eversana.com/insights/pharmatizing-ai-eversanas-bold-vision-for-its-ai-accelerator/) - [Staying Ahead of the Curve in Pharmacovigilance: Mid-Year Pharmacovigilance Inspection Report 2025: Saudi Food & Drug Authority (SFDA) ](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-mid-year-pharmacovigilance-inspection-report-2025-saudi-food-drug-authority-sfda/) - [Staying Ahead of the Curve in Pharmacovigilance: Module VI Addendum II – Masking of Personal Data in Individual Case Safety (GVP)](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-module-vi-addendum-ii-masking-of-personal-data-in-individual-case-safety-gvp/) - [Insights from BIO with OS Therapies](https://www.eversana.com/insights/insights-from-bio-with-os-therapies/) - [Case Study: Transforming Market Access with NAVLIN Insights KPI](https://www.eversana.com/insights/case-study-transforming-market-access-with-navlin-insights-kpi/) - Download the full case study to see how NAVLIN Insights KPI helps you measure, communicate, and maximize your market access success. - [Empowering Scientific Dialogue: Key Takeaways from the FDA's SIUU Guidance](https://www.eversana.com/insights/key-takeaways-fda-siuu-guidance/) - Discover the latest insights from the FDA's finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this article, our EVERSANA ONCOLOGY experts explore how to align strategy with compliance while maximizing the impact of data across Explore how the FDA’s final SIUU guidance is reshaping scientific exchange at congresses like ASCO. Learn how pharma brands can stay compliant while maximizing data impact through strategic rep engagement, booth design, and digital tools. - [Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes](https://www.eversana.com/insights/strategic-order-to-cash-drives-real-revenue-outcomes/) - Align Order to Cash and Revenue Management to eliminate operational blind spots, reduce deductions and improve gross-to-net performance. - [Navigating the Not-So-Direct Path to Access – A Pharmacist’s Perspective](https://www.eversana.com/insights/navigating-the-not-so-direct-path-to-access-a-pharmacists-perspective/) - Direct-to-Patient represents a fundamental shift toward patient-centric commercialization that prioritizes transparency, efficiency and direct engagement. - [Understanding the Inflation Reduction Act: Inflation Rebates](https://www.eversana.com/insights/understanding-the-inflation-reduction-act-inflation-rebates/) - [Staying Ahead of the Curve in Pharmacovigilance: Inspection Metrics Report for 2023 by Egyptian Drug Authority (EDA)](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-inspection-metrics-report-for-2023-by-egyptian-drug-authority-eda/) - [Staying Ahead of the Curve in Pharmacovigilance: ANVISA RDC No. 967/25](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-anvisa-rdc-no-967-25/) - [Staying Ahead of the Curve in Pharmacovigilance: Decentralized Manufacture — UK Guidelines of Good Pharmacovigilance Practices](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-decentralized-manufacture-uk-guidelines-of-good-pharmacovigilance-practices/) - [Reimagining Patient Health Experiences: A New Paradigm for Transforming Lives](https://www.eversana.com/insights/reimagining-patient-health-experiences-a-new-paradigm-for-transforming-lives/) - Pharma isn't just implementing new tech, they're creating entirely new patient experiences that let people thrive as they are, not as we think they should be. - [Leveraging the Expertise of Medical Affairs to Create Global Value with Efficient, Cross-functional Collaboration](https://www.eversana.com/insights/leveraging-the-expertise-of-medical-affairs-to-create-global-value-with-efficient-cross-functional-collaboration/) - [Pioneering the Path: How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies](https://www.eversana.com/insights/medical-affairs-pre-post-launch-strategies/) - Learn how Medical Affairs teams and activities redefine healthcare delivery and serve as a vital link between clinical deployment and product commercialization to improve patient outcomes. - [3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks](https://www.eversana.com/insights/3-questions-you-need-to-answer-before-partnering-with-integrated-delivery-networks/) - [Price Right or Pay Later](https://www.eversana.com/insights/price-right-or-pay-later/) - In this article, EVERSANA details why it is critical to approach pricing deliberately – and proposes a better way to develop pricing strategies. - [Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways](https://www.eversana.com/insights/adherence-redefined-evolving-approaches-to-adherence-in-oncology-clinical-pathways/) - Our white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,”delves into the shifting landscape of oncology treatment adherence. - [Left-Right-Left: The Latest in Pharma-Payer Ping Pong](https://www.eversana.com/insights/left-right-left-the-latest-in-pharma-payer-ping-pong/) - [EVERSANA Returns as Global Host and Presenting Sponsor for Frontiers Health 2025](https://www.eversana.com/insights/eversana-returns-as-global-host-and-presenting-sponsor-for-frontiers-health-2025/) - [Most Favored Nation Pricing | Insights and Implications for Manufacturers](https://www.eversana.com/insights/most-favorable-nation-pricing-insights-and-implications-for-manufacturers/) - [Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey](https://www.eversana.com/insights/demystifying-market-access-a-must-read-for-navigating-the-lab-to-patient-journey/) - [Staying Ahead of the Curve in Pharmacovigilance: Outcome of GVP Inspections by NPRA](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-outcome-of-gvp-inspections-by-npra/) - [Staying Ahead of the Curve in Pharmacovigilance: CIOMS XIV Draft "Artificial Intelligence in Pharmacovigilance"](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-cioms-xiv-artificial-intelligence-in-pharmacovigilance/) - [Celebrating Excellence: Two EVERSANA Leaders Named 2025 PM360 ELITE 100 Winners](https://www.eversana.com/insights/celebrating-excellence-two-eversana-leaders-named-2025-pm360-elite-100-winners/) - [Staying Ahead of the Curve in Pharmacovigilance: Emerging Regulations and Their Implications in Saudi Arabia](https://www.eversana.com/insights/staying-ahead-of-the-curve-in-pharmacovigilance-emerging-regulations-and-their-implications-in-saudi-arabia/) - [Health Disparity Solutions Build Healthier Communities and a More Equitable Medical Landscape](https://www.eversana.com/insights/health-disparity-solutions-build-healthier-communities-and-a-more-equitable-medical-landscape/) - Learn how social determinants of health impact global health equity and discover how EVERSANA combats inequitable healthcare access in underserved communities. - [New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency](https://www.eversana.com/insights/new-models-of-benefits-verification-solve-for-complexity-accelerate-speed-to-therapy-and-deliver-price-transparency/) - [Think Tank 2025 Pharma Forecast: What Lies Ahead for the Industry in 2025?](https://www.eversana.com/insights/think-tank-2025-pharma-forecast-what-lies-ahead-for-the-industry-in-2025/) - [Maximizing Medical Affairs and MSL Impact: How Choosing a Strategic Launch Partner Propels Success](https://www.eversana.com/insights/maximizing-medical-affairs-and-msl-impact-how-choosing-a-strategic-launch-partner-propels-success/) - Discover how Medical Science Liaisons (MSLs) drive success in pharmaceutical launches. Explore a case study and key elements for high-impact MSL teams. - [Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice](https://www.eversana.com/insights/making-cutting-edge-cancer-treatments-accessible-advancing-car-t-therapy-to-the-community-practice/) - This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy cancer cells. Historically limited to later lines of treatment due to potential side effects and the need for individualized This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. - [CASE STUDY: Transforming Clinical Trials with EVERSANA](https://www.eversana.com/insights/case-study-transforming-clinical-trials-with-eversana/) - EVERSANA’s Direct-to-Participant model boosts trial access, speeds enrollment and streamlines logistics—accelerating life-changing therapies to market. - [Unlock the Power of Indirect Treatment Comparisons (ITC) with Industry Experts](https://www.eversana.com/insights/unlock-the-power-of-indirect-treatment-comparisons-itc-with-industry-experts/) - This course is designed to provide professionals with invaluable insights and practical experience in optimizing ITC strategies for global programs. - [Unlocking Pharma Success: Mike Ryan's Pre-Conference Talk at Reuters Pharma 2025](https://www.eversana.com/insights/unlocking-pharma-success-mike-ryans-pre-conference-talk-at-reuters-pharma-2025/) - [Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer](https://www.eversana.com/insights/rwe-illuminates-value-of-first-line-cdk4-6i-in-metastatic-breast-cancer/) - Explore the significant clinical benefits of first-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer through real-world evidence, highlighting insights from an updated systematic literature review. - [Case Study: Increasing Product Adoption Rate through EVERSANA's Digital Hub Portal](https://www.eversana.com/insights/case-study-increasing-product-adoption-rate-through-eversanas-digital-hub-portal/) - [The End of the Blockbuster: Adapting to a New Pharmaceutical Landscape With a New Commercialization Model ](https://www.eversana.com/insights/the-end-of-the-blockbuster-adapting-to-a-new-pharmaceutical-landscape-with-a-new-commercialization-model/) - [Evaluating Talazoparib Plus Enzalutamide Against Standard of Care Therapies in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison](https://www.eversana.com/insights/evaluating-talazoparib-matching-adjusted-indirect-comparison/) - To aid clinical decision-making in treatment selection, the Value & Evidence team at EVERSANA conducted a matching-adjusted indirect comparison (MAIC) between these therapies. This - [Optimizing Specialty Pharmacy Networks: A Best-in-Class Approach for Rare Disease Therapies](https://www.eversana.com/insights/optimizing-specialty-pharmacy-networks-a-best-in-class-approach-for-rare-disease-therapies/) - Optimize rare disease therapy access with EVERSANA’s specialty pharmacy solutions, enhancing adherence, support and outcomes - [Overcoming the Odds: How EVERSANA Helped a Family Navigate Their Rare Disease Journey](https://www.eversana.com/insights/overcoming-the-odds-how-eversana-helped-a-family-navigate-their-rare-disease-journey/) - A family's rare disease journey highlights the power of expert care, unwavering support and EVERSANA’s role in ensuring seamless access to life-saving treatment. - [Enhancing Medical Strategies Through Effective Literature Surveillance](https://www.eversana.com/insights/enhancing-medical-strategies-through-effective-literature-surveillance/) - [EVERSANA Wins AI Excellence Award for 4th Straight Year, Building on Legacy of Innovation](https://www.eversana.com/insights/eversana-wins-ai-excellence-award-for-4th-straight-year-building-on-legacy-of-innovation/) - [Rare Disease Care in India: A Path to Positive Impact](https://www.eversana.com/insights/rare-disease-care-in-india-a-path-to-positive-impact/) - Explore the current landscape of rare disease management in India, highlighting key policies, advancements in research and government initiatives. - [Capital Efficient Commercialization: A New Model for Success](https://www.eversana.com/insights/capital-efficient-commercialization/) - By leveraging EVERSANA's COMPLETE Commercialization® model, more than 50% of infrastructure investment can be avoided. SG&A costs drop to less than 20% without sacrificing quality. - [Boosting Pharma Efficiency: A New Model for Asset Value Retention](https://www.eversana.com/insights/a-new-model-for-asset-value-retention/) - EVERSANA COMPLETE Commercialization® offers a new model that allows clinical-stage companies to maximize the commercial potential of their asset while retaining the majority of the asset’s life cycle value. - [Maximizing Sales with AI: A Strategic Roadmap for Success](https://www.eversana.com/insights/maximizing-sales-with-ai-a-strategic-roadmap-for-success/) - Explore strategies for utilizing AI in sales, from using tools for lead generation and customer insights to optimizing sales forecasting and personalization. - [Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe](https://www.eversana.com/insights/securing-launch-success-within-the-context-of-the-new-eu-health-technology-assessment-regulation-htar-landscape-in-europe/) - This article explores the new EU Health Technology Assessment regulation and the introduction of a Joint Clinical Assessment (JCA) process, enabling timely and informed decisions regarding the pricing and reimbursement of health products. - [Revolutionizing Customer Experience: The Role of AI in Enhancing MI Contact Center Operations](https://www.eversana.com/insights/revolutionizing-customer-experience-the-role-of-ai-in-enhancing-mi-contact-center-operations/) - [The Path to Maximizing Revenue: How to Simplify Pharmaceutical Commercialization and Find Optimum Success](https://www.eversana.com/insights/the-path-to-maximizing-revenue-how-to-simplify-pharmaceutical-commercialization-and-find-optimum-success/) - EVERSANA COMPLETE Commercialization® combines EVERSANA’s full suite of services into a unified, seamless solution that ensures every aspect of commercialization is optimized for success. - [Successfully Navigating the Complexity of Market Access Across Europe to Improve Health Equity](https://www.eversana.com/insights/successfully-navigating-the-complexity-of-market-access-across-europe-to-improve-health-equity/) - This article explores the challenges of bringing new drug therapies to market in Europe due to the fragmented reimbursement landscape and highlights solutions like harmonizing HTA processes, implementing Risk-Sharing Agreements, and improving data integration to enhance health equity and patient access. - [Next-Generation Brand Planning: Some (Unexpected) Worrying Trends Demand a Rethink on Brand Planning](https://www.eversana.com/insights/next-generation-brand-planning-some-unexpected-worrying-trends-demand-a-rethink-on-brand-planning/) - [The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA](https://www.eversana.com/insights/the-integral-role-of-global-indirect-treatment-comparison-in-europes-jca/) - Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. - [Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success](https://www.eversana.com/insights/integrated-commercialization-model-proves-valuable-in-launch-success/) - The pharmaceutical industry faces complex global market challenges. EVERSANA COMPLETE Commercialization® is here to help. - [EVERSANA Named Global Host and Presenting Sponsor of Frontiers Health 2024, Bringing Innovators Together Across Europe and Beyond to Transform Healthcare](https://www.eversana.com/insights/eversana-named-global-host-and-presenting-sponsor-for-frontiers-health-2024-bringing-innovators-together-across-europe-and-beyond-to-transform-healthcare/) - [European Parliament's Revision of the General Pharmaceutical Legislation](https://www.eversana.com/insights/eu-parliaments-revision-of-the-general-pharmaceutical-legislation/) - Learn about the European Parliament's adopted revision of pharmaceutical legislation and its potential impact on market access in Europe. - [Point-of-Care (POC) Diagnostics: Transformation From Pre- to Post- Pandemic: An Asian Perspective](https://www.eversana.com/insights/point-of-care-poc-diagnostics-transformation-from-pre-to-post-pandemic-an-asian-perspective/) - Dive into the post-pandemic landscape and see how POC diagnostics are integrating into broader healthcare ecosystems, including remote care and telemedicine. - [Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison](https://www.eversana.com/insights/evaluating-parp-inhibitors-in-metastatic-castration-resistant-prostate-cancer-a-matching-adjusted-indirect-comparison/) - [Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders](https://www.eversana.com/insights/successfully-navigating-global-commercialization-frontiers24/) - Innovators in oncology, rare, and infectious diseases share their journeys to global commercialization and launch excellence. - [The Importance of Quality-of-Life Metrics in mCRPC](https://www.eversana.com/insights/the-importance-of-quality-of-life-metrics-in-mcrpc/) - [Insight from Frontiers Health: Harnessing Machine Learning to Transform Clinical Outcomes](https://www.eversana.com/insights/insight-from-frontiers-health-harnessing-machine-learning-to-transform-clinical-outcomes/) - [A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs](https://www.eversana.com/insights/a-review-of-indirect-treatment-comparisons-itcs-in-regulatory-approval-reimbursement-and-pricing-recommendations-for-oncology-drugs/) - This comprehensive literature review highlights the global acceptance and contribution of ITCs to oncology reimbursement recommendations and pricing decisions made by varying authorities with diverse assessment frameworks across North America, Europe, and the Asia-Pacific region. - [In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts](https://www.eversana.com/insights/global-launch-ambitions-continuous-paradigm-shift/) - Kyle Jenne shares invaluable insights into navigating the complexities of global commercialization strategies, with a particular focus on Europe. - [The Increasing Role of AI in Improving the Diagnostic Imaging Landscape](https://www.eversana.com/insights/the-increasing-role-of-ai-in-improving-the-diagnostic-imaging-landscape/) - Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, "The Increasing Role of AI in Improving the Diagnostic Imaging Landscape." - [Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare](https://www.eversana.com/insights/insights-from-sahara-conference-harnessing-real-world-data-and-ai-to-transform-healthcare/) - Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare - [Finding the Human Element Amid the Algorithms](https://www.eversana.com/insights/finding-the-human-element-amid-the-algorithms/) - [Embarking on the Care Journey: Strategies for Engaging Patients Pre- and Post-Diagnosis](https://www.eversana.com/insights/embarking-on-the-care-journey-strategies-for-engaging-patients-pre-and-post-diagnosis/) - [New Insights into Brain Volume Loss in MS](https://www.eversana.com/insights/new-insights-into-brain-volume-loss-in-ms/) - The study provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing multiple sclerosis. - [Unlocking the Power of Tender Data to Drive Post-LOE Pricing Strategy ](https://www.eversana.com/insights/unlocking-the-power-of-tender-data-to-drive-post-loe-pricing-strategy/) - [OpenAI’s new o1 Series models’ focus on “reasoning” and what it could mean to lifesciences brands and marketers](https://www.eversana.com/insights/openais-new-o1-series-models-focus-on-reasoning-and-what-it-could-mean-to-lifesciences-brands-and-marketers/) - [Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024](https://www.eversana.com/insights/behind-the-breakthroughs-and-practice-changing-advances-insights-from-esmo-2024/) - Learn the topline observations and trends from ESMO 2024 and key takeaways for the potential impact on oncology commercialization and marketing efforts. - [AI, Digital Therapeutics Transformation & Cross-Industry Collaboration – What’s On Tap at Frontiers Health](https://www.eversana.com/insights/ai-digital-therapeutics-transformation-cross-industry-collaboration-whats-on-tap-at-frontiers-health/) - [Enhancing Patient Adherence and Sales Outcomes in Advanced Prostate Cancer Treatment Through Proactive Push Alerts](https://www.eversana.com/insights/enhancing-patient-adherence-and-sales-outcomes-in-advanced-prostate-cancer-treatment-through-proactive-push-alerts/) - [Digital Therapeutics: A Necessity for Italy - Insights from Roberto Ascione and Alberta Spreafico](https://www.eversana.com/insights/digital-therapeutics-a-necessity-for-italy-insights-from-roberto-ascione-and-alberta-spreafico/) - [Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky](https://www.eversana.com/insights/understanding-idns-and-what-they-mean-to-the-pharmaceutical-industry-qa-with-greg-skalicky/) - [The Evolving Landscape of HCP Engagement and the Role of Medical Information in This Era of Digital Innovation](https://www.eversana.com/insights/the-evolving-landscape-of-hcp-engagement-and-the-role-of-medical-information-in-this-era-of-digital-innovation/) - [RWEsearch 2024 | Innovating Clinical Trial Design with Real World Evidence](https://www.eversana.com/insights/rwesearch-2024-innovating-clinical-trial-design-with-real-world-evidence/) - At the RWEsearch Annual Summit 2024, hosted by Healthark Insights, Chris Cameron, Chief Scientific Officer at EVERSANA, emphasized that advancements in Real World Evidence will accelerate with ongoing learning and use of technology and AI. - [EVERSANA's Commitment to Health Innovation in Europe: Leading the Charge at Frontiers Health 2024](https://www.eversana.com/insights/eversanas-commitment-to-health-innovation-in-europe-leading-the-charge-at-frontiers-health-2024/) - [Filling the Missing Spaces in Your Network Meta-Analysis: The Role of Surrogate Models](https://www.eversana.com/insights/filling-the-missing-spaces-in-your-network-meta-analysis-the-role-of-surrogate-models/) - [Transforming Systematic Literature Reviews: Leveraging AI for Efficiency and Rigor](https://www.eversana.com/insights/systematic-literature-reviews-leveraging-ai/) - [Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft](https://www.eversana.com/insights/unveiling-challenges-analyzing-stakeholder-feedback-on-the-eu-joint-clinical-assessment-implementation-act-and-its-impact-on-the-latest-draft/) - [The AI Revolution in HEOR: How ChatGPT-4o and Multi-AI Agents Are Shaping the Future](https://www.eversana.com/insights/ai-revolution-in-heor-how-chatgpt-4o-and-multi-ai-agents-are-shaping/) - Learn how AI, particularly ChatGPT-4o, is transforming the HEOR field with its enhanced speed and capabilities - [A Matching-Adjusted Indirect Comparison (MAIC) of Guselkumab Versus Risankizumab in Patients With Moderate-to-Severe Plaque Psoriasis](https://www.eversana.com/insights/a-matching-adjusted-indirect-comparison-maic-of-guselkumab-versus-risankizumab-in-patients-with-moderate-to-severe-plaque-psoriasis/) - The Value & Evidence team at EVERSANA indirectly compared guselkumab and risankizumab using an unanchored MAIC on change from baseline PASI scores. - [Enhancing Quality of Life in Advanced Breast Cancer: The Role of Palbociclib](https://www.eversana.com/insights/enhancing-quality-of-life-in-advanced-breast-cancer-the-role-of-palbociclib/) - [Understanding Key Reforms for High-Cost Drugs in EU4+UK Markets](https://www.eversana.com/insights/understanding-key-reforms-for-high-cost-drugs-in-eu4uk-markets/) - Complete the form to download the full paper to gain valuable insights and stay ahead in the ever-evolving world of high-cost drug reforms. - [The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric](https://www.eversana.com/insights/the-future-of-global-commercialization-unified-data-driven-and-patient-centric/) - Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies - [EVERSANA Experts On-Stage at Frontiers Health 2024](https://www.eversana.com/insights/eversana-experts-on-stage-at-frontiers-health-2024/) - [Redefining Field Deployment – Bridging “Share of Voice” with “Share of Influence” for Lasting Impact](https://www.eversana.com/insights/redefining-field-deployment/) - This article explores challenges facing field deployment strategies in the pharma industry and how EVERSANA's deployment model offers strategic solutions. - [EVERSANA's Predictive Analytics: A Capabilities Compendium](https://www.eversana.com/insights/eversanas-predictive-analytics-a-capabilities-compendium/) - This analysis, conducted by DePuy Synthes and supported by EVERSANA’s Value & Evidence group, investigated the budget impact of MI-TLIF versus O-TLIF for single-level fusion from a European hospital perspective. - [National Institutes of Health Taps EVERSANA for Research on the Impact of Rare Disease on Patients, Healthcare System](https://www.eversana.com/insights/national-institutes-of-health-taps-eversana-for-research-on-the-impact-of-rare-disease-on-patients-healthcare-system/) - [IDN Trends, Insights and Strategies Every Manufacturer Should Know](https://www.eversana.com/insights/idn-trends-insights-and-strategies-every-manufacturer-should-know/) - Integrated delivery networks (IDNs) are transforming healthcare and creating better outcomes through effective partnerships, data analytics and digital tools. - [Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward](https://www.eversana.com/insights/accelerated-approval-pathways-manufacturers-left-to-grapple-with-risk-versus-reward/) - [Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies](https://www.eversana.com/insights/overcoming-the-commercialization-challenges-of-personalized-cancer-immunotherapies/) - Learn about the opportunities and challenges such as pricing, turnaround times, manufacturability, and scalability for personalized cancer immunotherapies. - [Q&A: Enhanced Protection and Consistency for PRCI in Canada](https://www.eversana.com/insights/prci-canada/) - This Q&A sheds light on the intricacies of the PCRI process, the technology behind it, and how it positions EVERSANA as a valuable partner for pharmaceutical companies. - [Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact](https://www.eversana.com/insights/evolving-dynamics-in-oncology-considerations-for-overcoming-commercialization-challenges-and-driving-greater-impact/) - Learn challenges and strategies for oncology commercialization. - [Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and Canada](https://www.eversana.com/insights/coordinated-north-american-launches/) - Discover the expertise of Deborah Brown, Ryan H. Brown, Kerem Can Alp, Adam Hardy, and Charles Pirraglia in orchestrating synchronized North American launches. - [M&A and BD&L Outlook and Perspectives on Commercial Due Diligence](https://www.eversana.com/insights/ma-bdl-cdd-webinar/) - In this webinar, industry leaders Faruk Abdullah, James Stephanou, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. - [Budget Impact Analysis of Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease in Europe](https://www.eversana.com/insights/budget-impact-analysis-of-minimally-invasive-versus-open-transforaminal-lumbar-interbody-fusion-for-lumbar-degenerative-disease-in-europe/) - This analysis, conducted by DePuy Synthes and supported by EVERSANA’s Value & Evidence group, investigated the budget impact of MI-TLIF versus O-TLIF for single-level fusion from a European hospital perspective. - [AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman](https://www.eversana.com/insights/ais-role-in-drug-launches-operations-and-drug-pricing-qa-with-abid-rahman/) - [Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability](https://www.eversana.com/insights/nice-rwe-framework-for-global-data-transportability/) - The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022 - [The Looming Legacy of Software as a Medical Device (SaMD) Misclassification Under Medical Device Directive (MDD)](https://www.eversana.com/insights/the-looming-legacy-of-software-as-a-medical-device-samd-misclassification-under-medical-device-directive-mdd/) - [Report: Integrated Delivery Network Trends and Engagement Strategies Every Drug Manufacturer Needs to Know](https://www.eversana.com/insights/idn-trends-and-engagement-strategies-for-drug-manufacturer/) - Unlock the full potential of your Integrated Delivery Network (IDN) strategies with EVERSANA's latest Market Research & Insights Report. Drug manufacturers are engaging with IDNs to address pain points and trends, optimize patient outcomes, and foster value-based care through innovative solutions. Dive into a detailed analysis of the latest trends and strategies within the IDN Drug manufacturers are engaging with IDNs to address pain points and trends, optimize patient outcomes, and foster value-based care through innovative solutions. Read the article to view EVERSANA's comprehensive list of actionable recommendations and next steps for implementation. - [Empower to Impact: Advocacy Training for Meaningful Change](https://www.eversana.com/insights/empower-to-impact-advocacy-training-for-meaningful-change/) - The objective of this comprehensive program is simple: to empower participants to become effective advocates with the foundational knowledge, advocacy fundamentals and practical skills necessary to drive meaningful change. - [Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling](https://www.eversana.com/insights/navigating-pharmaceutical-success-harnessing-data-analytics-and-predictive-modeling/) - Discover how EVERSANA leverages data analytics and predictive modeling to offer tailored solutions for navigating challenges and driving commercial success. - [Integrated Delivery Networks (IDNs): Driving Change in Drug Access and Utilization](https://www.eversana.com/insights/idns-driving-change-in-drug-access-and-utilization/) - Manufacturers must align with IDNs' priorities, design tailored strategies and understand IDN operations to enhance patient outcomes and achieve market success. - [The New AMCP Dossier Format Version 5.0: Key Implications for Strategic Approach](https://www.eversana.com/insights/the-new-amcp-dossier-format-version-5-0-key-implications-for-strategic-approach/) - The AMCP Format 5.0, an industry standard for formulary submissions in the United States, includes guidance on health disparities, real-world evidence (RWE), and digital therapeutics. EVERSANA’s research contributes to understanding health disparities and the role of RWE in healthcare decision-making. - [Transforming the Future of Pharma Commercialization Through Medical Affairs](https://www.eversana.com/insights/transforming-the-future-of-pharma-commercialization-through-medical-affairs/) - [Unlocking Success: Exploring Critical Factors for Launching Orphan Drugs](https://www.eversana.com/insights/unlocking-success-exploring-critical-factors-for-launching-orphan-drugs/) - In this video, EVERSANA's Ashely Cox and Sid Agrawal sit down to discuss strategies for overcoming challenges to successfully launch orphan drugs. - [Strategic Launch: Accelerating Innovative Therapies in the Chinese Market](https://www.eversana.com/insights/strategic-launch-accelerating-innovative-therapies-in-the-chinese-market/) - In this webinar, we will share relevant examples regarding how other life science companies responded to the various business environmental changes in China and discuss how European pharmaceutical companies can enter the China market successfully by leveraging newer pathways. - [Market Access and the Inflation Reduction Act](https://www.eversana.com/insights/market-access-and-the-inflation-reduction-act/) - Understand the implications of the Inflation Reduction Act (IRA) Medicare changes and how to navigate the new dynamic with a successful market access strategy. - [Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC](https://www.eversana.com/insights/crizotinib-nsclc-effectiveness/) - [A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices](https://www.eversana.com/insights/a-review-of-worldwide-indirect-treatment-comparison-itc-guidelines-and-best-practices/) - The Value & Evidence team at EVERSANA in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized ITC guidelines around the world, including those of various international organizations, regulatory bodies and health technology assessment agencies. - [Key Trends in Global Product Launch](https://www.eversana.com/insights/key-trends-in-global-product-launch/) - Key trends in global product launch including IRA, net price transparency, health equity, predictive pricing & sequence changes, along with potential impact. - [Championing Women’s Health and Equity](https://www.eversana.com/insights/championing-womens-health-and-equity/) - [Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services](https://www.eversana.com/insights/patient-centric-approach-to-clinical-trial-support-leveraging-medical-information-services/) - Discover current clinical trial statistics and trends and how EVERSANA’s MI Contact Center team elevates brand satisfaction and adoption by providing unparalleled patient support, including real examples from two EVERSANA clients. - [FDA Guidance and Considerations for Scientific Exchange Communication Strategies](https://www.eversana.com/insights/fda-guidance-and-considerations-for-scientific-exchange-communication-strategies/) - Explore the latest draft FDA guidance regarding scientific exchange communication and learn the potential risks and opportunities it poses to pharmaceutical manufacturers moving forward. - [Updated Guidance May Ease MDR Transition for SaMD Manufacturers](https://www.eversana.com/insights/updated-guidance-may-ease-mdr-transition-for-samd-manufacturers/) - Learn the impacts of the updated version of the MDR guidance, MDCG 2020-3 Rev. 1, released in May. - [Navigating the Evolution of Precision Medicine: Data-Driven Strategies for Life Sciences Commercialization](https://www.eversana.com/insights/navigating-the-evolution-of-precision-medicine-data-driven-strategies-for-life-sciences-commercialization/) - [Bridging “Share of Voice” with “Share of Influence” for Lasting Impact](https://www.eversana.com/insights/bridging-share-of-voice-with-share-of-influence-for-lasting-impact/) - Discover strategies for manufacturers to align with IDNs, build influence among stakeholders, improve patient access and achieve successful product launches. - [Equip FRMs with the Right Tools to Unlock Patient Access](https://www.eversana.com/insights/equip-frms-with-the-right-tools-to-unlock-patient-access/) - Learn how equipping Field Reimbursement Managers with the right tools helps expand patient access and how EVERSANA's ACTICS eAccess accelerates time to therapy. - [Optimizing Patient-Centered Care: Strategies for Improving Health Outcomes](https://www.eversana.com/insights/optimizing-patient-centered-care/) - Learn about the impact of health insurance in India's evolving healthcare context and how private health insurance plays a crucial role in providing access to quality healthcare and innovative therapies. - [Celebrating Excellence: Two EVERSANA Leaders Named to PM360 Elite 100 List](https://www.eversana.com/insights/celebrating-excellence-two-eversana-leaders-named-to-pm360-elite-100-list/) - [Maximizing Sales Impact in a Hybrid World](https://www.eversana.com/insights/maximizing-sales-impact-hybrid-world/) - [Leveraging Generative AI in Brand Planning: Insights from Second Annual Pharmaceutical Brand Planning Survey](https://www.eversana.com/insights/generative-ai-brand-planning/) - Unlock the potential of generative AI in brand planning with insights from EVERSANA's second annual Pharmaceutical Brand Planning Survey. - [Single-Arm Data: Turning Limitations into Strengths with Numbers](https://www.eversana.com/insights/single-arm-data-turning-limitations-into-strengths-with-numbers/) - EVERSANA’s Value & Evidence team has extensive experience conducting SLRs and meta-analyses, supporting strategy, and providing world-class statistical solutions. - [Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products](https://www.eversana.com/insights/eight-key-strategic-considerations-when-launching-a-global-indirect-treatment-comparison-program-for-new-products/) - [Commercial Key Success Factors (KSFs) for Global Drug Development Programs](https://www.eversana.com/insights/commercial-key-success-factors-global-drug-development/) - Discover the essential Commercial Key Success Factors (KSFs) that drive triumph in global drug development programs. - [Predicting Telehealth Use through the Power of Machine Learning: Insights from EVERSANA to Be Shared at Upcoming PMSA Conference.](https://www.eversana.com/insights/predicting-telehealth-use-machine-learning/) - [Decoding EMA’s Blueprint on Real-World Evidence](https://www.eversana.com/insights/decoding-emas-blueprint-rwe/) - Whether it involves maneuvering through the intricacies of RWE generation or deciphering the ramifications of the latest EMA directives, EVERSANA is primed to work with our clients at every juncture. - [What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry](https://www.eversana.com/insights/what-eversanas-growing-abstract-count-at-ispor-u-s-means-to-the-heor-industry/) - [Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs](https://www.eversana.com/insights/understanding-icers-2024-protocol-for-assessing-unsupported-price-increases-on-prescription-drugs/) - [The Hospital of the Future and How Data, Digital and AI Merge to Make Care Better](https://www.eversana.com/insights/the-hospital-of-the-future-and-how-data-digital-and-ai-merge-to-make-care-better/) - [Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur](https://www.eversana.com/insights/growing-eversanas-value-evidence-global-footprint-with-the-additions-of-monique-martin-pamela-vo-and-deepika-thakur/) - [Unlocking Insights: EVERSANA's Value & Evidence Team's Impact on Economic and Healthcare Resource Utilization Outcomes in Robotic vs. Manual Total Knee Arthroplasty](https://www.eversana.com/insights/economic-hcru-outcomes-tka/) - The Value & Evidence team at EVERSANA conducted the first systematic literature review and meta-analysis to compare HCRU outcomes for robotic versus manual TKA. - [Current Trends in Medical Review of Promotional and Non-Promotional Materials](https://www.eversana.com/insights/current-trends-in-medical-review-of-promotional-and-non-promotional-materials/) - [Considerations for the Development of Interactive / Innovative Medical Information Content – Insights from a Service Provider](https://www.eversana.com/insights/considerations-for-the-development-of-interactive-innovative-medical-information-content-insights-from-a-service-provider/) - [Navigating the Frontier: Generative AI Revolutionizing Healthcare and Life Sciences](https://www.eversana.com/insights/navigating-the-frontier-generative-ai-revolutionizing-healthcare-and-life-sciences/) - This paper sheds light on the pivotal role of Artificial Intelligence (AI), particularly Generative AI, authored by. Let's embark on a journey to explore how AI is revolutionizing the industry. - [Future-Proofing Demands Proof: How Innovators Are Transforming Pharma Commercialization](https://www.eversana.com/insights/future-proofing-demands-proof-how-innovators-are-transforming-pharma-commercialization/) - In the fast-evolving landscape of pharmaceuticals, staying ahead demands more than just adapting to today's challenges – it requires pioneering the future. Introducing intentional innovation, the sweet spot where blue-sky imagination meets on-the-ground effort. It’s being able to not only ideate, but to actually accomplish the groundbreaking “firsts”. Much of the conversation about innovation focuses on pharma commercialization, ai, innovation - [Excel in Market Access Success: Key Considerations for Leveraging Your Evidence](https://www.eversana.com/insights/market-access-leveraging-evidence/) - Early payer engagement streamlines evidence gathering for trials, aligning with coverage needs & boosting approval odds. - [Navigating Successful Partnerships in the Pharmaceutical Industry: Insights from Shorla Oncology CEO Sharon Cunningham](https://www.eversana.com/insights/navigating-successful-partnerships-shorla-oncology/) - Sharon Cunningham, CEO and Co-Founder of Shorla Oncology, shares invaluable insights gleaned from her experience, shedding light on the key factors that contribute to successful collaborations in the pharmaceutical arena. - [Empowering Success: EVERSANA's Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act](https://www.eversana.com/insights/empowering-success-cms-drug-negotiations-ira/) - [Uncovering Health Disparities: Exploring Social Determinants of Metastatic Prostate Cancer Survival](https://www.eversana.com/insights/uncovering-health-disparities-mpc/) - [CES 2024 Recap – How the Future of Healthcare Will Continue to Be Driven By Innovation & AI](https://www.eversana.com/insights/ces-2024-recap-how-the-future-of-healthcare-will-continue-to-be-driven-by-innovation-ai/) - [EVERSANA’s High-Quality HEOR Methods Recognized in Published Independent Review](https://www.eversana.com/insights/heor-methods-recognized/) - [HemGenix Shines in Collaborative ITC Analysis: EVERSANA and CSL Behring Propel Gene Therapy to the Forefront in Hemophilia B Treatment](https://www.eversana.com/insights/hemgenix-shines-in-collaborative-itc-analysis-eversana-and-csl-behring-propel-gene-therapy-to-the-forefront-in-hemophilia-b-treatment/) - [Transforming Pharmaceutical Commercialization: Eight Key Insights for Success](https://www.eversana.com/insights/navigating-pharmaceutical-commercialization-eight-key-insights-for-success/) - [Impact of the European Union Medical Device Regulation Extension on Legacy Devices](https://www.eversana.com/insights/impact-of-the-eu-mdr-extension-on-legacy-devices/) - [Employ an Integrated Market Access Strategy to Deliver Brand Success](https://www.eversana.com/insights/employ-an-integrated-market-access-strategy-to-deliver-brand-success/) - [Commercializing Digital Health as Durable Medical Equipment: A Conversation with BearingOn.Health](https://www.eversana.com/insights/commercializing-digital-health-as-durable-medical-equipment-a-conversation-with-bearingon-health/) - EVERSANA’s Brian Abraham, Senior Director of Market Access and Patient Access joins Adam Kaufman of BearingOn.Health to digital health commercialization and reimbursement models and their implications around regulatory, pricing and market access. - [Linking Channel Distribution & 3PL to Non-Traditional Commercialization Touchpoints](https://www.eversana.com/insights/linking-channel-distribution-3pl-to-non-traditional-commercialization-touchpoints/) - [Seven Key Takeaways From a Week at AWS re:Invent 2023 ](https://www.eversana.com/insights/seven-key-takeaways-from-a-week-at-aws-reinvent-2023/) - [There's a New Way to Omnichannel: Orchestrating Experience to Drive Sales, Savings and Satisfaction](https://www.eversana.com/insights/theres-a-new-way-to-omnichannel-orchestrating-experience-to-drive-sales-savings-and-satisfaction/) - [Unveiling the Future: AI Opportunities in FDA Compliance, Insights from the OPQ Symposium](https://www.eversana.com/insights/unveiling-the-future-ai-challenges-in-fda-compliance-insights-from-the-opq-symposium/) - [The Data-Driven Revolution: AI's Impact on Pharmaceutical Quality in Digital Therapy](https://www.eversana.com/insights/the-data-driven-revolution-ais-impact-on-pharmaceutical-quality-in-digital-therapy/) - [Incorporating Medical Science Liaisons Early and Often Amplifies Impact and Delivers Stronger Patient Outcomes](https://www.eversana.com/insights/incorporating-medical-science-liaisons-early-and-often-amplifies-impact-and-delivers-stronger-patient-outcomes/) - Discover how MSLs provide critical therapeutic-wide education and combine first class clinical and business acumen throughout a product’s entire life cycle. - [Navigating the Evolving Landscape of Internet Healthcare in China: Development Status, Challenges, and Future Prospects](https://www.eversana.com/insights/navigating-the-evolving-landscape-of-internet-healthcare-in-china-development-status-challenges-and-future-prospects/) - [Driving Patient-First Affordability in Seconds – Not Days: Accelerating Time to Therapy](https://www.eversana.com/insights/driving-patient-first-affordability-in-seconds-not-days-accelerating-time-to-therapy/) - This webinar covers issues facing eBVs and how an innovative approach can improve price transparency and provide stakeholders access to a self-service platform. - [Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies](https://www.eversana.com/insights/adapting-to-change-examining-the-implications-of-new-eu-regulations-on-commercialisation-from-the-perspectives-of-patients-providers-and-pharma-companies/) - When navigating Europe and its substantial recent policy changes, companies need to take precautionary steps beginning at the pre-clinical stage, all the way through to market access. - [Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)](https://www.eversana.com/insights/utilization-of-indirect-treatment-comparison-itc-external-control-arms-eca-and-patient-reported-outcome-measures-proms/) - Two significant trends have emerged in HTA methodologies in recent years: the increasing utilization of ITC/ECA and the incorporation of PROMs. Learn more. - [Your Guide to Developing a Best-in-Class Specialty Pharmacy Network Strategy](https://www.eversana.com/insights/your-guide-to-developing-a-best-in-class-specialty-pharmacy-network-strategy/) - [Integrating the Pillars of Global Pricing Governance](https://www.eversana.com/insights/integrating-the-pillars-of-global-pricing-governance/) - [Innovative Approaches to 340B Claims Data Identification](https://www.eversana.com/insights/innovative-approaches-to-340b-claims-data-identification/) - [Forecasting in the Age of Value-Based Agreements](https://www.eversana.com/insights/forecasting-in-the-age-of-value-based-agreements/) - Revenue forecasting challenges and opportunities in value-based contracting agreements. - [Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced Data Analytics](https://www.eversana.com/insights/patient-id-cgt-machine-learning/) - It is critical to develop an efficient tool to not only identify CGT patients but also to understand the referral pathway so that manufacturers can determine where the patients are and influence key players in the referral pathway. - [Considerations for Globalization of Medical Information Services: A Service Partner Perspective](https://www.eversana.com/insights/considerations-for-globalization-of-medical-information-services-a-service-partner-perspective/) - [Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment](https://www.eversana.com/insights/navigating-an-ever-evolving-canadian-market-access-and-reimbursement-environment/) - In an ever-changing Canadian market access environment, the right partner is key. EVERSANA has a proven track record in all aspects of Canadian HTA, market access and pricing. - [APACMed Digital Health Reimbursement Policy Forum](https://www.eversana.com/insights/apac-digital-health-reimbursement-policy-forum/) - This paper provides a high-level view for industry players and payers of where their individual markets stand in terms of reimbursement policies for digital health and the challenges that complicate the process of funding and reimbursing such technologies from the payer’s perspective. - [Unlocking Global Success: The Crucial Role of Integrated HEOR Programs in New Product Launches](https://www.eversana.com/insights/integrated-heor-programs/) - [Orchestrating Experiences That Simultaneously Drive Brand Impact and Customer Delight](https://www.eversana.com/insights/orchestrating-experiences-to-drive-high-engagement-and-deliver-brand-results-and-customer-satisfaction/) - Discover challenges and solutions facing omnichannel implementation and how EVERSANA ORCHESTRATE™ transcends limitations of traditional omnichannel solutions. - [Continuous Manufacturing of Pharmaceutical Products: The New Norm](https://www.eversana.com/insights/continuous-manufacturing-of-pharmaceutical-products-the-new-norm/) - Discover the benefits and challenges of continuous manufacturing (CM), a way to manufacture products from end to end on a single, uninterrupted production line. - [Key Considerations When Operationalizing Revenue Management](https://www.eversana.com/insights/key-considerations-when-operationalizing-revenue-management/) - [Peeking Behind the PBM-lead GPO Curtain](https://www.eversana.com/insights/peeking-behind-the-pbm-led-gpo-curtain/) - [The Art of Simplifying Pharmacovigilance - Part V: Deconstructing Automation](https://www.eversana.com/insights/the-art-of-simplifying-pharmacovigilance-part-v-deconstructing-automation/) - [Maximizing Product Launch Success: The Importance of Conducting Comprehensive Business Simulation Exercises](https://www.eversana.com/insights/maximizing-product-launch-success-the-importance-of-conducting-comprehensive-business-simulation-exercises/) - Learn how incorporating business simulation exercises helps manufacturers achieve proper launch preparedness through true end-to-end testing of multiple critical functions. - [The Rising Demand for Light Medical Aesthetic in China](https://www.eversana.com/insights/the-rising-demand-for-light-medical-aesthetic-in-china/) - [Revolutionizing Vaccines: The Rise of mRNA Technology in China](https://www.eversana.com/insights/revolutionizing-vaccines-mrna-china/) - Learn how mRNA vaccines are transforming the field and paving the way for more targeted and efficient immunization strategies in China. - [Maximizing Potential: Essential Steps for Successful Commercialization of Cell and Gene Therapies](https://www.eversana.com/insights/maximizing-potential-successful-commercialization-cgt/) - [The Art of Simplifying Pharmacovigilance – Part III: Unlocking Efficiency Through Consolidation](https://www.eversana.com/insights/the-art-of-simplifying-pharmacovigilance-part-iii-unlocking-efficiency-through-consolidation/) - [The Art of Simplifying Pharmacovigilance – Part IV: Streamlining Vendor Engagement for Marketing Authorization Holders](https://www.eversana.com/insights/the-art-of-simplifying-pharmacovigilance-streamlining-vendor-engagement-for-marketing-authorization-holders/) - [The Art of Simplifying Pharmacovigilance – Part II: Change Adoption](https://www.eversana.com/insights/the-art-of-simplifying-pharmacovigilance-part-ii-change-adoption/) - [The Art of Simplifying Pharmacovigilance – Part I: Connecting the Dots](https://www.eversana.com/insights/the-art-of-simplifying-pharmacovigilance-part-i-connecting-the-dots/) - [Optimizing and Accelerating Membership Management Within the Healthcare Industry](https://www.eversana.com/insights/optimizing-and-accelerating-membership-management-within-the-healthcare-industry/) - [European Commission's Long-awaited Pharma Legislation Review Gets Mixed Reception](https://www.eversana.com/insights/european-commissions-long-awaited-pharma-legislation-review-gets-mixed-reception/) - [Case Study: Primary Research Meets Data-Driven Sources and Technology to Form Powerful Market Access Solutions](https://www.eversana.com/insights/case-study-primary-research-meets-data-driven-sources-and-technology-to-form-powerful-market-access-solutions/) - [Position Your Future-Facing Strategy on Digital Therapeutics (DTx) in China](https://www.eversana.com/insights/position-your-future-facing-strategy-on-digital-therapeutics-dtx-in-china/) - The article discusses the potential of DTx in China's healthcare system and how it can help pharma and MedTech companies address the challenges presented by the country's aging population and healthcare demands. - [Improving the Patient Experience with Digital Tools](https://www.eversana.com/insights/improving-patient-experience-communication-for-rare-ultra-rare-disease-patients-by-leveraging-digital-tools/) - [Significance of Promotional and Non-Promotional Materials Review Support Services](https://www.eversana.com/insights/significance-of-promotional-non-promotional-materials-review-support-services/) - [Bending the “Commercialization Curve” in Large Pharma](https://www.eversana.com/insights/bending-the-commercialization-curve-in-large-pharma/) - [The Influx of Generic Launches Leaves Narrow Opportunities for Multiple Sclerosis Access](https://www.eversana.com/insights/the-influx-of-generic-launches-leaves-narrow-opportunities-for-multiple-sclerosis-access/) - [Pricing Complexities of a Combination Therapy](https://www.eversana.com/insights/pricing-complexities-of-a-combination-therapy/) - [Create a Comprehensive Experience by Optimizing Forward-thinking Omnichannel Strategies](https://www.eversana.com/insights/create-a-comprehensive-experience-by-optimizing-forward-thinking-omnichannel-strategies/) - Learn what tactics manufacturers should include in their omnichannel strategy check list for more effective and profitable results. - [The Future of Omnichannel is Here. Don’t Get Left Behind.](https://www.eversana.com/insights/the-future-of-omnichannel-is-here-dont-get-left-behind/) - Discover how next-gen omnichannel can heighten brands’ success by modernizing outdated techniques and processes, and how EVERSANA’s model increases therapy adoption. - [The IDeaS Initiative: Pilot Study to Assess the Impact of Rare Diseases on Patients and Healthcare Systems](https://www.eversana.com/insights/the-ideas-initiative-pilot-study-to-assess-the-impact-of-rare-diseases-on-patients-and-healthcare-systems/) - [Artificial Intelligence and Machine Learning Use in Patient Safety](https://www.eversana.com/insights/artificial-intelligence-and-machine-learning-use-in-patient-safety/) - [Critical Success Factors for Launching Products with Fast Track, PRIME, or ILAP Designation](https://www.eversana.com/insights/critical-success-factors-for-launching-products-with-fast-track-prime-or-ilap-designation/) - [2023 Outlook Of China Healthcare Industry: Remaining Pragmatic While Moving Up The Value Chain](https://www.eversana.com/insights/2023-outlook-china-healthcare-industry-maintaining/) - [The Necessity of Mapping the Tumor Journey for Oncology Marketers](https://www.eversana.com/insights/the-necessity-of-mapping-the-tumor-journey-for-oncology-marketers/) - [Value Proposition of Medical Information Services: Current Perspectives from the Industry](https://www.eversana.com/insights/value-proposition-of-medical-information-services-current-perspectives-from-the-industry/) - [Case Study: Waste Reduction through Packaging Optimization](https://www.eversana.com/insights/case-study-waste-reduction-through-packaging-optimization/) - [Solving the Wastage Challenge Through Predictive Analytics and Modeling](https://www.eversana.com/insights/solving-the-wastage-challenge-through-predictive-analytics-and-modeling/) - [Elevating Field Reimbursement Manager Performance through Insights & Comparative Data](https://www.eversana.com/insights/elevating-field-relationship-manager-performance-through-insights-comparative-data/) - [Case Study: Optimizing use of Field Reimbursement Managers](https://www.eversana.com/insights/case-study-optimizing-use-of-field-reimbursement-managers/) - [Use of Machine Learning to Accurately Size Market Potential and Optimize Sales and Marketing Resources](https://www.eversana.com/insights/use-of-machine-learning-to-accurately-size-market-potential-and-optimize-sales-and-marketing-resources/) - [Achieving Digital Enlightenment in 2023 and Beyond](https://www.eversana.com/insights/achieving-digital-enlightenment-in-2023-and-beyond/) - [Video: New Cardiovascular Events after COVID-19 Infection](https://www.eversana.com/insights/video-new-cardiovascular-events-after-covid-19-infection/) - [Next Generation Brand Planning: Fueling Brand Plan Efficiency Through Seamless Integration](https://www.eversana.com/insights/next-generation-brand-planning-fueling-brand-plan-efficiency-through-seamless-integration/) - [Successful Launches in Europe: Complex, but Not Complicated?](https://www.eversana.com/insights/successful-launches-in-europe-complex-but-not-complicated/) - [The Pitfalls of Government Price Setting: Value Assessments in the U.S. vs. Germany](https://www.eversana.com/insights/the-pitfalls-of-government-price-setting-value-assessments-in-the-u-s-vs-germany/) - [Filling Evidence Gaps Through Consensus: Revisiting the Delphi Technique](https://www.eversana.com/insights/filling-evidence-gaps-through-consensus-revisiting-the-delphi-technique/) - [The Future of Pharma - A Provocative Perspective](https://www.eversana.com/insights/the-future-of-pharma-a-provocative-perspective/) - In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Mike Ryan.They discuss the future of pharma and the impact of recent advancements in healthcare. - [How Generative AI and Synthetic Content Will Revolutionize Healthcare](https://www.eversana.com/insights/how-generative-ai-and-synthetic-content-will-revolutionize-healthcare/) - [Critical Success Factors for Launching Products with Orphan Drug Designation](https://www.eversana.com/insights/critical-success-factors-for-launching-products-with-orphan-drug-designation/) - [The State of National Healthcare Policy and Pricing Webinar 2023](https://www.eversana.com/insights/the-state-of-national-healthcare-policy-and-pricing-webinar-2023/) - [Account Engagement Excellence: How Advanced Analytics Can Enable Next-Generation Account Segmentation](https://www.eversana.com/insights/how-advanced-analytics-can-enable-next-generation-account-segmentation/) - [Bringing a CPT Code to Life to Help in the Fight Against Cancer](https://www.eversana.com/insights/bringing-a-cpt-code-to-life-to-help-in-the-fight-against-cancer/) - [The Expanding Oncology Market Prompts Reevaluation of Field Team Training Procedures and Skill Set to Impact Frontline Success](https://www.eversana.com/insights/the-expanding-oncology-market-prompts-reevaluation-of-field-team-training-procedures-and-skill-set-to-impact-frontline-success/) - [Trade & Channel Strategies: Partnership Pavilion Panel](https://www.eversana.com/insights/trade-channel-strategies-partnership-pavilion-panel/) ## Research - [Value, Quality, and Reimbursement](https://www.eversana.com/research/value-quality-and-reimbursement/) - [Value-Based Contracting Evolution](https://www.eversana.com/research/value-based-contracting-evolution/) - [SPOPTIMIZER by EVERSANA™](https://www.eversana.com/research/spoptimizer/) - [Regional and Blues Health Plan Profiles](https://www.eversana.com/research/regional-and-blues-health-plan-profiles/) - [Specialty Pharmacies and Distributors](https://www.eversana.com/research/specialty-pharmacies-and-distributors/) - [Regional Account Trends](https://www.eversana.com/research/regional-account-trends/) - [Quality Performance and Priorities](https://www.eversana.com/research/quality-performance-and-priorities/) - [Patient Services and Hubs](https://www.eversana.com/research/patient-services-and-hubs/) - [Organized Customer Account Trends](https://www.eversana.com/research/organized-customer-account-trends/) - [Oncology Pathways Engagement](https://www.eversana.com/research/oncology-pathways/) - [National Account Profiles](https://www.eversana.com/research/national-account-profiles/) - [Medical Group Trends](https://www.eversana.com/research/medical-group-trends/) - [Marketplace Dynamics: Therapeutic Area of Choice](https://www.eversana.com/research/marketplace-dynamics-therapeutic-area-of-choice/) - [Marketplace Dynamics: Multiple Sclerosis](https://www.eversana.com/research/marketplace-dynamics-multiple-sclerosis/) - [Marketplace Dynamics: Autoimmune](https://www.eversana.com/research/marketplace-dynamics-autoimmune/) - [Leading Payer Account Trends](https://www.eversana.com/research/leading-payer-account-trends/) - [Insurance and Benefit Design: Government](https://www.eversana.com/research/insurance-and-benefit-design-government/) - [Insurance and Benefit Design: Commercial](https://www.eversana.com/research/insurance-and-benefit-design-commercial/) - [Health System Profiles](https://www.eversana.com/research/health-system-profiles/) - [Employer Trends and Management Decisions](https://www.eversana.com/research/employer-trends-and-management-decisions/) - [Customer Relationships with MCOs](https://www.eversana.com/research/customer-relationships-with-mcos/) - [Customer Relationships with IDNs](https://www.eversana.com/research/customer-relationships-with-idns/) - [Consumer Product Selection Insights](https://www.eversana.com/research/consumer-product-selection-insights/) - [COVID-19 Payer Pulse](https://www.eversana.com/research/covid-19-payer-pulse/) - [Cancer Center Profiles](https://www.eversana.com/research/cancer-center-profiles-2/) - [Hospital Sales Force Effectiveness](https://www.eversana.com/research/hospital-sales-force-effectiveness/) - [Alternative Payment Models](https://www.eversana.com/research/alternative-payment-methods/) ## Teams - [EVERSANA Team](https://www.eversana.com/teams/eversana-team/) - [NAVLIN Insights Team](https://www.eversana.com/teams/health-strategies-insights-team/) - [NAVLIN Price & Access Data](https://www.eversana.com/teams/pricentric-team/) - [Seeker Health](https://www.eversana.com/teams/seeker-health/) ## Thought Leaders - [Jimmy El Hokayem](https://www.eversana.com/thought-leaders/jimmy-el-hokayem/) - [Gregory Skalicky](https://www.eversana.com/thought-leaders/greg-skalicky/) - [Pete Riojas](https://www.eversana.com/thought-leaders/pete-riojas/) - [Vinod Bombale](https://www.eversana.com/thought-leaders/vinod-bombale/) - [Stefanie Paganelli](https://www.eversana.com/thought-leaders/stefanie-paganelli/) - [Imtiaz Samjoo](https://www.eversana.com/thought-leaders/imtiaz-samjoo/) - [Anja Haltner, MSc](https://www.eversana.com/thought-leaders/anja-haltner-msc/) - [Di Wang](https://www.eversana.com/thought-leaders/di-wang/) - Di is a senior biostatistician on Value & Evidence team at EVERSANA, with extensive experience in conducting indirect treatment comparisons. - [John Neal](https://www.eversana.com/thought-leaders/john-neal/) - [Susan Beach BSN, MBA](https://www.eversana.com/thought-leaders/susan-beach-bsn-mba/) - [Praveen Gupta](https://www.eversana.com/thought-leaders/55688/) - [Samie Ahmed, PharmD, MS](https://www.eversana.com/thought-leaders/samie-ahmed-pharmd-ms/) - [Amber Svardal, MSN, RN, OCN](https://www.eversana.com/thought-leaders/amber-svardal-msn-rn-ocn/) - [Beth Giblin, PharmD](https://www.eversana.com/thought-leaders/beth-giblin-pharmd/) - [Farah Toublan, Ph.D.](https://www.eversana.com/thought-leaders/55435/) - [Allen Zhou](https://www.eversana.com/thought-leaders/allen-zhou/) - Allen Zhou is an Associate Director at EVERSANA who specializes in economic modelling. - [David Garcia](https://www.eversana.com/thought-leaders/david-garcia/) - David Garcia is an Associate Director in the Health Economics & Outcomes Research group at EVERSANA. - [Aaron Uydess](https://www.eversana.com/thought-leaders/aaron-uydess/) - [Kamalpreet Mann](https://www.eversana.com/thought-leaders/kamalpreet-mann/) - [Sumeet Singh](https://www.eversana.com/thought-leaders/sumeet-singh/) - [Vaishnavi Gowda, MPhil, PhD](https://www.eversana.com/thought-leaders/vaishnavi-gowda-phd/) - [Susan Giacalone, MSN, BCMAS, MSL-BC](https://www.eversana.com/thought-leaders/susan-giacalone-msn-bcmas-msl-bc/) - [Anita Yadav](https://www.eversana.com/thought-leaders/anita-yadav/) - [Nelly Andresen](https://www.eversana.com/thought-leaders/nelly-andresen/) - Nelly Andresen - [Natalia Gandarillas, MPharm](https://www.eversana.com/thought-leaders/natalia-gandarillas-mpharm/) - [Megan Bourque, PhD](https://www.eversana.com/thought-leaders/megan-bourque-phd/) - [Vikram Anand](https://www.eversana.com/thought-leaders/vikram-anand/) - [Anna Nero](https://www.eversana.com/thought-leaders/anna-nero/) - [Kim Thomas, PhD](https://www.eversana.com/thought-leaders/kim-thomas-phd/) - [Chris Drudge](https://www.eversana.com/thought-leaders/chris-drudge/) - Chris Drudge is an Associate Director at EVERSANA and has been a member of the Value & Evidence team since 2019. - [Richard Wenzel, PhD](https://www.eversana.com/thought-leaders/richard-wenzel-phd/) - [Megan Seyboth](https://www.eversana.com/thought-leaders/megan-seyboth/) - [Heather Miller](https://www.eversana.com/thought-leaders/heather-miller/) - [Dr. Vivek Ahuja](https://www.eversana.com/thought-leaders/dr-vivek-ahuja/) - [Jayme Etzel](https://www.eversana.com/thought-leaders/jamie-etzel/) - [Shivani Shah](https://www.eversana.com/thought-leaders/43386/) - [Karen Chiang](https://www.eversana.com/thought-leaders/karen-chiang/) - [Narayan Tripathi](https://www.eversana.com/thought-leaders/narayan-tripathi/) - [Lindsay Reel, PharmD](https://www.eversana.com/thought-leaders/lindsay-reel/) - [Christina Christos](https://www.eversana.com/thought-leaders/christina-christos/) - [Avi Kwatra](https://www.eversana.com/thought-leaders/avi-kwatra/) - [Abid Rahman](https://www.eversana.com/thought-leaders/abid-rahman/) - [Faruk Capan](https://www.eversana.com/thought-leaders/38661/) - [Andrew Ying](https://www.eversana.com/thought-leaders/andrew-ying/) - [David Byram](https://www.eversana.com/thought-leaders/david-byram/) - Currently, David co-leads the EVERSANA U.S. Pricing and Market Access practice and leads the EVERSANA MANAGEMENT CONSULTING practice in the EU and UK as well. - [Nitin Kumar](https://www.eversana.com/thought-leaders/50673/) - [Laurie Lucas](https://www.eversana.com/thought-leaders/laurie-lucas/) - [Vanitha Sankaran, PhD](https://www.eversana.com/thought-leaders/vanith-sankaran-phd/) - [Matt Baniak](https://www.eversana.com/thought-leaders/matt-baniak/) - [Sofiya Portuhay](https://www.eversana.com/thought-leaders/sofiya-portuhay/) - At EVERSNA, Sofiya has supported systematic and targeted literature reviews across various disease areas, such as various cancers, pulmonary arterial hypertension and angioedema, etc. - [Paolo Correale](https://www.eversana.com/thought-leaders/paolo-correale/) - [Pamela Vo](https://www.eversana.com/thought-leaders/pamela-vo/) - [Mike Ryan](https://www.eversana.com/thought-leaders/mike-ryan/) - [Mary Anderson](https://www.eversana.com/thought-leaders/mary-anderson/) - Mary leads medical communication affiliate for both global and U.S.-based business.Mary leads medical communication affiliate for both global and U.S.-based business. She is a healthcare professional with deep expertise in both promotional medical education and medical affairs-focused scientific communications. Mary has led medical communications divisions for several companies, including a 13-year stint at Ogilvy Health. Most recently, she led the medical education efforts at Haymarket Media US. - [Michael DeLuca, PharmD, MBA, MSRA](https://www.eversana.com/thought-leaders/michael-deluca/) - [Jordan Hayes](https://www.eversana.com/thought-leaders/jordan-hayes/) - [Barry Vucsko](https://www.eversana.com/thought-leaders/40028/) - [Joe Wellington, MD](https://www.eversana.com/thought-leaders/joe-wellington-md/) - Joe brings a foundation of clinical experience and strategic leadership, working across all stages of the brand lifecycle in medical communications for more than a decade.Joe brings a foundation of clinical experience and strategic leadership, working across all stages of the brand lifecycle in medical communications for more than a decade. After earning his MD from Case Western Reserve University, he held academic appointments instructing both medical and nursing students. He has extensive experience across multiple therapeutic categories in medical - [Jane Richter](https://www.eversana.com/thought-leaders/jane-richter/) - Jane has more than 18 years of pharmaceutical and medical communications experience, as well as experience in the financial services and telecommunications industries. Jane has more than 18 years of pharmaceutical and medical communications experience, as well as experience in the financial services and telecommunications industries. She delivers high-quality, customized, medical communications programs that integrate medical science, creativity, learning principles, and behavioral change principles. Jane is passionate about providing innovative and engaging educational experiences to healthcare professionals with - [Francis Namouk](https://www.eversana.com/thought-leaders/francis-namouk/) - Francis leads global business development at EVERSANA INTOUCH MedComm. Brooke Francis leads global business development at EVERSANA INTOUCH MedComm. He is a serial entrepreneur whose passion is to improve patient outcomes by focusing on creative scientific storytelling and immersive educational experiences. He has over 20 years of digital expertise within the life science and consumer health sectors. After completing an MFA in design and technology at Parsons School of - [Emily Bradshaw](https://www.eversana.com/thought-leaders/emily-bradshaw/) - [Ramaa Nathan, PhD](https://www.eversana.com/thought-leaders/ramaa-nathan-phd/) - [Matt Doyle](https://www.eversana.com/thought-leaders/matt-doyle/) - Matt Doyle is senior vice president of finance and accounting at EVERSANA. Matt provides financial leadership and support for EVERSANA COMPLETE Commercialization partnerships. - [Nolan Kleinhenz](https://www.eversana.com/thought-leaders/nolan-kleinhenz/) - Nolan Kleinhenz, engagement manager at EVERSANA MANAGEMENT CONSULTING, is a life sciences professional with a background in biology and business administration. - [John Kenny](https://www.eversana.com/thought-leaders/john-kenny/) - As head of strategic planning, John is responsible for working with the strategic planning team to continually evolve EVERSANA INTOUCH’s strategic point of view and approach. - [Farah Ahmad](https://www.eversana.com/thought-leaders/farah-ahmad/) - [David Frey](https://www.eversana.com/thought-leaders/david-frey/) - [Sean Sweeny](https://www.eversana.com/thought-leaders/sean-sweeny/) - [Jennifer Meeuwsen](https://www.eversana.com/thought-leaders/jennifer-meeuwsen/) - Jennifer is the Executive Vice President of Complete Commercialization at EVERSANA, a leading provider of commercialization services to the life sciences industry. - [Alex Moore, PhD](https://www.eversana.com/thought-leaders/alex-moore-phd/) - [Sarah Walsh](https://www.eversana.com/thought-leaders/sarah-walsh/) - Sarah is a Manager on the Value & Evidence team at EVERSANA and provides statistical support and guidance on evidence synthesis projects. - [Rhett Figliuzzi](https://www.eversana.com/thought-leaders/rhett-figliuzzi/) - Rhett is an Associate Manager on Evidence Synthesis team at EVERSANA and provides support on literature reviews and other evidence synthesis projects for pharmaceuticals and medical devices. - [Samantha Craigie](https://www.eversana.com/thought-leaders/samantha-craigie/) - [Abril Oliva Ramirez](https://www.eversana.com/thought-leaders/abril-oliva-ramirez/) - [Elizabeth Halloran](https://www.eversana.com/thought-leaders/elizabeth-halloran/) - [Gerardo Peccia](https://www.eversana.com/thought-leaders/gerardo-peccia/) - [Alexandra Hall](https://www.eversana.com/thought-leaders/47578/) - Alex is an associate manager on the Value & Evidence team at EVERSANA and supports various projects in Health Economics and Outcomes Research (HEOR). - [Andrew Hanhauser](https://www.eversana.com/thought-leaders/andrew-hanhauser/) - [Kirk Szafranski](https://www.eversana.com/thought-leaders/kirk-szafranski/) - Kirk Szafranski is a Director, HEOR in the Value & Evidence Division at EVERSANA. - [Leena Patel](https://www.eversana.com/thought-leaders/leena-patel/) - [Beatrice Suero](https://www.eversana.com/thought-leaders/beatrice-suero/) - Beatrice has experience in all aspects of HEOR, including indirect treatment comparisons, economic modelling, systematic literature reviews, and RWE. - [Lindsey Starkman](https://www.eversana.com/thought-leaders/lindsey-starkman/) - Lindsey is an Associate Manager, Market Access and Pricing on the Value & Evidence Team at EVERSANA - [Belal Howidi](https://www.eversana.com/thought-leaders/belal-howidi/) - [Christopher Olsen](https://www.eversana.com/thought-leaders/christopher-olsen/) - Christopher is a Research Assistant II in the Evidence Synthesis group at EVERSANA. - [Fatemeh Mirzayeh Fashami](https://www.eversana.com/thought-leaders/fatemeh-mirzayeh-fashami/) - Fatemeh is a Research Associate in the Value & Evidence Division at EVERSANA, with experience in evidence synthesis, value communications, and economic modelling. - [Ankita Kambli](https://www.eversana.com/thought-leaders/ankita-kambli/) - [Alberta Spreafico, Ph.D, MBA](https://www.eversana.com/thought-leaders/alberta-spreafico-ph-d-mba/) - [Barkha Patel](https://www.eversana.com/thought-leaders/barkha-patel/) - [Adam Hardy](https://www.eversana.com/thought-leaders/adam-hardy/) - [Irene Zahirovic, PhD](https://www.eversana.com/thought-leaders/irene-zahirovic-phd/) - [Gustav Ando](https://www.eversana.com/thought-leaders/gustav-ando/) - [Varun Pandey, PhD](https://www.eversana.com/thought-leaders/varun-pandey-phd/) - [Carolyn Quon, PharmD](https://www.eversana.com/thought-leaders/carolyn-quon-pharmd/) - [Heather Cameron, PhD](https://www.eversana.com/thought-leaders/heather-cameron-phd/) - [Sarah Henry, PhD](https://www.eversana.com/thought-leaders/sarah-henry-phd/) - [Anne Marie Robertson](https://www.eversana.com/thought-leaders/anne-marie-robertson/) - [Jordan Schell](https://www.eversana.com/thought-leaders/jordan-schell/) - [Tim Lewis](https://www.eversana.com/thought-leaders/tim-lewis/) - [Anastasiya Markvarde](https://www.eversana.com/thought-leaders/anastasiya-markvarde/) - [Drew McCormick](https://www.eversana.com/thought-leaders/drew-mccormick/) - [Ngoc Nguyen](https://www.eversana.com/thought-leaders/ngoc-nguyen/) - [Sarah Kane](https://www.eversana.com/thought-leaders/sarah-kane/) - Sarah has 10+ years of professional experience across biotechnology and HEOR sectors. Within the Value & Evidence team at EVERSANA, Sarah supports numerous aspects of HEOR, including economic modelling, systematic literature reviews, meta-analyses and value communications. - [Roberto Ascione](https://www.eversana.com/thought-leaders/roberto-ascione/) - [Dan Feldman](https://www.eversana.com/thought-leaders/dan-feldman/) - [Kim Middleton](https://www.eversana.com/thought-leaders/kim-middleton/) - [Lisa Kaindl](https://www.eversana.com/thought-leaders/lisa-kaindl/) - [Aidian Dineen](https://www.eversana.com/thought-leaders/aidian-dineen/) - [Deepika Thakur](https://www.eversana.com/thought-leaders/deepika-thakur/) - [Mary Mehrabian, PharmD, BCGP, BCMAS](https://www.eversana.com/thought-leaders/mary-mehrabian-pharmd-bcgp-bcmas/) - [Calvin Fujimoto](https://www.eversana.com/thought-leaders/calvin-fujimoto/) - [Joey Pecoraro](https://www.eversana.com/thought-leaders/joey-pecoraro/) - [Kory Dillman](https://www.eversana.com/thought-leaders/kory-dillman/) - [Sneha Varma](https://www.eversana.com/thought-leaders/sneha-varma/) - [Kevin Yin](https://www.eversana.com/thought-leaders/kevin-yin/) - [Haritha Sama](https://www.eversana.com/thought-leaders/haritha-sama/) - [Kerem Can Alp](https://www.eversana.com/thought-leaders/kerem-can-alp/) - [Katya Svoboda](https://www.eversana.com/thought-leaders/katya-svoboda/) - [Tanuj Mehra](https://www.eversana.com/thought-leaders/tanuj-mehra/) - [Austin Lansing](https://www.eversana.com/thought-leaders/austin-lansing/) - [Emily Rosta, MSc](https://www.eversana.com/thought-leaders/emily-rosta-msc/) - [Becky Hooper](https://www.eversana.com/thought-leaders/becky-hooper/) - [Suzanne Greenwood, RN, BSN](https://www.eversana.com/thought-leaders/suzanne-greenwood-rn-bsn/) - [Natalie Rush](https://www.eversana.com/thought-leaders/natalie-rush/) - [Neil Rock](https://www.eversana.com/thought-leaders/neil-rock/) - [Keyla Badillo, PhD](https://www.eversana.com/thought-leaders/keyla-badillo-phd/) - Keyla's experience in life sciences and healthcare consulting spans several therapeutic areas, such as oncology, neurology, women’s health, and rare disease. - [Xavier Aparicio](https://www.eversana.com/thought-leaders/xavier-aparicio/) - Xavier has worked on a variety of engagements across the Market Access and Launch & Complete Commercialization practices, and he brings focused expertise in the therapeutic areas of neuroscience and gastroenterology. - [Erion Lipo](https://www.eversana.com/thought-leaders/erion-lipo/) - Erion has leveraged his foundational academic knowledge to perform market research, develop pipeline prioritization strategies, and conduct competitive intelligence on behalf of medical device and pharmaceutical companies. - [Vivienne Ho, PhD](https://www.eversana.com/thought-leaders/vivienne-ho-phd/) - As an Associate Partner at EVERSANA MANAGEMENT CONSULTING, Vivienne Ho combines over five years of pharmaceutical consulting experience with 10 years of biomedical research and scientific training to provide support from strategy to execution. - [Justin Averback](https://www.eversana.com/thought-leaders/justin-averback/) - Justin Averback is an Associate Partner at EVERSANA MANAGEMENT CONSULTING, with experience across the development lifecycle, including product commercialization, market research, project management, and brand strategy. - [Chad McAuliffe](https://www.eversana.com/thought-leaders/chad-mcauliffe/) - [Sean Rapson](https://www.eversana.com/thought-leaders/sean-rapson/) - [Faruk Abdullah](https://www.eversana.com/thought-leaders/faruk-abdullah/) - [Maneesh Gupta](https://www.eversana.com/thought-leaders/maneesh-gupta/) - [Pierantonio Russo, MD, FCPP, FAAP, STS](https://www.eversana.com/thought-leaders/pierantonio-russo-md-fcpp-faap-sts/) - [Nick Gilmour](https://www.eversana.com/thought-leaders/nick-gilmour/) - [Dr. Daniel Tisak](https://www.eversana.com/thought-leaders/dr-daniel-tisak/) - [Leana Wood](https://www.eversana.com/thought-leaders/leana-wood/) - [Lindsey Buyskes, B Pharm](https://www.eversana.com/thought-leaders/lindsey-buyskes-b-pharm/) - [Keith Steward](https://www.eversana.com/thought-leaders/keith-steward/) - [Mike Webster](https://www.eversana.com/thought-leaders/mike-webster/) - [Nicole Ferko](https://www.eversana.com/thought-leaders/nicole-ferko/) - [Amanda Samuels](https://www.eversana.com/thought-leaders/amanda-samuels/) - [Cynthia Grandjean](https://www.eversana.com/thought-leaders/cynthia-grandjean/) - [Kristen Reilly](https://www.eversana.com/thought-leaders/kristen-reilly/) - [Ryan Crane](https://www.eversana.com/thought-leaders/ryan-crane/) - [Sharon Donofrio](https://www.eversana.com/thought-leaders/sharon-donofrio/) - [Christine Malmberg](https://www.eversana.com/thought-leaders/christine-malmberg/) - [Jennifer Bartosh](https://www.eversana.com/thought-leaders/jennifer-bartosh/) - [Chris Cameron, PhD](https://www.eversana.com/thought-leaders/chris-cameron-phd/) - [Nick Rambke](https://www.eversana.com/thought-leaders/nick-rambke-2/) - [Ariel Salmang](https://www.eversana.com/thought-leaders/ariel-salmang/) - Ariel has over 20 years of providing impactful digital strategies and implementation across multiple industries, from media and FMCG to telecommunications and healthcare, where he has spent the last 10+ years focusing on the digital evolution of pharma companies and the creation of impactful digital brand and sales drivers. - [George Wright](https://www.eversana.com/thought-leaders/george-wright/) - George Wright is a Manager, HEOR at EVERSANA and has worked on numerous medical device projects to provide clients with the tools they need to engage and inform their customers. - [Andrew Grojean](https://www.eversana.com/thought-leaders/39027/) - [Jonathan Vu](https://www.eversana.com/thought-leaders/jonathan-vu/) - [Lisa Stafford, MS](https://www.eversana.com/thought-leaders/lisa-stafford-ms/) - [Mike DeLaroche](https://www.eversana.com/thought-leaders/mike-delaroche/) - [David Robinson](https://www.eversana.com/thought-leaders/david-robinson/) - [Dino Tsamparlis](https://www.eversana.com/thought-leaders/dino-tsamparlis/) - [Paul Maurer](https://www.eversana.com/thought-leaders/paul-maurer/) - [Carole Robinson](https://www.eversana.com/thought-leaders/carole-robinson/) - [Brenda McWhorter](https://www.eversana.com/thought-leaders/brenda-mcwhorter/) - [Matthew Chong](https://www.eversana.com/thought-leaders/matthew-chong/) - [Naveen Sandhu](https://www.eversana.com/thought-leaders/naveen-sandhu/) - [Krista Pinto](https://www.eversana.com/thought-leaders/krista-pinto/) - [Bryan Tyo](https://www.eversana.com/thought-leaders/bryan-tyo/) - [John Chatas](https://www.eversana.com/thought-leaders/john-chatas/) - [Jason Thomas](https://www.eversana.com/thought-leaders/jason-thomas/) - [Jim Burke](https://www.eversana.com/thought-leaders/jim-burke/) - [Joshua Gauci](https://www.eversana.com/thought-leaders/joshua-gauci/) - [Ari Mendell, MSc, PhD](https://www.eversana.com/thought-leaders/ari-mendell-msc-phd/) - [Scot Buchanan](https://www.eversana.com/thought-leaders/scot-buchanan/) - [Sokhna Mbacke](https://www.eversana.com/thought-leaders/sokhna-mbacke/) - [Sydney Jopling](https://www.eversana.com/thought-leaders/sydney-jopling/) - [Gideon Chow](https://www.eversana.com/thought-leaders/gideon-chow/) - [Michelle Siu](https://www.eversana.com/thought-leaders/michelle-siu/) - [Ekta Saraiya](https://www.eversana.com/thought-leaders/ekta-saraiya/) - [Charles Pirraglia](https://www.eversana.com/thought-leaders/charles-pirraglia/) - [Chris Quesenberry](https://www.eversana.com/thought-leaders/chris-quesenberry/) - [Tim Healey](https://www.eversana.com/thought-leaders/tim-healey/) - [Robert Blank](https://www.eversana.com/thought-leaders/robert-blank/) - [Michael Hillan](https://www.eversana.com/thought-leaders/michael-hillan/) - [C. J. Deitrick](https://www.eversana.com/thought-leaders/c-j-deitrick/) - [Shraddha Bhange, MD, MBBS, Msc.](https://www.eversana.com/thought-leaders/shraddha-bhange-md-mbbs-msc/) - [Jim Charnetski](https://www.eversana.com/thought-leaders/jim-charnetski/) - [Rana Qadeer, MSc](https://www.eversana.com/thought-leaders/rana-qadeer-msc/) - [Laura Clark, MS](https://www.eversana.com/thought-leaders/laura-clark/) - [Chris Lagoeiro](https://www.eversana.com/thought-leaders/chris-lagoeiro/) - [Howard Flushman](https://www.eversana.com/thought-leaders/howard-flushman/) - [Patrick Beers](https://www.eversana.com/thought-leaders/patrick-beers/) - [David Morton](https://www.eversana.com/thought-leaders/david-morton/) - [Sybil Mead](https://www.eversana.com/thought-leaders/sybil-mead/) - [Marissa Moriarty](https://www.eversana.com/thought-leaders/marissa-moriarty/) - [Jennifer Sparano](https://www.eversana.com/thought-leaders/jennifer-sparano/) - [Thomas Barton](https://www.eversana.com/thought-leaders/thomas-barton/) - [Magdi Stino](https://www.eversana.com/thought-leaders/magdi-stino/) - [Amy Peek](https://www.eversana.com/thought-leaders/amy-peek/) - [Michael Kurland](https://www.eversana.com/thought-leaders/michael-kurland/) - [Gary Watson](https://www.eversana.com/thought-leaders/gary-watson/) - [Danny Williams](https://www.eversana.com/thought-leaders/danny-williams/) - [Penny Bemus](https://www.eversana.com/thought-leaders/penny-bemus/) - [Alan Crowther](https://www.eversana.com/thought-leaders/alan-crowther/) - [Rachel Williams](https://www.eversana.com/thought-leaders/rachel-williams/) ## Downloads - [From Science to Value: Strategic Asset Valuation for Biotech Licensing and Fundraising](https://www.eversana.com/?post_type=dlm_download&p=50653) - [EVERSANA_Overview_01212026](https://www.eversana.com/?post_type=dlm_download&p=54181) - [The-Oncologists-Next-Ally-Why-Cancer-Is-Forging-the-Future-of-Clinical-AI_3248-POV_.pdf](https://www.eversana.com/?post_type=dlm_download&p=53601) - [AI-at-ESMO-2025_POV.pdf](https://www.eversana.com/?post_type=dlm_download&p=53349) - [Most-Favored-Nation-Model.pdf](https://www.eversana.com/?post_type=dlm_download&p=52834) - [Most-Favored-Nation-Model_POV_TL_30310925-1.pdf](https://www.eversana.com/?post_type=dlm_download&p=52796) - [POV-O2C-Rev-Management.pdf](https://www.eversana.com/?post_type=dlm_download&p=51706) - [Most Favorable Nation Pricing](https://www.eversana.com/?post_type=dlm_download&p=50717) - [Most Favorable Nation Pricing Discussion - EMC](https://www.eversana.com/?post_type=dlm_download&p=50712) - [Harnessing the Digital Voice: High-Impact Social Listening for Pharma in the Diverse APAC Landscape](https://www.eversana.com/?post_type=dlm_download&p=50501) - [The Evidence Gap No One Talks About](https://www.eversana.com/?post_type=dlm_download&p=50206) - [Uncovering the Drivers of Satisfaction for Patient Services](https://www.eversana.com/?post_type=dlm_download&p=50230) - [CASE STUDY: Transforming Clinical Trials with EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=50074) - [Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe](https://www.eversana.com/?post_type=dlm_download&p=49259) - [Optimizing Specialty Pharmacy Networks: A Best-in-Class Approach for Rare Disease Therapies](https://www.eversana.com/?post_type=dlm_download&p=49818) - [The End of the Blockbuster](https://www.eversana.com/?post_type=dlm_download&p=49736) - [Maximizing Sales with AI: A Strategic Roadmap for Success](https://www.eversana.com/?post_type=dlm_download&p=49540) - [Rare Disease Care in India: A Path to Positive Impact](https://www.eversana.com/?post_type=dlm_download&p=49535) - [One Team, One Voice: The Impact of Centralized Medical Content Development](https://www.eversana.com/?post_type=dlm_download&p=49530) - [Revolutionizing Customer Experience: The Role of AI in Enhancing MI Contact](https://www.eversana.com/?post_type=dlm_download&p=49420) - [Enhancing Medical Strategies Through Effective Literature Surveillance](https://www.eversana.com/?post_type=dlm_download&p=49415) - [Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice](https://www.eversana.com/?post_type=dlm_download&p=49372) - [The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA](https://www.eversana.com/?post_type=dlm_download&p=49039) - [AGAINST THE ODDS: Managing the Uncertainty of FDA Approval for Emerging Companies](https://www.eversana.com/?post_type=dlm_download&p=37193) - [Association between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes](https://www.eversana.com/?post_type=dlm_download&p=48564) - [Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia](https://www.eversana.com/?post_type=dlm_download&p=48518) - [Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways](https://www.eversana.com/?post_type=dlm_download&p=48282) - [Function Over Fashion: Implementing Value-Based Contracts Successfully](https://www.eversana.com/?post_type=dlm_download&p=10348) - [Optimizing and Accelerating Membership Management Within the Healthcare Industry](https://www.eversana.com/?post_type=dlm_download&p=38745) - [Gross-to-Net: Challenges and Best Practices](https://www.eversana.com/?post_type=dlm_download&p=23205) - [The Promise of a Direct-to-Patient Model – Breaking Down What’s Really Needed for Better Patient Access](https://www.eversana.com/?post_type=dlm_download&p=47382) - [2024 U.S. Pharma Outlook Report](https://www.eversana.com/?post_type=dlm_download&p=47366) - [Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and Canada](https://www.eversana.com/?post_type=dlm_download&p=47331) - [How to Ensure Speed and Efficiency When Launching in Canada](https://www.eversana.com/?post_type=dlm_download&p=35093) - [EVERSANA's Predictive Analytics: A Capabilities Compendium](https://www.eversana.com/?post_type=dlm_download&p=47122) - [The Evolving Landscape of HCP Engagement and the Role of Medical Information in This Era of Digital Innovation](https://www.eversana.com/?post_type=dlm_download&p=47056) - [Clinical Data Portability for Regulatory Submissions Across Global Markets](https://www.eversana.com/?post_type=dlm_download&p=47006) - [Reinventing Launch: The Gold Standard of Drug Commercialization](https://www.eversana.com/?post_type=dlm_download&p=23541) - [Navigating the Complexities of Patient Care With Digital and Human Touchpoints](https://www.eversana.com/?post_type=dlm_download&p=26062) - [Report: Integrated Delivery Network Trends and Engagement Strategies](https://www.eversana.com/?post_type=dlm_download&p=46545) - [In-Depth with an Industry Leader](https://www.eversana.com/?post_type=dlm_download&p=46635) - [Ask The Expert: EVERSANA’s e-Commerce Platform Enables Manufacturers to Sell Directly to Customers](https://www.eversana.com/?post_type=dlm_download&p=22874) - [Maximizing Medical Affairs and MSL Impact](https://www.eversana.com/?post_type=dlm_download&p=46594) - [Optimizing Product Commercialization in Today’s IDN Environment](https://www.eversana.com/?post_type=dlm_download&p=46328) - [Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies](https://www.eversana.com/?post_type=dlm_download&p=41810) - [Digital Guide to Commercializing Complex Therapeutics](https://www.eversana.com/?post_type=dlm_download&p=41364) - [Navigating the Evolution of Precision Medicine: Data-Driven Strategies for Life Sciences Commercialization](https://www.eversana.com/?post_type=dlm_download&p=45908) - [Maximizing Sales Impact in a Hybrid World](https://www.eversana.com/?post_type=dlm_download&p=45802) - [Bridging “Share of Voice” with “Share of Influence” for Lasting Impact](https://www.eversana.com/?post_type=dlm_download&p=45854) - [RWE IN MANAGED ACCESS AGREEMENTS OF NICE: A GAME-CHANGER OR LIMITED CONTRIBUTOR](https://www.eversana.com/?post_type=dlm_download&p=45709) - [Reversing the Complexity of Oncology Commercialization](https://www.eversana.com/?post_type=dlm_download&p=25184) - [Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling](https://www.eversana.com/?post_type=dlm_download&p=45400) - [Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare](https://www.eversana.com/?post_type=dlm_download&p=45218) - [Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact](https://www.eversana.com/?post_type=dlm_download&p=45140) - [Leveraging the Expertise of Medical Affairs to Create Global Value with Efficient, Cross-functional Collaboration](https://www.eversana.com/?post_type=dlm_download&p=44900) - [Future-Proofing Demands Proof: How Innovators Are Transforming Pharma Commercialization](https://www.eversana.com/?post_type=dlm_download&p=44868) - [Considerations for the Development of Interactive](https://www.eversana.com/?post_type=dlm_download&p=44780) - [Current Trends in Medical Review of Promotional and Non-Promotional Materials](https://www.eversana.com/?post_type=dlm_download&p=44773) - [Redefining Field Deployment – Bridging “Share of Voice” with “Share of Influence” for Lasting Impact](https://www.eversana.com/?post_type=dlm_download&p=44414) - [Canada - Accessibility Policy](https://www.eversana.com/?post_type=dlm_download&p=44302) - [Canada - Alternative Format Request and Feedback Form](https://www.eversana.com/?post_type=dlm_download&p=44297) - [Canada - Accessibility Multi-Year Plan 2023](https://www.eversana.com/?post_type=dlm_download&p=44294) - [EVERSANA's Outsourcing Compliance Solutions](https://www.eversana.com/?post_type=dlm_download&p=44269) - [FDA Compliance Solutions](https://www.eversana.com/?post_type=dlm_download&p=44256) - [Navigating Pharmaceutical Commercialization: Eight Key Insights for Success](https://www.eversana.com/?post_type=dlm_download&p=42602) - [Repairing the Patient Journey: How Pharma Can Fix the Obvious](https://www.eversana.com/?post_type=dlm_download&p=44185) - [DES Labeling Matrix](https://www.eversana.com/?post_type=dlm_download&p=44036) - [Linking Channel Distribution & 3PL to Non-Traditional Commercialization Touchpoints](https://www.eversana.com/?post_type=dlm_download&p=43976) - [CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility](https://www.eversana.com/?post_type=dlm_download&p=21718) - [PHARMA LAUNCHES WITH A SpaceX PHILOSOPHY: How an Innovative Contract Commercialization Approach Can Yield Quantifiable Launch Cost Savings](https://www.eversana.com/?post_type=dlm_download&p=21229) - [Incorporating Medical Science Liaisons Early and Often Amplifies Impact and Delivers Stronger Patient Outcomes](https://www.eversana.com/?post_type=dlm_download&p=43725) - [Navigating the Evolving Landscape of Internet Healthcare in China](https://www.eversana.com/?post_type=dlm_download&p=43683) - [Utilization of Indirect Treatment Comparison](https://www.eversana.com/?post_type=dlm_download&p=43416) - [ISPOR EUROPE 2023 - POSTER SESSIONS](https://www.eversana.com/?post_type=dlm_download&p=43115) - [ACTICs_eAccess_Sell-Sheet_-1.pdf](https://www.eversana.com/?post_type=dlm_download&p=42966) - [New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency](https://www.eversana.com/?post_type=dlm_download&p=42868) - [Orchestrating Experiences That Simultaneously Drive Brand Impact and Customer Delight](https://www.eversana.com/?post_type=dlm_download&p=42671) - [Considerations for Globalization of Medical Information Services: A Service Partner Perspective](https://www.eversana.com/?post_type=dlm_download&p=42731) - [Continuous Manufacturing of Pharmaceutical Products: The New Norm](https://www.eversana.com/?post_type=dlm_download&p=42563) - [The Role of RWE in Expediting the Drug Approval Process](https://www.eversana.com/?post_type=dlm_download&p=42291) - [Maximizing Product Launch Success](https://www.eversana.com/?post_type=dlm_download&p=42271) - [Unlocking the Power of Data, Artificial Intelligence and Digital Innovations](https://www.eversana.com/?post_type=dlm_download&p=41948) - [Health Disparity Solutions Build Healthier Communities and a More Equitable Medical Landscape](https://www.eversana.com/?post_type=dlm_download&p=41658) - [Past and Present U.S. Public Health Laws and Regulations, and Their Impact on the Corresponding FDA Regulated Products and Industries](https://www.eversana.com/?post_type=dlm_download&p=41237) - [Reimagining the SpecialtyRx Patient Journey Through the Lens of a Digital Consumer](https://www.eversana.com/?post_type=dlm_download&p=41203) - [CASE STUDY: Protecting Gross-to-Net through Enhanced 340B Validations](https://www.eversana.com/?post_type=dlm_download&p=40976) - [Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services](https://www.eversana.com/?post_type=dlm_download&p=40951) - [Matching-Adjusted Indirect Comparison](https://www.eversana.com/?post_type=dlm_download&p=40934) - [The IDeaS Initiative: Pilot Study to Assess the Impact of Rare Diseases on Patients and Healthcare Systems](https://www.eversana.com/?post_type=dlm_download&p=40824) - [Role of Decentralized Trials for Newer Drug Approvals](https://www.eversana.com/?post_type=dlm_download&p=40779) - [Left-Right-Left: The Latest in Pharma-Payer Ping Pong](https://www.eversana.com/?post_type=dlm_download&p=40271) - [Create a Comprehensive Experience by Optimizing Forward-thinking Omnichannel Strategies](https://www.eversana.com/?post_type=dlm_download&p=40716) - [The Future of Omnichannel is Here. Don’t Get Left Behind.](https://www.eversana.com/?post_type=dlm_download&p=40712) - [Seven Challenges Traditional Omnichannel Tactics Cannot Overcome](https://www.eversana.com/?post_type=dlm_download&p=40707) - [EVERSANA’s Omnichannel Advisory Council - Interview Insights Summary](https://www.eversana.com/?post_type=dlm_download&p=40651) - [From Limitations to Expansions: How Prioritizing Patients' Speed to Therapy Drives Therapy Adoption](https://www.eversana.com/?post_type=dlm_download&p=40598) - [Foundations of Global Pricing Governance](https://www.eversana.com/?post_type=dlm_download&p=40576) - [Case Study: Optimizing use of Field Reimbursement Managers](https://www.eversana.com/?post_type=dlm_download&p=39921) - [Primary Research Meets Data-Driven Sources and Technology to Form Powerful Market Access Solutions for Biopharmaceutical Companies](https://www.eversana.com/?post_type=dlm_download&p=40486) - [2023 Outlook Of China Healthcare Industry](https://www.eversana.com/?post_type=dlm_download&p=40407) - [The Necessity of Mapping the Tumor Journey for Oncology Marketers](https://www.eversana.com/?post_type=dlm_download&p=40323) - [Employ an Integrated Market Access Strategy to Deliver Brand Success](https://www.eversana.com/?post_type=dlm_download&p=40219) - [Solving the Wastage Challenge Through Predictive Analytics and Modeling](https://www.eversana.com/?post_type=dlm_download&p=40160) - [FG](https://www.eversana.com/?post_type=dlm_download&p=40111) - [Elevating Field Relationship Manager Performance through Insights & Comparative Data](https://www.eversana.com/?post_type=dlm_download&p=40012) - [Navigating Routes to Commercial Excellence in Cell and Gene Therapy](https://www.eversana.com/?post_type=dlm_download&p=39938) - [Use of Machine Learning to Accurately Size Market Potential and Optimize Sales and Marketing Resources](https://www.eversana.com/?post_type=dlm_download&p=39971) - [Case Study: Waste Reduction through Packaging Optimization](https://www.eversana.com/?post_type=dlm_download&p=39908) - [Next Generation Brand Planning: Fueling Brand Plan Efficiency Through Seamless Integration](https://www.eversana.com/?post_type=dlm_download&p=39849) - [Value Proposition of Medical Information Services: Current Perspectives from the Industry](https://www.eversana.com/?post_type=dlm_download&p=39827) - [Achieving Digital Enlightenment in 2023 and Beyond](https://www.eversana.com/?post_type=dlm_download&p=39814) - [EVERSANA-PS-Scorecard-2023](https://www.eversana.com/?post_type=dlm_download&p=39776) - [Successfully Navigating Self-Commercialisation in Europe](https://www.eversana.com/?post_type=dlm_download&p=39626) - [Successful Launches in Europe: Complex, but Not Complicated?](https://www.eversana.com/?post_type=dlm_download&p=39596) - [Critical Success Factors for Launching Products with Orphan Drug Designation](https://www.eversana.com/?post_type=dlm_download&p=39103) - [Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward](https://www.eversana.com/?post_type=dlm_download&p=39559) - [Can Telehealth Accelerate the Uptake of Digital Therapeutics?](https://www.eversana.com/?post_type=dlm_download&p=39230) - [WP_1Q23_EMC_Orphan Indications](https://www.eversana.com/?post_type=dlm_download&p=39342) - [How Generative AI and Synthetic Content Will Revolutionize Healthcare](https://www.eversana.com/?post_type=dlm_download&p=39048) - [Bending the “Commercialization Curve” in Large Pharma](https://www.eversana.com/?post_type=dlm_download&p=38760) - [Missed Connection or Meant to Be?](https://www.eversana.com/?post_type=dlm_download&p=38681) - [How Advanced Analytics Can Enable Next-Generation Account Segmentation](https://www.eversana.com/?post_type=dlm_download&p=38664) - [The Expanding Oncology Market Prompts Reevaluation of Field Team Training Procedures and Skill Set to Impact Frontline Success](https://www.eversana.com/?post_type=dlm_download&p=38577) - [NAVLIN Insights Oncology Pathways Case Study](https://www.eversana.com/?post_type=dlm_download&p=38089) - [Pivot Pros: How EVERSANA™ Course Corrected When the Market Changed](https://www.eversana.com/?post_type=dlm_download&p=38504) - [INVISIBLE ORCHESTRATION: How Behind-the-Scenes Collaboration of Patient Services and Field Deployment Teams Delivers a Seamless Front-of-House Brand Experience](https://www.eversana.com/?post_type=dlm_download&p=38477) - [Adult Vaccine Landscape in APAC: The Need for Change](https://www.eversana.com/?post_type=dlm_download&p=38444) - [Access Challenges for Severe Infectious Diseases](https://www.eversana.com/?post_type=dlm_download&p=38206) - [Establishing the Patient Access Mission during Clinical Development](https://www.eversana.com/?post_type=dlm_download&p=37899) - [Establishing the Patient Access Mission during Clinical Development](https://www.eversana.com/?post_type=dlm_download&p=37883) - [Payer Oncology Access Management in 2022](https://www.eversana.com/?post_type=dlm_download&p=37799) - [Emerging Trends in the APAC MedTech Market](https://www.eversana.com/?post_type=dlm_download&p=37765) - [Accelerate Patient Therapy Adoption by Eliminating Obstructive Pain Points](https://www.eversana.com/?post_type=dlm_download&p=37521) - [Evolution of Digital Apps to Total Wellness Solutions](https://www.eversana.com/?post_type=dlm_download&p=37466) - [Developing Best-in-class Copay Programs for Gross-to-Net](https://www.eversana.com/?post_type=dlm_download&p=37456) - [Elevate Your Brand to New Heights by Utilizing National Account Managers](https://www.eversana.com/?post_type=dlm_download&p=37315) - [Making Magic Practical: Leveraging Salesforce Marketing Cloud Personalization to Power the Next Gen Rep](https://www.eversana.com/?post_type=dlm_download&p=37290) - [Social Determinants of Health – What Pharma Can Do!](https://www.eversana.com/?post_type=dlm_download&p=36493) - [Digital Medicine Capabilities Brochure](https://www.eversana.com/?post_type=dlm_download&p=36769) - [Plasma derived medicinal products – What is the way forward?](https://www.eversana.com/?post_type=dlm_download&p=36648) - [Single-Cell Multiomics: Opportunities, Challenges, and the Evolving Business Model](https://www.eversana.com/?post_type=dlm_download&p=36580) - [Successful Early-Stage Out-Licensing Requirements](https://www.eversana.com/?post_type=dlm_download&p=36596) - [Flipping the Script to Disrupt, Redefine and Accelerate the Patient Care Journey](https://www.eversana.com/?post_type=dlm_download&p=36438) - [CASE STUDY: Leveraging machine learning models in patient identification and behavior prediction for rare disease indications](https://www.eversana.com/?post_type=dlm_download&p=36450) - [Three Keys to Value for Unlocking the Promise of Cell Therapies](https://www.eversana.com/?post_type=dlm_download&p=36379) - [Customer Centric Approach to Medical Affairs Leveraging Digital Technology](https://www.eversana.com/?post_type=dlm_download&p=36245) - [Commercialization Strategies in Oncology — The Right Partner Can Reduce Risk and Boost Rewards](https://www.eversana.com/?post_type=dlm_download&p=36224) - [Legacy Pharma Brands – A Good Investment?](https://www.eversana.com/?post_type=dlm_download&p=29889) - [Is Telemedicine Here to Stay?](https://www.eversana.com/?post_type=dlm_download&p=29884) - [An Innovative Approach to Comprehensive Key Opinion Leader (KOL) Mapping](https://www.eversana.com/?post_type=dlm_download&p=29670) - [Evolution of Integrated Mental Health Treatment Models in Southeast Asia (SEA)](https://www.eversana.com/?post_type=dlm_download&p=29713) - [Challenges of Scaling Up Cell Therapy to New Geographies](https://www.eversana.com/?post_type=dlm_download&p=29627) - [Booming but Constrained: Digital Therapeutics for Mental Health in APAC](https://www.eversana.com/?post_type=dlm_download&p=29541) - [Need for RWE in Consumer Health and Its Impact in Managing Lifecycle of Consumer Health Products](https://www.eversana.com/?post_type=dlm_download&p=29438) - [KAM Reimagined: Building a Strategic Framework to Empower Key Account Management](https://www.eversana.com/?post_type=dlm_download&p=29373) - [Operational Concerns for Key Enacted and Proposed Changes Under Medicare and Medicaid](https://www.eversana.com/?post_type=dlm_download&p=29365) - [DES System - Donor Eligibility Outsourcing Services](https://www.eversana.com/?post_type=dlm_download&p=21659) - [Defining the Rare Disease Patient Journey to Support Commercialization of Therapy](https://www.eversana.com/?post_type=dlm_download&p=26396) - [Demystifying Data and Analytics - How to Advance Clinical and Business Objectives](https://www.eversana.com/?post_type=dlm_download&p=26114) - [Pharmaceutical Distribution - Right-Sizing the Channel Strategy for Maximum Impact](https://www.eversana.com/?post_type=dlm_download&p=26024) - [Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases](https://www.eversana.com/?post_type=dlm_download&p=25955) - [What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)](https://www.eversana.com/?post_type=dlm_download&p=25409) - [Reframing the Challenges of Access and ROI](https://www.eversana.com/?post_type=dlm_download&p=25805) - [Reigniting Revenue for Established Brands](https://www.eversana.com/?post_type=dlm_download&p=25845) - [Understanding Current Trends and Needs: Medical Information Contact Center Services](https://www.eversana.com/?post_type=dlm_download&p=25210) - [Importance of Impactful Medical Information Content](https://www.eversana.com/?post_type=dlm_download&p=25038) - [THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization](https://www.eversana.com/?post_type=dlm_download&p=24932) - [A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022](https://www.eversana.com/?post_type=dlm_download&p=24521) - [Why Launching in Europe Is Unlike Launching Anywhere Else](https://www.eversana.com/?post_type=dlm_download&p=24126) - [Launch Sequencing and Market Prioritization in an Evolving Global Market](https://www.eversana.com/?post_type=dlm_download&p=24100) - [The Power to Know When: Balancing Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers](https://www.eversana.com/?post_type=dlm_download&p=24145) - [China’s 6th Round of Volume Based Procurement (VBP)](https://www.eversana.com/?post_type=dlm_download&p=23914) - [China 2021 NRDL Overview](https://www.eversana.com/?post_type=dlm_download&p=24111) - [Rx-to-OTC Switch Tips: Identifying the Right Timing, Conditions, and Approach for Rx-to-OTC Conversion](https://www.eversana.com/?post_type=dlm_download&p=24073) - [Considering Commercial Success During Clinical Development: Maintaining a Global Perspective](https://www.eversana.com/?post_type=dlm_download&p=23871) - [China's Seventh Round of VBP: Insulin](https://www.eversana.com/?post_type=dlm_download&p=23904) - [PAP: Co-Pay is Evolving](https://www.eversana.com/?post_type=dlm_download&p=23732) - [Applying the Scientific Method as the Cornerstone of Brand Insights and Strategy](https://www.eversana.com/?post_type=dlm_download&p=23653) - [Four Ways Predictive Analytics Can Strengthen Your Commercialization Efforts](https://www.eversana.com/?post_type=dlm_download&p=23639) - [The Transforming Landscape of Digital Therapeutics Reimbursement](https://www.eversana.com/?post_type=dlm_download&p=23635) - [Three Keys To Value For Unlocking The Promise Of Cell Therapies](https://www.eversana.com/?post_type=dlm_download&p=23604) - [Unlock Europe To Create Value](https://www.eversana.com/?post_type=dlm_download&p=23599) - [A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes](https://www.eversana.com/?post_type=dlm_download&p=23526) - [Pricentric Insights - May Newsletter](https://www.eversana.com/?post_type=dlm_download&p=23509) - [Pricentric Insights - June Newsletter](https://www.eversana.com/?post_type=dlm_download&p=23503) - [Ask the Expert - Specialty Pharmacies and Specialty Distributors - Updated](https://www.eversana.com/?post_type=dlm_download&p=22203) - [Sell'n Gene Therapies: A Landscape Assessment of Cell and Gene Therapy Reimbursement](https://www.eversana.com/?post_type=dlm_download&p=14167) - [Telling the Whole Story: An Integrated Approach to Value Proposition Creation](https://www.eversana.com/?post_type=dlm_download&p=23152) - [Health Technology Assessment in the Asia Pacific Region](https://www.eversana.com/?post_type=dlm_download&p=23083) - [The Need for RWE Studies in APAC and the Impact on Product Life Cycle Management](https://www.eversana.com/?post_type=dlm_download&p=23086) - [Measuring the Impact of Coordinated Field and Digital Engagement Through Network Influence: An Omnichannel Case Study](https://www.eversana.com/?post_type=dlm_download&p=22941) - [Bridging The Patient Support Gap With Integrated Technology Solutions And Strategies](https://www.eversana.com/?post_type=dlm_download&p=22594) - [How Do You Know Your Portfolio Process Is Adding Value?](https://www.eversana.com/?post_type=dlm_download&p=22123) - [Assessing Market Opportunity and Entry Challenges in Mental Health Disorders](https://www.eversana.com/?post_type=dlm_download&p=22184) - [China VBR Round 6 Insulin](https://www.eversana.com/?post_type=dlm_download&p=22102) - [Building a Life Sciences Digital Ecosystem](https://www.eversana.com/?post_type=dlm_download&p=22145) - [Increasing the Value of Community Health Workers](https://www.eversana.com/?post_type=dlm_download&p=22138) - [Novel Antibiotic Opportunity in China](https://www.eversana.com/?post_type=dlm_download&p=22128) - [Digital Therapeutics: Where Technology Meets Healthcare](https://www.eversana.com/?post_type=dlm_download&p=22115) - [Test Download](https://www.eversana.com/?post_type=dlm_download&p=2773) - [Test 2 Download](https://www.eversana.com/?post_type=dlm_download&p=2782) - [How well do you really know your patients](https://www.eversana.com/?post_type=dlm_download&p=3466) - [The Brink of the Biosimilar Revolution](https://www.eversana.com/?post_type=dlm_download&p=3478) - [Precision Medicine Meets Precision Patient Support](https://www.eversana.com/?post_type=dlm_download&p=3495) - [Product Master Data Management](https://www.eversana.com/?post_type=dlm_download&p=3501) - [Medicare & Medicaid: A Rollback on Rebates](https://www.eversana.com/?post_type=dlm_download&p=3506) - [Biosimilar Pricing in Europe](https://www.eversana.com/?post_type=dlm_download&p=3553) - [Put Your Patient Services Program to the Test](https://www.eversana.com/?post_type=dlm_download&p=3994) - [Medicare Part D: Closing the Coverage Gap](https://www.eversana.com/?post_type=dlm_download&p=4150) - [Medicaid Drug Classification: Civil Monetary Penalties](https://www.eversana.com/?post_type=dlm_download&p=4158) - [Membership Management Challenges and Best Practices](https://www.eversana.com/?post_type=dlm_download&p=4216) - [Pharmaceutical Contracting from Volume to Value](https://www.eversana.com/?post_type=dlm_download&p=4219) - [Market Access Macrotrends Research Agenda](https://www.eversana.com/?post_type=dlm_download&p=4516) - [Patient-Centered Engagement: Wrapping Value Around Life Science Services](https://www.eversana.com/?post_type=dlm_download&p=4585) - [Reimbursement Dynamics for Women's Health Drugs](https://www.eversana.com/?post_type=dlm_download&p=4600) - [EVERSANA - Case Study- Every Patient Matters](https://www.eversana.com/?post_type=dlm_download&p=4704) - [EVERSANA - Case Study - Access Matters](https://www.eversana.com/?post_type=dlm_download&p=4746) - [EVERSANA - Case Study - Pricing Matters](https://www.eversana.com/?post_type=dlm_download&p=4758) - [EVERSANA - Case Study - WAC Pricing Strategies](https://www.eversana.com/?post_type=dlm_download&p=4761) - [EVERSANA - Case Study - Every Relationship Matters](https://www.eversana.com/?post_type=dlm_download&p=4783) - [EVERSANA - Case Study - Every Patient Matters](https://www.eversana.com/?post_type=dlm_download&p=4786) - [EVERSANA - Case Study - Share of Voice Matters](https://www.eversana.com/?post_type=dlm_download&p=4817) - [EVERSANA - Case Study - Standardization and Scale](https://www.eversana.com/?post_type=dlm_download&p=4833) - [Case](https://www.eversana.com/?post_type=dlm_download&p=4948) - [EVERSANA - Case Study - Safety and Effectiveness](https://www.eversana.com/?post_type=dlm_download&p=4837) - [EVERSANA - Case Study - Every Life Matters](https://www.eversana.com/?post_type=dlm_download&p=4949) - [EVERSANA - Case Study - Every Hour Matters](https://www.eversana.com/?post_type=dlm_download&p=4952) - [EVERSANA - Case Study - Education Matters](https://www.eversana.com/?post_type=dlm_download&p=4972) - [EVERSANA - Case Study - Access Matters](https://www.eversana.com/?post_type=dlm_download&p=4981) - [EVERSANA - Case Study - Preferred Status](https://www.eversana.com/?post_type=dlm_download&p=4985) - [Research Agenda- Delivery of Care](https://www.eversana.com/?post_type=dlm_download&p=5003) - [Research Agenda - IDN Profiles](https://www.eversana.com/?post_type=dlm_download&p=5006) - [Research Agenda - Insurance & Benefit Design](https://www.eversana.com/?post_type=dlm_download&p=5009) - [Pushing Your Frontline Into A New Frontier](https://www.eversana.com/?post_type=dlm_download&p=5083) - [Driving the Commercialization of Regenerative Medicine](https://www.eversana.com/?post_type=dlm_download&p=5107) - [ARE WE TRANSFORMING IN THE RIGHT WAY?](https://www.eversana.com/?post_type=dlm_download&p=5180) - [Are You Ready For Patient Services 2.0?](https://www.eversana.com/?post_type=dlm_download&p=5491) - [Navigating Channel Distribution in a New (and more complex) Biopharma World](https://www.eversana.com/?post_type=dlm_download&p=5586) - [Innovative Therapies Call for an Integrated Drug Safety and Compliance Model](https://www.eversana.com/?post_type=dlm_download&p=5598) - [Facilitating Positive Patient Outcomes at the Frontline](https://www.eversana.com/?post_type=dlm_download&p=5924) - [Adopting a Patient-Centric Approach to Ensure Safe and Effective Use](https://www.eversana.com/?post_type=dlm_download&p=6225) - [German and United Kingdom Physicians Express Frustration with Health System Challenges](https://www.eversana.com/?post_type=dlm_download&p=6243) - [Considerations for Compliance with the EU GDPR](https://www.eversana.com/?post_type=dlm_download&p=6260) - [Considerations for Compliance with the EU General Data Protection Regulation (GDPR)](https://www.eversana.com/?post_type=dlm_download&p=6262) - [How do we pay for a cure?](https://www.eversana.com/?post_type=dlm_download&p=6369) - [Global Biosimilar Competitor Assessment](https://www.eversana.com/?post_type=dlm_download&p=6739) - [Navigating the Cycle of Supply Chain Complexity](https://www.eversana.com/?post_type=dlm_download&p=6750) - [Gross-to-Net Improvement Through Holistic Revenue Enhancement](https://www.eversana.com/?post_type=dlm_download&p=6819) - [Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review](https://www.eversana.com/?post_type=dlm_download&p=6889) - [Clinical Trial Recruitment for Ultra Rare Disease](https://www.eversana.com/?post_type=dlm_download&p=6904) - [Clinical Trial Recruitment for Neurodegenerative Disease](https://www.eversana.com/?post_type=dlm_download&p=6909) - [Clinical Trial Recruitment for Breast Cancer with Genetic Modifier](https://www.eversana.com/?post_type=dlm_download&p=6912) - [Clinical Trial Recruitment for Prostate Cancer](https://www.eversana.com/?post_type=dlm_download&p=6915) - [Ask the Expert - Specialty Pharmacies and Specialty Distributors](https://www.eversana.com/?post_type=dlm_download&p=7074) - [Reimbursement Dynamics For Women's Health Drugs](https://www.eversana.com/?post_type=dlm_download&p=7107) - [Ask the Expert - Digital Therapeutics](https://www.eversana.com/?post_type=dlm_download&p=7135) - [EVERSANA POSTER ABSTRACTS AT ASH 2019](https://www.eversana.com/?post_type=dlm_download&p=7171) - [Artificial Intelligence and the Future of Medical Information Services](https://www.eversana.com/?post_type=dlm_download&p=7225) - [Technology and Compliance Equals Improved Models of Care](https://www.eversana.com/?post_type=dlm_download&p=7230) - [The Impact of Technology on Advancing Diabetes Care](https://www.eversana.com/?post_type=dlm_download&p=7234) - [Pathways for Paying for Rare Disease Treatments](https://www.eversana.com/?post_type=dlm_download&p=7240) - [Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem](https://www.eversana.com/?post_type=dlm_download&p=7258) - [Delivering Value in the Era of Empowered Patients](https://www.eversana.com/?post_type=dlm_download&p=7262) - ["Ask the Expert" about Digital Therapeutics](https://www.eversana.com/?post_type=dlm_download&p=7268) - [U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines](https://www.eversana.com/?post_type=dlm_download&p=7341) - [ICER’s Unsupported Price Increase Assessment](https://www.eversana.com/?post_type=dlm_download&p=7366) - [Is ICER Increasing Influence in the USA Over Time?](https://www.eversana.com/?post_type=dlm_download&p=7485) - [Social Media for Clinical Trial Patient Recruitment](https://www.eversana.com/?post_type=dlm_download&p=7619) - [Increase Your Speed to Market](https://www.eversana.com/?post_type=dlm_download&p=7668) - [Market Access to Current and Future Rare Disease Treatments](https://www.eversana.com/?post_type=dlm_download&p=7738) - [ACCESSEXPRESS by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=7993) - [HTANAVIGATOR by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=8009) - [Seeker Health by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=8012) - [How Does Real World Evidence Ensure Market Access](https://www.eversana.com/?post_type=dlm_download&p=8037) - [How Does Real World Evidence Ensure Market Access?](https://www.eversana.com/?post_type=dlm_download&p=8154) - [How the "Power of Why" Can Improve Adherence Rates in Rare Disease](https://www.eversana.com/?post_type=dlm_download&p=8175) - [Commercialization of Digital Therapies](https://www.eversana.com/?post_type=dlm_download&p=8432) - [Alexa, Can You Transform Healthcare?](https://www.eversana.com/?post_type=dlm_download&p=8541) - [Evolving Processes to Manage Value-Based Contracts](https://www.eversana.com/?post_type=dlm_download&p=8592) - [The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need](https://www.eversana.com/?post_type=dlm_download&p=8638) - [Pricentric ONE by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=8655) - [PriceRight by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=8658) - [HTANAVIGATOR Infographic](https://www.eversana.com/?post_type=dlm_download&p=8727) - [Health Strategies Insights by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=8730) - [Oncology Treatment Access in 2020](https://www.eversana.com/?post_type=dlm_download&p=8738) - [Improving Patient Adherence with Behavioral Health Technology](https://www.eversana.com/?post_type=dlm_download&p=8752) - [Looking to Launch or Commercialise in the US? Start with the Right Commercial Partner.](https://www.eversana.com/?post_type=dlm_download&p=9061) - [How to Maximize the Value of New Advances in Oncology](https://www.eversana.com/?post_type=dlm_download&p=9101) - [Validate and Inform your Account Access Strategies and Tactics](https://www.eversana.com/?post_type=dlm_download&p=9114) - [Oncology Brand Access and Insights Solutions](https://www.eversana.com/?post_type=dlm_download&p=9166) - [Ask the Experts: Real World Evidence](https://www.eversana.com/?post_type=dlm_download&p=9267) - [How the Power of Why Can Improve Adherence Rates in Rare Disease](https://www.eversana.com/?post_type=dlm_download&p=9269) - [Improving Patient Adherence with Behavioral Health Technology](https://www.eversana.com/?post_type=dlm_download&p=9271) - [The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need](https://www.eversana.com/?post_type=dlm_download&p=9277) - [A Landscape Assessment of Cell and Gene Therapy Reimbursement](https://www.eversana.com/?post_type=dlm_download&p=9328) - [THE RADICAL IMPLICATIONS OF INDICATION-SPECIFIC PRICING](https://www.eversana.com/?post_type=dlm_download&p=9331) - [DON’T POKE THE BEAR: THE EFFECT OF PHARMACEUTICAL PRICING ON PERCEPTION AND FUTURE INNOVATION](https://www.eversana.com/?post_type=dlm_download&p=9334) - [INTEGRATED DELIVERY NETWORKS Learning to Engage With a New Customer With Very Different Needs](https://www.eversana.com/?post_type=dlm_download&p=9337) - [Looking to Launch or Commercialise in the US?](https://www.eversana.com/?post_type=dlm_download&p=9348) - [Oncology Market: Outlook of Brand Access and Insights](https://www.eversana.com/?post_type=dlm_download&p=9636) - [What is Your Data Integration and Analytics Platform Strategy?](https://www.eversana.com/?post_type=dlm_download&p=9849) - [Defining the Digital Space Infographic](https://www.eversana.com/?post_type=dlm_download&p=10011) - [ACCESSEXPRESS® Payer Coverage and Reimbursement Case Study](https://www.eversana.com/?post_type=dlm_download&p=10015) - [COVID-19 Payer Pulse White Paper](https://www.eversana.com/?post_type=dlm_download&p=10060) - [Clinical Pathways and Policy to Guard Against Misaligned Incentives](https://www.eversana.com/?post_type=dlm_download&p=10234) - [PharmaVOICE Showcase Connected Health](https://www.eversana.com/?post_type=dlm_download&p=10267) - [Pricentric Newsletter April 2020](https://www.eversana.com/?post_type=dlm_download&p=10411) - [How COVID-19 Has Changed Payer Engagement Strategies](https://www.eversana.com/?post_type=dlm_download&p=10590) - [PharmaVOICE Outsourced Commercialization Showcase](https://www.eversana.com/?post_type=dlm_download&p=10620) - [PharmaVOICE Showcase on Connected Health and IoMT](https://www.eversana.com/?post_type=dlm_download&p=10740) - [PharmaVOICE Showcase on Real-World Evidence](https://www.eversana.com/?post_type=dlm_download&p=10783) - [Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease](https://www.eversana.com/?post_type=dlm_download&p=10789) - [PharmaVOICE Precision Medicine Showcase](https://www.eversana.com/?post_type=dlm_download&p=11638) - [SPOPTIMIZER by EVERSANA: Product Features](https://www.eversana.com/?post_type=dlm_download&p=11864) - [Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs](https://www.eversana.com/?post_type=dlm_download&p=11980) - [Pricentric Insights: June 2020](https://www.eversana.com/?post_type=dlm_download&p=12046) - [The 2020 Playbook Addendum: Augment Your Frontline to Boost Sales Momentum](https://www.eversana.com/?post_type=dlm_download&p=12075) - [SPOPTIMIZER by EVERSANA](https://www.eversana.com/?post_type=dlm_download&p=12173) - [Patient Engagement During the COVID-19 Pandemic](https://www.eversana.com/?post_type=dlm_download&p=12234) - [Brand Access Marketplace Dynamics: Autoimmune](https://www.eversana.com/?post_type=dlm_download&p=12437) - [Brand Access Marketplace Dynamics: HIV](https://www.eversana.com/?post_type=dlm_download&p=12443) - [Brand Access Marketplace Dynamics: Multiple Sclerosis](https://www.eversana.com/?post_type=dlm_download&p=12445) - [Brand Access Marketplace Dynamics: Respiratory](https://www.eversana.com/?post_type=dlm_download&p=12447) - [How COVID-19 will Change the Patient Journey, Reimbursement, and Care Delivery](https://www.eversana.com/?post_type=dlm_download&p=12511) - [COVID-19’s Impact on Autoimmune Brands](https://www.eversana.com/?post_type=dlm_download&p=12690) - [COVID-19’s Impact on HIV Brands](https://www.eversana.com/?post_type=dlm_download&p=12696) - [COVID-19’s Impact on Multiple Sclerosis Brands](https://www.eversana.com/?post_type=dlm_download&p=12698) - [COVID-19’s Impact on Respiratory Brands](https://www.eversana.com/?post_type=dlm_download&p=12703) - [ICER's Alternative Pricing Models: New Threats to Biopharmaceutical's Profitability and Innovation](https://www.eversana.com/?post_type=dlm_download&p=12712) - [Developing Global Indirect Treatment Comparison Programs for Market Access](https://www.eversana.com/?post_type=dlm_download&p=12746) - [Evidence Standards for Medical Device Adoption by US Hospitals](https://www.eversana.com/?post_type=dlm_download&p=12760) - [PSM and Bayesian Hierarchical Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer](https://www.eversana.com/?post_type=dlm_download&p=12765) - [Leading and Decision-Making in Uncertain Times](https://www.eversana.com/?post_type=dlm_download&p=12770) - [Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis](https://www.eversana.com/?post_type=dlm_download&p=12878) - [Where Health Systems are in the Shift to Value: Four Categories](https://www.eversana.com/?post_type=dlm_download&p=12948) - [Targeted Digital Patient Engagement](https://www.eversana.com/?post_type=dlm_download&p=12955) - [State of AR and VR Today](https://www.eversana.com/?post_type=dlm_download&p=12969) - [Ask the Expert: Digital in Pharma | The Critical Questions](https://www.eversana.com/?post_type=dlm_download&p=12978) - [Accelerating Rare Liver Disease Study Enrollment](https://www.eversana.com/?post_type=dlm_download&p=12987) - [Advancing Beyond the Traditional Patient Adherence Model](https://www.eversana.com/?post_type=dlm_download&p=13018) - [CMS Proposed Medicaid Rule: Best Price Impacts of Value-Based Purchasing, Co-Pay Assistance Programs, and More](https://www.eversana.com/?post_type=dlm_download&p=13067) - [How Pharma Can Meet Commercialization and Marketing Challenges During COVID-19](https://www.eversana.com/?post_type=dlm_download&p=13106) - [Pricentric Insights: July 2020](https://www.eversana.com/?post_type=dlm_download&p=13114) - [China 3rd VBP List](https://www.eversana.com/?post_type=dlm_download&p=13167) - [Methodology for Predicting Switching Behaviors in Patients](https://www.eversana.com/?post_type=dlm_download&p=13202) - [Using Predictive Analytics and Machine Learning to Transfer Healthcare](https://www.eversana.com/?post_type=dlm_download&p=13213) - [China Drug List](https://www.eversana.com/?post_type=dlm_download&p=13531) - [Infographic-DTxVsData](https://www.eversana.com/?post_type=dlm_download&p=13721) - [ES Overview + POV](https://www.eversana.com/?post_type=dlm_download&p=13825) - [THE 2020 PLAYBOOK ADDENDUM: AUGMENT YOUR FRONTLINE TO BOOST SALES MOMENTUM](https://www.eversana.com/?post_type=dlm_download&p=13954) - [The New Gold Standard of Drug Commercialization](https://www.eversana.com/?post_type=dlm_download&p=13985) - [The Evolving World of Artificial Intelligence: Rare Disease Impact](https://www.eversana.com/?post_type=dlm_download&p=14187) - [The Chronic Microcap Trap](https://www.eversana.com/?post_type=dlm_download&p=14206) - [Proposed selection result table for national centralized drug procurement (GY-YD2020-1)](https://www.eversana.com/?post_type=dlm_download&p=14267) - [At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?](https://www.eversana.com/?post_type=dlm_download&p=14811) - [Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard](https://www.eversana.com/?post_type=dlm_download&p=15259) - [Advancing Beyond the Traditional Patient Adherence Model](https://www.eversana.com/?post_type=dlm_download&p=15291) - [PharmaVOICE-Commercial-Influencer-Greg-Skalicky-Oct-2020](https://www.eversana.com/?post_type=dlm_download&p=15300) - [HSI Research Panel Policy](https://www.eversana.com/?post_type=dlm_download&p=15341) - [HSI Research Panel FAQ](https://www.eversana.com/?post_type=dlm_download&p=15344) - [When A Curveball Threatens Your Product's Launch](https://www.eversana.com/?post_type=dlm_download&p=15470) - [Italy Tackles HTA, Pricing and Reimbursement Reforms](https://www.eversana.com/?post_type=dlm_download&p=15525) - [e-Book “2020: Stories That Shaped Commercialization”](https://www.eversana.com/?post_type=dlm_download&p=15478) - [MARKET ACCESS AND TREATMENT OUTCOMES: Shifting From the Volume of Data to the Value of Insights](https://www.eversana.com/?post_type=dlm_download&p=15584) - [DO GERMANY’S NEW HEMOPHILIA REGULATIONS HAVE WIDER-REACHING IMPLICATIONS?](https://www.eversana.com/?post_type=dlm_download&p=15849) - [The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal](https://www.eversana.com/?post_type=dlm_download&p=16126) - [APAC Valuation Case Study](https://www.eversana.com/?post_type=dlm_download&p=16324) - [Russia | List of Pediatric Rare Diseases and Orphan Drugs Covered by Special Fund](https://www.eversana.com/?post_type=dlm_download&p=16620) - [How Does the Biden Administration Want to ‘Take on Pharma?’](https://www.eversana.com/?post_type=dlm_download&p=16753) - [How Does the Biden Administration Want to ‘Take on Pharma?’](https://www.eversana.com/?post_type=dlm_download&p=17489) - [High-Efficiency Commercialization for High-Science Brands](https://www.eversana.com/?post_type=dlm_download&p=17742) - [2020 PC Trends Newsletter](https://www.eversana.com/?post_type=dlm_download&p=17800) - [Trump's "Most-Favored Nations" Rule: 2020 Was the Year of Reference Pricing in the United States](https://www.eversana.com/?post_type=dlm_download&p=17876) - [A Look Back at IRP in 2020](https://www.eversana.com/?post_type=dlm_download&p=17879) - [When America Sneezes, the World Catches a Cold: How Changes to U.S. Drug Pricing Will Affect the Globe](https://www.eversana.com/?post_type=dlm_download&p=17917) - [Case Study: Early-Stage Asset Valuation](https://www.eversana.com/?post_type=dlm_download&p=17938) - [Trump's "Most-Favored Nations" Rule--2020 Was the Year of Reference Pricing in the United States](https://www.eversana.com/?post_type=dlm_download&p=17947) - [Europe Set to Tackle Its New Pharmaceutical Strategy From 2021](https://www.eversana.com/?post_type=dlm_download&p=17950) - [How Better Alignment Propels Your Brand's Success](https://www.eversana.com/?post_type=dlm_download&p=17970) - [Saudi Arabia Rolls Out New Pricing Guidelines](https://www.eversana.com/?post_type=dlm_download&p=17999) - [Preserving the Value of Mature Brands in the “New Norm”](https://www.eversana.com/?post_type=dlm_download&p=18010) - [Alternative Product Distribution Model: Where Agility Meets Profitability](https://www.eversana.com/?post_type=dlm_download&p=18356) - [China's Fifth Round of VBP Drugs](https://www.eversana.com/?post_type=dlm_download&p=19777) - [Integrated Communication Channels Enhance Customer Engagement and Drive Future Decision-Making](https://www.eversana.com/?post_type=dlm_download&p=20048) - [China VBP 5 Tender Results](https://www.eversana.com/?post_type=dlm_download&p=20877) - [The Patient Access Paradox: How the New CMS Rule Could Prioritize Drug Pricing Before Clinical Decision-Making](https://www.eversana.com/?post_type=dlm_download&p=21134) - [BREAKING THROUGH LAUNCH BARRIERS: Critical Success Factors for Launching Products With Breakthrough Therapy Designation](https://www.eversana.com/?post_type=dlm_download&p=21307) - [The Patient Access Paradox](https://www.eversana.com/?post_type=dlm_download&p=21572) - [DES System - Tissue Compliance](https://www.eversana.com/?post_type=dlm_download&p=21656) - [DES System - FDA Compliance Solutions](https://www.eversana.com/?post_type=dlm_download&p=21662) - [Next Gen Commercialization: Accelerating Patient Access to Life-Changing Therapies](https://www.eversana.com/?post_type=dlm_download&p=21850) - [EVERSANA Patient Hero](https://www.eversana.com/?post_type=dlm_download&p=9140) - [340B-Drug-Pricing-Challenges-and-Best-Practices_EVERSANA_White-Paper.pdf](https://www.eversana.com/?post_type=dlm_download&p=5170) - [Case Study: Launching a New Therapy for HER2-Positive Metastatic Breast Cancer](https://www.eversana.com/?post_type=dlm_download&p=21123) - [EUROPEAN GENERICS PRICING & TENDERING JULY 21](https://www.eversana.com/?post_type=dlm_download&p=20894) - [Engaging Oncology Patients and Providers in the Age of COVID and Beyond](https://www.eversana.com/?post_type=dlm_download&p=20885) - [Expect More From Your Omnichannel Strategy and Investments](https://www.eversana.com/?post_type=dlm_download&p=19438) - [Infographic: Omnichannel for Pharma Manufacturers](https://www.eversana.com/?post_type=dlm_download&p=20035) - [Visualizing EVERSANA's Omnichannel Activation Model](https://www.eversana.com/?post_type=dlm_download&p=19539) - [AUDIT FROM ANYWHERE: UPGRADE YOUR QUALITY SYSTEM AUDIT PROGRAMS](https://www.eversana.com/?post_type=dlm_download&p=19755) - [Precision Medicine and Predictive Action Drive Measurable Impact for Patients](https://www.eversana.com/?post_type=dlm_download&p=19097) - [The Crush: How COVID-19 Is Impacting Mature Brand Revenue & Long-Term Value](https://www.eversana.com/?post_type=dlm_download&p=18456) - [Why Are We Settling for Mediocre Patient Services Programs?](https://www.eversana.com/?post_type=dlm_download&p=13942) - [The Power of Working Together with the Rare Disease Community](https://www.eversana.com/?post_type=dlm_download&p=15795) - [Transforming the Patient Experience](https://www.eversana.com/?post_type=dlm_download&p=15645) - [Patient-Driven PAP Model](https://www.eversana.com/?post_type=dlm_download&p=15393) - [HEOR Programs for Orphan Drugs: Key Activities and Timelines](https://www.eversana.com/?post_type=dlm_download&p=15037) - [Autoimmune Patient Services Best Practices](https://www.eversana.com/?post_type=dlm_download&p=8371) ## Categories - [Eversana](https://www.eversana.com/category/eversana/) - [Press Releases](https://www.eversana.com/category/press-releases/) - [Pricentric One Blog](https://www.eversana.com/category/pricentric-one-blog/) - [Press Coverage](https://www.eversana.com/category/press-coverage/) - [Engage](https://www.eversana.com/category/engage/) - [Careers](https://www.eversana.com/category/careers/) ## Tags - [press release](https://www.eversana.com/tag/press-release/) - [EVERSANA](https://www.eversana.com/tag/eversana/) - [Jim Lang](https://www.eversana.com/tag/jim-lang/) - [Asia Pacific Expansion](https://www.eversana.com/tag/asia-pacific-expansion/) - [Cryoport](https://www.eversana.com/tag/cryoport/) - [gene therapy](https://www.eversana.com/tag/gene-therapy/) - [CAR T-Cell](https://www.eversana.com/tag/car-t-cell/) - [supply chain solutions](https://www.eversana.com/tag/supply-chain-solutions/) - [breakthrough devices](https://www.eversana.com/tag/breakthrough-devices/) - [Brent Vaughan](https://www.eversana.com/tag/brent-vaughan/) - [Cognoa](https://www.eversana.com/tag/cognoa/) - [digital medicine](https://www.eversana.com/tag/digital-medicine/) - [pediatric behavioral health](https://www.eversana.com/tag/pediatric-behavioral-health/) - [3PL](https://www.eversana.com/tag/3pl/) - [Danny Williams](https://www.eversana.com/tag/danny-williams/) - [Channel Management](https://www.eversana.com/tag/channel-management/) - [Distribution](https://www.eversana.com/tag/distribution/) - [VAWD](https://www.eversana.com/tag/vawd/) - [Suzanne Greenwood](https://www.eversana.com/tag/suzanne-greenwood/) - [Greg Skalicky](https://www.eversana.com/tag/greg-skalicky/) - [Oncology](https://www.eversana.com/tag/oncology/) - [Medical Science Liaison](https://www.eversana.com/tag/medical-science-liaison/) - [Careers](https://www.eversana.com/tag/careers/) - [Great Place to Work](https://www.eversana.com/tag/great-place-to-work/) - [Fred Skinner](https://www.eversana.com/tag/fred-skinner/) - [Cornerstone Financial Group](https://www.eversana.com/tag/cornerstone-financial-group/) - [HEOR](https://www.eversana.com/tag/heor/) - [Daniel Grima](https://www.eversana.com/tag/daniel-grima/) - [Chris Cameron](https://www.eversana.com/tag/chris-cameron/) - [Melissa Thompson](https://www.eversana.com/tag/melissa-thompson/) - [EVERSANA ENGAGE](https://www.eversana.com/tag/eversana-engage/) - [Seth Gordon](https://www.eversana.com/tag/seth-gordon/) - [marketing agency](https://www.eversana.com/tag/marketing-agency/) - [EVOKE](https://www.eversana.com/tag/evoke/) - [Gimoti](https://www.eversana.com/tag/gimoti/) - [Innovation](https://www.eversana.com/tag/innovation/) - [Integrated Solutions](https://www.eversana.com/tag/integrated-solutions/) - [EVERSANA CONSULTING](https://www.eversana.com/tag/eversana-consulting/) - [EVERSANA MANAGEMENT CONSULTING](https://www.eversana.com/tag/eversana-management-consulting/) - [revenue management](https://www.eversana.com/tag/revenue-management/) - [management consulting](https://www.eversana.com/tag/management-consulting/) - [Ed Cox](https://www.eversana.com/tag/ed-cox/) - [digital therapeutics](https://www.eversana.com/tag/digital-therapeutics/) - [DTx](https://www.eversana.com/tag/dtx/) - [market access](https://www.eversana.com/tag/market-access/) - [ICER](https://www.eversana.com/tag/icer/) - [HTA](https://www.eversana.com/tag/hta/) - [Pricentric ONE](https://www.eversana.com/tag/pricentric-one/) - [Japan](https://www.eversana.com/tag/japan/) - [Daiichi Sankyo](https://www.eversana.com/tag/daiichi-sankyo/) - [New Drug Application](https://www.eversana.com/tag/new-drug-application/) - [Italy](https://www.eversana.com/tag/italy/) - [COVID-19](https://www.eversana.com/tag/covid-19/) - [AIFA](https://www.eversana.com/tag/aifa/) - [drug supply](https://www.eversana.com/tag/drug-supply/) - [England](https://www.eversana.com/tag/england/) - [PrEP](https://www.eversana.com/tag/prep/) - [NHS England](https://www.eversana.com/tag/nhs-england/) - [HIV](https://www.eversana.com/tag/hiv/) - [Gilead](https://www.eversana.com/tag/gilead/) - [Mylan](https://www.eversana.com/tag/mylan/) - [Vertex](https://www.eversana.com/tag/vertex/) - [Canada](https://www.eversana.com/tag/canada/) - [Cystic Fibrosis](https://www.eversana.com/tag/cystic-fibrosis/) - [reimbursement](https://www.eversana.com/tag/reimbursement/) - [Orphan Drugs](https://www.eversana.com/tag/orphan-drugs/) - [Rare Diseases](https://www.eversana.com/tag/rare-diseases/) - [Brazil](https://www.eversana.com/tag/brazil/) - [ANVISA](https://www.eversana.com/tag/anvisa/) - [Belgium](https://www.eversana.com/tag/belgium/) - [pricing contracts](https://www.eversana.com/tag/pricing-contracts/) - [Transparent Bill](https://www.eversana.com/tag/transparent-bill/) - [United States](https://www.eversana.com/tag/united-states/) - [FDA](https://www.eversana.com/tag/fda/) - [biosimilar](https://www.eversana.com/tag/biosimilar/) - [insulin](https://www.eversana.com/tag/insulin/) - [regulation](https://www.eversana.com/tag/regulation/) - [Denmark](https://www.eversana.com/tag/denmark/) - [Iceland](https://www.eversana.com/tag/iceland/) - [Norway](https://www.eversana.com/tag/norway/) - [Nordic Tendering](https://www.eversana.com/tag/nordic-tendering/) - [generic](https://www.eversana.com/tag/generic/) - [Spain](https://www.eversana.com/tag/spain/) - [centralized purchase](https://www.eversana.com/tag/centralized-purchase/) - [autoimmune diseases](https://www.eversana.com/tag/autoimmune-diseases/) - [immunosuppressants](https://www.eversana.com/tag/immunosuppressants/) - [clinical development](https://www.eversana.com/tag/clinical-development/) - [Ireland](https://www.eversana.com/tag/ireland/) - [IPHA](https://www.eversana.com/tag/ipha/) - [new medicines policy](https://www.eversana.com/tag/new-medicines-policy/) - [drug prices](https://www.eversana.com/tag/drug-prices/) - [NHSA](https://www.eversana.com/tag/nhsa/) - [China](https://www.eversana.com/tag/china/) - [drugs](https://www.eversana.com/tag/drugs/) - [centralized drug purchase](https://www.eversana.com/tag/centralized-drug-purchase/) - [Luxembourg](https://www.eversana.com/tag/luxembourg/) - [Angency for Medicines](https://www.eversana.com/tag/angency-for-medicines/) - [ALMPS](https://www.eversana.com/tag/almps/) - [drug safety](https://www.eversana.com/tag/drug-safety/) - [South Korea](https://www.eversana.com/tag/south-korea/) - [drug approval](https://www.eversana.com/tag/drug-approval/) - [Netherlands](https://www.eversana.com/tag/netherlands/) - [Germany](https://www.eversana.com/tag/germany/) - [e-Prescriptions](https://www.eversana.com/tag/e-prescriptions/) - [drug shortages](https://www.eversana.com/tag/drug-shortages/) - [EU](https://www.eversana.com/tag/eu/) - [European Medicine Agency](https://www.eversana.com/tag/european-medicine-agency/) - [Keytruda](https://www.eversana.com/tag/keytruda/) - [Merck](https://www.eversana.com/tag/merck/) - [PMDA](https://www.eversana.com/tag/pmda/) - [Eli Lilly](https://www.eversana.com/tag/eli-lilly/) - [Novo Nordisk](https://www.eversana.com/tag/novo-nordisk/) - [cancer drugs](https://www.eversana.com/tag/cancer-drugs/) - [AstraZeneca](https://www.eversana.com/tag/astrazeneca/) - [Janssen](https://www.eversana.com/tag/janssen/) - [Brigham Hyde](https://www.eversana.com/tag/brigham-hyde/) - [data analytics](https://www.eversana.com/tag/data-analytics/) - [artificial intelligence](https://www.eversana.com/tag/artificial-intelligence/) - [Concerto HealthAI](https://www.eversana.com/tag/concerto-healthai/) - [Forbes Technology Council](https://www.eversana.com/tag/forbes-technology-council/) - [MIT](https://www.eversana.com/tag/mit/) - [AveXis](https://www.eversana.com/tag/avexis/) - [Novartis](https://www.eversana.com/tag/novartis/) - [Spinal Muscular Atrophy](https://www.eversana.com/tag/spinal-muscular-atrophy/) - [SMA](https://www.eversana.com/tag/sma/) - [Czech Republic](https://www.eversana.com/tag/czech-republic/) - [Kelly Baker](https://www.eversana.com/tag/kelly-baker/) - [CFO](https://www.eversana.com/tag/cfo/) - [OptumRx](https://www.eversana.com/tag/optumrx/) - [eligibility](https://www.eversana.com/tag/eligibility/) - [United Kingdom](https://www.eversana.com/tag/united-kingdom/) - [UK](https://www.eversana.com/tag/uk/) - [clinical trial](https://www.eversana.com/tag/clinical-trial/) - [patient access](https://www.eversana.com/tag/patient-access/) - [inflammatory disease](https://www.eversana.com/tag/inflammatory-disease/) - [ISPOR](https://www.eversana.com/tag/ispor/) - [Ovarian Cancer](https://www.eversana.com/tag/ovarian-cancer/) - [Ethicon](https://www.eversana.com/tag/ethicon/) - [Alcon](https://www.eversana.com/tag/alcon/) - [Europe](https://www.eversana.com/tag/europe/) - [The Netherlands](https://www.eversana.com/tag/the-netherlands/) - [Remdesivir](https://www.eversana.com/tag/remdesivir/) - [EMA](https://www.eversana.com/tag/ema/) - [CAR-T Cells](https://www.eversana.com/tag/car-t-cells/) - [Alleanza Against Cancer](https://www.eversana.com/tag/alleanza-against-cancer/) - [National Health Insurance](https://www.eversana.com/tag/national-health-insurance/) - [Asia Pacific](https://www.eversana.com/tag/asia-pacific/) - [Pharmaceuticals](https://www.eversana.com/tag/pharmaceuticals/) - [drugmakers](https://www.eversana.com/tag/drugmakers/) - [regulations](https://www.eversana.com/tag/regulations/) - [Minnesota](https://www.eversana.com/tag/minnesota/) - [North America](https://www.eversana.com/tag/north-america/) - [ICER review](https://www.eversana.com/tag/icer-review/) - [FDA approval](https://www.eversana.com/tag/fda-approval/) - [Deciphera](https://www.eversana.com/tag/deciphera/) - [Seattle Genetics](https://www.eversana.com/tag/seattle-genetics/) - [healthcare](https://www.eversana.com/tag/healthcare/) - [Finland](https://www.eversana.com/tag/finland/) - [Sweden](https://www.eversana.com/tag/sweden/) - [Nordic](https://www.eversana.com/tag/nordic/) - [vaccine](https://www.eversana.com/tag/vaccine/) - [supply chain](https://www.eversana.com/tag/supply-chain/) - [The Centers for Medicare & Medicaid](https://www.eversana.com/tag/the-centers-for-medicare-medicaid/) - [diabetes](https://www.eversana.com/tag/diabetes/) - [Medicare](https://www.eversana.com/tag/medicare/) - [Medicaid](https://www.eversana.com/tag/medicaid/) - [WHO](https://www.eversana.com/tag/who/) - [Multiple Sclerosis](https://www.eversana.com/tag/multiple-sclerosis/) - [Pfizer](https://www.eversana.com/tag/pfizer/) - [AbbVie](https://www.eversana.com/tag/abbvie/) - [CADTH](https://www.eversana.com/tag/cadth/) - [reference pricing](https://www.eversana.com/tag/reference-pricing/) - [Greece](https://www.eversana.com/tag/greece/) - [BMS](https://www.eversana.com/tag/bms/) - [Bristol-Myers Squibb](https://www.eversana.com/tag/bristol-myers-squibb/) - [immunotherapy](https://www.eversana.com/tag/immunotherapy/) - [priority review](https://www.eversana.com/tag/priority-review/) - [vaccines](https://www.eversana.com/tag/vaccines/) - [National Health System (SNS)](https://www.eversana.com/tag/national-health-system-sns/) - [access](https://www.eversana.com/tag/access/) - [antibiotics](https://www.eversana.com/tag/antibiotics/) - [Genentech](https://www.eversana.com/tag/genentech/) - [Roche](https://www.eversana.com/tag/roche/) - [Amgen](https://www.eversana.com/tag/amgen/) - [Celgene](https://www.eversana.com/tag/celgene/) - [Keytuda](https://www.eversana.com/tag/keytuda/) - [Panama](https://www.eversana.com/tag/panama/) - [Latin America](https://www.eversana.com/tag/latin-america/) - [Australia](https://www.eversana.com/tag/australia/) - [Havas](https://www.eversana.com/tag/havas/) - [data & analytyics](https://www.eversana.com/tag/data-analytyics/) - [big data](https://www.eversana.com/tag/big-data/) - [pharma](https://www.eversana.com/tag/pharma/) - [AI](https://www.eversana.com/tag/ai/) - [machine learning](https://www.eversana.com/tag/machine-learning/) - [Pakistan](https://www.eversana.com/tag/pakistan/) - [Real World Evidence](https://www.eversana.com/tag/real-world-evidence/) - [indirect comparison](https://www.eversana.com/tag/indirect-comparison/) - [Indonisia](https://www.eversana.com/tag/indonisia/) - [National Regulatory Authorities](https://www.eversana.com/tag/national-regulatory-authorities/) - [ASEAN](https://www.eversana.com/tag/asean/) - [AOK](https://www.eversana.com/tag/aok/) - [Health Fund](https://www.eversana.com/tag/health-fund/) - [VBP](https://www.eversana.com/tag/vbp/) - [Value-Based Procurement](https://www.eversana.com/tag/value-based-procurement/) - [vineti](https://www.eversana.com/tag/vineti/) - [cell and gene therapy](https://www.eversana.com/tag/cell-and-gene-therapy/) - [data and analytics](https://www.eversana.com/tag/data-and-analytics/) - [scipher](https://www.eversana.com/tag/scipher/) - [HVH](https://www.eversana.com/tag/hvh/) - [Pediatrics](https://www.eversana.com/tag/pediatrics/) - [PTC Therapeutics](https://www.eversana.com/tag/ptc-therapeutics/) - [Switzerland](https://www.eversana.com/tag/switzerland/) - [SUS](https://www.eversana.com/tag/sus/) - [breast cancer](https://www.eversana.com/tag/breast-cancer/) - [complete commercialization](https://www.eversana.com/tag/complete-commercialization/) - [Christopher Quesenberry](https://www.eversana.com/tag/christopher-quesenberry/) - [India](https://www.eversana.com/tag/india/) - [Cadila Pharmaceuticals](https://www.eversana.com/tag/cadila-pharmaceuticals/) - [cancer](https://www.eversana.com/tag/cancer/) - [insurance](https://www.eversana.com/tag/insurance/) - [Field Solutions](https://www.eversana.com/tag/field-solutions/) - [Alkemy](https://www.eversana.com/tag/alkemy/) - [therapies](https://www.eversana.com/tag/therapies/) - [training & development](https://www.eversana.com/tag/training-development/) - [life sciences](https://www.eversana.com/tag/life-sciences/) - [software](https://www.eversana.com/tag/software/) - [CRM](https://www.eversana.com/tag/crm/) - [PPMA Virtual](https://www.eversana.com/tag/ppma-virtual/) - [palette life sciences](https://www.eversana.com/tag/palette-life-sciences/) - [Solesta](https://www.eversana.com/tag/solesta/) - [digital health](https://www.eversana.com/tag/digital-health/) - [EU28](https://www.eversana.com/tag/eu28/) - [mirum](https://www.eversana.com/tag/mirum/) - [Maralixibat](https://www.eversana.com/tag/maralixibat/) - [integrated deals](https://www.eversana.com/tag/integrated-deals/) - [Symphony](https://www.eversana.com/tag/symphony/) - [Compile](https://www.eversana.com/tag/compile/) - [gene](https://www.eversana.com/tag/gene/) - [Roivant](https://www.eversana.com/tag/roivant/) - [commercialization](https://www.eversana.com/tag/commercialization/) - [datavant](https://www.eversana.com/tag/datavant/) - [ACTICS by EVERSANA](https://www.eversana.com/tag/actics-by-eversana/) - [WorldQuant Predictive](https://www.eversana.com/tag/worldquant-predictive/) - [patient outcomes](https://www.eversana.com/tag/patient-outcomes/) - [patient adherence](https://www.eversana.com/tag/patient-adherence/) - [Bhaskar Sambasivan](https://www.eversana.com/tag/bhaskar-sambasivan/) - [HUB services](https://www.eversana.com/tag/hub-services/) - [salesforce](https://www.eversana.com/tag/salesforce/) - [MacroGenics](https://www.eversana.com/tag/macrogenics/) - [margetuximab](https://www.eversana.com/tag/margetuximab/) - [Scott Koenig](https://www.eversana.com/tag/scott-koenig/) - [safety](https://www.eversana.com/tag/safety/) - [pharmacovigilance](https://www.eversana.com/tag/pharmacovigilance/) - [automation](https://www.eversana.com/tag/automation/) - [ArisGlobal](https://www.eversana.com/tag/arisglobal/) - [compliance](https://www.eversana.com/tag/compliance/) - [Procurement](https://www.eversana.com/tag/procurement/) - [CMO](https://www.eversana.com/tag/cmo/) - [Contract Manufacturing](https://www.eversana.com/tag/contract-manufacturing/) - [Commercial services](https://www.eversana.com/tag/commercial-services/) - [HealthJump](https://www.eversana.com/tag/healthjump/) - [zosano pharma](https://www.eversana.com/tag/zosano-pharma/) - [Qtrypta](https://www.eversana.com/tag/qtrypta/) - [migraines](https://www.eversana.com/tag/migraines/) - [policy](https://www.eversana.com/tag/policy/) - [pricediscrepancies](https://www.eversana.com/tag/pricediscrepancies/) - [nhi](https://www.eversana.com/tag/nhi/) - [mhlw](https://www.eversana.com/tag/mhlw/) - [alamo pharma](https://www.eversana.com/tag/alamo-pharma/) - [peter marchesini](https://www.eversana.com/tag/peter-marchesini/) - [#bio](https://www.eversana.com/tag/bio/) - [#executiveorder](https://www.eversana.com/tag/executiveorder/) - [#hhs](https://www.eversana.com/tag/hhs/) - [#lawsuit](https://www.eversana.com/tag/lawsuit/) - [#mostfavorednations](https://www.eversana.com/tag/mostfavorednations/) - [#referencepricing(irp)](https://www.eversana.com/tag/referencepricingirp/) - [approval](https://www.eversana.com/tag/approval/) - [biontech](https://www.eversana.com/tag/biontech/) - [mhra](https://www.eversana.com/tag/mhra/) - [moderna](https://www.eversana.com/tag/moderna/) - [mrna](https://www.eversana.com/tag/mrna/) - [sars](https://www.eversana.com/tag/sars/) - [Humanigen](https://www.eversana.com/tag/humanigen/) - [lenzilumab](https://www.eversana.com/tag/lenzilumab/) - [Emergency Authorization Usage](https://www.eversana.com/tag/emergency-authorization-usage/) - [antitumor](https://www.eversana.com/tag/antitumor/) - [cardiovascular](https://www.eversana.com/tag/cardiovascular/) - [clinicalpathways](https://www.eversana.com/tag/clinicalpathways/) - [electronicrecordkeeping](https://www.eversana.com/tag/electronicrecordkeeping/) - [healthcosts](https://www.eversana.com/tag/healthcosts/) - [hospitalmanagement](https://www.eversana.com/tag/hospitalmanagement/) - [medicalexaminations](https://www.eversana.com/tag/medicalexaminations/) - [medicalserviceprices](https://www.eversana.com/tag/medicalserviceprices/) - [nhc](https://www.eversana.com/tag/nhc/) - [rationaldruguse](https://www.eversana.com/tag/rationaldruguse/) - [treatmentguidelines](https://www.eversana.com/tag/treatmentguidelines/) - [baizean](https://www.eversana.com/tag/baizean/) - [beigene](https://www.eversana.com/tag/beigene/) - [camrelizumab](https://www.eversana.com/tag/camrelizumab/) - [discount](https://www.eversana.com/tag/discount/) - [junshi](https://www.eversana.com/tag/junshi/) - [nrdl](https://www.eversana.com/tag/nrdl/) - [pd-1](https://www.eversana.com/tag/pd-1/) - [price](https://www.eversana.com/tag/price/) - [shanghai](https://www.eversana.com/tag/shanghai/) - [tuovi](https://www.eversana.com/tag/tuovi/) - [biosimilars](https://www.eversana.com/tag/biosimilars/) - [budgetimpact](https://www.eversana.com/tag/budgetimpact/) - [costeffectiveness](https://www.eversana.com/tag/costeffectiveness/) - [drugcombination](https://www.eversana.com/tag/drugcombination/) - [generics](https://www.eversana.com/tag/generics/) - [innovativedrugs](https://www.eversana.com/tag/innovativedrugs/) - [negotiations](https://www.eversana.com/tag/negotiations/) - [orphandrugs](https://www.eversana.com/tag/orphandrugs/) - [pricereductions](https://www.eversana.com/tag/pricereductions/) - [pricingandreimbursement](https://www.eversana.com/tag/pricingandreimbursement/) - [repricing](https://www.eversana.com/tag/repricing/) - [risksharingagreements](https://www.eversana.com/tag/risksharingagreements/) - [sfda](https://www.eversana.com/tag/sfda/) - [therapeuticalternatives](https://www.eversana.com/tag/therapeuticalternatives/) - [based](https://www.eversana.com/tag/based/) - [chip](https://www.eversana.com/tag/chip/) - [cms](https://www.eversana.com/tag/cms/) - [homehealthcare](https://www.eversana.com/tag/homehealthcare/) - [negotiation](https://www.eversana.com/tag/negotiation/) - [payment](https://www.eversana.com/tag/payment/) - [pbm](https://www.eversana.com/tag/pbm/) - [rebate](https://www.eversana.com/tag/rebate/) - [sdoh](https://www.eversana.com/tag/sdoh/) - [value](https://www.eversana.com/tag/value/) - [cellandgenetherapy](https://www.eversana.com/tag/cellandgenetherapy/) - [earlyaccess](https://www.eversana.com/tag/earlyaccess/) - [innovativedrug](https://www.eversana.com/tag/innovativedrug/) - [paybeck](https://www.eversana.com/tag/paybeck/) - [specialfund](https://www.eversana.com/tag/specialfund/) - [spendingceiling](https://www.eversana.com/tag/spendingceiling/) - [ssn](https://www.eversana.com/tag/ssn/) - [agency](https://www.eversana.com/tag/agency/) - [atmp](https://www.eversana.com/tag/atmp/) - [cell](https://www.eversana.com/tag/cell/) - [commission](https://www.eversana.com/tag/commission/) - [drug](https://www.eversana.com/tag/drug/) - [european](https://www.eversana.com/tag/european/) - [medicines](https://www.eversana.com/tag/medicines/) - [recommendation](https://www.eversana.com/tag/recommendation/) - [outofpocketcosts](https://www.eversana.com/tag/outofpocketcosts/) - [pbms](https://www.eversana.com/tag/pbms/) - [pcma](https://www.eversana.com/tag/pcma/) - [phrma](https://www.eversana.com/tag/phrma/) - [pricechanges](https://www.eversana.com/tag/pricechanges/) - [rebates](https://www.eversana.com/tag/rebates/) - [savings](https://www.eversana.com/tag/savings/) - [senatefinancecommittee](https://www.eversana.com/tag/senatefinancecommittee/) - [asahikasei](https://www.eversana.com/tag/asahikasei/) - [clinicaldata](https://www.eversana.com/tag/clinicaldata/) - [astellas](https://www.eversana.com/tag/astellas/) - [daiichisankyo](https://www.eversana.com/tag/daiichisankyo/) - [databank](https://www.eversana.com/tag/databank/) - [datasamples](https://www.eversana.com/tag/datasamples/) - [eisai](https://www.eversana.com/tag/eisai/) - [immunology](https://www.eversana.com/tag/immunology/) - [inflammation](https://www.eversana.com/tag/inflammation/) - [jpma](https://www.eversana.com/tag/jpma/) - [ncbn](https://www.eversana.com/tag/ncbn/) - [neurology](https://www.eversana.com/tag/neurology/) - [nda](https://www.eversana.com/tag/nda/) - [iterum therapeutics](https://www.eversana.com/tag/iterum-therapeutics/) - [union](https://www.eversana.com/tag/union/) - [bidding](https://www.eversana.com/tag/bidding/) - [bmi](https://www.eversana.com/tag/bmi/) - [centralizedprocurement](https://www.eversana.com/tag/centralizedprocurement/) - [gqce](https://www.eversana.com/tag/gqce/) - [hospital](https://www.eversana.com/tag/hospital/) - [purchaseagreement](https://www.eversana.com/tag/purchaseagreement/) - [volumebasedprocurement](https://www.eversana.com/tag/volumebasedprocurement/) - [acquisitions](https://www.eversana.com/tag/acquisitions/) - [addedvalue](https://www.eversana.com/tag/addedvalue/) - [blockbusterdrugs](https://www.eversana.com/tag/blockbusterdrugs/) - [domesticproduction](https://www.eversana.com/tag/domesticproduction/) - [drugsupply](https://www.eversana.com/tag/drugsupply/) - [industrialliaisonprogram](https://www.eversana.com/tag/industrialliaisonprogram/) - [kpbma](https://www.eversana.com/tag/kpbma/) - [mergers](https://www.eversana.com/tag/mergers/) - [r&d](https://www.eversana.com/tag/rd/) - [action](https://www.eversana.com/tag/action/) - [care](https://www.eversana.com/tag/care/) - [life](https://www.eversana.com/tag/life/) - [of](https://www.eversana.com/tag/of/) - [aria](https://www.eversana.com/tag/aria/) - [consip](https://www.eversana.com/tag/consip/) - [sintelplatform](https://www.eversana.com/tag/sintelplatform/) - [g-ba](https://www.eversana.com/tag/g-ba/) - [pricing](https://www.eversana.com/tag/pricing/) - [rwd](https://www.eversana.com/tag/rwd/) - [rwe](https://www.eversana.com/tag/rwe/) - [zolgensma](https://www.eversana.com/tag/zolgensma/) - [monitoring](https://www.eversana.com/tag/monitoring/) - [340bprogram](https://www.eversana.com/tag/340bprogram/) - [consolidation](https://www.eversana.com/tag/consolidation/) - [healthplans](https://www.eversana.com/tag/healthplans/) - [healthstrategiesinsights](https://www.eversana.com/tag/healthstrategiesinsights/) - [hospitals](https://www.eversana.com/tag/hospitals/) - [markups](https://www.eversana.com/tag/markups/) - [outpatientsetting](https://www.eversana.com/tag/outpatientsetting/) - [prescriptiondrug](https://www.eversana.com/tag/prescriptiondrug/) - [pricetransparency](https://www.eversana.com/tag/pricetransparency/) - [comirnaty](https://www.eversana.com/tag/comirnaty/) - [initiative](https://www.eversana.com/tag/initiative/) - [johnson](https://www.eversana.com/tag/johnson/) - [pre](https://www.eversana.com/tag/pre/) - [purchase](https://www.eversana.com/tag/purchase/) - [africa](https://www.eversana.com/tag/africa/) - [coronavirus](https://www.eversana.com/tag/coronavirus/) - [covid](https://www.eversana.com/tag/covid/) - [dosing](https://www.eversana.com/tag/dosing/) - [schedule](https://www.eversana.com/tag/schedule/) - [real word data](https://www.eversana.com/tag/real-word-data/) - [chronic disease](https://www.eversana.com/tag/chronic-disease/) - [patient services](https://www.eversana.com/tag/patient-services/) - [Eyenovia](https://www.eversana.com/tag/eyenovia/) - [ophthalmic](https://www.eversana.com/tag/ophthalmic/) - [PDUFA](https://www.eversana.com/tag/pdufa/) - [COMPLETE E](https://www.eversana.com/tag/complete-e/) - [krista](https://www.eversana.com/tag/krista/) - [pinto](https://www.eversana.com/tag/pinto/) - [leadership](https://www.eversana.com/tag/leadership/) - [hall of femme](https://www.eversana.com/tag/hall-of-femme/) - [Douglas Foerster](https://www.eversana.com/tag/douglas-foerster/) - [Charles Moun](https://www.eversana.com/tag/charles-moun/) - [Mark Mulder](https://www.eversana.com/tag/mark-mulder/) - [Global Products](https://www.eversana.com/tag/global-products/) - [Lupin](https://www.eversana.com/tag/lupin/) - [Biotech](https://www.eversana.com/tag/biotech/) - [Phase 3](https://www.eversana.com/tag/phase-3/) - [Cart-t](https://www.eversana.com/tag/cart-t/) - [PM360 ELite](https://www.eversana.com/tag/pm360-elite/) - [awards](https://www.eversana.com/tag/awards/) - [thenetworkone](https://www.eversana.com/tag/thenetworkone/) - [london](https://www.eversana.com/tag/london/) - [marketing services](https://www.eversana.com/tag/marketing-services/) - [European expansion](https://www.eversana.com/tag/european-expansion/) - [MedRythms](https://www.eversana.com/tag/medrythms/) - [chronic stroke walking deficits](https://www.eversana.com/tag/chronic-stroke-walking-deficits/) - [MR-001](https://www.eversana.com/tag/mr-001/) - [Owen McCarthy](https://www.eversana.com/tag/owen-mccarthy/) - [S3 Connect](https://www.eversana.com/tag/s3-connect/) - [Mike Ryan](https://www.eversana.com/tag/mike-ryan/) - [EVERSANA COMPLETE Commercialization](https://www.eversana.com/tag/eversana-complete-commercialization/) - [apabetalone](https://www.eversana.com/tag/apabetalone/) - [GENinCode](https://www.eversana.com/tag/genincode/) - [cardiovascular disease](https://www.eversana.com/tag/cardiovascular-disease/) - [compliance services](https://www.eversana.com/tag/compliance-services/) - [medical information](https://www.eversana.com/tag/medical-information/) - [PharmaD](https://www.eversana.com/tag/pharmad/) - [evoke pharma](https://www.eversana.com/tag/evoke-pharma/) - [gastrointestinal](https://www.eversana.com/tag/gastrointestinal/) - [Accelera Canada](https://www.eversana.com/tag/accelera-canada/) - [Gastroparesis Awareness Month](https://www.eversana.com/tag/gastroparesis-awareness-month/) - [Shorla](https://www.eversana.com/tag/shorla/) - [leukemia](https://www.eversana.com/tag/leukemia/) - [SH-111](https://www.eversana.com/tag/sh-111/) - [T-cell leukemia](https://www.eversana.com/tag/t-cell-leukemia/) - [PharmaVOICE](https://www.eversana.com/tag/pharmavoice/) - [Digital Therapeutics Alliance](https://www.eversana.com/tag/digital-therapeutics-alliance/) - [PM360](https://www.eversana.com/tag/pm360/) - [MI](https://www.eversana.com/tag/mi/) - [phactMI](https://www.eversana.com/tag/phactmi/) - [Pharma Collaboration for Transparent Medical Information](https://www.eversana.com/tag/pharma-collaboration-for-transparent-medical-information/) - [Corporate Partner membership](https://www.eversana.com/tag/corporate-partner-membership/) - [U.S.](https://www.eversana.com/tag/u-s/) - [MINDPAX](https://www.eversana.com/tag/mindpax/) - [Bipolar Disease](https://www.eversana.com/tag/bipolar-disease/) - [Bipolar Disorder](https://www.eversana.com/tag/bipolar-disorder/) - [Protean](https://www.eversana.com/tag/protean/) - [Merger](https://www.eversana.com/tag/merger/) - [acquisition](https://www.eversana.com/tag/acquisition/) - [Intouch](https://www.eversana.com/tag/intouch/) - [Intouch Group](https://www.eversana.com/tag/intouch-group/) - [M&A](https://www.eversana.com/tag/ma/) - [full-service agency](https://www.eversana.com/tag/full-service-agency/) - [EUCOPE](https://www.eversana.com/tag/eucope/) - [European Confederation of Pharmaceutical Entrepreneurs](https://www.eversana.com/tag/european-confederation-of-pharmaceutical-entrepreneurs/) - [European Union](https://www.eversana.com/tag/european-union/) - [Q BioMed](https://www.eversana.com/tag/q-biomed/) - [cancer bone palliation radiotherapy](https://www.eversana.com/tag/cancer-bone-palliation-radiotherapy/) - [Artrya](https://www.eversana.com/tag/artrya/) - [CT scans](https://www.eversana.com/tag/ct-scans/) - [coronary artery disease](https://www.eversana.com/tag/coronary-artery-disease/) - [cardiac](https://www.eversana.com/tag/cardiac/) - [PM360 Innovations Award](https://www.eversana.com/tag/pm360-innovations-award/) - [Most Innovative Strategy](https://www.eversana.com/tag/most-innovative-strategy/) - [EVERSANA's Omnichannel Activation Model](https://www.eversana.com/tag/eversanas-omnichannel-activation-model/) - [Real-world data](https://www.eversana.com/tag/real-world-data/) - [OWP Pharmaceuticals](https://www.eversana.com/tag/owp-pharmaceuticals/) - [neuroscience disorders](https://www.eversana.com/tag/neuroscience-disorders/) - [Dave Goyer](https://www.eversana.com/tag/dave-goyer/) - [data ana](https://www.eversana.com/tag/data-ana/) - [integra connect](https://www.eversana.com/tag/integra-connect/) - [EHR](https://www.eversana.com/tag/ehr/) - [THREAD](https://www.eversana.com/tag/thread/) - [ACTICS](https://www.eversana.com/tag/actics/) - [John Reites](https://www.eversana.com/tag/john-reites/) - [Vault Top Rankings](https://www.eversana.com/tag/vault-top-rankings/) - [NAVLIN](https://www.eversana.com/tag/navlin/) - [Global Pricing](https://www.eversana.com/tag/global-pricing/) - [Health Strategies Insights](https://www.eversana.com/tag/health-strategies-insights/) - [PriceRight](https://www.eversana.com/tag/priceright/) - [UpScript Health](https://www.eversana.com/tag/upscript-health/) - [Digital Transformation](https://www.eversana.com/tag/digital-transformation/) - [patient journey](https://www.eversana.com/tag/patient-journey/) - [telehealth](https://www.eversana.com/tag/telehealth/) - [commercialisation](https://www.eversana.com/tag/commercialisation/) - [Vector Pharma](https://www.eversana.com/tag/vector-pharma/) - [EMEA](https://www.eversana.com/tag/emea/) - [Amy Peek](https://www.eversana.com/tag/amy-peek/) - [Nicholas Capanear](https://www.eversana.com/tag/nicholas-capanear/) - [ELITE Winners](https://www.eversana.com/tag/elite-winners/) - [Creative Agency](https://www.eversana.com/tag/creative-agency/) - [Field Deployment](https://www.eversana.com/tag/field-deployment/) - [Limitless Minds](https://www.eversana.com/tag/limitless-minds/) - [Russell Wilson](https://www.eversana.com/tag/russell-wilson/) - [Behavioral Assessments](https://www.eversana.com/tag/behavioral-assessments/) - [recruitment](https://www.eversana.com/tag/recruitment/) - [LIving Well](https://www.eversana.com/tag/living-well/) - [Prosoma](https://www.eversana.com/tag/prosoma/) - [Nemaura](https://www.eversana.com/tag/nemaura/) - [complete](https://www.eversana.com/tag/complete/) - [hiring](https://www.eversana.com/tag/hiring/) - [jobs](https://www.eversana.com/tag/jobs/) - [national hispanic heritage month](https://www.eversana.com/tag/national-hispanic-heritage-month/) - [Patient Minded](https://www.eversana.com/tag/patient-minded/) - [Vishal Wable](https://www.eversana.com/tag/vishal-wable/) - [data](https://www.eversana.com/tag/data/) - [JP Morgan Healthcare](https://www.eversana.com/tag/jp-morgan-healthcare/) - [Complete Commerci](https://www.eversana.com/tag/complete-commerci/) - [Martin Luther King Jr. Day](https://www.eversana.com/tag/martin-luther-king-jr-day/) - [Eric Terry](https://www.eversana.com/tag/eric-terry/) - [Embrace Diversity](https://www.eversana.com/tag/embrace-diversity/) - [Cultural Beliefs](https://www.eversana.com/tag/cultural-beliefs/) - [Deployment Solutions](https://www.eversana.com/tag/deployment-solutions/) - [Sean O'Connor](https://www.eversana.com/tag/sean-oconnor/) - [career](https://www.eversana.com/tag/career/) - [pharmaceutical sales](https://www.eversana.com/tag/pharmaceutical-sales/) - [training](https://www.eversana.com/tag/training/) - [learning](https://www.eversana.com/tag/learning/) - [development](https://www.eversana.com/tag/development/) - [Black History Month](https://www.eversana.com/tag/black-history-month/) - [Diversity](https://www.eversana.com/tag/diversity/) - [Equity](https://www.eversana.com/tag/equity/) - [Inclusion](https://www.eversana.com/tag/inclusion/) - [DEI](https://www.eversana.com/tag/dei/) - [Heather Rae Martin](https://www.eversana.com/tag/heather-rae-martin/) - [Ashley Washington](https://www.eversana.com/tag/ashley-washington/) - [Jeanetta Wafford](https://www.eversana.com/tag/jeanetta-wafford/) - [O'Brian Shaw](https://www.eversana.com/tag/obrian-shaw/) - [Nicole McCann-Davis](https://www.eversana.com/tag/nicole-mccann-davis/) - [Von Myart](https://www.eversana.com/tag/von-myart/) - [Mychal Yisrael](https://www.eversana.com/tag/mychal-yisrael/) - [Digestive Disease Week](https://www.eversana.com/tag/digestive-disease-week/) - [Xspray Pharma](https://www.eversana.com/tag/xspray-pharma/) - [Anna Smith](https://www.eversana.com/tag/anna-smith/) - [NAVLIN Daily](https://www.eversana.com/tag/navlin-daily/) - [journalism](https://www.eversana.com/tag/journalism/) - [NICE](https://www.eversana.com/tag/nice/) - [ATMPs](https://www.eversana.com/tag/atmps/) - [EUnetHTA](https://www.eversana.com/tag/eunethta/) - [price transparency](https://www.eversana.com/tag/price-transparency/) - [inflation policies](https://www.eversana.com/tag/inflation-policies/) - [apac](https://www.eversana.com/tag/apac/) - [Career Blog](https://www.eversana.com/tag/career-blog/) - [Consulting](https://www.eversana.com/tag/consulting/) - [Chemomouthpiece](https://www.eversana.com/tag/chemomouthpiece/) - [Hodgkin's Lymphoma](https://www.eversana.com/tag/hodgkins-lymphoma/) - [Breakthrough Device Designation](https://www.eversana.com/tag/breakthrough-device-designation/) - [Crystal Merklin](https://www.eversana.com/tag/crystal-merklin/) - [global logistics](https://www.eversana.com/tag/global-logistics/) - [Outsourced Solutions](https://www.eversana.com/tag/outsourced-solutions/) - [nurse](https://www.eversana.com/tag/nurse/) - [clinical nurse coordinator](https://www.eversana.com/tag/clinical-nurse-coordinator/) - [Carla Yorro](https://www.eversana.com/tag/carla-yorro/) - [national nurses week](https://www.eversana.com/tag/national-nurses-week/) - [international nurses day](https://www.eversana.com/tag/international-nurses-day/) - [DDW](https://www.eversana.com/tag/ddw/) - [acute lymphoblastic leukemia](https://www.eversana.com/tag/acute-lymphoblastic-leukemia/) - [Elizabeth Rooney](https://www.eversana.com/tag/elizabeth-rooney/) - [Julie Quarcini](https://www.eversana.com/tag/julie-quarcini/) - [EVERSANA INTOUCH](https://www.eversana.com/tag/eversana-intouch/) - [Angela Fukuda](https://www.eversana.com/tag/angela-fukuda/) - [Asian American Pacific Islander Heritage Month](https://www.eversana.com/tag/asian-american-pacific-islander-heritage-month/) - [AAPI](https://www.eversana.com/tag/aapi/) - [AAPI Month](https://www.eversana.com/tag/aapi-month/) - [Yaral Pharma](https://www.eversana.com/tag/yaral-pharma/) - [Renalytix](https://www.eversana.com/tag/renalytix/) - [kidney disease](https://www.eversana.com/tag/kidney-disease/) - [KidneyIntelX](https://www.eversana.com/tag/kidneyintelx/) - [China Resources Pharmaceutical Group](https://www.eversana.com/tag/china-resources-pharmaceutical-group/) - [Clios Award](https://www.eversana.com/tag/clios-award/) - [Eras the Line](https://www.eversana.com/tag/eras-the-line/) - [Cannes](https://www.eversana.com/tag/cannes/) - [Creativity](https://www.eversana.com/tag/creativity/) - [Aster Kaltmayer](https://www.eversana.com/tag/aster-kaltmayer/) - [Michael Tatasciore](https://www.eversana.com/tag/michael-tatasciore/) - [Mark Arnold](https://www.eversana.com/tag/mark-arnold/) - [David Lando](https://www.eversana.com/tag/david-lando/) - [Amazon](https://www.eversana.com/tag/amazon/) - [Mary Harbin](https://www.eversana.com/tag/mary-harbin/) - [Program Management](https://www.eversana.com/tag/program-management/) - [patient centered](https://www.eversana.com/tag/patient-centered/) - [plenary session](https://www.eversana.com/tag/plenary-session/) - [dave gonyer](https://www.eversana.com/tag/dave-gonyer/) - [Ramaa Nathan](https://www.eversana.com/tag/ramaa-nathan/) - [boomerang](https://www.eversana.com/tag/boomerang/) - [omnichannel](https://www.eversana.com/tag/omnichannel/) - [EVERSANA ORCHESTRATE](https://www.eversana.com/tag/eversana-orchestrate/) - [medical access](https://www.eversana.com/tag/medical-access/) - [pharmacy](https://www.eversana.com/tag/pharmacy/) - [specialty pharmacy](https://www.eversana.com/tag/specialty-pharmacy/) - [pharmacy warehouse](https://www.eversana.com/tag/pharmacy-warehouse/) - [warehouse](https://www.eversana.com/tag/warehouse/) - [warehouse operations](https://www.eversana.com/tag/warehouse-operations/) - [PharmaVoice 100](https://www.eversana.com/tag/pharmavoice-100/) - [Sy Pretorius](https://www.eversana.com/tag/sy-pretorius/) - [Healthware](https://www.eversana.com/tag/healthware/) - [Frontiers Health](https://www.eversana.com/tag/frontiers-health/) - [National Disability Employment Awareness Month](https://www.eversana.com/tag/national-disability-employment-awareness-month/) - [disability](https://www.eversana.com/tag/disability/) - [NDEAM](https://www.eversana.com/tag/ndeam/) - [Joan Oldham](https://www.eversana.com/tag/joan-oldham/) - [Emelia Patterson](https://www.eversana.com/tag/emelia-patterson/) - [Diveristy](https://www.eversana.com/tag/diveristy/) - [Kevin Klitz](https://www.eversana.com/tag/kevin-klitz/) - [Culture](https://www.eversana.com/tag/culture/) - [Awareness](https://www.eversana.com/tag/awareness/) - [Christina Christos](https://www.eversana.com/tag/christina-christos/) - [Heather Christensen](https://www.eversana.com/tag/heather-christensen/) - [Nicole Ferko](https://www.eversana.com/tag/nicole-ferko/) - [Ryan Clarke](https://www.eversana.com/tag/ryan-clarke/) - [Denis Francis](https://www.eversana.com/tag/denis-francis/) - [Gulafsha Bhat](https://www.eversana.com/tag/gulafsha-bhat/) - [Tianshu Liu](https://www.eversana.com/tag/tianshu-liu/) - [Ryan Thai Minh Long](https://www.eversana.com/tag/ryan-thai-minh-long/) - [Twinkle Soni](https://www.eversana.com/tag/twinkle-soni/) - [Magdalena Rudnikowska](https://www.eversana.com/tag/magdalena-rudnikowska/) - [philanthropy](https://www.eversana.com/tag/philanthropy/) - [give back](https://www.eversana.com/tag/give-back/) - [community](https://www.eversana.com/tag/community/) - [holidays](https://www.eversana.com/tag/holidays/) - [toy drive](https://www.eversana.com/tag/toy-drive/) - [fooddrive](https://www.eversana.com/tag/fooddrive/) - [vault](https://www.eversana.com/tag/vault/) - [Top Employer](https://www.eversana.com/tag/top-employer/) - [Rare Disease](https://www.eversana.com/tag/rare-disease/) - [Rare Disease Day](https://www.eversana.com/tag/rare-disease-day/) - [Penny Bemus](https://www.eversana.com/tag/penny-bemus/) - [Beyond the Diagnosis](https://www.eversana.com/tag/beyond-the-diagnosis/) - [Tonix Pharma](https://www.eversana.com/tag/tonix-pharma/) - [Faruk Abdullah](https://www.eversana.com/tag/faruk-abdullah/) - [Staista](https://www.eversana.com/tag/staista/) - [Pharmaceutical Consulting](https://www.eversana.com/tag/pharmaceutical-consulting/) - [AI Excellence Award](https://www.eversana.com/tag/ai-excellence-award/) - [AWS](https://www.eversana.com/tag/aws/) - [Women's History Month](https://www.eversana.com/tag/womens-history-month/) - [International Women's Day](https://www.eversana.com/tag/international-womens-day/) - [Women Leadership](https://www.eversana.com/tag/women-leadership/) - [Women Leaders](https://www.eversana.com/tag/women-leaders/) - [pharmaphorum](https://www.eversana.com/tag/pharmaphorum/) - [aanhpi](https://www.eversana.com/tag/aanhpi/) - [asian american](https://www.eversana.com/tag/asian-american/) - [pacific islander](https://www.eversana.com/tag/pacific-islander/) - [native hawaiian](https://www.eversana.com/tag/native-hawaiian/) - [heritage](https://www.eversana.com/tag/heritage/) - [Lupus](https://www.eversana.com/tag/lupus/) - [Patients](https://www.eversana.com/tag/patients/) - [Diabetic Gastroparesis](https://www.eversana.com/tag/diabetic-gastroparesis/) - [TEDAVI](https://www.eversana.com/tag/tedavi/) - [Faruk Capan](https://www.eversana.com/tag/faruk-capan/) - [Angela Tenuta](https://www.eversana.com/tag/angela-tenuta/) - [ConTIPI](https://www.eversana.com/tag/contipi/) - [women's health](https://www.eversana.com/tag/womens-health/) - [ProVate](https://www.eversana.com/tag/provate/) - [Berlin](https://www.eversana.com/tag/berlin/) - [Global](https://www.eversana.com/tag/global/) - [Expansion](https://www.eversana.com/tag/expansion/) - [Oracle](https://www.eversana.com/tag/oracle/) - [PV](https://www.eversana.com/tag/pv/) - [Hispanic Heritage Month](https://www.eversana.com/tag/hispanic-heritage-month/) - [Memphis](https://www.eversana.com/tag/memphis/) - [Great Plac t](https://www.eversana.com/tag/great-plac-t/) - [Workplace](https://www.eversana.com/tag/workplace/) - [accommodations](https://www.eversana.com/tag/accommodations/) - [value and evidence](https://www.eversana.com/tag/value-and-evidence/) - [v&e](https://www.eversana.com/tag/ve/) - [strategic planning](https://www.eversana.com/tag/strategic-planning/) - [medical](https://www.eversana.com/tag/medical/) - [poland](https://www.eversana.com/tag/poland/) - [URAC](https://www.eversana.com/tag/urac/) - [medical regulatory review](https://www.eversana.com/tag/medical-regulatory-review/) - [Modus Create](https://www.eversana.com/tag/modus-create/) - [Iterum](https://www.eversana.com/tag/iterum/) - [ORLYNVAHT](https://www.eversana.com/tag/orlynvaht/) - [Waltz Health](https://www.eversana.com/tag/waltz-health/) - [Mark Thierer](https://www.eversana.com/tag/mark-thierer/) - [Xcovery](https://www.eversana.com/tag/xcovery/) - [ENSACOVE](https://www.eversana.com/tag/ensacove/) - [ensartinib](https://www.eversana.com/tag/ensartinib/) - [NSCLC](https://www.eversana.com/tag/nsclc/) - [ALK inhibitor](https://www.eversana.com/tag/alk-inhibitor/) - [Candel Therapeutics](https://www.eversana.com/tag/candel-therapeutics/) - [Aglatimagene besadenovec](https://www.eversana.com/tag/aglatimagene-besadenovec/) - [Gene-based therapies](https://www.eversana.com/tag/gene-based-therapies/) - [Prostate Cancer](https://www.eversana.com/tag/prostate-cancer/) - [Mike Guarino](https://www.eversana.com/tag/mike-guarino/) - [healthcare marketing](https://www.eversana.com/tag/healthcare-marketing/) - [life sciences marketing](https://www.eversana.com/tag/life-sciences-marketing/) - [Jen Norton](https://www.eversana.com/tag/jen-norton/) ## Agendas - [Account Access](https://www.eversana.com/research_agendas/account-access/) - [Brand Access](https://www.eversana.com/research_agendas/brand-access/) - [Market Access](https://www.eversana.com/research_agendas/market-access/) - [Patient Access](https://www.eversana.com/research_agendas/patient-access/) ## Authors - [Faruk Abdullah](https://www.eversana.com/insights_authors/faruk-abdullah/) - [Penny Bemus](https://www.eversana.com/insights_authors/penny-bemus/) - [Jim Burke](https://www.eversana.com/insights_authors/jim-burke__trashed/) - [Alan Crowther](https://www.eversana.com/insights_authors/alan-crowther/) - [Sean Rapson](https://www.eversana.com/insights_authors/sean-rapson/) - [Danny Williams](https://www.eversana.com/insights_authors/danny-williams/) - [Leana Wood](https://www.eversana.com/insights_authors/leana-wood/) - [Robert Blank](https://www.eversana.com/insights_authors/robert-blank/) - [Chris Lagoeiro](https://www.eversana.com/insights_authors/chris-lagoeiro/) - [Andrew Hanhauser](https://www.eversana.com/insights_authors/andrew-hanhauser/) - [Michael Kurland](https://www.eversana.com/insights_authors/michael-kurland/) - [Krista Pinto](https://www.eversana.com/insights_authors/krista-pinto/) - [Suzanne Greenwood, RN, BSN](https://www.eversana.com/insights_authors/suzanne-greenwood-rn-bsn__trashed/) - [Mike Ryan](https://www.eversana.com/insights_authors/mike-ryan/) - [Chris Cameron, PhD](https://www.eversana.com/insights_authors/chris-cameron-phd/) - [Nicole Ferko](https://www.eversana.com/insights_authors/nicole-ferko/) - [Heather Cameron, PhD](https://www.eversana.com/insights_authors/heather-cameron-phd/) - [Vikram Anand](https://www.eversana.com/insights_authors/vikram-anand/) - [Chad McAuliffe](https://www.eversana.com/insights_authors/chad-mcauliffe/) - [Maria Kirsch](https://www.eversana.com/insights_authors/maria-kirsch/) - [Tanuj Mehra](https://www.eversana.com/insights_authors/tanuj-mehra/) - [Carolyn Quon, PharmD](https://www.eversana.com/insights_authors/carolyn-quon-pharmd/) - [Jim Charnetski](https://www.eversana.com/insights_authors/jim-charnetski/) - [Maneesh Gupta](https://www.eversana.com/insights_authors/maneesh-gupta/) - [Jennifer Bartosh](https://www.eversana.com/insights_authors/jennifer-bartosh/) - [Katya Svoboda](https://www.eversana.com/insights_authors/katya-svoboda/) - [Mike deLaroche](https://www.eversana.com/insights_authors/mike-delaroche/) - [Anne Marie Robertson](https://www.eversana.com/insights_authors/anne-marie-robertson/) - [Matt Doyle](https://www.eversana.com/insights_authors/matt-doyle/) - [Tim Healey](https://www.eversana.com/insights_authors/tim-healey/) - [Susan Giacalone, MSN, BCMAS, MSL-BC](https://www.eversana.com/insights_authors/susan-giacalone-msn-bcmas-msl-bc/) - [Chris Quesenberry](https://www.eversana.com/insights_authors/chris-quesenberry/) - [Andrew Therrien, PhD](https://www.eversana.com/insights_authors/andrew-therrien-phd/) - [Ryan Clarke, LL.B](https://www.eversana.com/insights_authors/ryan-clarke-ll-b/) - [Christine Malmberg](https://www.eversana.com/insights_authors/christine-malmberg/) - [Kamalpreet Mann](https://www.eversana.com/insights_authors/kamalpreet-mann/) - [David Frey](https://www.eversana.com/insights_authors/david-frey/) - [John Chatas](https://www.eversana.com/insights_authors/john-chatas/) - [Paul Maurer](https://www.eversana.com/insights_authors/paul-maurer/) - [Adam Hardy](https://www.eversana.com/insights_authors/adam-hardy/) - [Joshua Gauci](https://www.eversana.com/insights_authors/joshua-gauci/) - [Hai Nguyen](https://www.eversana.com/insights_authors/hai-nguyen/) - [Michael DeLuca](https://www.eversana.com/insights_authors/michael-deluca/) - [Pierantonio Russo, MD, FCPP, FAAP, STS](https://www.eversana.com/insights_authors/pierantonio-russo-md-fcpp-faap-sts/) - [Ramaa Nathan, PhD](https://www.eversana.com/insights_authors/ramaa-nathan-phd/) - [Kory Dillman](https://www.eversana.com/insights_authors/kory-dillman/) - [Gregory Skalicky](https://www.eversana.com/insights_authors/greg-skalicky/) - [Xavier Aparicio](https://www.eversana.com/insights_authors/xavier-aparicio/) - [Susan GiacaloneMSN, BCMAS, MSL-BC](https://www.eversana.com/insights_authors/susan-giacalonemsn-bcmas-msl-bc/) - [Marshall Kemp](https://www.eversana.com/insights_authors/marshall-kemp__trashed/) - [Barry Vucsko](https://www.eversana.com/insights_authors/barry-vucsko__trashed/) - [Nick Rambke](https://www.eversana.com/insights_authors/nick-rambke__trashed/) - [Paolo Correale](https://www.eversana.com/insights_authors/paolo-correale/) - [Erion Lipo](https://www.eversana.com/insights_authors/erion-lipo/) - [Justin Averback](https://www.eversana.com/insights_authors/justin-averback/) - [Lisa Stafford](https://www.eversana.com/insights_authors/lisa-stafford/) - [Keyla Badillo, PhD](https://www.eversana.com/insights_authors/keyla-badillo-phd/) - [Faruk Capan](https://www.eversana.com/insights_authors/faruk-capan/) - [Jonathan Vu](https://www.eversana.com/insights_authors/jonathan-vu/) - [Faruk Capan](https://www.eversana.com/insights_authors/38661/) - [Megan Bourque, PhD](https://www.eversana.com/insights_authors/megan-bourque-phd/) - [Andrew Grojean](https://www.eversana.com/insights_authors/andrew-grojean/) - [Dianna Cohen](https://www.eversana.com/insights_authors/39126/) - [Imtiaz Samjoo](https://www.eversana.com/insights_authors/imtiaz-samjoo/) - [George Wright](https://www.eversana.com/insights_authors/george-wright/) - [Kerem Can Alp](https://www.eversana.com/insights_authors/kerem-can-alp/) - [Ariel Salmang](https://www.eversana.com/insights_authors/ariel-salmang/) - [Dr. Vivek Ahuja](https://www.eversana.com/insights_authors/dr-vivek-ahuja/) - [Barry Vucsko](https://www.eversana.com/insights_authors/40028/) - [Nick Rambke](https://www.eversana.com/insights_authors/nick-rambke-2/) - [Sharon Donofrio](https://www.eversana.com/insights_authors/sharon-donofrio/) - [Timothy Bass](https://www.eversana.com/insights_authors/40367/) - [Sumeet Singh](https://www.eversana.com/insights_authors/sumeet-singh/) - [Vivek Ahuja](https://www.eversana.com/insights_authors/vivek-ahuja/) - [Kristen Reilly](https://www.eversana.com/insights_authors/kristen-reilly/) - [Amanda Samuels](https://www.eversana.com/insights_authors/amanda-samuels/) - [Ryan H. Brown](https://www.eversana.com/insights_authors/ryan-h-brown/) - [Kirk Szafranski](https://www.eversana.com/insights_authors/kirk-szafranski/) - [Dr. Daniel Tisak](https://www.eversana.com/insights_authors/dr-daniel-tisak/) - [Keith Steward](https://www.eversana.com/insights_authors/keith-steward/) - [Mike Webster](https://www.eversana.com/insights_authors/mike-webster/) - [Aaron Uydess](https://www.eversana.com/insights_authors/aaron-uydess/) - [Varun Pandey, PhD](https://www.eversana.com/insights_authors/varun-pandey-phd/) - [Lindsey Buyskes, B Pharm](https://www.eversana.com/insights_authors/lindsey-buyskes-b-pharm/) - [Abid Rahman](https://www.eversana.com/insights_authors/abid-rahman/) - [Shivani Shah](https://www.eversana.com/insights_authors/43386/) - [Natalie Rush](https://www.eversana.com/insights_authors/natalie-rush/) - [Anja Haltner, MSc](https://www.eversana.com/insights_authors/anja-haltner-msc/) - [Becky Hooper](https://www.eversana.com/insights_authors/becky-hooper/) - [Ben Gauthier](https://www.eversana.com/insights_authors/ben-gauthier/) - [Emily Rosta, MSc](https://www.eversana.com/insights_authors/emily-rosta-msc/) - [Austin Lansing](https://www.eversana.com/insights_authors/austin-lansing/) - [Kevin Yin](https://www.eversana.com/insights_authors/kevin-yin/) - [Narayan Tripathi](https://www.eversana.com/insights_authors/narayan-tripathi/) - [Jordan Schell](https://www.eversana.com/insights_authors/jordan-schell/) - [Sneha Varma](https://www.eversana.com/insights_authors/sneha-varma/) - [Mary Mehrabian, PharmD, BCGP, BCMAS](https://www.eversana.com/insights_authors/mary-mehrabian-pharmd-bcgp-bcmas/) - [Joey Pecoraro](https://www.eversana.com/insights_authors/joey-pecoraro/) - [Calvin Fujimoto](https://www.eversana.com/insights_authors/calvin-fujimoto/) - [Alberta Spreafico, Ph.D, MBA](https://www.eversana.com/insights_authors/alberta-spreafico-ph-d-mba/) - [Pamela Vo](https://www.eversana.com/insights_authors/pamela-vo/) - [Deepika Thakur](https://www.eversana.com/insights_authors/deepika-thakur/) - [Aidian Dineen](https://www.eversana.com/insights_authors/aidian-dineen/) - [Lisa Kaindl](https://www.eversana.com/insights_authors/lisa-kaindl/) - [Leena Patel](https://www.eversana.com/insights_authors/leena-patel/) - [Sean Sweeny](https://www.eversana.com/insights_authors/sean-sweeny/) - [John Kenny](https://www.eversana.com/insights_authors/john-kenny/) - [Dan Feldman](https://www.eversana.com/insights_authors/dan-feldman/) - [Roberto Ascione](https://www.eversana.com/insights_authors/roberto-ascione/) - [Sarah Kane](https://www.eversana.com/insights_authors/sarah-kane/) - [Beatrice Suero](https://www.eversana.com/insights_authors/beatrice-suero/) - [Lindsey Starkman](https://www.eversana.com/insights_authors/lindsey-starkman/) - [Belal Howidi](https://www.eversana.com/insights_authors/belal-howidi/) - [Ngoc Nguyen](https://www.eversana.com/insights_authors/ngoc-nguyen/) - [Fatemeh Mirzayeh Fashami](https://www.eversana.com/insights_authors/fatemeh-mirzayeh-fashami/) - [Drew McCormick](https://www.eversana.com/insights_authors/drew-mccormick/) - [Tim Lewis](https://www.eversana.com/insights_authors/tim-lewis/) - [Anastasiya Markvarde](https://www.eversana.com/insights_authors/anastasiya-markvarde/) - [Gurdip Daffu, PhD](https://www.eversana.com/insights_authors/gurdip-daffu-phd__trashed/) - [Christopher Olsen](https://www.eversana.com/insights_authors/christopher-olsen/) - [Irene Zahirovic, PhD](https://www.eversana.com/insights_authors/irene-zahirovic-phd/) - [Stefanie Paganelli](https://www.eversana.com/insights_authors/stefanie-paganelli/) - [Barkha Patel](https://www.eversana.com/insights_authors/barkha-patel/) - [Alexandra Hall](https://www.eversana.com/insights_authors/47578/) - [Ashish Saini](https://www.eversana.com/insights_authors/ashish-saini/) - [Vanitha Sankaran](https://www.eversana.com/insights_authors/vanitha-sankaran/) - [Vanitha Sankaran, PhD](https://www.eversana.com/insights_authors/vanith-sankaran-phd/) - [Gerardo Peccia](https://www.eversana.com/insights_authors/gerardo-peccia/) - [Elizabeth Halloran](https://www.eversana.com/insights_authors/elizabeth-halloran/) - [Abril Oliva Ramirez](https://www.eversana.com/insights_authors/abril-oliva-ramirez/) - [Samantha Craigie](https://www.eversana.com/insights_authors/samantha-craigie/) - [Rhett Figliuzzi](https://www.eversana.com/insights_authors/rhett-figliuzzi/) - [Justin Chase](https://www.eversana.com/insights_authors/justin-chase/) - [Sarah Walsh](https://www.eversana.com/insights_authors/sarah-walsh/) - [Alex Moore, PhD](https://www.eversana.com/insights_authors/alex-moore-phd/) - [Di Wang](https://www.eversana.com/insights_authors/di-wang/) - [Jennifer Meeuwsen](https://www.eversana.com/insights_authors/jennifer-meeuwsen/) - [Farah Ahmad](https://www.eversana.com/insights_authors/farah-ahmad/) - [Emily Bradshaw](https://www.eversana.com/insights_authors/emily-bradshaw/) - [Nolan Kleinhenz](https://www.eversana.com/insights_authors/nolan-kleinhenz/) - [Mary Anderson](https://www.eversana.com/insights_authors/mary-anderson/) - [Jordan Hayes](https://www.eversana.com/insights_authors/jordan-hayes/) - [Michael DeLuca, PHARMD, MBA, MSRA](https://www.eversana.com/insights_authors/michael-deluca-2/) - [Lindsay Reel, PharmD](https://www.eversana.com/insights_authors/lindsay-reel/) - [Sofiya Portuhay](https://www.eversana.com/insights_authors/sofiya-portuhay/) - [Nitin Kumar](https://www.eversana.com/insights_authors/nitin-kumar/) - [Nitin Kumar](https://www.eversana.com/insights_authors/50673/) - [EVERSANA](https://www.eversana.com/insights_authors/eversana/) - [David Byram](https://www.eversana.com/insights_authors/david-byram/) - [Andrew Ying](https://www.eversana.com/insights_authors/andrew-ying/) - [Avi Kwatra](https://www.eversana.com/insights_authors/avi-kwatra/) - [Christina Christos](https://www.eversana.com/insights_authors/christina-christos/) - [Meaghan Bartlett](https://www.eversana.com/insights_authors/meaghan-bartlett/) - [Karen Chiang](https://www.eversana.com/insights_authors/karen-chiang/) - [Megan Seyboth](https://www.eversana.com/insights_authors/megan-seyboth/) - [Heather Miller](https://www.eversana.com/insights_authors/heather-miller/) - [Jayme Etzel](https://www.eversana.com/insights_authors/jamie-etzel-2/) - [Richard Wenzel, PhD](https://www.eversana.com/insights_authors/richard-wenzel-phd/) - [Chris Drudge](https://www.eversana.com/insights_authors/chris-drudge/) - [Kim Thomas, PhD](https://www.eversana.com/insights_authors/kim-thomas-phd/) - [Anna Nero](https://www.eversana.com/insights_authors/anna-nero/) - [Nelly Andresen](https://www.eversana.com/insights_authors/nelly-andresen/) - [Natalia Gandarillas, MPharm](https://www.eversana.com/insights_authors/natalia-gandarillas-mpharm/) - [Anita Yadav](https://www.eversana.com/insights_authors/anita-yadav/) - [Chad Gibson](https://www.eversana.com/insights_authors/chad-gibson__trashed/) - [David Garcia](https://www.eversana.com/insights_authors/david-garcia/) - [Allen Zhou](https://www.eversana.com/insights_authors/allen-zhou/) - [Farah Toublan](https://www.eversana.com/insights_authors/farah-toublan/) - [John Neal](https://www.eversana.com/insights_authors/john-neal/) - [Beth Giblin, PharmD](https://www.eversana.com/insights_authors/beth-giblin-pharmd/) - [Amber Svardal, MSN, RN, OCN](https://www.eversana.com/insights_authors/amber-svardal-msn-rn-ocn/) - [Samie Ahmed, PharmD, MS](https://www.eversana.com/insights_authors/samie-ahmed-pharmd-ms/) - [Praveen Gupta](https://www.eversana.com/insights_authors/55688/) - [Susan Beach BSN, MBA](https://www.eversana.com/insights_authors/susan-beach-bsn-mba/) - [Vinod Bombale](https://www.eversana.com/insights_authors/vinod-bombale/) - [Pete Riojas](https://www.eversana.com/insights_authors/pete-riojas/) - [Jimmy El Hokayem](https://www.eversana.com/insights_authors/jimmy-el-hokayem/) ## Conditions - [Eye](https://www.eversana.com/conditions_taxonomy/eye/) - [Overactive bladder](https://www.eversana.com/conditions_taxonomy/overactive-bladder/) - [Prostate Cancer](https://www.eversana.com/conditions_taxonomy/prostate-cancer/) - [Multiple Sclerosis](https://www.eversana.com/conditions_taxonomy/multiple-sclerosis/) - [COVID-19](https://www.eversana.com/conditions_taxonomy/covid-19/) - [ATTR-CM](https://www.eversana.com/conditions_taxonomy/attr-cm/) - [Brain Arteriovenous Malformations](https://www.eversana.com/conditions_taxonomy/brain-arteriovenous-malformations/) - [Lung Cancer](https://www.eversana.com/conditions_taxonomy/lung-cancer/) - [AL amyloidosis](https://www.eversana.com/conditions_taxonomy/al-amyloidosis/) - [Skeletal-related events](https://www.eversana.com/conditions_taxonomy/skeletal-related-events/) - [Cataract and Retinal](https://www.eversana.com/conditions_taxonomy/cataract-and-retinal/) - [Cancer](https://www.eversana.com/conditions_taxonomy/cancer/) - [Osteoporosis](https://www.eversana.com/conditions_taxonomy/osteoporosis/) - [Atrial Fibrillation](https://www.eversana.com/conditions_taxonomy/atrial-fibrillation/) - [AML](https://www.eversana.com/conditions_taxonomy/aml/) - [Ulcerative Colitis](https://www.eversana.com/conditions_taxonomy/ulcerative-colitis/) - [Stroke](https://www.eversana.com/conditions_taxonomy/stroke/) - [Intracranial aneurysm](https://www.eversana.com/conditions_taxonomy/intracranial-aneurysm/) - [Arteriovenous Malformation](https://www.eversana.com/conditions_taxonomy/arteriovenous-malformation/) - [Gastroesophageal reflux disease](https://www.eversana.com/conditions_taxonomy/gastroesophageal-reflux-disease/) - [Relapsed or Refractory Multiple Myeloma](https://www.eversana.com/conditions_taxonomy/relapsed-or-refractory-multiple-myeloma/) - [Psoriasis](https://www.eversana.com/conditions_taxonomy/psoriasis/) - [Psoriatic Arthritis](https://www.eversana.com/conditions_taxonomy/psoriatic-arthritis/) - [chronic myeloid leukemia](https://www.eversana.com/conditions_taxonomy/chronic-myeloid-leukemia/) - [Relapsing-Remitting Multiple Sclerosis](https://www.eversana.com/conditions_taxonomy/relapsing-remitting-multiple-sclerosis/) - [ATTR cardiomyopathy](https://www.eversana.com/conditions_taxonomy/attr-cardiomyopathy/) - [Transthyretin amyloid polyneuropathy (ATTR-PN)](https://www.eversana.com/conditions_taxonomy/transthyretin-amyloid-polyneuropathy-attr-pn/) - [Breast Cancer](https://www.eversana.com/conditions_taxonomy/breast-cancer/) - [Obesity](https://www.eversana.com/conditions_taxonomy/obesity/) - [Rare & Orphan Diseases](https://www.eversana.com/conditions_taxonomy/rare-orphan-diseases/) - [Oncology](https://www.eversana.com/conditions_taxonomy/oncology/) - [Diabetes/Endocrine/Metabolic Disorders](https://www.eversana.com/conditions_taxonomy/diabetes-endocrine-metabolic-disorders/) - [Urinary/Kidney Disorders](https://www.eversana.com/conditions_taxonomy/urinary-kidney-disorders/) ## Content Types - [Blog](https://www.eversana.com/insights_contenttype/blog/) - [Article](https://www.eversana.com/insights_contenttype/article/) - [White Paper](https://www.eversana.com/insights_contenttype/white-paper/) - [Case Study](https://www.eversana.com/insights_contenttype/case-study/) - [Reports](https://www.eversana.com/insights_contenttype/reports/) - [News Alert](https://www.eversana.com/insights_contenttype/news-alert/) - [Webinar](https://www.eversana.com/insights_contenttype/webinar/) - [Ask the Expert](https://www.eversana.com/insights_contenttype/ask-the-expert/) - [Infographic](https://www.eversana.com/insights_contenttype/infographic/) - [PowerPoint](https://www.eversana.com/insights_contenttype/powerpoint/) - [Video](https://www.eversana.com/insights_contenttype/video/) - [Podcast](https://www.eversana.com/insights_contenttype/podcast/) - [Digital Guide](https://www.eversana.com/insights_contenttype/digital-guide/) - [KOL Content](https://www.eversana.com/insights_contenttype/kol-content/) ## External Feeds - [Navlin.com](https://www.eversana.com/external_feed/navlin-com/) - [EVERSANAconsulting.com](https://www.eversana.com/external_feed/eversanaconsulting-com/) ## Insights Topics - [Brand Insights](https://www.eversana.com/insights_taxonomy/brand-insights/) - [Brand Development](https://www.eversana.com/insights_taxonomy/brand-development/) - [Cell and Gene Therapies](https://www.eversana.com/insights_taxonomy/cell-and-gene-therapies/) - [Complex Therapies](https://www.eversana.com/insights_taxonomy/complex-therapies/) - [Commercialization](https://www.eversana.com/insights_taxonomy/commercialization/) - [COMPLETE Commercialization](https://www.eversana.com/insights_taxonomy/complete-commercialization/) - [COVID-19](https://www.eversana.com/insights_taxonomy/covid19/) - [Clinical Trials](https://www.eversana.com/insights_taxonomy/clinical-trials/) - [Regulatory Compliance](https://www.eversana.com/insights_taxonomy/regulatory-compliance/) - [Artificial Intelligence & Machine Learning](https://www.eversana.com/insights_taxonomy/artificial-intelligence-machine-learning/) - [Data and Analytics](https://www.eversana.com/insights_taxonomy/data-and-analytics/) - [Digital Health](https://www.eversana.com/insights_taxonomy/digital-therapeutics/) - [Field Solutions](https://www.eversana.com/insights_taxonomy/field-solutions/) - [HTA](https://www.eversana.com/insights_taxonomy/hta/) - [Launch Strategy](https://www.eversana.com/insights_taxonomy/launch-strategy/) - [Pricing](https://www.eversana.com/insights_taxonomy/pricing/) - [Patient Services](https://www.eversana.com/insights_taxonomy/patient-services/) - [Product Launch](https://www.eversana.com/insights_taxonomy/product-launch/) - [Market Access](https://www.eversana.com/insights_taxonomy/market-access/) - [Oncology](https://www.eversana.com/insights_taxonomy/oncology/) - [Patient Support & Adherence](https://www.eversana.com/insights_taxonomy/patient-support-and-adherence/) - [Integrated Compliance](https://www.eversana.com/insights_taxonomy/pharmacovigilance/) - [Rare Diseases](https://www.eversana.com/insights_taxonomy/rare-diseases/) - [Real World Evidence](https://www.eversana.com/insights_taxonomy/real-world-evidence/) - [Revenue Management](https://www.eversana.com/insights_taxonomy/revenue-management/) - [Specialty Pharmacies](https://www.eversana.com/insights_taxonomy/specialty-pharmacies/) - [Mature Brands](https://www.eversana.com/insights_taxonomy/mature-brands/) - [Telehealth](https://www.eversana.com/insights_taxonomy/telehealth/) - [HCP Engagement](https://www.eversana.com/insights_taxonomy/hcp-engagement/) - [Channel Distribution](https://www.eversana.com/insights_taxonomy/channel-distribution/) - [Payers](https://www.eversana.com/insights_taxonomy/payers/) - [Providers](https://www.eversana.com/insights_taxonomy/providers/) - [Reimbursement](https://www.eversana.com/insights_taxonomy/reimbursement/) - [Market Shaping](https://www.eversana.com/insights_taxonomy/market-shaping/) - [Agency](https://www.eversana.com/insights_taxonomy/agency/) - [Insights - Med Information](https://www.eversana.com/insights_taxonomy/medical-information/) - [Learning & Performance](https://www.eversana.com/insights_taxonomy/learning-performance/) - [information](https://www.eversana.com/insights_taxonomy/information/) - [Medical Affairs](https://www.eversana.com/insights_taxonomy/medical-affairs/) - [HEOR](https://www.eversana.com/insights_taxonomy/heor/) - [Medical Information](https://www.eversana.com/insights_taxonomy/medical-information-2/) - [Medical Legal Review](https://www.eversana.com/insights_taxonomy/medical-legal-review/) - [Medical Legal Regulatory Review Process](https://www.eversana.com/insights_taxonomy/medical-legal-regulatory-review-process/) - [Pharmacovigilance](https://www.eversana.com/insights_taxonomy/pharmacovigilance-2/) - [Quality Assurance](https://www.eversana.com/insights_taxonomy/quality-assurance/) - [Regulatory Strategy](https://www.eversana.com/insights_taxonomy/regulatory-strategy/) - [Advocacy](https://www.eversana.com/insights_taxonomy/advocacy/) - [Tendering](https://www.eversana.com/insights_taxonomy/tendering/) - [Direct-to-Patient](https://www.eversana.com/insights_taxonomy/direct-to-patient/) ## Media Types - [Webinar](https://www.eversana.com/contentlibrary_taxonomy/webinar/) - [Case Study](https://www.eversana.com/contentlibrary_taxonomy/case-studies/) - [Video](https://www.eversana.com/contentlibrary_taxonomy/video/) - [Article](https://www.eversana.com/contentlibrary_taxonomy/article/) - [Scientific Insights](https://www.eversana.com/contentlibrary_taxonomy/article/scientific-insights/) - [Brochure](https://www.eversana.com/contentlibrary_taxonomy/brochure/) ## Regions - [Middle East](https://www.eversana.com/thoughtleaders_regions/middle-east/) - [North America](https://www.eversana.com/thoughtleaders_regions/north-america/) - [Europe](https://www.eversana.com/thoughtleaders_regions/europe/) - [Asia](https://www.eversana.com/thoughtleaders_regions/asia/) - [South America](https://www.eversana.com/thoughtleaders_regions/south-america/) ## Regions - [North America](https://www.eversana.com/insights_regions/north-america/) - [South America](https://www.eversana.com/insights_regions/south-america/) - [Europe](https://www.eversana.com/insights_regions/europe/) - [Asia](https://www.eversana.com/insights_regions/asia/) - [Africa](https://www.eversana.com/insights_regions/africa/) - [Australia](https://www.eversana.com/insights_regions/australia/) - [Middle East](https://www.eversana.com/insights_regions/middle-east/) - [Antarctica](https://www.eversana.com/insights_regions/antarctica/) - [Global](https://www.eversana.com/insights_regions/global/) - [Asia Pacific](https://www.eversana.com/insights_regions/asia-pacific/) ## Teams - [Value & Evidence](https://www.eversana.com/teams/value-evidence/) ## Teams - [NAVLIN Price & Access Data](https://www.eversana.com/insights_teams/pricentric-team/) - [EVERSANA Team](https://www.eversana.com/insights_teams/eversana-team/) - [NAVLIN Insights Team](https://www.eversana.com/insights_teams/health-strategies-insights-team/) ## Topics - [Pricing, Reimbursement & Market Access](https://www.eversana.com/thoughtleaders_taxonomy/pricing-reimbursement-marketaccess/) - [Consulting (Strategy Management & Regulatory)](https://www.eversana.com/thoughtleaders_taxonomy/consulting-strategy-management-regulatory/) - [Patient Journey](https://www.eversana.com/thoughtleaders_taxonomy/patient-journey/) - [Stakeholder Engagement & Promotion (Patients, Payers, Providers)](https://www.eversana.com/thoughtleaders_taxonomy/stakeholder-engagement-promotion-patients-payers-providers/) - [Data & Software (Pricing, HEOR)](https://www.eversana.com/thoughtleaders_taxonomy/data-software-pricing-heor/) - [Research & Insights](https://www.eversana.com/thoughtleaders_taxonomy/research-insights/) - [Field Sales & Reimbursement](https://www.eversana.com/thoughtleaders_taxonomy/field-sales-reimbursement/) - [Revenue Management](https://www.eversana.com/thoughtleaders_taxonomy/revenue-management/) - [Medical Information & Pharmacovigilance](https://www.eversana.com/thoughtleaders_taxonomy/medical-information-pharmacovigilance/) - [Affordability Programs (PAP, Copay)](https://www.eversana.com/thoughtleaders_taxonomy/affordability-programs-pap-copay/) - [Hub & Adherence Solutions](https://www.eversana.com/thoughtleaders_taxonomy/hub-adherence-solutions/) - [Specialty & Direct-to-Patient Distribution](https://www.eversana.com/thoughtleaders_taxonomy/specialty-direct-to-patient-distribution/) - [Global Channel Management & 3PL](https://www.eversana.com/thoughtleaders_taxonomy/global-channel-management-3pl/) - [Immuno-oncology](https://www.eversana.com/thoughtleaders_taxonomy/immuno-oncology/) - [HEOR](https://www.eversana.com/thoughtleaders_taxonomy/heor/) - [RWE](https://www.eversana.com/thoughtleaders_taxonomy/rwe/) - [Forecasting Activities](https://www.eversana.com/thoughtleaders_taxonomy/forecasting-activities/) - [Brand Plan Development](https://www.eversana.com/thoughtleaders_taxonomy/brand-plan-development/) - [Medical Communication Programs](https://www.eversana.com/thoughtleaders_taxonomy/medical-communication-programs/) - [Patient Services](https://www.eversana.com/thoughtleaders_taxonomy/patient-services/) - [Commercialization](https://www.eversana.com/thoughtleaders_taxonomy/commercialization/) - [Clinical Trials](https://www.eversana.com/thoughtleaders_taxonomy/clinical-trials/) - [Patients](https://www.eversana.com/thoughtleaders_taxonomy/patients/) - [Payers](https://www.eversana.com/thoughtleaders_taxonomy/payers/) - [Providers](https://www.eversana.com/thoughtleaders_taxonomy/providers/) - [Regulatory](https://www.eversana.com/thoughtleaders_taxonomy/regulatory/) - [Data and Software](https://www.eversana.com/thoughtleaders_taxonomy/data-and-software/) - [Health Economic Marketing](https://www.eversana.com/thoughtleaders_taxonomy/health-economic-marketing/) - [Medical Devices](https://www.eversana.com/thoughtleaders_taxonomy/medical-devices/) - [Health Research Methods](https://www.eversana.com/thoughtleaders_taxonomy/health-research-methods/) - [Peer-Reviewed Publications](https://www.eversana.com/thoughtleaders_taxonomy/peer-reviewed-publications/) - [Market Access](https://www.eversana.com/thoughtleaders_taxonomy/market-access/) - [Managed Markets](https://www.eversana.com/thoughtleaders_taxonomy/managed-markets/) - [Health Economic Research](https://www.eversana.com/thoughtleaders_taxonomy/health-economic-research/) - [Emerging Technology](https://www.eversana.com/thoughtleaders_taxonomy/emerging-technology/) - [Digital Health](https://www.eversana.com/thoughtleaders_taxonomy/digital-health/) - [Digital Medicine](https://www.eversana.com/thoughtleaders_taxonomy/digital-medicine/) - [Data & Analytics](https://www.eversana.com/thoughtleaders_taxonomy/data-analytics/) - [Artificial Intelligence (AI)](https://www.eversana.com/thoughtleaders_taxonomy/artificial-intelligence-ai/) - [Marketing and Advertising](https://www.eversana.com/thoughtleaders_taxonomy/marketing-and-advertising/) - [Clinical Research](https://www.eversana.com/thoughtleaders_taxonomy/clinical-research/) - [Regulatory Compliance](https://www.eversana.com/thoughtleaders_taxonomy/regulatory-compliance/) - [Digital Technology](https://www.eversana.com/thoughtleaders_taxonomy/digital-technology/) - [Managed Care](https://www.eversana.com/thoughtleaders_taxonomy/managed-care/) - [Rare Disease](https://www.eversana.com/thoughtleaders_taxonomy/rare-disease/) - [Medical Education](https://www.eversana.com/thoughtleaders_taxonomy/medical-education/) - [Product Launch](https://www.eversana.com/thoughtleaders_taxonomy/product-launch/) - [Operational Transformation](https://www.eversana.com/thoughtleaders_taxonomy/operational-transformation/) - [Market Research](https://www.eversana.com/thoughtleaders_taxonomy/market-research/) - [Compliance](https://www.eversana.com/thoughtleaders_taxonomy/compliance/) - [Pharmacovigilance](https://www.eversana.com/thoughtleaders_taxonomy/pharmacovigilance/) - [Safety Surveillance](https://www.eversana.com/thoughtleaders_taxonomy/safety-surveillance/) - [Medical Information](https://www.eversana.com/thoughtleaders_taxonomy/medical-information/) - [Medical Affairs](https://www.eversana.com/thoughtleaders_taxonomy/medical-affairs/) - [Training](https://www.eversana.com/thoughtleaders_taxonomy/training/) - [Education](https://www.eversana.com/thoughtleaders_taxonomy/education/) - [Client Services](https://www.eversana.com/thoughtleaders_taxonomy/client-services/) - [Sales](https://www.eversana.com/thoughtleaders_taxonomy/sales/) - [Complex Therapies](https://www.eversana.com/thoughtleaders_taxonomy/complex-therapies/) - [Management](https://www.eversana.com/thoughtleaders_taxonomy/management/) - [Leadership](https://www.eversana.com/thoughtleaders_taxonomy/leadership/) - [Oncology](https://www.eversana.com/thoughtleaders_taxonomy/oncology/) - [Employee Development](https://www.eversana.com/thoughtleaders_taxonomy/employee-development/) - [Project Management](https://www.eversana.com/thoughtleaders_taxonomy/project-management/) - [Consulting (Strategy Management and HTA requirements)](https://www.eversana.com/thoughtleaders_taxonomy/consulting-strategy-management-and-hta-requirements/) - [Launch Readiness](https://www.eversana.com/thoughtleaders_taxonomy/launch-readiness/) - [Neurology/CNS](https://www.eversana.com/thoughtleaders_taxonomy/neurology-cns/) - [Learning and Performance](https://www.eversana.com/thoughtleaders_taxonomy/learning-and-performance/) - [Quality Consulting](https://www.eversana.com/thoughtleaders_taxonomy/quality-consulting/) ## Topics - [Blood](https://www.eversana.com/contentlibrary_topics_taxonomy/blood/) - [Brain](https://www.eversana.com/contentlibrary_topics_taxonomy/brain/) - [Cardiac](https://www.eversana.com/contentlibrary_topics_taxonomy/cardiac/) - [Cardiovascular](https://www.eversana.com/contentlibrary_topics_taxonomy/cardiovascular/) - [COVID-19](https://www.eversana.com/contentlibrary_topics_taxonomy/covid-19/) - [Digestive](https://www.eversana.com/contentlibrary_topics_taxonomy/digestive/) - [Gastrointestinal](https://www.eversana.com/contentlibrary_topics_taxonomy/gastrointestinal/) - [Multiple Sclerosis](https://www.eversana.com/contentlibrary_topics_taxonomy/multiple-sclerosis/) - [Nervous System](https://www.eversana.com/contentlibrary_topics_taxonomy/nervous-system/) - [Neurovascular](https://www.eversana.com/contentlibrary_topics_taxonomy/neurovascular/) - [Oncology](https://www.eversana.com/contentlibrary_topics_taxonomy/oncology/) - [Psoriasis](https://www.eversana.com/contentlibrary_topics_taxonomy/psoriasis/) - [Psoriatic Arthritis](https://www.eversana.com/contentlibrary_topics_taxonomy/psoriatic-arthritis/) - [Urology](https://www.eversana.com/contentlibrary_topics_taxonomy/urology/) - [Vision](https://www.eversana.com/contentlibrary_topics_taxonomy/vision/) - [Respiratory](https://www.eversana.com/contentlibrary_topics_taxonomy/respiratory/) - [Lung](https://www.eversana.com/contentlibrary_topics_taxonomy/lung/) - [Eye](https://www.eversana.com/contentlibrary_topics_taxonomy/eye/) - [Skeletal](https://www.eversana.com/contentlibrary_topics_taxonomy/skeletal/) - [Urinary](https://www.eversana.com/contentlibrary_topics_taxonomy/urinary/) - [Immune](https://www.eversana.com/contentlibrary_topics_taxonomy/immune/) - [Proton pump inhibitors (PPIs)](https://www.eversana.com/contentlibrary_topics_taxonomy/proton-pump-inhibitors-ppis/) - [Rheumatology](https://www.eversana.com/contentlibrary_topics_taxonomy/rheumatology/) - [Ophthalmology](https://www.eversana.com/contentlibrary_topics_taxonomy/ophthalmology/) - [Medical Devices](https://www.eversana.com/contentlibrary_topics_taxonomy/medical-devices/) - [Feasibility assessment](https://www.eversana.com/contentlibrary_topics_taxonomy/feasibility-assessment/) - [ITC](https://www.eversana.com/contentlibrary_topics_taxonomy/itc/) - [Breast Cancer](https://www.eversana.com/contentlibrary_topics_taxonomy/breast-cancer/) - [Digital Health & Digital Therapeutics](https://www.eversana.com/contentlibrary_topics_taxonomy/digital-health-digital-therapeutics/) - [Diabetes](https://www.eversana.com/contentlibrary_topics_taxonomy/diabetes/) - [Compliance](https://www.eversana.com/contentlibrary_topics_taxonomy/compliance/) - [Neurology](https://www.eversana.com/contentlibrary_topics_taxonomy/neurology/)
Version History
Version 16/16/2026, 8:02:09 AMvalid
612099 bytes
Categories
blognewse-commerceeducationtechnologybusinesshealthfinancefoodsportssocial
Visit Website
Explore the original website and see their AI training policy in action.
Visit eversana.comContent Types
postspagesproductsapiguidesreviewscomments
Recent Access
No recent access
API Access
Canonical URL:
https://llmscentral.com/eversana.com/llms.txt
API Endpoint:
/api/llms?domain=eversana.com